,PageNo,Text
0,page_1,"['Clinical Study Protocol', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717', '(Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and', 'Adolescents', 'Study Number TV50717-CNS-30046', 'NCT03452943', 'Protocol Approval Date: 25 March 2019']"
1,page_2,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Clinical Study Protocol with Amendment 05', 'Study Number TV50717-CNS-30046', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine)', 'for the Treatment of Tourette Syndrome in Children and Adolescents', 'Phase 2/3', 'IND number: 127692; NDA number: NA; EudraCT number: 2016-000622-19', 'Original Protocol Approval Date: 26 February 2016', 'Protocol Amendment 05 Approval Date: 25 March 2019', 'Sponsor', 'Teva Branded Pharmaceutical', 'Products R&D, Inc.', '41 Moores Road', 'Frazer, Pennsylvania 19355', 'United States of America', ""Teva's Development Partner"", 'Nuvelution TS Pharma, Inc.', '101 Main Street, 12th Floor', 'Cambridge, Massachusetts 02142', 'United States of America', 'Confidentiality Statement', 'This clinical study will be conducted in accordance with current Good Clinical Practice (GCP) as directed', 'by the provisions of the International Council for Harmonisation (ICH); United States (US) Code of', 'Federal Regulations (CFR), and European Union (EU) Directives and Regulations (as applicable in the', ""region of the study); national country legislation; and the sponsor's Standard Operating Procedures"", '(SOPs).', 'This document contains confidential and proprietary information (including confidential commercial', 'information pursuant to 21CFR§20.61) and is a confidential communication of Teva Branded', 'Pharmaceutical Products R&D and/or its affiliates and Nuvelution TS Pharma, INC. The recipient agrees', 'that no information contained herein may be published or disclosed without written approval from the', 'sponsor.', '© 2019 Teva Branded Pharmaceutical Products R&D, Inc. and Nuvelution TS Pharma, INC. All rights', 'reserved.', '1']"
2,page_3,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'AMENDMENT HISTORY', 'The protocol for Study TV50717-CNS-30046 (original protocol dated 26 February 2016) has', 'been amended and reissued as follows:', 'Amendment 05', '25 March 2019', '86 patients randomized/enrolled to date', 'Amendment 04', '13 September 2018', '35 patients randomized/enrolled to date', 'Amendment 03', '06 November 2017', 'No patients randomized/enrolled to date', 'Amendment 02', '03 October 2017', 'No patients randomized/enrolled to date', 'Amendment 01', '22 June 2017', 'No patients randomized/enrolled to date', 'The Summary of Changes to the Protocol includes the corresponding reason/justification for', 'each change and is provided in Section 17.', '2']"
3,page_4,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'INVESTIGATOR AGREEMENT', 'Original Protocol Dated 26 February 2016', 'Amendment 05 Dated 25 March 2019', 'IND number: 127692; EudraCT number: 2016-000622-19', 'Article 45 or 46 of 1901/2006 does not apply', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine)', 'for the Treatment of Tourette Syndrome in Children and Adolescents', 'Principal Investigator:', 'Title:', 'Address of Investigational Center:', 'Tel:', 'I have read the protocol with amendment 05 and agree that it contains all necessary details for', 'carrying out this study. I am qualified by education, experience, and training to conduct this', 'clinical research study. The signature below constitutes agreement with this protocol and', 'attachments, and provides assurance that this study will be conducted according to all', 'stipulations of the protocol, including all statements regarding confidentiality, and according to', 'national or local legal and regulatory requirements and applicable regulations and guidelines.', 'I will make available the protocol and all information on the investigational medicinal product', '(IMP) that were furnished to me by the sponsor to all physicians and other study personnel', 'reporting to me who participate in this study and will discuss this material with them to ensure', 'that they are fully informed regarding the IMP and the conduct of the study. I agree to keep', 'records on all patient information, IMP shipment and return forms, and all other information', 'collected during the study, in accordance with national and local Good Clinical Practice (GCP)', 'regulations as well as all other national and international laws and regulations.', 'Principal Investigator', 'Signature', 'Date', '3']"
4,page_5,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'SPONSOR PROTOCOL APPROVAL', ""Sponsor's Authorized"", 'Signature', 'Date', 'Representative', 'Mar 25,2019', '4']"
5,page_6,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'COORDINATING INVESTIGATOR AGREEMENT', 'Original Protocol Dated 26 February 2016', 'Amendment 05 Dated 25 March 2019', 'IND number: 127692; EudraCT number: 2016-000630-22', 'Article 45 or 46 of 1901/2006 does not apply', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine)', 'for the Treatment of Tourette Syndrome in Children and Adolescents', 'I have read the protocol with amendment 05 and agree that it contains all necessary details for', 'carrying out this study. I am qualified by education, experience, and training to conduct this', 'clinical research study. The signature below constitutes agreement with this protocol and', 'attachments, and provides assurance that this study will be conducted according to all', 'stipulations of the protocol, including all statements regarding confidentiality, and according to', 'national and local legal and regulatory requirements and applicable regulations and guidelines.', 'I will make available the protocol and all information on the investigational medicinal product', '(IMP) that were furnished to me by the sponsor to all physicians and other study personnel', 'reporting to me who participate in this study and will discuss this material with them to ensure', 'that they are fully informed regarding the IMP and the conduct of the study. I agree to keep', 'records on patient information, IMPs shipment and return forms, and other information collected', 'during the study, in accordance with my responsibilities under the function of the coordinating', 'investigator and in accordance with national and local GCP regulations as well as all other', 'national and international laws and regulations. In addition I will assume the responsibility of', 'the', 'coordinating investigator according to a separate contract.', 'Coordinating Investigator', 'Title:', 'Address of Investigational Center:', 'Tel:', 'Coordinating Investigator', 'Signature', 'Date', '07/25/2019', '5']"
6,page_7,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'COORDINATING INVESTIGATOR AGREEMENT', 'Original Protocol Dated 26 February 2016', 'Amendment 05 Dated 25 March 2019', 'IND number: 127692; EudraCT number: 2016-000630-22', 'Article 45 or 46 of 1901/2006 does not apply', 'A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine)', 'for the Treatment of Tourette Syndrome in Children and Adolescents', 'I have read the protocol with amendment 05 and agree that it contains all necessary details for', 'carrying out this study. I am qualified by education, experience, and training to conduct this', 'clinical research study. The signature below constitutes agreement with this protocol and', 'attachments, and provides assurance that this study will be conducted according to all', 'stipulations of the protocol, including all statements regarding confidentiality, and according to', 'national and local legal and regulatory requirements and applicable regulations and guidelines.', 'I will make available the protocol and all information on the investigational medicinal product', '(IMP) that were furnished to me by the sponsor to all physicians and other study personnel', 'reporting to me who participate in this study and will discuss this material with them to ensure', 'that they are fully informed regarding the IMP and the conduct of the study. I agree to keep', 'records on patient information, IMPs shipment and return forms, and other information collected', 'during the study, in accordance with my responsibilities under the function of the coordinating', 'investigator and in accordance with national and local GCP regulations as well as all other', 'national and international laws and regulations. In addition I will assume the responsibility of the', 'coordinating investigator according to a separate contract.', 'Coordinating Investigator', 'Title:', 'Address of Investigational Center:', 'Tel:', 'Coordinating Investigator', 'Signaturi', 'Date', '3/25/19', '6']"
7,page_8,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'LABORATORY AND OTHER DEPARTMENTS AND INSTITUTIONS', 'Central Institutional Review Board', 'Copernicus Group IRB', '1 Triangle Drive', 'Durham, NC 27709', 'USA', 'Central Clinical Laboratory', 'Q2 Solutions (Quest) LLC', '27027 Tourney Road, Suite 2E', 'Valencia, CA 91355', 'USA', 'Electronic Data Capture', 'Medidata RAVE (through Syneos Health)', 'Contract Research Organization; Safety and Efficacy Data Analysis', 'Syneos Health, LLC', '1030 Sync Street', 'Morrisville, NC 27560', 'USA', 'Central Electrocardiogram Evaluation', 'ERT', '1818 Market Street 10th Floor', 'Philadelphia, PA 19103', 'USA', 'Integrated Response Technology', 'Endpoint', '55 Francisco Street, Suite 200', 'San Francisco, CA 94133', 'USA', 'ePRO, eCOA, and Scales Training', 'Bracket Global, LLC', '575 East Swedesford Road, Suite 200', 'Wayne, PA 19087', 'USA', '7']"
8,page_9,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', ""Sponsor's Authorized Representative:"", 'Teva Branded Pharmaceutical Products R&D, Inc.', 'Legal Representative of the Sponsor in the EU', 'For medical issues, contact the physician listed below:', '8']"
9,page_10,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'For protocol issues, contact the study leaders listed below:', 'For operational issues, contact the Head of Operations listed below:', 'For serious adverse events:', 'Send by e-mail to the local safety officer (LSO)/Syneos Health. The email address will be', 'provided in the serious adverse event report form. In the event of difficulty transmitting the form,', ""contact the sponsor's study personnel identified above for further instruction."", '9']"
10,page_11,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'CLINICAL STUDY PROTOCOL SYNOPSIS', 'Study TV50717-CNS-30046', 'Title of Study: A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the', 'Treatment of Tourette Syndrome in Children and Adolescents', 'Sponsor: Teva Branded Pharmaceutical Products R&D, Inc., 41 Moores Road, Frazer, Pennsylvania 19355, United', 'States of America', ""Sponsor's Development Partner: Nuvelution TS Pharma, Inc., 101 Main Street, 12th Floor, Cambridge,"", 'Massachusetts 02142, United States of America', 'Investigational New Drug (IND) Number: 127692 New Drug Application (NDA) Number: Not available', 'EudraCT Number: 2016-000622-19', 'Name of Active Ingredient: Deutetrabenazine', 'Name of Investigational Medicinal Product (IMP): TEV-50717 (previously SD-809)', 'Type of the Study: Efficacy and Safety (Phase 2/3)', 'Number of Investigational Centers Planned: Approximately 50', 'Countries Planned: North America, Russia, and Europe', 'Planned Study Period: Planned start in January 2018 with a duration of approximately 15 months', 'Number of Patients Planned: Approximately 116 (58 per treatment arm; TEV-50717 versus placebo randomized', 'in a 1:1 ratio stratified by age at baseline [6 to 11 years, 12 to 16 years])', 'Study Population: Male and female patients between 6 and 16 years of age (inclusive) with tics associated with', 'Tourette syndrome (TS)', 'Primary Objective: The primary objective of this study is to evaluate the efficacy of TEV-50717 to reduce motor', 'and phonic tics associated with TS.', 'Secondary Objectives: The secondary objective of the study is to evaluate the safety and tolerability of titration and', 'maintenance therapy with TEV-50717.', 'Study Endpoints:', 'Primary Efficacy Endpoint:', 'Change in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS) from baseline to', 'week 12', 'Key Secondary Efficacy Endpoints:', '1. Change in the Tourette Syndrome-Clinical Global Impression (TS-CGI) score from baseline to week 12', '2.', 'Change in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) score from baseline to', 'week 12', '3. Change in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL)', 'activities of daily living (ADL) subscale score from baseline to week 12', 'Exploratory Endpoints:', '10']"
11,page_12,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Safety Endpoints:', 'Incidence of adverse events', 'Observed values and changes from baseline in vital signs', ""Observed values and change from baseline in the Children's Depression Inventory, Second Edition"", '(CDI-2), Parent and Self-report Profiles', ""Observed values in the Children's Columbia-Suicide Severity Rating Scale (C-SSRS)"", 'Observed values in electrocardiogram (ECG) parameters and shifts from screening for clinically', 'significant abnormal findings', 'Observed values and changes from screening in clinical laboratory parameters (hematology, chemistry,', 'and urinalysis)', 'Pharmacokinetic Endpoint:', 'The pharmacokinetics of the alpha-dihydrotetrabenazine (-HTBZ) and beta-dihydrotetrabenazine', '(B-HTBZ) metabolites of TEV-50717, and other metabolites (as needed), will be explored based on', 'sparse sampling at week 12.', 'General Design and Methodology:', 'This is a Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study in which patients with ties', 'associated with TS will be invited to participate. Patients who qualify for the study will be centrally randomized in a', '1:1 ratio (stratified by age at baseline [6 to 11 years, 12 to 16 years]) to receive either TEV-50717 or placebo.', 'Throughout the study, patients will interact regularly with investigative site personnel, in clinic and by telephone, for', 'the evaluation of safety, tic severity, and behavioral status (in clinic only). The target dose for each patient receiving', 'TEV-50717 will be based on body weight and cytochrome P450 2D6 (CYP2D6) impairment status at baseline.', 'Patients will be classified as CYP2D6 impaired if they are receiving a strong CYP2D6 inhibitor or are a CYP2D6', 'poor metabolizer based on blinded assessment of CYP2D6 genotype at baseline. CYP2D6 status will be used by', 'Interactive Response Technology (IRT) for randomization into the study. The dose of IMP for each patient will be', 'titrated to an optimal level followed by maintenance therapy at that dose. Investigators will be blinded to CYP', 'status, with a dose cap for poor metabolizers prespecified by the IRT. The overall treatment period will be 12 weeks', 'in duration, including a titration period of 7 weeks, a maintenance period of 5 weeks, followed by a washout period', 'of 1 week', 'For the YGTSS, input from the caregiver/adult is required.', 'For both the TS-PGII and', ', input from the caregiver/adult is permitted. For all other scales, for children', '13 years of age and under, interviews may be performed separately or jointly with the caregiver/adult as appropriate', 'or defined by the scale; for children over 13 years of age, caregiver/adult involvement is strongly encouraged.', '11']"
12,page_13,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Questions should be directed to the child, but the caregiver/adult should be encouraged to add relevant information.', 'It should be noted that the CDI-2 has individual parent and child questionnaires.', 'Patients who complete the study may be eligible to begin participation in an open-label safety extension study', 'TV50717-CNS-30047 after the end of the washout period. At the week 13 visit, patients may choose to enter', 'Study TV50717-CNS-30047 (on that day), or they will have an additional week to make a decision and return for', 'day 1. Patients not participating in Study TV50717-CNS-30047 will have a follow-up telephone contact to evaluate', 'safety 1 week after the end of the washout period (2 weeks after their last dose of IMP).', ""Screening period (up to 31 days): After informed consent/assent, depending on the child's age, as appropriate, is"", 'obtained, patients who are stable from a medical and psychiatric standpoint will undergo a screening evaluation,', 'including medical history, physical and neurological examination, laboratory testing, and 12-lead ECG, along with', 'rating scales to assess severity, frequency, and impairment of ties and comorbid TS symptoms and behavioral status.', 'At the discretion of the investigator, the screening visit may be divided into 2 visits if the visit length is felt to be too', 'burdensome for the patient. If the screening visit is divided into 2 visits, the blood sample should be obtained during', 'the first of the 2 visits. Patients who have received comprehensive behavioral intervention for tics (CBIT) for TS or', 'cognitive behavioral therapy (CBT) for obsessive-compulsive disorder (OCD) may participate in this study as long', 'as therapy was completed at least 4 weeks prior to screening. Patients will return to the clinic on day 1 for baseline', 'procedures and to re-confirm eligibility. Patients may be rescreened 1 time if there is a change in the status of the', 'patient regarding eligibility for the study. (Note: Details of rescreening must be approved and documented by the', 'medical monitor and/or Clinical Surveillance and Training [CST] team.)', 'YGTSS Rater Certification: All investigators and subinvestigators who will be administering the YGTSS from', 'screening through the end of study visit must undergo and pass a Rater Certification Program which will be', 'provided separately from this protocol. Every effort must be made to ensure that the same certified rater administers', 'the YGTSS to a specific patient at all visits, especially at the baseline and week 12/early termination visits.', 'However, if due to unforeseen circumstances the same rater is absolutely unavailable to complete a visit rating, the', 'YGTSS can be administered only by another certified individual from that study site.', 'Titration period (7 weeks): Patients who remain eligible for participation in the study will be randomized at the', 'baseline visit (day 1), and that evening (ie, after the study visit) will receive 6 mg of blinded IMP with food. Tablets', 'should be taken with food (eg, a snack) and should not be taken on an empty stomach. The titration scheme and', 'maximum dose will be determined by body weight and CYP2D6 impairment status at baseline, as shown in the', 'tables below. Patients and their caregiver/adult will interact weekly with the clinical research staff, either by', 'telephone contact or clinic visit from week 1 through week 7 of the titration period, in order to evaluate safety and', 'establish a dose of IMP that optimally reduces tics and is well tolerated (optimal dose). Safety evaluations during', 'titration include assessment of vital signs, monitoring for adverse events and concomitant medications, 12-lead', 'ECGs, and rating scales for depression and suicidality.', 'In-person (in-clinic) study visits will be scheduled at weeks 2, 4, and 6, and telephone contacts will be scheduled for', 'weeks 1, 3, 5, and 7 in order to assess tic severity and adverse events. The dose of the IMP should be increased on a', 'weekly basis until one of the following criteria is met:', 'The investigator determines there has been a clinically meaningful reduction in tics as indicated by', 'a', 'sustained reduction in the TS-CGI.', 'The patient experiences a protocol-defined ""clinically significant"" adverse event (defined as an adverse', 'event that is related to study medication and is either moderate or severe in intensity or meets the', 'criteria for a serious adverse event).', ""The maximum allowable dose is reached based on the patient's weight and CYP2D6 impairment status"", 'at baseline.', '12']"
13,page_14,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Although dose adjustments can be made up to and including the week 7 telephone call, if a stable dose is reached', 'before then, the patient should continue on that dose (ie, the dose should not be increased further) for the remainder', 'of the titration period and throughout maintenance dosing, unless there is a change in symptoms during the titration', 'period. If a patient experiences a ""clinically significant"" adverse event attributable to the IMP, the investigator will', 'determine if a dose reduction or suspension is necessary. If the determination that a patient requires a dose reduction', 'or suspension is made during a telephone contact, an unscheduled clinic visit should be conducted as soon as', 'practicable thereafter.', 'Dose adjustments should be made based on all available information, including the patient and caregiver/adult', 'reports of adverse events and tic reduction, the clinical assessment of safety and efficacy by the investigator, and', ""information from rating scales. At the end of the titration period, the patient's dose will be established for the"", 'maintenance period.', 'Maintenance period (5 weeks): Patients will continue to receive their maintenance dose over the next 5 weeks,', 'although dose reductions for adverse events are allowed. Patients will return to the clinic at weeks 9 and 12 for', 'assessments of safety and efficacy. At week 12, patients will undergo a complete evaluation, including physical and', 'neurological examination, safety laboratory testing, and 12-lead ECG, CDI-2, and C-SSRS assessments, as well as', 'the YGTSS, TS-CGI, TS-PGII,', 'and C&A-GTS-QOL. In addition, patients', 'will undergo pharmacokinetic sampling at week 12.', 'Washout period and follow-up: All patients will discontinue IMP at the week 12 visit and will return 1 week later', 'for evaluation of safety and tic reduction (week 13). Patients who complete the study may be eligible to begin', 'participation in the open-label safety extension study, TV50717-CNS-30047, at that time. For this study, the', 'follow-up period is defined as 1 week of washout for patients who will participate in the open-label safety extension', 'study TV50717-CNS-30047 and 2 weeks after the last dose of IMP (1 week after the end of the washout period) for', 'patients who will not roll over into the open-label safety extension study TV50717-CNS-30047. At the week 13', 'visit, patients may choose to enter Study TV50717-CNS-30047 (on that day), or they will have an additional week', 'to make a decision and return for day 1. Patients not participating in Study TV50717-CNS-30047 will have a', 'follow-up telephone contact for safety evaluation 1 week after the end of the washout period (2 weeks after their last', 'dose of IMP [week 14]).', 'Prohibited drugs will remain the same during the washout period for patients who will participate in the open-label', 'extension study TV50717-CNS-30047', 'Patients who will not participate in the extension study (Study TV50717-CNS-30047) may begin/resume tic therapy', 'medication after the first week of the washout period.', 'Method of Blinding and Randomization:', 'Patients will be randomly assigned to receive treatment with TEV-50717 or matching placebo in a 1:1 ratio using an', 'IRT. Patients will be stratified by age at baseline (6 to 11 years, 12 to 16 years). Patients and investigators will', ""remain blinded to treatment assignment during the study. In addition, the sponsor's clinical personnel and all"", 'vendors (with the exception of the IRT vendor and the bioanalytical sample analysis vendor) involved in the study', 'will be blinded to the IMP identity until the database has been locked for analysis and the treatment assignments are', 'revealed. After unblinding of this study, the study site may remain blinded to patient treatment assignments until', 'completion of the safety extension study TV50717-CNS-30047.', 'IMP Dose, Mode of Administration, and Administration Rate:', 'IMP will be administered as oral tablets at a starting dose of 6 mg. Titration schemes based on body weight at', 'baseline are shown in the tables below. The maximum daily dose is determined by body weight and CYP2D6', 'impairment status at baseline (see the table below). Although dose adjustments can be made up to and including the', '13']"
14,page_15,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'week 7 telephone call, if a stable dose is reached before then, the patient should continue taking that dose for the', 'remainder of the titration period and throughout maintenance dosing. If a patient experiences a ""clinically', 'significant"" adverse event that is attributed to the IMP, the investigator will determine if a dose reduction or', ""suspension is necessary. At the end of the titration period, the patient's dose will be established for the maintenance"", 'period. If a patient experiences an adverse event during the maintenance period and the investigator believes a dose', 'reduction in warranted, the dose may be reduced.', 'TEV-50717 tablets are available in the following dose strengths: 6, 9, 12, 15, and 18 mg, all of which are identical in', 'size, shape, and color (white). The IMP will be supplied in 40-count blister packs. The placebo tablets and', 'packaging will match those for TEV-50717.', 'IMP will be administered as follows:', 'IMP should be swallowed whole and taken with food. Tablets should be taken with food (eg, a snack)', 'and should not be taken on an empty stomach.', 'Dosing will be based on body weight and CYP2D6 impairment status at the baseline visit, as shown in', 'the tables below.', 'The starting dose is 6 mg in all patients. Daily doses will be administered twice daily, approximately', '8 to 10 hours apart during the day. A minimum of 6 hours should elapse between doses. If a patient', 'misses a dose, and it is within 6 hours of their next dose, the missed dose should be skipped.', 'After week 1, dose increases may not occur more frequently than every 5 days.', 'Dose reductions, if required, should be in increments of 6 mg. If more than 1 dose reduction is', 'required for an adverse event, the medical monitor must be notified.', 'During the titration period, the dose of IMP should be adjusted weekly according to the table below to', 'identify a dose level that optimally reduces tics and is well tolerated. Investigators will be blinded to', 'CYP status, with a dose cap for poor metabolizers prespecified by the IRT.', 'Maximum Daily Dose of IMP by Study Day and Weight Category at Baseline', 'Weight category', 'Study daya', '20 to <30 kg', '30 to <40 kg', '>40 kg', 'CYP', 'Not', 'Impaired', 'Not', 'Impaired', 'Not impaired', 'Impaired', 'impairment', 'impaired', 'impaired', 'status', 'Day 1-7', '6 mg', '6 mg', '6 mg', '6 mg', '6 mg (Days 1', '6 mg (Days 1', 'and 2)', 'and 2)', '12 mgb', '12 mgb', 'Day 8-14', '12 mg', '12 mg', '12 mg', '12 mg', '18 mg', '18 mg', 'Day 15-21', '18 mg', '18 mg', '18 mg', '18 mg', '24 mg', '24 mg', 'Day 22-28', '18 mg', '18 mg', '24 mg', '24 mg', '30 mg', '30 mg', 'Day 29-35', '24 mg', '18 mg', '30 mg', '24 mg', '36 mg', '36 mg', 'Day 36-42', '24 mg', '18 mg', '36 mg', '24 mg', '42 mg', '36 mg', 'Day 43-49', '30 mg', '18 mg', '42 mg', '24 mg', '48 mg', '36 mg', 'a', 'Administration of a given dose will take place throughout the days indicated. The new dose starts the morning', 'after the telephone contact or the morning after the clinic visit (ie, Days 8, 15, 22, 29, 36, and 43), as applicable.', 'b', 'Patients will receive 6 mg on days 1 and 2, and 12 mg starting on day 3.', '14']"
15,page_16,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'bid=twice a day; CYP=cytochrome P450; IMP=investigational medicinal product.', 'Note: CYP impaired=patients who are receiving a strong CYP2D6 inhibitor or who are a CYP2D6 poor', 'metabolizer. The investigator, in consultation with the patient and caregiver/adult, will determine if a dose increase', 'is warranted to achieve optimal tic reduction.', 'IMP: TEV-50717', 'Reference Therapy: Placebo', 'Duration of Patient Participation: This study will consist of up to a 31-day screening period, a 12-week', 'double-blind treatment period, and a 1-week washout period. Patients who complete the study may be eligible to', 'begin participation in an open-label safety extension study TV50717-CNS-30047 after the end of the washout', 'period. Patients not participating in Study TV50717-CNS-3004 will have a follow-up telephone contact to evaluate', 'safety 1 week after the end of the washout period (2 weeks after their last dose of IMP). Patients are expected to', 'participate in this study for its entire duration, which is a minimum of 14 weeks.', 'Inclusion Criteria: Patients may be enrolled in the study if they meet all of the following criteria:', 'a.', 'Patient is 6 to 16 years of age, inclusive, at baseline.', 'b.', 'Patient weighs at least 44 pounds (20 kg) at baseline.', 'c.', 'Patient meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-VTM)', 'diagnostic criteria for TS and, in the opinion of the investigator, patient, and caregiver/adult, the', ""patient's active tics are causing distress or impairment."", 'd.', 'Patient has a TTS of 20 or higher on the YGTSS at screening and baseline.', 'e.', 'Patient is able to swallow study medication whole.', 'f.', 'Patient and caregiver/adult are willing to adhere to the medication regimen and to comply with all', 'study procedures.', 'g. Patient is in good general health, as indicated by medical and psychiatric history as well as physical', 'and neurological examination.', 'h.', ""In the investigator's opinion, the patient and caregiver/adult have the ability to understand the nature of"", 'the study and its procedures, and the patient is expected to complete the study as designed.', 'i.', ""Patient and caregiver/adult provide written informed consent/assent, depending on the child's age, as"", 'appropriate, according to local regulations.', 'j.', 'Females who are postmenarchal or >12 years of age may be included only if they have a negative', 'beta-human chorionic gonadotropin (B-HCG) test at baseline or are sterile. Definitions of sterile are', 'given in Appendix L.', 'k.', 'Females who are postmenarchal or >12 years of age whose male partners are potentially fertile (ie, no', 'vasectomy) must use highly effective birth control methods for the duration of the study (ie, starting at', 'screening) and for 30 days or 5 half-lives, whichever is longer after last dose of IMP. Further details', 'are included in Appendix L.', 'Exclusion Criteria: Patients will not be enrolled in this study if they meet any of the following criteria:', 'a.', 'Patient has a neurologic disorder other than TS that could obscure the evaluation of tics.', 'b.', ""The patient's predominant movement disorder is stereotypy (coordinated movements that repeat"", 'continually and identically) associated with autism spectrum disorder.', '15']"
16,page_17,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'c.', 'Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.', 'd.', 'Patient has clinically significant depression at screening or baseline.', 'Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks', 'before screening.', 'e.', 'Patient has a history of suicidal intent or related behaviors within 2 years of screening:', '- previous intent to act on suicidal ideation with a specific plan, irrespective of level of', 'ambivalence, at the time of suicidal thought', '-', 'previous suicidal preparatory acts or behavior', 'f.', 'Patient has a history of a previous actual, interrupted, or aborted suicide attempt.', 'g.', 'Patient has a first-degree relative who has completed suicide.', 'h.', 'Patient has clinically significant OCD at baseline that, in the opinion of the investigator, is the primary', 'cause of impairment.', 'i.', 'Patient has received CBIT for TS or CBT for OCD within 4 weeks of screening.', 'j.', 'Patient has received any of the following concomitant medications for tics within the specified', 'exclusionary windows of first dose:', '-', 'within 3 months: depot neuroleptics, botulinum toxin, or tetrabenazine', '-', 'within 4 weeks: cannabidiol oil and valbenazine', '-', 'within 21 days: reserpine', '-', 'within 14 days: neuroleptics (oral), typical and atypical antipsychotics (see Appendix A),', 'metoclopramide, levodopa, and dopamine agonists', 'Note: Use of stimulant medications, including amphetamine, methylphenidate, and', 'lisdexamfetamine, is allowed if primary use is for the treatment of ADHD, dosing has been stable', 'for at least 2 weeks before screening, and no changes to dose or frequency are anticipated during', 'the course of the study.', 'Note: Use of atomoxetine is allowed if the primary use is for the treatment of ADHD, dosing has', 'been stable for at least 4 weeks before screening, and no changes to dose or frequency are', 'anticipated during the course of the study.', 'Note: Use of benzodiazepines is allowed if primary use is not for tics and dosing has been stable', 'for at least 4 weeks before screening.', 'Note: Use of topiramate (up to 200 mg/day) is allowed if dosing has been stable for at least', '4 weeks before screening.', '-', 'Note: Use of guanfacine or clonidine is allowed regardless of indication (ie, if prescribed for ties', 'or Tourette syndrome) if the dosing has been stable for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study. If discontinuation of', 'either medication is anticipated due to ineffectiveness, poor tolerability, or patient/caregiver', 'preference, discontinuation should occur 4 or more weeks prior to the screening visit.', 'k.', 'Patient has received treatment with deep brain stimulation, or transmagnetic stimulation, or', 'transcranial direct current stimulation for reduction of tics within 4 weeks of the screening visit.', '1.', 'Patient has an unstable or serious medical illness at screening or baseline', '16']"
17,page_18,"['Placebo-Controlled tudy-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""m. Patient has a QT interval corrected for heart rate using Fridericia's formula (QTcF) interval value"", '>450 msec (males) or >460 msec (females) or >480msec (with right bundle branch block) on 12-lead', 'ECG at screening, OR requires treatment with drugs known to prolong the QT interval (see', 'Appendix A, Table 6 for a complete list of prohibited QT-prolonging drugs).', 'n.', 'Patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, or', 'uncompensated heart failure.', 'o.', 'Patient has evidence of hepatic impairment, as indicated by:', '-', 'aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 X the upper limit of', 'the normal range (ULN) at screening', '-', 'alkaline phosphatase (ALP) or total bilirubin (Tbil) >2 X ULN at screening', ""Note: Patients with Gilbert's Syndrome are eligible to participate if approved by the medical"", 'monitor.', 'Note: Patients with abnormalities in 2 or more of the following clinical laboratory parameters', 'must be approved for enrollment by the medical monitor: AST, ALT, ALP, and Tbil.', 'p.', 'Patient has evidence of clinically significant renal impairment, indicated by a serum creatinine', '>1.5 X ULN at screening.', 'q. Patient has received a monoamine oxidase inhibitor within 14 days of the baseline visit.', 'r.', 'Patient has a known allergy to any of the components of the IMP.', 'S.', 'Patient has participated in an investigational drug or device study and received IMP/intervention', 'within 30 days or 5 drug half-lives of baseline, whichever is longer.', 't.', 'The patient is a pregnant or lactating female or plans to become pregnant during the study.', 'u.', 'Patient has a history of or acknowledges alcohol-related disorder in the previous 12 months, as defined', 'in the DSM-VTM', 'V. Patient has a positive urine drug screen test result or is unable to refrain from substance abuse', 'throughout the study.', 'W. Patient has a DSM diagnosis based on the MINI Kid Inventory modules performed at screening that, in', 'the opinion of the investigator, makes the patient unsuitable for the study.', 'Measures and Time Points:', 'Primary Efficacy Measures and Time Points: YGTSS (to calculate TTS): Screening; baseline; and weeks 2,', '4, 6, 9, 12, and 13', 'Key Secondary Efficacy Measures and Time Points:', '1. TS-CGI: baseline and weeks 2, 4, 6, 9, 12, and 13', '2. TS-PGII: baseline and weeks 2, 4, 6, 9, 12, and 13', '3.', 'C&A-GTS-QOL ADL subscale: baseline, week 6, and week 12', 'Exploratory Measures and Time Points:', '17']"
18,page_19,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Safety Measures and Time Points:', 'adverse events and concomitant medications: from the signing of the informed consent/assent,', ""depending on the child's age, as appropriate, through follow-up, inclusive of all visits and telephone"", 'contacts', 'physical examination: screening and week 12', 'neurological examination: screening and week 12', 'vital signs: screening; baseline; and weeks 2, 4, 6, 9, 12, and 13', 'Note: orthostatic blood pressure and pulse at baseline and weeks 4 and 12', 'MINI Kid: screening', ""Children's C-SSRS"", '-', 'Baseline/screening scale: screening', '-', 'Since Last Visit scale: baseline and weeks 2, 4, 6, 9, 12, and 13', 'CDI-2 (Parent and Self-Report versions): screening; baseline; and weeks 2, 4, 6, 9, 12, and 13', '12-lead ECG: screening; baseline; and weeks 4, 6, and 12', 'clinical laboratory tests (serum chemistry, hematology, and urinalysis): screening and week 12', 'pregnancy testing: screening, baseline, and weeks 4 and 12', 'drug screen: Screening and week 12', 'Pharmacokinetic Measures and Time Points:', 'Blood samples will be obtained for the measurement of plasma concentrations of TEV-50717', '(deutetrabenazine), a-HTBZ, ß-HTBZ, and other metabolites, as needed. Blood sampling for pharmacokinetic', 'analysis will be performed at the week 12 visit. Two samples will be collected. The first sample will be', 'collected upon arrival at the clinic. The second sample will be collected 2 to 3 hours after the first', 'pharmacokinetic sample collection. The time between samples should be maximized in order to provide the', 'most useful information. Patients with early morning visits (ie, within 2 hours of their scheduled AM dosing)', 'should take their dose in the clinic after the first pharmacokinetic sample is collected.', 'Patients will be provided with a diary to provide critical information on dosing before the week 12 visit. The', 'date and time of the last dose of study medication before the week 12 visit should be recorded in the diary by', 'the patient or caregiver/adult. The site will document the date and time of the sample collection. Prior to the', 'clinic visit on week 12, patients will be reminded to record the start time of their last meal and the time of their', 'last dose in their diary', 'Plasma samples for both a-HTBZ and ß-HTBZ metabolites will be pooled with previous data and incorporated', 'into a population pharmacokinetic analysis. The population pharmacokinetic analysis will result in a final', 'structural model that best describes the data. A covariate assessment will evaluate the relationship between', 'potential covariates (ie, body weight, age, height, etc) and concentrations of -HTBZ and ß-HTBZ metabolites.', 'The final population pharmacokinetic analysis will be included in a separate report. Exposure-response (eg,', 'pharmacodynamic [PD] and/or safety endpoints) may be assessed if the appropriate data are available.', ""At the screening visit, a blood sample (3 mL) will be obtained for analysis of CYP2D6 genotype. The patient's"", 'genotype for CYP2D6 will remain blinded during the conduct of the study.', '18']"
19,page_20,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Allowed and Disallowed Medications Before and During the Study:', 'See Appendix A for details of allowed and disallowed medications.', 'Statistical Considerations:', 'Sample Size Rationale: It is estimated that approximately 58 patients per arm will enable a power of at least 90% to', 'detect a beneficial standardized effect of 63% or more when the TEV-50717 arm is compared to placebo (difference', 'of 6.0 in the change from baseline to week 12 in TTS, assuming a standard deviation of 9.5 in each arm) in a 2-sided', 'type I error rate of 5% after accounting for potential dropouts.', 'Analysis of Primary Endpoint: The primary efficacy endpoint for this study is the change in the TTS of the', 'YGTSS from baseline to week 12. The primary analysis will be a mixed-model repeated-measures model with the', 'change in the TTS as the dependent variable. The model will include fixed effects for treatment group, week', '(5 levels: Weeks 2, 4, 6, 9, and 12), and the treatment group by week interaction. The baseline TTS, region, and age', 'group at baseline will be included as covariates. The unstructured covariance matrix for repeated observations', 'within patients will be used. The least squares means of the change in TTS from baseline at week 12 will be', 'compared (the active treatment arm and the placebo arm) using a 2-sided test at the alpha=0.05 level of significance.', 'In addition, actual values and changes in the TTS from baseline to each visit will be summarized using descriptive', 'statistics.', 'Analysis of Key Secondary Endpoints: A hierarchical (fixed-sequence) testing approach will be used for the', 'analysis of the primary and key secondary endpoints to maintain the experiment-wise type I error rate of 5%. If an', 'endpoint is not statistically significant, confirmatory hypothesis testing will not be carried out on the remaining', 'hypotheses, and remaining hypotheses will be considered exploratory rather than confirmatory. The change in the', 'TS-CGI (1) and C&A-GTS-QOL ADL subscale (3) scores from baseline to week 12 will be summarized and', 'analyzed in the same fashion as the primary analysis, with the exception that the baseline value of the given', 'endpoint will be included as the covariate. TS-PGII (2) will be analyzed using a Cochran-Mantel-Haenszel row', 'mean score test with a modified ridit score that controls for age group.', 'Exploratory Analyses:', '19']"
20,page_21,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Multiple Comparisons and Multiplicity: The hierarchical testing method will be used to maintain the', 'experiment-wise type I error of 5% level for the primary and key secondary analyses. The primary efficacy endpoint', 'will first be tested at the 5% type I error level. If the p-value of the primary analysis is 0.05, the secondary', 'hypotheses will be tested in the order listed for the secondary endpoints until either an analysis produces a', 'p-value >0.05 or all analyses result in a p-value 0.05.', 'Analysis of Pharmacokinetic Endpoint: Samples collected for pharmacokinetic analysis will be quantified for', 'a-HTBZ and B-HTBZ active metabolites and will be analyzed using population pharmacokinetic techniques.', 'Analysis methods will be detailed in a separate population pharmacokinetic analysis plan. Exploratory', 'pharmacokinetic/PD analysis may be performed on PD/safety endpoints.', 'Safety Analyses: All adverse events will be coded using the Medical Dictionary for Regulatory Activities. Each', 'patient will be counted only once in each preferred term or system organ class category for the analyses of safety.', 'Summaries will be presented for all adverse events, adverse events determined by the investigator to be related to', 'study treatment, serious adverse events, and adverse events causing withdrawal from the study. Summaries will be', 'presented by treatment group and for all patients. Patient listings of serious adverse events and adverse events', 'leading to withdrawal will be presented.', 'Observed values and changes from baseline in laboratory results and vital signs will be summarized descriptively.', 'Observed values in ECG parameters will be summarized, and counts and percentages of abnormal findings will be', 'presented. In addition, the number and percentage of patients with on-treatment QTcF values >450, >480, or', '>500 msec and change from baseline >30 or >60 msec will be presented.', 'The use of concomitant medications will be summarized by therapeutic class using descriptive statistics.', 'Concomitant medications will include all medications taken while the patient is treated with IMP.', 'Observed values in the C-SSRS and observed values and changes from baseline in the CDI-2 (Parent and Self-report', 'versions) will be presented by treatment group for all patients.', '20']"
21,page_22,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'TABLE OF CONTENTS', 'TITLE PAGE', '1', 'AMENDMENT HISTORY', '2', 'INVESTIGATOR AGREEMENT', '3', 'COORDINATING INVESTIGATOR AGREEMENT', '5', 'COORDINATING INVESTIGATOR AGREEMENT', '6', 'LABORATORY AND OTHER DEPARTMENTS AND INSTITUTIONS', '7', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', '8', 'CLINICAL STUDY PROTOCOL SYNOPSIS', '10', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', '30', '1.', 'BACKGROUND INFORMATION', '33', '1.1.', 'Introduction', '33', '1.2.', 'Name and Description of IMP', '34', '1.3.', 'Findings from Nonclinical and Clinical Studies', '34', '1.3.1.', 'Nonclinical Studies', '34', '1.3.1.1.', 'Nonclinical Pharmacology', '34', '1.3.1.2.', 'Nonclinical Pharmacokinetics and Drug Metabolism', '35', '1.3.1.3.', 'Toxicology', '35', '1.3.2.', 'Clinical Studies', '36', '1.3.2.1.', 'Clinical Pharmacology Studies', '36', '1.3.2.2.', 'Clinical Safety and Efficacy Studies', '37', '1.3.2.3.', 'Pharmacometrics Analysis of TEV-50717 Active Metabolites to Support', 'Dose Selection and Pharmacokinetic Characterization in a Pediatric', 'Population', '37', '1.4.', 'Known and Potential Risks and Benefits to Human Patients', '38', '1.5.', 'Selection of Drugs and Dosages', '38', '1.5.1.', 'Justification for Dosage of Active Drug', '38', '1.5.2.', 'Justification for Use of Placebo', '38', '1.6.', 'Compliance Statement', '39', '1.7.', 'Study Population and Justification', '39', '1.8.', 'Location and Study Duration', '39', '2.', 'PURPOSE OF THE STUDY AND STUDY OBJECTIVES', '40', '2.1.', 'Purpose of the Study', '40', '21']"
22,page_23,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '2.2.', 'Study Objectives', '40', '2.2.1.', 'Primary Objective', '40', '2.2.2.', 'Secondary Objective', '40', '2.3.', 'Study Endpoints', '40', '2.3.1.', 'Primary Efficacy Endpoint', '40', '2.3.2.', 'Key Secondary Efficacy Endpoints', '40', '2.3.3.', 'Exploratory Endpoints', '40', '2.3.4.', 'Safety Endpoints', '41', '2.3.5.', 'Pharmacokinetic Endpoint', '41', '3.', 'STUDY DESIGN', '42', '3.1.', 'General Design and Study Schema', '42', '3.1.1.', 'Overall Design and Screening Period', '42', '3.1.2.', 'Screening Period', '42', '3.1.3.', 'Titration Period', '43', '3.1.4.', 'Maintenance Period', '44', '3.1.5.', 'Washout Period and Follow-up', '44', '3.2.', 'Justification for Study Design', '45', '3.3.', 'Primary and Secondary Efficacy Measures and Time Points', '46', '3.3.1.', 'Primary Efficacy Measure and Time Points', '46', '3.3.2.', 'Key Secondary Efficacy Measures and Time Points', '46', '3.3.3.', 'Exploratory Measures and Time Points', '46', '3.4.', 'Safety Measures and Time Points', '46', '3.5.', 'Pharmacokinetic Measures and Time Points', '47', '3.6.', 'Randomization and Blinding', '47', '3.7.', 'Maintenance of Randomization and Blinding', '48', '3.7.1.', 'Randomization', '48', '3.7.2.', 'Blinding/Unblinding', '48', '3.7.3.', 'Independent Data Monitoring Committee', '49', '3.8.', 'Drugs Used in the Study', '49', '3.8.1.', 'IMP', '49', '3.8.2.', 'Placebo', '50', '3.9.', 'Drug Supply and Accountability', '50', '3.9.1.', 'Drug Storage and Security', '50', '22']"
23,page_24,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.9.2.', 'Drug Accountability', '50', '3.10.', 'Duration of Patient Participation and Justification', '50', '3.11.', 'Stopping Rules and Discontinuation Criteria', '50', '3.12.', 'Source Data Recorded on the Case Report Form', '51', '3.13.', 'Study Procedures', '51', '3.13.1.', 'Procedures for Screening and Enrollment', '56', '3.13.1.1.', 'YGTSS Rater Certification', '57', '3.13.2.', 'Procedures Before IMP Treatment (Baseline/Day 1)', '57', '3.13.3.', 'Procedures During IMP Treatment', '59', '3.13.3.1.', 'Titration Period (Baseline/ Day 1 Through 7)', '59', '3.13.3.2.', 'Maintenance Period', '60', '3.13.4.', 'Procedures After IMP Treatment', '62', '3.13.4.1.', 'Week 13', '63', '3.13.4.2.', 'Week 14', '64', '3.13.5.', 'Unscheduled Visits', '64', '4.', 'SELECTION AND WITHDRAWAL OF PATIENTS', '66', '4.1.', 'Patient Inclusion Criteria', '66', '4.2.', 'Patient Exclusion Criteria', '66', '4.3.', 'Justification for Key Inclusion and Exclusion Criteria', '69', '4.4.', 'Withdrawal Criteria and Procedures', '69', '5.', 'TREATMENT OF PATIENTS', '71', '5.1.', 'Drugs Administered During the Study', '71', '5.2.', 'Restrictions', '72', '5.3.', 'Prior and Concomitant Therapy or Medication', '73', '5.4.', 'Procedures for Monitoring Patient Compliance', '73', '5.5.', 'Dose Reduction and Temporary IMP Discontinuation', '74', '5.6.', 'Total Blood Volume', '74', '6.', 'ASSESSMENT OF EFFICACY', '76', '6.1.', 'Primary Efficacy Measure and Justification', '76', '6.2.', 'Key Secondary Efficacy and Exploratory Measures', '76', '6.2.1.', 'Tourette Syndrome-Clinical Global Impression', '76', '6.2.2.', 'Tourette Syndrome-Patient Global Impression of Impact', '76', '6.2.3.', 'Tourette Syndrome-Patient Global Impression of Severity', '77', '23']"
24,page_25,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6.2.4.', 'Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Scale', '77', '6.2.5.', 'Yale Global Tic Severity Scale', '77', '6.2.6.', '77', '6.2.7.', ""Children's Yale-Brown Obsessive-Compulsive Scale"", '78', '7.', 'ASSESSMENT OF SAFETY', '79', '7.1.', 'Adverse Events', '79', '7.1.1.', 'Definition of an Adverse Event', '79', '7.1.2.', 'Recording and Reporting Adverse Events', '80', '7.1.3.', 'Severity of an Adverse Event', '80', '7.1.4.', 'Relationship of an Adverse Event to the IMP', '81', '7.1.5.', 'Serious Adverse Events', '81', '7.1.5.1.', 'Definition of a Serious Adverse Event', '82', '7.1.5.2.', 'Expectedness', '82', '7.1.5.3.', 'Reporting a Serious Adverse Event', '83', '7.1.6.', 'Protocol-Defined Adverse Events of Special Interest', '85', '7.1.7.', 'Withdrawal Due to an Adverse Event', '85', '7.1.8.', 'Protocol Deviations Because of an Adverse Event', '85', '7.2.', 'Psychometric Rating Scales', '85', '7.2.1.', 'Mini International Neuropsychiatric Interview for Children and Adolescents', '86', '7.2.2.', 'Columbia-Suicide Severity Rating Scale', '86', '7.2.3.', ""Children's Depression Inventory, Second Edition"", '87', '7.3.', 'Pregnancy', '87', '7.4.', 'Medication Error and Special Situations Related to the Investigational', 'Medicinal Product', '88', '7.5.', 'Clinical Laboratory Tests', '89', '7.5.1.', 'Serum Chemistry, Hematology, and Urinalysis', '89', '7.5.2.', 'Other Clinical Laboratory Tests', '90', '7.5.2.1.', 'Human Chorionic Gonadotrophin Test', '90', '7.5.2.2.', 'Urine Drug Screen', '90', '7.5.3.', 'Cytochrome P450 2D6 Genotyping', '91', '7.6.', 'Vital Signs', '91', '7.7.', 'Electrocardiography', '91', '7.8.', 'Physical Examinations', '92', '24']"
25,page_26,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.9.', 'Assessment of Suicidality', '92', '7.10.', 'Neurological Examinations', '93', '7.11.', 'Concomitant Therapy or Medication', '93', '7.12.', 'Methods and Timing of Assessing, Recording, and Analyzing Safety Data', '93', '8.', 'ASSESSMENT OF PHARMACOKINETICS AND SCREENING', 'ASSESSMENTS', '94', '8.1.', 'Pharmacokinetic Assessment', '94', '8.2.', 'Pharmacodynamics Assessment', '94', '8.3.', 'Pharmacogenetics', '94', '8.3.1.', 'CYP2D6 Genotyping/Pharmacogenetics', '94', '9.', 'STATISTICS', '96', '9.1.', 'Sample Size and Power Considerations', '96', '9.2.', 'Analysis Sets', '96', '9.2.1.', 'Intent-to-Treat Analysis Set', '96', '9.2.2.', 'Safety Analysis Set', '96', '9.2.3.', 'Modified Intent-to-Treat Analysis Set', '96', '9.2.4.', 'Per-Protocol Analysis Set', '96', '9.3.', 'Data Handling Conventions', '97', '9.4.', 'Study Population', '97', '9.4.1.', 'Patient Disposition', '97', '9.4.2.', 'Demographic and Baseline Characteristics', '97', '9.5.', 'Efficacy Analysis', '97', '9.5.1.', 'Primary Endpoint', '97', '9.5.2.', 'Key Secondary Endpoints', '97', '9.5.3.', 'Exploratory Endpoints', '98', '9.5.4.', 'Planned Method of Analysis', '98', '9.5.4.1.', 'Primary Efficacy Analysis', '98', '9.5.4.2.', 'Sensitivity Analysis', '99', '9.5.4.3.', 'Key Secondary Efficacy Analyses', '99', '9.5.4.4.', 'Exploratory Analyses', '99', '9.6.', 'Multiple Comparisons and Multiplicity', '100', '9.7.', 'Safety Endpoints and Analysis', '100', '9.7.1.', 'Safety Endpoints', '100', '25']"
26,page_27,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9.7.2.', 'Safety Analysis', '100', '9.8.', 'Pharmacokinetic Analysis', '101', '9.9.', 'Planned Interim Analysis', '101', '9.10.', 'Reporting Deviations from the Statistical Plan', '101', '10.', 'DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS', '102', '11.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '103', '11.1.', 'Protocol Amendments and Protocol Deviations and Violations', '103', '11.1.1.', 'Protocol Amendments', '103', '11.1.2.', 'Protocol Violations', '103', '11.2.', 'Information to Study Personnel', '103', '11.3.', 'Study Monitoring', '104', '11.4.', 'Clinical Product Complaints', '104', '11.4.1.', 'Product Complaint Information Needed from the Investigational Center', '105', '11.4.2.', 'Handling of IMP at the Investigational Center', '105', '11.4.3.', 'Adverse Events or Serious Adverse Events Associated with a Product', 'Complaint', '106', '11.4.4.', 'Documenting a Product Complaint', '106', '11.5.', 'Audit and Inspection', '106', '12.', 'ETHICS', '107', '12.1.', 'Informed Consent/Assent', '107', '12.2.', 'Competent Authorities and Independent Ethics Committees/Institutional', 'Review Boards', '107', '12.3.', 'Confidentiality Regarding Study Patients', '107', '12.4.', 'Declaration of the End of Clinical Study', '108', '12.5.', 'Registration of the Clinical Study', '108', '13.', 'DATA HANDLING, DATA QUALITY CONTROL, AND RECORD', 'KEEPING', '109', '13.1.', 'Data Collection', '109', '13.2.', 'Data Quality Control', '109', '13.3.', 'Archiving of Case Report Forms and Source Documents', '110', '13.3.1.', 'Sponsor Responsibilities', '110', '13.3.2.', 'Investigator Responsibilities', '110', '14.', 'FINANCING AND INSURANCE', '112', '26']"
27,page_28,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '15.', 'REPORTING AND PUBLICATION OF RESULTS', '113', '16.', 'REFERENCES', '114', '17.', 'SUMMARY OF CHANGES TO PROTOCOL', '116', '17.1.', 'Amendment 01 Dated 22 June 2017', '116', '17.2.', 'Amendment 02 Dated 03 October 2017', '136', '17.3.', 'Amendment 03 Dated 06 November 2017', '164', '17.4.', 'Amendment 04 Dated 13 September 2018', '173', '17.5.', 'Amendment 05 Dated 25 March 2019', '195', 'APPENDIX A. ALLOWED AND DISALLOWED MEDICATIONS', '205', 'APPENDIX B. DISTRIBUTION OF AUC BY WEIGHT CATEGORIES AND', 'CYP2D6 STATUS', '209', 'APPENDIX C. MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW', 'FOR CHILDREN AND ADOLESCENTS', '210', ""APPENDIX D. CHILDREN'S DEPRESSION INVENTORY, SECOND EDITION,"", 'PARENT AND SELF-REPORT PROFILES', '228', ""APPENDIX E. CHILDREN'S COLUMBIA-SUICIDE SEVERITY RATING SCALE"", '236', ""APPENDIX F. CHILDREN'S YALE-BROWN OBSESSIVE-COMPULSIVE SCALE"", '242', 'APPENDIX G. YALE GLOBAL TIC SEVERITY SCALE', '255', 'APPENDIX H.', '264', 'APPENDIX I.', '265', 'APPENDIX J.', '267', 'APPENDIX K.', '268', 'APPENDIX L.', '27']"
28,page_29,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'LIST OF TABLES', 'Table 1:', 'Study Procedures and Assessments', '52', 'Table 2:', 'Maximum Daily Dose of IMP by Study Day and Weight Category at', 'Baseline', '72', 'Table 3:', 'Blood Volumes', '75', 'Table 4:', 'Clinical Laboratory Tests', '90', 'Table 5:', 'Allowed Medications', '205', 'Table 6:', 'Prohibited QTc-Prolonging Drugs', '207', 'Table 7:', 'Prohibited Antipsychotic Drugs', '207', 'Table 8:', 'Other Prohibited Drugs', '208', '28']"
29,page_30,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'LIST OF FIGURES', 'Figure 1: Overall Study Schema', '45', 'Figure 2: Distribution of AUC of Total (a+B)-HTBZ for Selected Doses Based on', 'Weight Categories', '209', '29']"
30,page_31,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Table of Abbreviations', 'Abbreviation or', 'Explanation', 'Specialist Term', '21CFR', 'Title 21 Code of Federal Regulations', 'ADHD', 'Attention Deficit Hyperactivity Disorder', '-HTBZ', 'alpha-dihydrotetrabenazine', 'ADL', 'activities of daily living', 'ALP', 'alkaline phosphatase', 'ALT', 'alanine aminotransferase (SGPT)', 'ANC', 'absolute neutrophil count', 'ANCOVA', 'analysis of covariance', 'AST', 'aspartate aminotransferase (SGOT)', 'AUC', 'area under the curve', 'ß-HCG', 'beta-human chorionic gonadotropin', 'ß-HTBZ', 'beta-dihydrotetrabenazine', 'bid', 'twice a day', 'BL', 'baseline visit', 'BP', 'blood pressure', 'BUN', 'blood urea nitrogen', 'CBIT', 'comprehensive behavioral intervention for tics', 'CBT', 'cognitive behavioral therapy', 'CDI-2', ""Children's Depression Inventory, Second Edition"", 'CDMS', 'clinical data management system', 'CNS', 'central nervous system', 'CRF', 'case report form', 'C-SSRS', 'Columbia-Suicide Severity Rating Scale', 'CST', 'Clinical Surveillance and Training', 'CYP', 'cytochrome P450', 'CYP2D6', 'cytochrome P450 2D6', 'DSM-VTM', 'Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition', '30']"
31,page_32,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Abbreviation or', 'Explanation', 'Specialist Term', 'ECG', 'electrocardiogram', 'ePRO', 'electronic patient-reported outcome', 'ET', 'early termination visit', 'FDA', 'Food and Drug Administration [United States)', 'GCP', 'Good Clinical Practice', 'GPSP', 'Global Patient Safety and Pharmacovigilance', 'C&A-GTS-QOL', 'Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life', 'HD', 'Huntington disease', 'IB', ""Investigator's Brochure"", 'ICH', 'International Council for Harmonisation (of Technical Requirements for', 'Registration of Pharmaceuticals for Human Use)', 'IDMC', 'Independent Data Monitoring Committee', 'IEC/IRB', 'Independent Ethics Committee/Institutional Review Board', 'IMP', 'investigational medicinal product', 'IND', 'Investigational New Drug [Application]', 'IRT', 'Interactive Response Technology', 'ITT', 'intent-to-treat', 'LDH', 'lactate dehydrogenase', 'LSO', 'local safety officer', 'MA', 'Marketing Authorization', 'MAOI', 'monoamine oxidase inhibitor', 'MINI Kid', 'Mini International Neuropsychiatric Interview For Children and Adolescents', '(version 6.0)', 'mITT', 'Modified Intent-to-Treat', 'NA', 'not available', 'NDA', 'New Drug Application', 'NOAEL', 'no-observed-adverse-effect level', 'OCD', 'obsessive-compulsive disorder', 'PD', 'pharmacodynamic', 'PGx', 'pharmacogenetics', '31']"
32,page_33,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Abbreviation or', 'Explanation', 'Specialist Term', 'PND', 'postnatal day', 'QTcF', ""QT interval corrected for heart rate using Fridericia's formula"", 'RBC', 'red blood cell', 'SD-809/TEV-50717', 'deutetrabenazine', 'SLV', 'Since Last Visit', 'SOP', 'Standard Operating Procedure', 'SUSAR', 'suspected unexpected serious adverse reaction', 'Tbil', 'total bilirubin', 'TD', 'tardive dyskinesia', 'TEAE', 'treatment-emergent adverse event', 'TS', 'Tourette syndrome', 'TS-CGI', 'Tourette Syndrome-Clinical Global Impression', 'TS-PGII', 'Tourette Syndrome-Patient Global Impression of Impact', 'TTS', 'Total Tic Score', 'U', 'unscheduled visit', 'UDS', 'urine drug screen', 'ULN', 'upper limit of the normal range', 'USA', 'United States of America', 'VAS', 'visual analog scale', 'VMAT2', 'vesicular monoamine transporter 2', 'WBC', 'white blood cell', 'YGTSS', 'Yale Global Tic Severity Scale', '32']"
33,page_34,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '1.', 'BACKGROUND INFORMATION', '1.1.', 'Introduction', 'Tourette syndrome (TS) is a neurodevelopmental disorder characterized by multiple motor and', 'phonic tics that frequently co-occurs with a variety of behavioral and psychiatric problems', '(Jankovic 2001, Jankovic and Kurlan 2011). Studies have suggested that up to 7% of school', 'children fulfill the diagnostic criteria for TS (Kurlan et al 2002). Tics are classified as either', 'simple or complex; simple motor tics include eye blinks, shoulder shrugs, while simple vocal tics', 'include grunting, coughing and sniffing. Complex motor tics include touching/tapping and', ""walking in patterns, while complex vocal tics include echolalia (repeating another's speech) and"", 'coprolalia (shouting obscenities or profanities) (Jankovic 2001, Shaw and Coffey 2014). TS was', 'thought to be a psychogenic disorder until improvement with neuroleptics was first observed in', 'the 1960s, leading to the theory of central dopaminergic hyperactivity as a possible mechanism', 'of tics associated with TS. When the symptoms impair function, most physicians utilize alpha', 'adrenergic drugs (guanfacine, clonidine), typical neuroleptics (haloperidol, pimozide,', 'fluphenazine), or atypical neuroleptics (olanzapine, ziprasidone, aripiprazole) to control tics', '(Gilbert and Jankovic 2014, Wijemanne et al 2014). In the United States of America (USA),', 'haloperidol and pimozide are approved for the treatment of tics associated with TS, while', 'aripiprazole carries a broader indication of ""for the treatment of TS"". Neuroleptics have the', 'potential for serious adverse effects, including tardive dyskinesia (TD), which typically', 'manifests as an irreversible orofacial stereotypy, and other forms of hyperkinetic movement', 'disorder (Waln and Jankovic 2013). Up to 25% of adults chronically treated with dopamine', 'receptor antagonists (neuroleptics; including the so-called ""atypical"" neuroleptics, such as', 'aripiprazole) eventually develop TD (Jankovic 1995, Pasricha et al 2006, Peña et al 2011).', 'Although elderly individuals, especially women, are particularly susceptible to developing TD,', 'this iatrogenic condition may also rarely occur in children (Mejia and Jankovic 2010).', 'Tetrabenazine, which depletes dopamine presynaptically, has been shown to be effective in', 'treating the tics associated with TS (Jain et al 2006, Jankovic 2015, Jankovic and Beach 1997,', 'Kenney et al 2007, Paleacu et al 2004, Porta et al 2008), but has not been documented to cause', 'TD in clinical use.', 'While generally effective in reducing the tics of TS, tetrabenazine is associated with frequent', 'adverse events, including somnolence, nausea, depression, insomnia, and parkinsonism, that may', 'limit its utility. Moreover, tetrabenazine is an immediate-release formulation with the following', 'limitations: (1) adverse events of tetrabenazine, such as somnolence, akathisia, and anxiety, are', 'often associated with peak concentration after dosing; (2) the active metabolites have short', 'half-lives, with the attendant requirement to dose the immediate-release formulation frequently;', 'and (3) the active metabolites alpha-dihydrotetrabenazine (a-HTBZ) and beta-', 'dihydrotetrabenazine (B-HTBZ) are either primarily (a) or exclusively (B) metabolized by', 'cytochrome P450 2D6 (CYP2D6). Polymorphisms in the CYP2D6 gene necessitate genotyping', 'to prevent poor metabolizers from experiencing significantly greater exposure to the active drug', 'moiety than extensive metabolizers (Mehanna et al 2013).', 'To address the limitations of commercial tetrabenazine (Xenazine8), Auspex, a wholly owned', 'subsidiary of Teva Pharmaceutical Products R&D, Inc, developed deutetrabenazine (referred to', '33']"
34,page_35,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'as TEV-50717, previously SD-809) that is eliminated more slowly than tetrabenazine.', 'TEV-50717 has been shown to reduce plasma fluctuation and dosing frequency and thus can', 'improve overall tolerability as compared to that of tetrabenazine. Data in patients receiving', 'TEV-50717 for the treatment of chorea associated with Huntington disease (HD) demonstrate a', 'favorable safety profile with low rates of neuropsychiatric adverse events. In TS patients with', 'troublesome motor and phonic tics, preliminary efficacy and safety data for TEV-50717 have', 'been generated in an open-label, Phase 1b pilot study (SD-809-C-17). Results of this study are', 'summarized in Section 1.3.2.2 and support further development of TEV-50717 for treatment of', 'tics associated with TS.', 'TEV-50717 was granted breakthrough status for treatment of TD by the Food and Drug', 'Administration (FDA) based on the results of Study SD-809-C-18, and NDA 209885 was', 'granted priority review status. TEV-50717 was approved for the treatment of chorea associated', 'with HD on 03 April 2017 and for the treatment of chorea associated with TD on', '30 August 2017.', '1.2.', 'Name and Description of IMP', 'TEV-50717 (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with', 'the chemical name (RR, SS)-1,3,4,6,7,11b-hexahydro-9,10-di(methoxy-d3)-3-(2-methylpropyl)-', 'H-benzo[a]quinolizin-2-one. TEV-50717 is provided for this study as 6-mg, 9-mg, 12-mg,', '15-mg, and 18-mg oral tablets, all of which are identical in size, shape, and color (white). The', 'investigational medicinal product (IMP) will be supplied in 40-count blister packs.', 'A more detailed description of the product is given in Section 3.8.', '1.3.', 'Findings from Nonclinical and Clinical Studies', 'Brief summaries of nonclinical pharmacology, pharmacokinetics, and toxicology studies and', 'clinical studies are provided in the following sections. More detailed information is provided in', ""the current Investigator's Brochure (IB)."", '1.3.1.', 'Nonclinical Studies', 'The key nonclinical study findings are provided below, with details available in the IB.', '1.3.1.1.', 'Nonclinical Pharmacology', 'TEV-50717 is a selectively deuterium-substituted VMAT2 inhibitor structurally related to', 'tetrabenazine. The metabolites formed from TEV-50717 (-HTBZ and ß-HTBZ) are potent', 'inhibitors of VMAT2 binding, with Ki values of 3.8 and 22 nM, respectively, that are similar to', 'previously reported values of their corresponding non-deuterated forms (Scherman et al 1988).', 'Off-target binding occurs to a similar extent with deuterated and non-deuterated -HTBZ and', 'ß-HTBZ. TEV-50717 and tetrabenazine in male rats at doses resulting in similar systemic', 'exposure to the test articles (-HTBZ and B-HTBZ) produced similar, expected, exaggerated', 'central nervous system (CNS) pharmacological effects. In particular, the adverse event of', 'catalepsy, a known response in rats to drugs which reduce CNS dopamine concentrations', '(Fuenmayor and Vogt 1979), was similar in magnitude after TEV-50717 and tetrabenazine', 'administration.', '34']"
35,page_36,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '1.3.1.2.', 'Nonclinical Pharmacokinetics and Drug Metabolism', 'In human liver S9, the metabolite profile of TEV-50717 overlapped with that of tetrabenazine. In', 'a', 'clinical comparative human 14C]-absorption, distribution, metabolism, and excretion and', 'mass-balance study, the approximately 22 metabolites of TEV-50717 were also metabolites of', 'tetrabenazine. Thus, previous clinical experience with tetrabenazine provides predictive', 'information about the safety of TEV-50717 and its metabolites.', 'Tetrabenazine, -HTBZ, and ß-HTBZ, and by extension, their deuterated forms, do not inhibit or', 'induce cytochrome P450 (CYP) isoenzymes at clinically relevant concentrations (Xenazine', 'Prescribing Information 2015). M1, a minor metabolite that may circulate in greater', 'concentrations as a metabolite of TEV-50717 as compared to tetrabenazine, is neither an', 'inhibitor of major CYP isozymes or transporters nor an inducer of CYP isozymes. M4, a major', 'metabolite of tetrabenazine and TEV-50717 is neither an inhibitor of major CYP isozymes or', 'transporters nor an inducer of CYP isozymes.', '1.3.1.3.', 'Toxicology', 'General and Reproductive Adult Toxicology: Oral administration of TEV-50717 in rats reduced', 'body weight gain, increased mammary hyperplasia, and produced estrous cycle changes, all of', 'which occurred with tetrabenazine at doses that produced similar systemic exposures to test', 'articles and metabolites. Mammary and estrus effects are likely consequences of reduced central', 'dopamine and subsequent increased prolactin, consistent with information in the Xenazine R', '(tetrabenazine) label. Oral administration of TEV-50717 in pregnant rats did not produce test', 'article-related embryofetal toxicities, even at doses that led to reduced body weight gain in dams.', 'Oral administration of metabolite M1 to pregnant rats from gestational days 6 to 17 produced no', 'test article-related maternal or fetal toxicities.', 'Genetic Toxicology: TEV-50717 and its a-HTBZ and ß-HTBZ metabolites were negative in in', 'vitro studies for mutagenicity (bacterial reverse mutation, or the Ames test) and for chromosomal', 'structural aberrations in human peripheral blood lymphocytes. Oral doses of TEV-50717 were', 'negative for inducing micronuclei in the bone marrow of treated mice.', 'Juvenile Toxicology: The effects of TEV-50717 on juvenile development was assessed in male', 'and female rats with oral dosing from weaning (postnatal day [PND] 21) to PND 71, similar to', 'human dosing from Year 2 through early adolescence and overlapping with TEV-50717 oral', 'dosing in a general adult toxicology study. The effects of M1 were assessed in male and female', 'juvenile rats from PND 25 to PND 70 with a recovery phase and postdosing reproductive', 'assessment.', 'TEV-50717 produced no test-article-related effects on learning and memory functions, on', 'histopathology assessments, on reproductive capacity (male and female fertility, estrus cyclicity),', 'or on intrauterine survival of embryos from matings during recovery from test article', 'administration. Adversely reduced body weight gain and adverse clinical observation of tremors', 'and in-cage hyperactivity were all noted in previous studies with adult rats; these effects have not', 'predicted adult clinical intolerance to TEV-50717. The highest dose level of M1 (50 mg/kg/day)', 'produced no test article-related toxicities (clinical observations, changes in body weight gain,', 'clinical pathology, histopathology, ophthalmology, and performance in learning and memory', 'tests).', '35']"
36,page_37,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The NOAEL (no-observed-adverse-effed level) for toxicities in juvenile rats is lower than that in', 'adults; however, the total (a+B)-HTBZ exposure multiples or safety margins comparing rat to', 'humans at the adult and juvenile age categories are similar. The potential for increased', 'sensitivity to the effects of TEV-50717 in pediatric patients is mitigated by 2 factors. First, the', 'effects of TEV-50717 on behavior and weight gain recovered with cessation of test article', 'administration in the juvenile rat toxicology study. Second, the clinical significance of tremors', 'and reduced body weight gain in rats dosed with TEV-50717 are unclear because these findings', 'were not adverse events of note in adults or adolescent patients. While hypoactivity in rats has', 'the potential to relate to clinical observations of somnolence, this adverse effect is controlled', 'with dose reduction. In clinical comparison, the adverse event profile of tetrabenazine in adult', 'patients is qualitatively similar to patients from approximately 22 months to 18 years of age (Jain', 'et al 2006, Kenney et al 2007, Porta et al 2008).', '1.3.2.', 'Clinical Studies', 'The clinical development plan for TEV-50717 to date includes:', '1 completed Phase 3 pivotal study for the treatment of chorea associated with HD', '1 completed Phase 3 long-term safety study in patients with HD', '2 completed Phase 2/3 and Phase 3 studies in patients with TD', 'Further details may be found in the IB.', '1.3.2.1.', 'Clinical Pharmacology Studies', 'Seven Phase 1 clinical pharmacology studies were conducted in healthy adult subjects. In', 'addition, sparse pharmacokinetic sampling was included in the Phase 3 studies with HD', 'patients where population pharmacokinetic analyses were performed to extensively evaluate', 'the pharmacokinetics and pharmacokinetics/pharmacodynamics relationship of TEV-50717. A', 'summary of the clinical pharmacology findings is provided in the IB.', 'Pharmacometric analyses of the active metabolites of TEV-50717 based on the Phase 1 clinical', 'pharmacology in healthy adult subjects were performed to support dose selection and', 'pharmacokinetic characterization in a pediatric population. Subsequently, a further', 'pharmacometric analysis of active metabolites following administration of TEV-50717 to', 'adolescent TS patients with tics (Study SD-809-C-17) was recently completed. The results of', 'these analyses are described in Section 1.3.2.3.', '36']"
37,page_38,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '1.3.2.2. Clinical Safety and Efficacy Studies', 'TEV-50717 has pharmacologic activity indistinguishable from tetrabenazine, a VMAT2 inhibitor', 'with established efficacy in treating the motor and phonic tics associated with TS.', '1.3.2.3.', 'Pharmacometrics Analysis of TEV-50717 Active Metabolites to Support Dose', 'Selection and Pharmacokinetic Characterization in a Pediatric Population', 'Population pharmacokinetic modeling of the TEV-50717 active metabolites -HTBZ and', 'ß-HTBZ has been performed throughout the clinical development program. Based on sequential', 'pharmacokinetic sampling data obtained in healthy subjects in the Phase 1 program, a structural', 'population pharmacokinetic model was developed to guide dose selection for HD patients with', 'chorea (SD-809-CLN-076) and subsequently optimized to better describe the', 'absorption/bioconversion profile of -HTBZ and ß-HTBZ (Study SD-809-CLN-077).', '37']"
38,page_39,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Employing the structural model defined in Study SD-809-CLN-077, sequential and sparse', 'pharmacokinetic sampling data obtained from Study SD-809-C-17 were combined with the', 'Phase 1 data employed in Study SD-809-CLN-077 to estimate the exposure total of (a+ß)-HTBZ', 'in adolescent patients (age 12 to 18 years) with TS and to simulate exposure in adolescent and', 'pediatric patients (age 6 to 11 years) with and without concomitant use of a strong CYP2D6', 'inhibitor across a range of doses (Appendix B). Population model parameters were re-estimated', 'for the combined Phase 1 and adolescent data obtained from patients in Study SD-809-C-17. The', 'model was used to simulate total (a+B)-HTBZ exposures across a range of body weights', 'corresponding to a pediatric and adolescent population according to the Centers for Disease', 'Control growth charts.', 'This analysis provides the basis for the dosing recommendations in Section 5.1.', '1.4.', 'Known and Potential Risks and Benefits to Human Patients', 'Additional information regarding benefits and risks to patients may be found in the current IB', 'and in the United States prescribing information for AUSTEDOT (deutetrabenazine).', '1.5.', 'Selection of Drugs and Dosages', 'A detailed description of IMP administration is presented in Section 5.1.', '1.5.1.', 'Justification for Dosage of Active Drug', 'The dose ranges to be evaluated in this study, based on body weight and CYP2D6 impairment', 'status at baseline, were selected on the basis of the safety, preliminary efficacy, and population', 'pharmacokinetic data generated from Study SD-809-C-17 (Table 2). In this study, TEV-50717', 'up to 18 mg twice daily (36 mg/day) was well tolerated and demonstrated clinically meaningful', 'benefit in adolescents with TS-associated tics. The dosages proposed in the present study aim to', 'match the exposure achieved in adults receiving up to 48 mg/day (24 mg twice daily), a level', 'previously demonstrated to be efficacious, safe, and well tolerated in patients with', 'HD-associated chorea.', 'IMP will be titrated on a weekly basis for 7 weeks, based on investigator, patient, and', 'parent/guardian assessments of tic reduction and adverse events. This dosing strategy is practical', 'in a clinical setting and affords sufficient time between dose steps for efficacy and safety to be', 'assessed. It is also consistent with the clinical application of tetrabenazine, another VMAT2', 'inhibitor with accepted efficacy in this population. A 5-week maintenance period is sufficient for', 'stable treatment to allow evaluation of safety and efficacy at the target dose.', '1.5.2.', 'Justification for Use of Placebo', 'As TS is not a progressive neurological disorder, and available treatments are for symptomatic', 'control, the use of placebo is justified in a short-term study where safety is carefully monitored.', '38']"
39,page_40,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Moreover, a placebo control is ideal for characterizing the efficacy and safety of an experimental', 'agent in a new study population.', '1.6.', 'Compliance Statement', 'This study will be conducted in full accordance with the International Council for Harmonisation', '(ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP) E6 and any applicable', 'national and local laws and regulations (eg, Title 21 Code of Federal Regulations [21CFR]', 'Parts 11, 50, 54, 56, 312, and 314, Directive 2001/20/EC of the European Parliament and of the', 'Council on the approximation of the laws, regulations, and administrative provisions of the', 'Member States relating to the implementation of GCP in the conduct of clinical studies on', 'medicinal products for human use). Any episode of noncompliance will be documented.', 'The investigator is responsible for performing the clinical study in accordance with this protocol', 'and the applicable GCP guidelines referenced above for collecting, recording, and reporting the', 'data accurately and properly. Agreement of the investigator to conduct and administer this', 'clinical study in accordance with the protocol will be documented in separate clinical study', 'agreements with the sponsor and other forms as required by national competent authorities in the', 'country where each investigational center is located.', 'The investigator is responsible for ensuring the privacy, health, and welfare of the patients during', 'and after the clinical study and must ensure that trained personnel are immediately available in', 'the event of a medical emergency. The investigator and the involved clinical study personnel', 'must be familiar with the background and requirements of the study and with the properties of', 'the IMP as described in the IB.', 'The principal investigator at each investigational center has the overall responsibility for the', 'conduct and administration of the clinical study at that investigational center and for contacts', 'with study management, with the Independent Ethics Committee/Institutional Review Board', '(IEC/IRB), and with competent authorities.', '1.7.', 'Study Population and Justification', 'The population to be studied includes children and adolescents, 6 through 16 years of age, with', ""TS. Per selection criteria, the participants' tics need to be troublesome and cause distress or"", 'impairment based on the assessment of the patient, parent/guardian, and investigator. Based on', 'these criteria, this is a study population in need of treatment.', '1.8.', 'Location and Study Duration', 'This study is planned to be conducted in North America, Russia, and Europe, at approximately', '50 centers. It is expected to start in January 2018 and have a duration of approximately', '15 months. Additional centers will be added, if needed. Expected duration of the study may also', 'be extended dependent on enrollment and other factors.', '39']"
40,page_41,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '2.', 'PURPOSE OF THE STUDY AND STUDY OBJECTIVES', '2.1.', 'Purpose of the Study', 'This is a Phase 2/3 study to evaluate the efficacy and safety of deutetrabenazine (TEV-50717)', 'tablets for the reduction of motor and phonic tics associated with TS in children and adolescents', '6 through 16 years of age.', '2.2.', 'Study Objectives', '2.2.1.', 'Primary Objective', 'The primary objective of this study is to evaluate the efficacy of TEV-50717 to reduce motor and', 'phonic tics associated with TS.', '2.2.2.', 'Secondary Objective', 'The secondary objective of the study is to evaluate the safety and tolerability of titration and', 'maintenance therapy with TEV-50717.', '2.3.', 'Study Enppoints', '2.3.1.', 'Primary Efficacy Endpoint', 'The primary efficacy endpoint is the change in the TTS of the YGTSS from baseline to week 12.', '2.3.2.', 'Key Secondary Efficacy Enppoints', 'The key secondary efficacy endpoints are as follows:', '1. Change in the TS-CGI score from baseline to week 12', '2. Change in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) score', 'from baseline to week 12', '3. Change in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life', '(C&A-GTS-QOL) activities of daily living (ADL) subscale score from baseline to', 'week 12', '2.3.3.', 'Exploratory Enppoints', 'Exploratory endpoints are as follows:', '40']"
41,page_42,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '2.3.4.', 'Safety Enppoints', 'The safety endpoints for this study are as follows:', 'incidence of adverse events', 'observed values and changes from baseline in vital signs', ""observed values and change from baseline in the Children's Depression Inventory,"", 'Second Edition (CDI-2), Parent and Self-report Profiles', ""observed values in the Children's Columbia-Suicide Severity Rating Scale (C-SSRS)"", 'observed values in electrocardiogram (ECG) parameters and shifts from screening for', 'clinically significant abnormal findings', 'observed values and changes from screening in clinical laboratory parameters', '(hematology, chemistry, and urinalysis)', '2.3.5.', 'Pharmacokinetic Endpoint', 'The pharmacokinetics of the a- and B-HTBZ metabolites of TEV-50717, and other metabolites', '(as needed), will be explored based on sparse sampling at week 12.', '41']"
42,page_43,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.', 'STUDY DESIGN', '3.1.', 'General Design and Study Schema', '3.1.1.', 'Overall Design and Screening Period', 'This is a Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study in which', 'patients with tics associated with TS will be invited to participate. Patients who qualify for the', 'study will be centrally randomized in a 1:1 ratio (stratified by age at baseline [6 to 11 years, 12 to', '16 years]) to receive either TEV-50717 or placebo. Throughout the study, patients will interact', 'regularly with investigative site personnel, in clinic and by telephone, for the evaluation of', 'safety, tic severity, and behavioral status (in clinic only). The target dose for each patient', 'receiving TEV-50717 will be based on body weight and CYP2D6 impairment status at baseline.', 'Patients will be classified as CYP2D6 impaired if they are receiving a strong CYP2D6 inhibitor', 'or are a CYP2D6 poor metabolizer based on blinded assessment of CYP2D6 genotype at', 'baseline. CYP2D6 status will be used by Interactive Response Technology (IRT) for', 'randomization into the study. The dose of IMP for each patient will be titrated to an optimal level', 'followed by maintenance therapy at that dose. Investigators will be blinded to CYP status, with a', 'dose cap for poor metabolizers prespecified by the IRT (Table 2 2). The overall treatment period', 'will be 12 weeks in duration, including a titration period of 7 weeks, a maintenance period of 5', 'weeks, followed by a washout period of 1 week.', 'For the YGTSS, input from the caregiver/adult is', 'required. For both the TS-PGII and', 'input from the caregiver/adult is permitted. For all', 'other scales, for children 13 years of age and under, interviews may be performed separately or', 'jointly with the caregiver/adult as appropriate or defined by the scale; for children over 13 years', 'of age, caregiver/adult involvement is strongly encouraged. Questions should be directed to the', 'child, but the caregiver/adult should be encouraged to add relevant information. It should be', 'noted that the CDI-2 has individual parent and child questionnaires.', 'Patients who complete the study may be eligible to begin participation in an open-label safety', 'extension study (TV50717-CNS-30047) after the end of the washout period. At the week 13', 'visit, patients may choose to enter Study TV50717-CNS-30047 (on that day), or they will have', 'an additional week to make a decision and return for day 1. Patients not participating in', 'Study TV50717-CNS-30047 will have a follow-up telephone contact to evaluate safety 1 week', 'after the end of the washout period (2 weeks after their last dose of IMP).', '3.1.2.', 'Screening Period', 'The screening period in this study is up to 31 days. After informed consent/assent, depending on', ""the child's age, as appropriate, is obtained, patients who are stable from a medical and"", 'psychiatric standpoint will undergo a screening evaluation, including medical history, physical', 'and neurological examination, laboratory testing, and 12-lead ECG, along with rating scales to', 'assess severity, frequency, and impairment of tics and comorbid TS symptoms and behavioral', 'status.', '42']"
43,page_44,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'At the discretion of the investigator, the screening visit may be divided into 2 visits if the visit', 'length is felt to be too burdensome for the patient. If the screening visit is divided into 2 visits,', 'the blood sample should be obtained during the first of the 2 visits. Patients who have received', 'comprehensive behavioral intervention for tics (CBIT) for TS or cognitive behavioral therapy', '(CBT) for obsessive-compulsive disorder (OCD) may participate in this study as long as therapy', 'was completed at least 4 weeks prior to screening. Patients will return to the clinic on day 1 to', 'perform baseline procedures and to reconfirm eligibility. Patients may be rescreened 1 time if', 'there is a change in the status of the patient regarding eligibility for the study. (Note: Details of', 'rescreening must be approved and documented by the medical monitor and/or Clinical', 'Surveillance and Training [CST] team.)', '3.1.3.', 'Titration Period', 'During the titration period (7 weeks), patients who remain eligible for participation in the study', 'will be randomized in a 1:1 ratio stratified by age (6 to 11 years, 12 to 16 years) at the baseline', 'visit (day 1), and that evening (ie, after the study visit) will receive 6 mg of blinded IMP with', 'food. Tablets should be taken with food (eg, a snack) and should not be taken on an empty', 'stomach. The titration scheme and maximum dose will be determined by body weight and', 'CYP2D6 impairment status at baseline, as shown in Table 2. Patients and their caregiver/adult', 'will interact weekly with the clinical research staff, either by telephone contact or clinic visit', 'from week 1 through week 7 of the titration period, in order to evaluate safety and establish a', 'dose of IMP that optimally reduces tics and is well tolerated (optimal dose). Safety evaluations', 'during titration include assessment of vital signs, monitoring for adverse events and concomitant', 'medications, 12-lead ECGs, and rating scales for depression and suicidality.', 'In-person (in-clinic) study visits will be scheduled at weeks 2, 4, and 6, and telephone contacts', 'will be scheduled for weeks 1, 3, 5, and 7 in order to assess tic severity and adverse events. The', 'dose of the IMP should be increased on a weekly basis until one of the following criteria is met:', 'The investigator determines that there has been a clinically meaningful reduction in', 'tics, as indicated by a sustained reduction in the TS-CGI', 'The patient experiences a protocol-defined ""clinically significant"" adverse event', '(defined as an adverse event that is related to study medication and is either moderate', 'or severe in intensity or meets the criteria for a serious adverse event).', ""The maximum allowable dose is reached, based on the patient's weight and CYP2D6"", 'impairment status at baseline.', 'Although dose adjustments can be made up to and including the week 7 telephone call, if a stable', 'dose is reached before then, the patient should continue on that dose (ie, the dose should not be', 'increased further) for the remainder of the titration period and throughout maintenance dosing,', 'unless there is a change in symptoms during the titration period. If a patient experiences a', '""clinically significant"" adverse event attributable to the IMP, the investigator will determine if a', 'dose reduction or suspension is necessary. If the determination that a patient requires a dose', 'reduction or suspension is made during a telephone contact, an unscheduled clinic visit should be', 'conducted as soon as practicable thereafter.', 'Dose adjustments should be made based on all available information, including the patient and', 'caregiver/adult reports of adverse events and tic reduction, the clinical assessment of safety and', '43']"
44,page_45,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'efficacy by the investigator, and information from rating scales. At the end of the titration period,', ""the patient's dose will be established for the maintenance period."", '3.1.4.', 'Maintenance Period', 'During the maintenance period (5 weeks), patients will continue to receive their maintenance', 'dose, although dose reductions for adverse events are allowed. Patients will return to the clinic at', 'weeks 9 and 12 for assessments of safety and efficacy. At week 12, patients will undergo a', 'complete evaluation, including physical and neurological examination, safety laboratory testing,', '12-lead ECG, CDI-2, and C-SSRS assessments, as well as the YGTSS, TS-CGI, TS-PGII,', ',', 'and C&A-GTS-QOL.', 'In addition, patients will undergo pharmacokinetic sampling at week 12.', '3.1.5.', 'Washout Period and Follow-up', 'All patients will discontinue IMP at the week 12 visit and will return 1 week later for evaluation', 'of safety and tic reduction (week 13). Patients who complete the study may be eligible to begin', 'participation in the open-label safety extension study TV50717-CNS-30047. For this study, the', 'follow-up period is defined as 1 week of washout for patients who will participate in the', 'open-label safety extension study TV50717-CNS-30047 and 2 weeks after the last dose of IMP', '(1 week after the end of the washout period) for patients who will not roll over into the', 'open-label safety extension study TV50717-CNS-30047. At the week 13 visit, patients may', 'choose to enter Study TV50717-CNS-30047 (on that day), or they will have an additional week', 'to make a decision and return for day 1. Patients not participating in Study TV50717-CNS-30047', 'will have a follow-up telephone contact to evaluate safety 1 week after the end of the washout', 'period (2 weeks after their last dose of IMP).', 'Prohibited drugs will remain the same during the washout period for patients who will participate', 'in the open-label extension study TV50717-CNS-30047.', 'Patients who will not participate in the extension study (Study TV50717-CNS-30047) may', 'begin/resume tic therapy medication after the first week of the washout period.', 'See Table 1 for study procedures and assessments.', 'See Figure 1 for study schema.', '44']"
45,page_46,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Figure 1:', 'Overall Study Schema', 'Maintenance', 'Wash', 'Follow', 'Screening', 'Titration Period', 'Therapy', 'out', 'Up', 'Week 12/', 'End-Of-', 'Baseline', 'ET', 'Study Visit', 'Up to', '1', '31 days', 'week', 'Day', 'Day', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', 'Week', '1', '3', '1', '2', '3', '4', '5', '6', '7', '9', '12', '13', '14c', '1:1 Randomization', 'TEV-50717 (58)', 'Placebo (58)', 'N=116', '> 40 kg', 'Option of', '6', '12', '18', '24', '30', '36', '42', '48', 'Stable maintenance', 'participation in', 'mg', 'mgb', 'mgb', 'mgb', 'mgb.', 'mg""', 'mg""b', 'mg³', 'dose', 'long term', 'safety study', '30 40kg', '6', '12', '18', '24', '30', '36', '42', 'Stable maintenance', 'mg', 'mgb', 'mgb', 'mg""b', 'mgb', 'mg', 'mga', 'dose', '=In-clinic', '20 < 30 kg', 'visit', '6', '12', '18', '24', '30', 'Stable maintenance', '= Telephone', 'mg', 'mgb', 'mg', 'mg""b', 'mga', 'Call', 'dose', 'a Maximum total daily dose for patients >40 kg is 48 mg/day (24 mg bid), 30 to <40 kg is 42 mg/day (21 mg bid),', 'and 20 to <30 kg is 30 mg/day (15 mg bid). For those considered CYP2D6 impaired, maximum daily dose for', 'patients >40 kg is 36 mg/day, 30 to <40 kg is 24 mg/day, and 20 to <30 kg is 18 mg/day (Table 2).', 'b', 'If a stable dose is reached before the indicated time, the patient should continue taking that dose for the remainder', 'of the titration period and throughout the maintenance therapy dosing.', 'c', 'This is a telephone contact for safety evaluation, required only for patients who will not roll over into the', 'open-label safety extension study TV50717-CNS-30047.', 'bid=twice a day; CYP=cytochrome P450; ET=early termination visit.', '3.2.', 'Justification for Study Design', 'At the present time, effective treatment options for TS are suboptimal and limited. As a chronic', 'condition impairing major life activities during childhood, such as occupational, social, and', 'educational activities, TS presents an area of significant unmet medical need in the pediatric', 'population.', 'Preliminary efficacy and safety data for TEV-50717 as a treatment for TS have been generated in', 'an open-label, Phase 1b pilot study (Study SD-809-C-17). Results of Study SD-809-C-17', 'supported further development of TEV-50717 as a treatment of TS.', 'Consequently, the standard placebo-controlled, double-blind study design (TEV-50717 versus', 'placebo in a 1:1 ratio) was chosen for the next study (ie, this Phase 2/3 study) to determine', 'whether IMP treatment results in a statistically significant effect on tics in patients with TS.', 'The justification for the choice of the comparator (placebo) is provided in Section 1.5.2, the', 'choice of dosage is discussed in Section 1.5.1, while the justifications for the choice of the', 'population and the inclusion and exclusion criteria for the study are provided in Section 1.7 and', 'Section 4.3, respectively.', '45']"
46,page_47,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.3.', 'Primary and Secondary Efficacy Measures and Time Points', 'A description of the efficacy measures is provided in Section 6.', '3.3.1.', 'Primary Efficacy Measure and Time Points', 'YGTSS (to calculate TTS): Screening; baseline; and weeks 2, 4, 6, 9, 12, and 13.', '3.3.2.', 'Key Secondary Efficacy Measures and Time Points', '1.', 'TS-CGI: baseline and weeks 2, 4, 6, 9, 12, and 13', '2.', 'TS-PGII: baseline and weeks 2, 4, 6, 9, 12, and 13', '3.', 'C&A-GTS-QOL ADL subscale: baseline, week 6, and week 12', '3.3.3.', 'Exploratory Measures and Time Points', '3.4.', 'Safety Measures and Time Points', 'adverse events and concomitant medications: from the signing of the informed', ""consent/assent, depending on the child's age, as appropriate, through follow-up,"", 'inclusive of all visits and telephone contacts', 'physical examination: screening and week 12', 'neurological examination: screening and week 12', 'vital signs: screening; baseline; and weeks 2, 4, 6, 9, 12, and 13', 'Note: orthostatic blood pressure (BP) and pulse at baseline and weeks 4 and 12', 'MINI Kid: screening', '46']"
47,page_48,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""Children's C-SSRS"", '- Baseline/screening scale: screening', '-', 'Since Last Visit [SLV] scale: baseline and weeks 2, 4, 6, 9, 12, and 13', 'CDI-2 (Parent and Self-Report versions): screening; baseline; and weeks 2, 4, 6, 9,', '12, and 13', '12-lead ECG: screening; baseline; and weeks 4, 6, and 12', 'clinical laboratory tests (serum chemistry, hematology, and urinalysis): screening and', 'week 12', 'pregnancy testing: screening, baseline, and weeks 4 and', '12', 'drug screen: screening and week 12', 'A description of the safety measures is provided in Section 7.', '3.5.', 'Pharmacokinetic Measures and Time Points', 'Blood samples will be obtained for the measurement of plasma concentrations of TEV-50717', '(deutetrabenazine), -HTBZ, ß-HTBZ, and other metabolites, as needed. Blood sampling for', 'pharmacokinetic analysis will be performed at the week 12 visit. Two samples will be collected.', 'The first sample will be collected upon arrival at the clinic. The second sample will be collected', '2 to 3 hours after the first pharmacokinetic sample collection. The time between samples should', 'be maximized in order to provide the most useful information.', 'A description of the pharmacokinetic measures is provided in Section 8.', '3.6.', 'Randomization and Blinding', 'This is a randomized, double-blind, placebo-controlled study. Patients will be randomly assigned', 'to receive treatment with TEV-50717 or matching placebo in a 1:1 ratio stratified by age at', 'baseline (6 to 11 years, 12 to 16 years). Patients and investigators will remain blinded to', 'treatment assignment during the study.', 'Patients will be centrally randomly assigned to the treatment groups by means of a', 'computer-generated randomization list after confirmation of all eligibility criteria. The creation', 'of the randomization list will be under the responsibility and oversight of Syneos Health.', ""In addition, the sponsor's clinical personnel and all vendors (with exception of the IRT vendor"", 'and the bioanalytical sample analysis vendor) involved in the study will be blinded to the IMP', 'identity until the database is locked for analysis and the treatment assignment revealed. After', 'unblinding of this study, the study site may remain blinded to patient treatment assignments until', 'completion of the safety extension study TV50717-CNS-30047.', 'The randomization list and treatment will be assigned to the relevant treatment groups through a', 'qualified service provider (ie, via IRT). The generation of the medication list and management of', 'the IRT system will be done by a qualified service provider under the oversight of Nuvelution TS', 'Pharma.', '47']"
48,page_49,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The staff member at the investigational center who will dispense the IMP will not know the', 'treatment given to each patient.', '3.7.', 'Maintenance of Randomization and Blinding', '3.7.1.', 'Randomization', 'Patient randomization codes will be maintained in a secure location within Syneos Health,', 'Biometrics. At the time of analysis, when treatment codes are needed, the Syneos Health', 'statistician assigned to the study will make a request to unblind and will receive the unblinded', 'codes.', '3.7.2.', 'Blinding/Unblinding', 'Pharmacokinetic data may be assessed during the study. For patients who have pharmacokinetic', 'sample bioanalysis and/or data analysis conducted, the individuals responsible for sample', 'bioanalysis and other responsible personnel will know who received IMP and who received', 'placebo during the study (of those patients only). Personnel responsible for bioanalysis will be', 'provided with the randomization code in order to facilitate the analysis. However, the personnel', 'responsible for bioanalysis and pharmacokinetic data analysis will not have access to clinical', 'safety and efficacy data, will not have any interaction with study personnel, and will provide', 'concentration data to other personnel in a manner that will not identify individual patients (ie, a', ""dummy patient identifier will be linked to an individual patient's concentration data)."", 'For information about personnel who may be aware of treatment assignments, see Section 3.6.', 'These individuals will not be involved in conduct of any study procedures or assessment of any', 'adverse events.', 'In case of a serious adverse event or pregnancy, or in cases when knowledge of the IMP', ""assignment is needed to make treatment decisions, the investigator may unblind the patient's"", 'IMP assignment as deemed necessary, mainly in emergency situations. Individual treatment', 'codes, indicating the treatment randomization for each randomized patient, will be available to', 'the investigator(s) and/or pharmacist(s) at the study center via the IRT system. If possible, the', 'sponsor should be notified of the event prior to breaking of the code. If this is not possible, the', ""sponsor should be notified immediately afterwards, and the patient's drug code assignment"", 'should not be revealed. Breaking of the treatment code can always be performed by the site', 'without prior approval by the sponsor.', 'When a blind is broken, the patient will be withdrawn from the study, and the event will be', 'recorded onto the case report form (CRF). However, if a patient is unblinded by mistake, the', 'investigator should discuss with the medical monitor whether or not the patient should be', 'withdrawn. The circumstances leading to the breaking of the code should be fully documented in', ""the investigator's study files and in the patient's source documentation. Treatment assignment"", 'should not be recorded in any study documents or source document.', 'In blinded studies, for adverse events that are defined as: suspected unexpected serious adverse', 'reactions (SUSARs) (ie, reasonable possibility; see Section 7.1.4), Global Patient Safety and', 'Pharmacovigilance (GPSP) may independently request that the treatment code be revealed (on a', 'case-by-case basis) to comply with regulatory requirements. The report will be provided in an', '48']"
49,page_50,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'unblinded manner for regulatory submission. If this occurs, blinding will be maintained for the', 'investigator and for other personnel involved in the conduct, analysis, and reporting of the data.', '3.7.3.', 'Independent Data Monitoring Committee', 'During the conduct of this study, an IDMC will review accumulating safety data on a regular', 'basis to ensure the continuing safety of the study patients and review of any study conduct', 'issues.', 'The IDMC will be composed of independent physicians with expertise in the relevant therapeutic', 'field and other relevant experts, such as a statistician. The IDMC will receive safety data', 'periodically which will be presented by masked treatment groups. They will have the right to', 'recommend modification of the study for safety reasons.', 'IDMC sessions can be open or closed. During open sessions, representatives of the sponsor may', 'be present, and information is provided and discussed in a blinded fashion. During closed', 'sessions, the only participants are members of the IDMC and the designated unblinded', 'statistician (if approved to be present).', 'If there is a request to unblind any individual treatment assignment, a written request from the', 'IDMC (as a committee), signed by the IDMC chairperson, should be made to the unblinded', 'statistician. The appropriate medical and operational personnel will be notified but will not', 'receive the unblinded treatment information. Any use of unblinded treatment assignments should', 'be clearly documented and reported to the sponsor at study termination.', 'The IDMC chairperson will communicate with Nuvelution TS Pharma in regard to issues', 'resulting from the conduct and clinical aspects of the study. Nuvelution TS Pharma and Syneos', 'Health will work closely with the committee to provide the necessary data for review.', 'The conduct and specific details regarding the IDMC sessions and requests to unblind any', 'blinded treatment assignment are outlined in the IDMC charter.', '3.8.', 'Drugs Used in the Study', '3.8.1.', 'IMP', 'The IMP is a matrix formulation and is designed as a gastro-erosional tablet to be administered', 'with food and should not be taken on an empty stomach. The IMP is coated with a white', 'polymer coating to aid in swallowing. TEV-50717 tablets have been manufactured according to', 'current Good Manufacturing Practice regulations. TEV-50717 tablets are available in the', 'following strengths: 6, 9, 12, 15, and 18 mg, all of which are identical in size, shape, and color', '(white). The IMP will be supplied in 40-count blister packs. The placebo tablets and packaging', 'will match those for TEV-50717. Each blister pack (40-count tablets per dose strength per blister', 'pack) will contain a sufficient supply of drug until the next specified visit/telephone contact, plus', 'overage to account for potential delays in study visits.', 'A more detailed description of administration procedures is given in Section 5.1.', '49']"
50,page_51,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.8.2.', 'Placebo', 'Placebo tablets match TEV-50717 tablets. The packaging will be the same as described for', 'TEV-50717 above.', 'A more detailed description of administration procedures is given in Section 5.1.', '3.9.', 'Drug Supply and Accountability', '3.9.1.', 'Drug Storage and Security', 'The IMP (TEV-50717 and placebo) should be stored protected from light, at a controlled room', 'temperature, 20°C to 25°C (68°F to 77°F); however, storage between 15°C and 20°C (59°F and', '68°F) is acceptable if there is no alternative. The IMP should be stored in a dry, securely locked,', 'substantially constructed cabinet or enclosure with access limited to authorized staff.', '3.9.2.', 'Drug Accountability', 'Each IMP shipment to the site will include a packing slip listing the contents of the shipment,', 'drug return instructions, and any applicable forms.', 'The investigator is responsible for ensuring that deliveries of IMP and other study materials from', 'the sponsor are correctly received, recorded, handled and stored safely and properly in', 'accordance with the local regulations, and used in accordance with this protocol.', 'A record of IMP accountability (ie, IMP and other materials received, used, retained, returned, or', 'destroyed) must be prepared and signed by the principal investigator or designee, with an', 'account given for any discrepancies. Empty, partially used, and unused IMP will be disposed of,', 'as agreed with the sponsor/development partner.', '3.10.', 'Duration of Patient Participation and Justification', 'This study will consist of up to a 31-day screening period, a 12-week double-blind treatment', 'period, and a 1-week washout period. Patients who complete the study may be eligible to begin', 'participation in an open-label safety extension study TV50717-CNS-30047 after the end of the', 'washout period. Patients not participating in Study TV50717-CNS-30047 will have a follow-up', 'telephone contact to evaluate safety 1 week after the end of the washout period (2 weeks after', 'their last dose of IMP).', 'Patients are expected to participate in this study for its entire duration, which is a minimum of', '14 weeks. See Section 12.4 for the definition of the end of the study.', '3.11.', 'Stopping Rules and Discontinuation Criteria', 'There are no formal rules for early termination of this study. During the conduct of the study,', 'serious adverse events will be reviewed (see Section 7.1.5) as they are reported from the', 'investigational center to identify safety concerns. The study may be terminated by the sponsor at', 'any time.', 'A patient may discontinue participation in the study at any time for any reason (eg, lack of', 'efficacy, consent withdrawn, and adverse event). The investigator and/or sponsor can withdraw a', '50']"
51,page_52,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'patient from the study at any time for any reason (eg, protocol violation or deviation as defined', 'in Section 11.1.2, noncompliance, or adverse event).', 'Please see Section 4.4 for the withdrawal criteria and procedures.', '3.12.', 'Source Data Recorded on the Case Report Form', 'All patient data must have supportive original source documentation in the medical records, or', 'equivalent, before they are transcribed onto the CRF. Data may not be recorded directly onto the', 'CRF and considered as source data unless the sponsor provides written instructions specifying', 'which data are permitted to be recorded directly onto the CRF, such as eScales.', 'If patient data are processed from other vendors (eg, clinical laboratory, central ECG, diary data),', 'the results will be sent to the investigational center, where they will be retained but not entered', 'into the CRF. These data may also be sent electronically to the sponsor (or organization', 'performing data management) for direct use with the clinical database (see Section 13.1). All', 'clinical patient data from other vendors will be available to the investigator.', ""The CRFs are filed in the sponsor's central file after study completion."", '3.13.', 'Study Procedures', 'Study procedures and assessments with their time points are presented in Table 1. During a visit,', 'study procedures and assessments should be performed in the order specified in the study', 'manual.', 'Detailed by-visit information is provided in the sections following the table. Detailed', 'descriptions of each assessment are provided in Section 6 (efficacy assessments), Section 7', '(safety assessments), and Section 8 (pharmacokinetic and other assessments).', '51']"
52,page_53,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 1:', 'Study Procedures and Assessments', 'Screening', 'BLa', 'Titration', 'Maintenance', 'Follow-up', 'U', 'Study weekb', 'Up to', 'Day', '1', '2', '3', '4', '5', '6', '7', '9', '12/ET°', '13', '14e', '31 days', '1c', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '7)', '14)', '21)', '28)', '35)', '42)', '49)', '63)', '84)', '91', '98)', 'Visit window (days)', '0', '3 days', '3 days from', 'days', 'Week 12', 'In-clinic visit', 'Xf', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Telephone contact', 'X', 'X', 'X', 'X', 'X', 'Evaluate/Adjust IMP', 'Xg', 'X', 'Xg', 'X', 'Xg', 'X', 'X', 'Informed consent/assent', 'X', 'Eligibility criteria', 'X', 'X', 'Medical history and psychiatric', 'X', 'history', 'Demographics', 'X', 'Vital signs and weighth', 'X', 'Xi', 'X', 'Xi', 'X', 'X', 'Xi', 'X', 'Physical examination', 'X', 'X', 'Neurological examination', 'X', 'X', 'Height', 'X', 'X', '12-lead ECGK', 'X', 'X', 'X', 'X', 'X', 'Pharmacokinetic blood sampling', 'X¹', 'Chemistry/Hematology/Urinalysis', 'X', 'X', 'Xm', 'Urine drug screen', 'X', 'X', 'Randomization', 'X', 'CYP2D6 genotype""', 'X', 'ß-HCG test°', 'X', 'X', 'Xj', '52']"
53,page_54,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 1:', 'Study Procedures and Assessments (Continued)', 'Screening', 'BLa', 'Titration', 'Maintenance', 'Follow-up', 'U', 'Study weekb', 'Up to', 'Day', '1', '2', '3', '4', '5', '6', '7', '9', '12/ET°', '13', '14e', '31 days', '1c', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '(Day', '7)', '14)', '21)', '28)', '35)', '42)', '49)', '63)', '84)', '91', '98)', 'Visit window (days)', '0', '3 days', '3 days from', 'days', 'Week 12', 'MINI Kidp,g', 'X', 'CDI-2 (Parent and Self-report)', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X¹', ""C-SSRS (Children's"", 'X', 'Baseline/Screen)', ""C-SSRS (Children's Since Last"", 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Xj', 'Visit)', 'YGTSS,', 'X', 'X', 'Xu', 'X', 'Xu', 'Xu', 'X', 'Xu', 'TS-CGIt', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'TS-PGIIt', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 't', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'XV', 'X', 'XY', 'C&A-GTS-QOL', 'X', 'X', 'X', 'Dispense IMPW', 'XX', 'XX', 'XX', 'Xy', 'Xy', 'Collect IMP', 'X', 'X', 'X', 'X', 'Xi', 'Assess IMP', 'X²', 'X', 'X2', 'X', 'X²', 'X', 'X²', 'X', 'X', 'X¹', 'accountability/compliance/suppli', 'Assess adverse events', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications', 'X', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'Xaa', 'a', 'The baseline visit will occur on the same day as the scheduled first dose of the IMP (day 1).', '53']"
54,page_55,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'b', 'Assessment to occur at the end of the study week.', 'c', 'Patients will be provided with a diary to record critical information on dosing. The date and time of the last dose of study medication before the week 12 visit', 'should be recorded in the diary by the patient or caregiver/adult. The site will document the date and time of the sample collection. Prior to the clinic visit on', 'week 12, patients will be reminded to record the start time of their last meal and the time of their last dose in their diary.', 'd For patients who withdraw prematurely, an early termination visit should be conducted as soon as possible after the last dose of IMP. All patients who', 'discontinue early will have a follow-up telephone contact for safety evaluation 2 weeks after their last dose of IMP; evaluations will be as described for', 'week 14 (Section 3.13.4.2).', 'e This visit is a telephone contact for safety evaluation, required only for patients who will not roll over into the open-label safety extension study TV50717-', 'CNS-30047.', 'f The screening visit may be conducted over 2 separate visits at the discretion of the investigator.', 'g Dose adjustment will be made by the investigator after telephone contact with the patient and caregiver/adult to evaluate tic reduction and adverse events.', 'h', 'Weight must be measured with shoes and outerwear off. Before pulse and BP are measured, the patient must be in a supine or semi-erect/seated position and', 'resting for at least 5 minutes (the same position and arm should be used each time vital signs are measured for a given patient).', 'i Orthostatic BP and pulse will be measured after patient is in a standing position for at least 3 minutes.', ""j Assessment to be completed at investigator's discretion."", 'k All ECGs will be performed after at least 5 minutes rest in a supine or semi-supine position.', '1 Two samples will be collected. The first sample will be collected upon arrival at the clinic. The second sample will be collected 2 to 3 hours after the first', 'pharmacokinetic sample collection. Patients with early morning visits (ie, within 2 hours of their scheduled AM dosing) should take their IMP dose in clinic', 'after the first pharmacokinetic sample is collected.', 'm Patients with clinically significant laboratory abnormalities at week 12 will have those laboratory evaluations repeated at the week 13 visit.', ""n The patient's genotype for CYP2D6 will be blinded during the conduct of the study."", 'o For females who are postmenarchal or >12 years of age, a urine test will be administered at baseline and week 4, while a serum test will be administered at', 'screening and week 12, and if clinically indicated.', 'p MINI Kid, (Children and Adolescents) modules to be used are: Major Depressive Episode (Module A), (Hypo) Manic Episode (Module D), OCD (Module J),', 'Alcohol Dependence/Abuse (Module L), Substance Dependence/Abuse (Non-alcohol; Module M), ADHD (Module O), Conduct Disorder (Module P), and', 'Psychotic Disorders and Mood Disorders with Psychotic Features (Module R).', 'q For children 13 years of age and under, interviews may be performed separately or jointly with the caregiver/adult as appropriate or defined by the scale. For', 'children over 13 years of age, caregiver/adult involvement is strongly encouraged. Questions should be directed to the child, but the caregiver/adult should be', 'encouraged to add relevant information.', 'r Children 6 years of age at baseline will not complete the Self-report version; the caregiver/adult will complete the Parent version.', 'S', 'Input from the caregiver/adult is required.', 't', 'The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be performed before any blood draws or ECG assessments.', 'u Perform assessment of ""Severity Ratings"" of the questionnaire. Inventory portions, ie, ""Motor Tic Symptom Checklist"" and ""Phonic Tic Symptom Checklist""', 'do not need to be performed.', 'V Perform the Severity Ratings of OCD symptoms (Questions 1 through 10) only. Checklist does not need to be performed.', 'W Contact IRT and dispense IMP and patient diary.', 'x IMP will be dispensed in the clinic; patients will receive doses for 2 weeks (current dose level and next dose level) to cover the telephone contacts. The site will', 'determine titration (ie, starting the next dose) for the patient by telephone. See Table 2 for baseline weight-based dosing titration.', '54']"
55,page_56,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'y Patients will receive doses for 3 weeks of treatment.', 'Z', 'The site needs to discuss the drug status during the telephone contacts to ensure the patient has adequate tablets, inform the patient if they should titrate, and', 'remind them to bring used and unused IMP blister packs to the next in-clinic visit.', 'will be instructed during the course of the study to notify the investigator if any new medication is prescribed, including over-the-counter', 'medications. Any prescribed medication should be reviewed with the investigator.', ""ADHD=Attention Deficit Hyperactivity Disorder; B-HCG=beta-human chorionic gonadotropin; BL=baseline visit; BP=blood pressure; CDI-2=Children's"", 'Depression Inventory, Second Edition, Parent and Self-report Profiles; C-SSRS=Columbia-Suicide Severity Rating Scale;', 'CYP2D6=cytochrome P450 2D6; ECG=electrocardiogram; ET=early termination visit; C&A-GTS-QOL=Child and Adolescent', 'Gilles', 'de', 'la', 'Tourette', 'Syndrome - Quality of Life; IMP=investigational medicinal product; IRT= Interactive Response Technology; MINI Kid=Mini International', 'Neuropsychiatric Interview For Children and Adolescents; OCD=obsessive-compulsive disorder; TS-CGI=Tourette Syndrome-Clinical Global', 'Impression;', 'TS-', 'PGII=Tourette Syndrome-Patient Global Impression of Impact;', 'U=unscheduled visit;', 'YGTSS=Yale Global Tic Severity Scale.', '55']"
56,page_57,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.13.1.', 'Procedures for Screening and Enrollment', 'A signed and dated informed consent form will be obtained from the parent/legally acceptable', ""representative, and a signed and dated assent, depending on the child's age, as appropriate, will"", 'be obtained from each patient before screening procedures commence, according to national', 'laws and local IEC/IRB requirements. Parents/legally acceptable representatives will', 'acknowledge and agree to the possible use of this information for the study by giving informed', 'consent.', 'A patient who is screened but not enrolled may be rescreened 1 time if there is a change in the', 'status of the patient regarding eligibility for the study. (Note: Details of rescreening must be', 'approved and documented by the medical monitor and/or CST team.)', 'The screening visit will take place not more than 31 days before the baseline visit. The screening', 'visit may be conducted over 2 separate visits at the discretion of the investigator. The following', 'procedures will be performed at screening:', ""obtain written informed consent/assent, depending on the child's age, as appropriate,"", 'before any other study-related procedures are performed', 'conduct clinic visit', 'review eligibility (inclusion and exclusion) criteria', 'inform patients of study restrictions and compliance requirements', 'review medical and psychiatric history', 'review demographics information', 'measure vital signs (pulse, BP, body temperature, and respiratory rate)', 'perform full physical and neurological examinations (including height and weight.', 'Note: Weight must be measured with shoes and outerwear off)', 'perform 12-lead ECG (Note: ECG will be performed after at least 5 minutes rest in a', 'supine or semi-supine position)', 'perform clinical laboratory tests, including chemical, hematological, and urine', 'analyses', 'obtain a blood sample (3 mL) for analysis of CYP2D6 genotype', 'perform urine drug screen (UDS)', 'perform a serum pregnancy (beta-human chorionic gonadotropin [ß-HCG]) test (only', 'in females who are postmenarchal or >12 years of age)', 'administer the following questionnaires (Note: For MINI Kid and C-SSRS, children', '13 years of age and under may be interviewed separately or jointly with the', 'caregiver/adult as appropriate or defined by the scale. For children over 13 years of', 'age, caregiver/adult involvement is strongly encouraged. Questions should be', 'directed to the child, but the caregiver/adult should be encouraged to add relevant', '56']"
57,page_58,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'information. The YGTSS questionnaire should be performed before any blood draws', 'or ECG assessments.):', '- MINI Kid (Note: The following modules will be used: Major Depressive', 'Episode [Module A], [Hypo] Manic Episode [Module D], OCD [Module J],', 'Alcohol Dependence/Abuse [Module L], Substance Dependence/Abuse [Non-', 'alcohol; Module M], Attention Deficit Hyperactivity Disorder [ADHD;', 'Module O], Conduct Disorder [Module P], and Psychotic Disorders and Mood', 'Disorders with Psychotic Features [Module R])', '-', 'CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', ""- C-SSRS (children's baseline/screening)"", '- YGTSS (Input from the caregiver/adult is required.)', 'review medication history and concomitant medications', 'inquire about adverse events', '3.13.1.1. YGTSS Rater Certification', 'All investigators and subinvestigators who will be administering the YGTSS from screening', 'through the end of study visit must undergo and pass a Rater Certification Program which will be', 'provided separately from this protocol. Every effort must be made to ensure that the same', 'certified rater administers the YGTSS to a specific patient at all visits, especially at the baseline', 'and week 12/early termination visits. However, if due to unforeseen circumstances the same rater', 'is absolutely unavailable to complete a visit rating, the YGTSS can be administered only by', 'another certified individual from that study site.', '3.13.2.', 'Procedures Before IMP Treatment (Baseline/Day 1)', 'Patients who meet the inclusion/exclusion criteria at screening will continue to the baseline visit,', 'when baseline evaluations will be conducted.', 'The following procedures will be performed at baseline:', 'conduct clinic visit', 'review eligibility (inclusion and exclusion) criteria', 'measure vital signs (orthostatic pulse and BP [after standing for at least 3 minutes],', 'body temperature, and respiratory rate)', 'measure weight (Note: Weight must be measured with shoes and outerwear off)', 'perform 12-lead ECG (Note: ECG will be performed after at least 5 minutes rest in a', 'supine or semi-supine position)', 'perform urine pregnancy (B-HCG) test (only in females who are postmenarchal or', '>12 years of age)', 'randomization with stratification by age at baseline (6 to 11 years, 12 to 16 years)', '57']"
58,page_59,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'administer the following questionnaires (Note: For C-SSRS,', 'and C&A-GTS-QOL, children 13 years of age and under may be', 'interviewed separately or jointly with the caregiver/adult as appropriate or defined by', 'the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should', 'be encouraged to add relevant information. The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be performed before any blood draws or ECG', 'assessments.):', '- CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', ""- C-SSRS (children's SLV)"", '- YGTSS (Input from the caregiver/adult is required.)', '- TS-CGI', '- TS-PGII (Input from the caregiver/adult is permitted.)', '-', '-', '-', '- C&A-GTS-QOL', 'dispense IMP (patients will receive doses for 2 weeks [current dose level and next', 'dose level to cover the telephone contacts) and patient diary', 'provide patients with a diary to record critical information on dosing', 'review concomitant medications', 'inquire about adverse events', 'A patient who is not enrolled in the study on the basis of results of baseline assessments (eg,', 'because inclusion and exclusion criteria were not met or enrollment did not occur within the', ""specified time) may be screened again 1 more time if there is a change in the patient's medical"", 'background, a modification of study entry criteria, or other relevant change. (Note: Details of', 'rescreening must be approved.)', 'Patients will be assigned a permanent unique number at screening (see Section 3.13.1). Patients', 'who continue to meet the inclusion/exclusion criteria at baseline will be randomized to a', 'treatment (active or placebo) using an IRT, and the appropriate IMP will be dispensed.', '58']"
59,page_60,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3.13.3.', 'Procedures During IMP Treatment', '3.13.3.1. Titration Period (Baseline/ Day 1 Through 7)', '3.13.3.1.1. Telephone Contacts (Weeks 1, 3, 5, and 7)', 'The following procedures/assessments will be performed via telephone contact at weeks 1, 3, 5,', 'and 7:', 'assess IMP accountability/compliance/supply status to ensure the patient has adequate', 'tablets, inform the patient if they should titrate, and remind them to bring used and', 'unused IMP blister packs to the next in-clinic visit', 'inquire about adverse events', 'review concomitant medications', 'If a patient experiences an adverse event that is reported during a telephone contact and is', 'probably related to the IMP, he or she will be brought to the clinic for evaluation (see', 'Section 3.13.5). Based on the telephone evaluation, the investigator will determine whether, with', 'the medication already provided, the patient should continue titration or reduce the dose. If', 'additional IMP is required, it would be ordered from the distributor and provided to the patient at', 'an unscheduled visit.', '3.13.3.1.2. Clinic Visits (Weeks 2, 4, and 6)', 'The following procedures/assessments will be performed at in-person clinic visits at weeks 2, 4,', 'and 6:', 'conduct clinic visit', 'evaluate and, if required, adjust IMP dose (see Section 5.1)', 'measure vital signs (pulse, BP, body temperature, and respiratory rate); at week 4', 'only, orthostatic BP and pulse should be measured after the patient is in standing', 'position for at least 3 minutes', 'measure weight (Note: Weight must be measured with shoes and outerwear off)', 'perform 12-lead ECG (weeks 4 and 6 only [Note: ECG will be performed after at', 'least 5 minutes rest in a supine or semi-supine position.])', 'perform urine pregnancy (B-HCG) test at week 4 (only in females who are', 'postmenarchal or >12 years of age)', 'administer the following questionnaires (Note: For C-SSRS,', ',', 'and C&A-GTS-QOL, children 13 years of age and under may be', 'interviewed separately or jointly with the caregiver/adult as appropriate or defined by', 'the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should', 'be encouraged to add relevant information. The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be performed before any blood draws or ECG', 'assessments.):', '59']"
60,page_61,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '-', 'CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', ""- C-SSRS (children's SLV)"", '-', 'YGTSS (Note: At weeks 2 and 6, perform assessment of ""Severity Ratings"" of', 'the questionnaire only. Inventory portions, ie, ""Motor Tic Symptom Checklist""', 'and ""Phonic Tic Symptom Checklist"" do not need to be performed. Input from', 'caregiver/adult is required.)', '- TS-CGI', '-', 'TS-PGII (Input from the caregiver/adult is permitted.)', '-', '-', '-', '- C&A-GTS-QOL (week 6 only)', 'dispense IMP (patients will receive doses for 2 weeks at week 2 and week 4 visits', '[current dose level and next dose level] and for 3 weeks at week 6 visit to cover the', 'telephone contacts) and patient diary', 'assess drug accountability and compliance', 'collect used and unused IMP blister packs', 'inquire about adverse events', 'review concomitant medications', '3.13.3.2. Maintenance Period', '3.13.3.2.1. Week 9', 'The following procedures/assessments will be performed at the in-person clinic visit during the', 'maintenance period of the study at week 9:', 'conduct clinic visit', 'measure vital signs (pulse, BP, body temperature, and respiratory rate)', 'measure weight (Note: weight must be measured with shoes and outerwear off)', 'administer the following questionnaires (Note: For C-SSRS and', ',', 'children 13 years of age and under may be interviewed separately or jointly with the', 'caregiver/adult as appropriate or defined by the scale. For children over 13 years of', 'age, caregiver/adult involvement is strongly encouraged. Questions should be', 'directed to the child, but the caregiver/adult should be encouraged to add relevant', '60']"
61,page_62,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'information. The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be', 'performed before any blood draws or ECG assessments.):', '- CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', '-', ""C-SSRS (children's SLV)"", '- YGTSS (Note: Perform assessment of ""Severity Ratings"" of the questionnaire.', 'Inventory portions, ie, ""Motor Tic Symptom Checklist"" and ""Phonic Tic', 'Symptom Checklist"" do not need to be performed. Input from caregiver/adult', 'is required.)', '- TS-CGI', '-', 'TS-PGII (Input from the caregiver/adult is permitted.)', '-', '-', 'dispense IMP (patients will receive doses for 3 weeks) and patient diary', 'assess drug accountability and compliance', 'collect used and unused IMP blister packs', 'inquire about adverse events', 'review concomitant medications', '3.13.3.2.2. Week 12/Early Termination', 'Dosing requirements for the week 12 visit must be followed to ensure appropriate', 'pharmacokinetic sample collection. Patients with early morning visits (ie, within 2 hours of their', 'scheduled AM dosing) should take their dose in clinic after the first pharmacokinetic sample is', 'collected. The date and time of the last dose of study medication before the week 12 visit should', 'be recorded in the diary by the patient or caregiver/adult. The site will document the date and', 'time of the sample collection. Prior to the clinic visit on week 12, patients will be reminded to', 'record the start time of their last meal and the time of their last dose in their diary. The following', 'procedures/assessments will be performed at the in-person clinic visit at week 12/early', 'termination:', 'conduct clinic visit', 'if a patient is withdrawn due to an adverse event, a blood sample for IMP', 'measurement should be taken, if possible. For week 12 visit only: Collect 2 blood', 'samples (5 mL each) for pharmacokinetic analysis (initial and 2 to 3 hours thereafter', 'as specified in Table 1)', 'measure vital signs (orthostatic pulse and BP [after standing for at least 3 minutes],', 'body temperature, and respiratory rate)', '61']"
62,page_63,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'perform full physical and neurological examinations (including height and weight;', 'note: weight must be measured with shoes and outerwear off)', 'perform 12-lead ECG (Note: ECG will be performed after at least 5 minutes rest in a', 'supine or semi-supine position.)', 'perform clinical laboratory tests, including chemical, hematological, and urine', 'analyses', 'perform UDS', 'perform serum pregnancy (B-HCG) test (only in females who are postmenarchal or', '>12 years of age)', 'administer the following questionnaires (Note: For C-SSRS,', 'and C&A-GTS-QOL, children 13 years of age and under may be', 'interviewed separately or jointly with the caregiver/adult as appropriate or defined by', 'the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should', 'be encouraged to add relevant information. The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be performed before any blood draws or ECG', 'assessments.):', '- CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', ""- C-SSRS (children's SLV)"", '- YGTSS (Input from the caregiver/adult is required.)', '- TS-CGI', '-', 'TS-PGII (Input from the caregiver/adult is permitted.)', '-', '-', '-', '- C&A-GTS-QOL', 'assess drug accountability and compliance', 'collect used and unused IMP blister packs', 'inquire about adverse events', 'review concomitant medications', '3.13.4.', 'Procedures After IMP Treatment', 'Patients who participate in the study in compliance with the protocol for at least 12 weeks of', 'double-blind treatment will be considered to have completed the study. See Section 12.4 for the', 'definition of the end of the study.', '62']"
63,page_64,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'All patients will discontinue IMP at the week 12 visit and will return 1 week later for evaluation', 'of safety and tic reduction (week 13 visit; see Section 3.13.4.1). Patients who complete the study', 'may be eligible to begin participation in an open-label safety extension study TV50717-CNS-', '30047. Patients not participating in Study TV50717-CNS-30047 will have a follow-up telephone', 'contact for safety evaluation 1 week after the end of the washout period (2 weeks after their last', 'dose of IMP [week 14 visit]; see Section 3.13.4.2).', 'For patients who withdraw prematurely an early termination visit (see Section 3.13.3.2.2 for', 'applicable procedures) should be conducted as soon as possible after the last dose of IMP. All', 'patients who discontinue early will have a follow-up telephone contact for safety evaluation', '2 weeks after their last dose of IMP; evaluations will be as described for week 14', '(Section 3.13.4.2). Additional details for patients who withdraw prematurely from the study are', 'described in Section 4.4.', 'As appropriate, patients should be treated with standard of care following termination of the', 'study.', 'Data from any efficacy evaluations performed after the specified time will not be collected on', 'the CRF; in the event, however, that such data are collected, these data will not be analyzed.', 'Patients with ongoing adverse events or clinically significant abnormal laboratory test results (as', 'interpreted by the investigator) will be monitored as described in Section 4.4 and Section 7.1.2.', '3.13.4.1. Week 13', 'The following procedures/assessments will be performed at the in-person clinic visit at week 13:', 'conduct clinic visit', 'measure vital signs (pulse, BP, body temperature, and respiratory rate)', 'measure weight (Note: weight must be measured with shoes and outerwear off)', 'for patients with clinically significant laboratory abnormalities at week 12, repeat', 'those laboratory evaluations at this visit', 'administer the following questionnaires (The YGTSS, TS-CGI, TS-PGII, and', 'questionnaires should be performed before any blood draws or ECG', 'assessments.):', '- CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', '-', ""C-SSRS (children's SLV; Note: Children 13 years of age and under may be"", 'interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult', 'involvement is strongly encouraged. Questions should be directed to the child,', 'but the caregiver/adult should be encouraged to add relevant information.)', '- YGTSS (Note: Perform assessment of ""Severity Ratings"" of the questionnaire.', 'Inventory portions, ie, ""Motor Tic Symptom Checklist"" and ""Phonic Tic', '63']"
64,page_65,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Symptom Checklist"" do not need to be performed. Input from the', 'caregiver/adult is required.)', '- TS-CGI', '-', 'TS-PGII (Input from the caregiver/adult is permitted.)', '-', '-', '(Note: Children 13 years of age and under may be', 'interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult', 'involvement is strongly encouraged. Questions should be directed to the child,', 'but the caregiver/adult should be encouraged to add relevant information.)', '(Note: Perform the Severity Ratings of OCD symptoms', '[Questions 1 through 10] only. Checklist assessments do not need to be', 'performed. Children 13 years of age and under may be interviewed separately', 'or jointly with the caregiver/adult as appropriate or defined by the scale. For', 'children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult', 'should be encouraged to add relevant information.)', 'inquire about adverse events', 'review concomitant medications', '3.13.4.2. Week 14', 'For patients not rolling over into open-label safety extension study, following', 'procedures/assessments will be performed via telephone contact at week 14:', 'inquire about adverse events', 'review concomitant medications', '3.13.5.', 'Unscheduled Visits', 'An unscheduled telephone contact may be performed at the discretion of the investigator.', 'An in-clinic unscheduled visit should be performed if a patient requires a dose adjustment for', 'adverse events reported during a telephone contact. An unscheduled visit may be performed at', 'any time during the study as deemed necessary by the investigator or at the request of the patient', 'or caregiver/adult. The date and reason for the unscheduled visit will be recorded on the CRF as', 'well as any other data obtained (eg, adverse events, concomitant medications and treatments, and', 'results from procedures or tests).', 'The following procedures/assessments will be performed at in-clinic unscheduled visits:', 'conduct clinic visit', 'evaluate and/or adjust IMP dose (see Section 5.1)', 'measure vital signs (pulse, BP, body temperature, and respiratory rate)', '64']"
65,page_66,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'measure weight (Note: Weight must be measured with shoes and outerwear off)', 'inquire about adverse events', 'review concomitant medications', 'The following procedures/assessments may be performed at unscheduled visits per the', ""investigator's discretion:"", 'measure height', 'perform physical examination', 'perform neurological examination', 'perform 12-lead ECG (Note: ECG will be performed after at least 5 minutes rest in a', 'supine or semi-supine position.)', 'perform clinical laboratory tests, including chemical, hematological, and urine', 'analyses', 'perform a urine/serum pregnancy (B-HCG) test (only in females who are', 'postmenarchal or >12 years of age)', 'administer the following questionnaires:', '- CDI-2, Parent and Self-report (Note: Children 6 years of age at baseline will', 'not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.)', ""- C-SSRS (children's SLV; Note: Children 13 years of age and under may be"", 'interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult', 'involvement is strongly encouraged. Questions should be directed to the child,', 'but the caregiver/adult should be encouraged to add relevant information.)', 'dispense additional IMP and patient diary, if applicable', 'collect used and unused IMP blister packs', 'assess drug accountability/compliance/supply', 'Other procedures may also be performed at the discretion of the investigator.', '65']"
66,page_67,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '4.', 'SELECTION AND WITHDRAWAL OF PATIENTS', 'Prospective waivers (exceptions) from study inclusion and exclusion criteria to allow patients to', 'be enrolled are not granted by sponsor or Syneos Health (see Section 11.1.2).', '4.1.', 'Patient Inclusion Criteria', 'Patients may be enrolled in this study only if they meet all of the following criteria:', 'a.', 'Patient is 6 to 16 years of age, inclusive, at baseline.', 'b. Patient weighs at least 44 pounds (20kg) at baseline.', 'c. Patient meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth', 'Edition (DSM-VTM) diagnostic criteria for TS and, in the opinion of the investigator,', ""patient, and caregiver/adult, the patient's active tics are causing distress or"", 'impairment.', 'd. Patient has a TTS of 20 or higher on the YGTSS at screening and baseline.', 'e.', 'Patient is able to swallow study medication whole.', 'f. Patient and caregiver/adult are willing to adhere to the medication regimen and to', 'comply with all study procedures.', 'g. Patient is in good general health, as indicated by medical and psychiatric history as', 'well as physical and neurological examination.', ""h. In the investigator's opinion, the patient and caregiver/adult have the ability to"", 'understand the nature of the study and its procedures, and the patient is expected to', 'complete the study as designed.', 'i.', 'Patient and caregiver/adult provide written informed consent/assent, depending on the', ""child's age, as appropriate, according to local regulations."", 'j.', 'Females who are postmenarchal or >12 years of age may be included only if they', 'have a negative ß-HCG test at baseline or are sterile. Definitions of sterile are given', 'in Appendix L.', 'k. Females who are postmenarchal or >12 years of age whose male partners are', 'potentially fertile (ie, no vasectomy) must use highly effective birth control methods', 'for the duration of the study (ie, starting at screening) and for 30 days or 5 half-lives,', 'whichever is longer after the last dose of IMP. Further details are included', 'in Appendix L.', '4.2.', 'Patient Exclusion Criteria', 'Patients will not be enrolled in this study if they meet any of the following criteria:', 'a. Patient has a neurologic disorder other than TS that could obscure the evaluation of', 'tics.', '66']"
67,page_68,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""b. The patient's predominant movement disorder is stereotypy (coordinated movements"", 'that repeat continually and identically) associated with autism spectrum disorder.', 'c. Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another', 'psychotic disorder.', 'd. Patient has clinically significant depression at screening or baseline.', 'Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose', 'for at least 6 weeks before screening.', 'e. Patient has a history of suicidal intent or related behaviors within 2 years of', 'screening:', '- previous intent to act on suicidal ideation with a specific plan, irrespective of', 'level of ambivalence, at the time of suicidal thought', '- previous suicidal preparatory acts or behavior', 'f.', 'Patient has a history of a previous actual, interrupted, or aborted suicide attempt.', 'g. Patient has a first-degree relative who has completed suicide.', 'h. Patient has clinically significant OCD at baseline that, in the opinion of the', 'investigator, is the primary cause of impairment.', 'i.', 'Patient has received CBIT for TS or CBT for OCD within 4 weeks of screening.', 'j.', 'Patient has received any of the following concomitant medications for ties within the', 'specified exclusionary windows of first dose:', '- within 3 months: Depot neuroleptics, botulinum toxin, or tetrabenazine', '-', 'within 4 weeks: cannabidiol oil and valbenazine', '- within 21 days: Reserpine', '- within 14 days: Neuroleptics (oral), typical and atypical antipsychotics', '(see Appendix A), metoclopramide, levodopa, and dopamine agonists', 'Note: Use of stimulant medications, including amphetamine, methylphenidate,', 'and lisdexamfetamine, is allowed if primary use is for the treatment of ADHD and', 'dosing has been stable for at least 2 weeks before screening and no changes to', 'dose or frequency are anticipated during the course of the study.', 'Note: Use of atomoxetine is allowed if the primary use is for the treatment of', 'ADHD and dosing has been stable for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study.', 'Note: Use of benzodiazepines is allowed if primary use is not for tics, and dosing', 'has been stable for at least 4 weeks before screening.', 'Note: Use of topiramate (up to 200 mg/day) is allowed if dosing has been stable', 'for at least 4 weeks before screening.', '- Note: Use of guanfacine or clonidine is allowed regardless of indication (ie, if', 'prescribed for tics or Tourette syndrome) if the dosing has been stable for at least', '67']"
68,page_69,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '4 weeks before screening and no changes to dose or frequency are anticipated', 'during the course of the study. If discontinuation of either medication is', 'anticipated due to ineffectiveness, poor tolerability, or patient/caregiver', 'preference, discontinuation should occur 4 or more weeks prior to the screening', 'visit.', 'k. Patient has received treatment with deep brain stimulation, transmagnetic stimulation,', 'or transcranial direct current stimulation for reduction of tics within 4 weeks of the', 'screening visit.', '1.', 'Patient has an unstable or serious medical illness at screening or baseline', ""m. Patient has a QT interval corrected for heart rate using Fridericia's formula (QTcF)"", 'interval value >450 msec (males) or >460 msec (females) or >480msec (with right', 'bundle branch block) on 12-lead ECG at screening, OR requires treatment with drugs', 'known to prolong the QT interval (see Appendix A, Table 6 for a complete list of', 'prohibited QT-prolonging drugs).', 'n.', 'Patients with a history of torsade de pointes, congenital long QT syndrome,', 'bradyarrhythmias, or uncompensated heart failure.', 'o. Patient has evidence of hepatic impairment, as indicated by:', '- aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 X', 'the upper limit of the normal range (ULN) at screening', '-', 'alkaline phosphatase (ALP) or total bilirubin (Tbil) >2 X ULN at screening', ""Note: Patients with Gilbert's Syndrome are eligible to participate, if approved by"", 'the medical monitor.', 'Note: Patients with abnormalities in 2 or more of the following clinical laboratory', 'parameters must be approved for enrollment by the medical monitor: AST, ALT,', 'ALP, and Tbil.', 'p.', 'Patient has evidence of clinically significant renal impairment, indicated by a serum', 'creatinine > 1.5 X ULN at screening.', 'q.', 'Patient has received a MAOI within 14 days of the baseline visit.', 'r.', 'Patient has a known allergy to any of the components of the IMP.', 'S.', 'Patient has participated in an investigational drug or device study and received', 'IMP/intervention within 30 days or 5 drug half-lives of baseline, whichever is longer.', 't.', 'The patient is a pregnant or lactating female, or plans to become pregnant during the', 'study.', 'u. Patient has a history of or acknowledges alcohol-related disorder in the previous', '12 months, as defined in the DSM-VTM', 'V.', 'Patient has a positive UDS test result, or is unable to refrain from substance abuse', 'throughout the study.', '68']"
69,page_70,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'W. Patient has a DSM diagnosis based on the MINI Kid modules performed at screening', 'that, in the opinion of the investigator, makes the patient unsuitable for the study.', '4.3.', 'Justification for Key Inclusion and Exclusion Criteria', 'Inclusion and exclusion criteria have been designed to minimize the risk to patients while', 'maintaining a consistent level of TS symptoms to allow detection and analysis of a drug effect.', 'Exclusion criteria were designed to exclude patients with concomitant conditions that may', 'increase their risk to drug treatment.', '4.4.', 'Withdrawal Criteria and Procedures', ""In accordance with the Declaration of Helsinki (in accordance with the applicable country's"", 'acceptance), each patient is free to withdraw from the study at any time. The investigator also', 'has the right to withdraw a patient from the study if any of the following events occur:', 'a.', 'intercurrent illness', 'b. adverse events (any patient who experiences an adverse event may be withdrawn', 'from the study or from study treatment at any time at the discretion of the investigator', 'or sponsor as indicated in Section 7.1.7)', 'c. pregnancy (see Section 7.3)', 'd.', 'other reasons concerning the health or well-being of the patient', 'e. lack of cooperation', 'f.', 'post-baseline QTcF value >500 msec or change from baseline >60 msec (as described', 'in Sections 4.3 and 7.1.7). The investigator should repeat the ECG assessment twice', 'and compare the average of the 2 pre-treatment QTcF values (baseline and screening)', 'to the average of the 3 post-baseline QTcF values. The IMP must be stopped for any', 'confirmed post-baseline QTcF value >500 msec or increase from baseline >60 msec.', 'g. when a blind is broken due to safety concerns (see Section 3.7.2). If a patient is', 'unblinded by mistake, the investigator should discuss with the medical monitor', 'whether or not the patient should be withdrawn.', 'h. if the investigator or the sponsor determines that the patient is not in compliance with', 'the study protocol, the investigator and the sponsor should determine whether the', 'patient should be withdrawn from the study (Section 5.4).', 'In addition, a patient may be withdrawn from the study as described in Sections 3.7, 3.11, 3.13.4,', '5.4, and 7.1.7.', 'Should a patient decide to withdraw after administration of IMP, or should the investigator', 'decide to withdraw the patient, all efforts will be made to complete and report all observations up', ""to the time of withdrawal. A complete final evaluation of the patient's withdrawal should be"", 'made as soon as possible after the last dose of IMP and an explanation given as to why the', 'patient is withdrawing or being withdrawn from the study. Assessments to be conducted at the', 'early termination visit are described in Section 3.13.3.2.2.', '69']"
70,page_71,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The reason for and date of withdrawal from the study must be recorded on the source', 'documentation and transcribed onto the CRF. If a patient withdraws consent, every attempt will', 'be made to determine the reason. If the reason for withdrawal is an adverse event or a potentially', 'clinically significant abnormal laboratory test result, monitoring will be continued at the', 'discretion of the investigator (eg, until the event has resolved or stabilized, until the patient is', 'referred to the care of a health care professional, or until a determination of a cause unrelated to', 'the IMP or study procedure is made). The specific event or test result must be recorded on the', 'source documentation and transcribed onto the CRF.', 'All patients who discontinue early will have a follow-up telephone contact for safety evaluation', '2 weeks after their last dose of IMP (Section 3.13.4).', 'A patient who is enrolled but does not complete the treatment period will not be replaced.', '70']"
71,page_72,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '5.', 'TREATMENT OF PATIENTS', '5.1.', 'Drugs Administered During the Study', 'IMP (see Section 3.8) will be administered as oral tablets at a starting dose of 6 mg. Titration', 'schemes based on body weight at baseline are shown in Table 2. The maximum daily dose is', 'determined by body weight and CYP2D6 impairment status at baseline. Although dose', 'adjustments can be made up to and including the week 7 telephone call, if a stable dose is', 'reached before then, the patient should continue taking that dose for the remainder of the titration', 'period and throughout maintenance dosing. If a patient experiences a ""clinically significant""', 'adverse event that is attributed to the IMP, the investigator will determine if a dose reduction or', ""suspension is necessary. At the end of the titration period, the patient's dose will be established"", 'for the maintenance period. If a patient experiences an adverse event during the maintenance', 'period and the investigator believes a dose reduction is warranted, the dose may be reduced.', 'IMP will be dispensed in the clinic. Patients will receive doses for 2 weeks at baseline, week 2,', 'and week 4 visits (current dose level and next dose level) to cover the telephone contacts. At', 'week 6 and week 9 visits, patients will receive doses for 3 weeks.', 'IMP will be administered as follows:', 'IMP should be swallowed whole and taken with food. Tablets should be taken with', 'food (eg, a snack) and should not be taken on an empty stomach.', 'Dosing will be based on body weight and CYP2D6 impairment status at the baseline', 'visit, as shown in Table 2.', 'The starting dose is 6 mg in all patients. Daily doses will be administered twice daily,', 'approximately 8 to 10 hours apart during the day. A minimum of 6 hours should', 'elapse between doses. If a patient misses a dose and it is within 6 hours of their next', 'dose, the missed dose should be skipped.', 'After week 1, dose increases may not occur more frequently than every 5 days.', 'Dose reductions, if required, should be in increments of 6 mg. If more than 1 dose', 'reduction is required for an adverse event, the medical monitor must be notified.', 'During the titration period, the dose of the IMP will be adjusted weekly according to', 'Table 2 to identify a dose level that optimally reduces tics and is well tolerated.', 'Investigators will be blinded to CYP status, with a dose cap for poor metabolizers', 'prespecified by the IRT.', 'IMP will be packaged in blister packs and provided for patients to take at home (see Section 3.8).', '71']"
72,page_73,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 2:', 'Maximum Daily Dose of IMP by Study Day and Weight Category at Baseline', 'Weight category', 'Study daya', '20 to <30 kg', '30 to <40 kg', '>40 kg', 'CYP', 'Not', 'Impaired', 'Not', 'Impaired', 'Not', 'Impaired', 'impairment', 'impaired', 'impaired', 'impaired', 'status', 'Day 1-7', '6 mg', '6 mg', '6 mg', '6 mg', '6 mg (Days', '6 mg (Days', '1 and 2)', '1 and 2)', '12 mgb', '12 mgb', 'Day 8-14', '12 mg', '12 mg', '12 mg', '12 mg', '18 mg', '18 mg', 'Day 15-21', '18 mg', '18 mg', '18 mg', '18 mg', '24 mg', '24 mg', 'Day 22-28', '18 mg', '18 mg', '24 mg', '24 mg', '30 mg', '30 mg', 'Day 29-35', '24 mg', '18 mg', '30 mg', '24 mg', '36 mg', '36 mg', 'Day 36-42', '24 mg', '18 mg', '36 mg', '24 mg', '42 mg', '36 mg', 'Day 43-49', '30 mg', '18 mg', '42 mg', '24 mg', '48 mg', '36 mg', 'a Administration of a given dose will take place throughout the days indicated. The new dose starts the morning', 'after the telephone contact or the morning after the clinic visit (ie, Days 8, 15, 22, 29, 36, and 43), as applicable.', 'b Patients will receive 6 mg on days 1 and 2, and 12 mg starting on day 3.', 'bid=twice a day; CYP=cytochrome P450; IMP=investigational medicinal product.', 'Note: CYP impaired patients are those patients who are receiving a strong CYP2D6 inhibitor or who are a CYP2D6', 'poor metabolizer. The investigator, in consultation with the patient and caregiver/adult, will determine if a dose', 'increase is warranted to achieve optimal tic reduction.', '5.2.', 'Restrictions', 'Medications prohibited before and/or during the study are described in Section 5.3.', 'While patients receiving strong CYP2D6 inhibitors such as paroxetine, fluoxetine, and', 'bupropion at baseline may be enrolled into this study, the addition or removal of strong CYP2D6', 'inhibitors during treatment is discouraged as this would have an effect on exposure to active', 'circulating drug. If the addition or removal of a strong CYP2D6 inhibitor is required from a', 'clinical perspective, the medical monitor should be contacted so an appropriate change in IMP', 'can be made. The use of quinidine and terbinafine are prohibited (see Appendix A, Table 8).', 'Restrictions in regard to sexual activity and required laboratory values are provided in the', 'inclusion and exclusion criteria.', 'As with other VMAT2 inhibitors (tetrabenazine, reserpine), patients should be advised that the', 'concomitant use of alcohol or other sedating drugs with TEV-50717 may have additive effects', 'and cause or worsen somnolence. Given the age of the study population, the use of alcohol', 'during this study is prohibited.', 'Patients should be advised not to drive a car or operate dangerous machinery until they', 'understand how TEV-50717 affects them.', '72']"
73,page_74,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Use of illicit drugs is prohibited from the time of signing of the informed consent/assent form', 'and throughout study participation.', 'Patients may not donate blood from the time of informed consent/assent, while taking the IMP,', 'and for 14 days after the last dose.', '5.3.', 'Prior and Concomitant Therapy or Medication', 'Any prior or concomitant therapy, medication, or procedure a patient has had within 3 months', 'before IMP administration and up to the end of the study period, including follow-up, will be', 'recorded on the CRF. Generic or trade name, indication, and dosage will be recorded. The', 'sponsor will encode all therapy and medication according to the World Health Organization drug', 'dictionary.', 'At each clinic visit after the screening visit, the investigator will ask patients whether they have', 'taken any medications (other than IMP), including over-the-counter medications, vitamins, or', 'herbal or nutritional supplements, since the previous visit. Parents/patients will be instructed', 'during the course of the study to notify the investigator if any new medication is prescribed,', 'including over-the-counter medications. Any prescribed medication should be reviewed with the', 'investigator. Indication, dosage, and start and end dates should be entered on the CRF.', 'Medications that are allowed, provided that conditions outlined in the table are met, are shown in', 'Appendix A, Table 5.', 'The medical monitor must be contacted if a patient is receiving (or has to begin or stop receiving', 'during the study) a medication that is associated with QTc prolongation or that is a known strong', 'CYP inhibitor. Addition of a strong CYP inhibitor is prohibited.', 'Prohibited medications that are associated with QTc prolongation are listed in Appendix A,', 'Table 6, while prohibited antipsychotic drugs are listed in Appendix A, Table 7.', '5.4.', 'Procedures for Monitoring Patient Compliance', 'The investigator will be responsible for monitoring patient compliance. A check of IMP', 'compliance will be performed during each visit after the initial dispensation of IMP, and IMP', 'accountability records will be completed. If the investigator or the sponsor determines that the', 'patient is not in compliance with the study protocol, the investigator and the sponsor should', 'determine whether the patient should be withdrawn. The IEC/IRB should be notified as required', 'by national and local regulations.', '73']"
74,page_75,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '5.5.', 'Dose Reduction and Temporary IMP Discontinuation', 'Dose Reduction', 'If a patient experiences a ""clinically significant"" adverse event that is attributed to IMP, the', 'investigator will determine if a dose reduction or suspension is necessary. Dose adjustments', 'should be made based on all available information, including the patient and caregiver/adult', 'reports of adverse events and tic reduction, the clinical assessment of safety and efficacy by the', 'investigator, and information from rating scales. If more than 1 dose reduction is required for', 'an adverse event, the medical monitor must be notified.', 'If the determination that a patient requires a dose reduction or suspension is made during a', 'telephone contact, an unscheduled clinic visit should be conducted as soon as practicable', 'thereafter.', 'Dose Suspension', 'Suspension of study medication for up to 1 week, if warranted for patient safety, is allowed. If', 'the patient restarts study medication within 7 days of suspension, the full dose of TEV-50717', 'may be resumed without titration. Suspensions of study medication for adverse events must', ""be reviewed with the medical monitor before therapy is restarted. If a subject's serum"", 'potassium or magnesium were tested and found to be below the lower limit of normal and', 'clinically significant, the laboratory test should be repeated at least once. If the abnormality in', 'the repeated laboratory test is consistent with the prior laboratory test, the IMP must be', 'suspended. The Medical Monitor must be contacted to determine the appropriate investigation', 'and treatment. TEV-50717 may only be restarted once serum potassium or magnesium have', 'normalized.', 'The reason for a dose reduction or suspension must be clearly documented.', 'If a dose reduction or suspension occurs before a scheduled clinic visit, the clinic visit will', 'be postponed so that efficacy evaluations can be performed at least 5 days after the change.', 'The patients who restart IMP treatment will follow the visit schedule as outlined in Table 1.', 'Patients who withdraw from the study will proceed as described in Section 4.4.', '5.6.', 'Total Blood Volume', 'The total volume of blood to be collected for each patient in this study is approximately 35 mL,', 'as detailed in Table 3.', '74']"
75,page_76,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 3:', 'Blood Volumes', 'Type of samples', 'Volume per sample', 'Total number of samples', 'Total volume', 'Clinical laboratory', '10 mL', '2', '20 mL', '(chemistry/hematology)', 'Pharmacokinetic', '5 mL', '1 time point (week 12) X 2 samples', '10 mL', 'CYP2D6 genotyping', '3 mL', '1', '3 mL', 'Optional', '2 mL', '1', '2 mL', 'pharmacogenetic', 'sample', 'Total', '35 mL', 'CYP2D6=cytochrome P450 2D6.', 'Note: beta human chorionic gonadotropin testing (in females who are postmenarchal or >12 years of age) is included', 'in the clinical laboratory sample.', '75']"
76,page_77,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6.', 'ASSESSMENT OF EFFICACY', 'Site-administered efficacy scales include the YGTSS and the', 'and self-administered', ',', 'efficacy scales include the TS-PGII,', 'and C&A-GTS-QOL.', '6.1.', 'Primary Efficacy Measure and Justification', 'The primary efficacy measure is the TTS of the YGTSS.', 'The YGTSS is administered at screening; baseline; and weeks 2, 4, 6, 9, 12, and 13:', 'Complete assessment (Checklist and Severity Ratings) at screening, baseline, and', 'weeks 4 and 12', 'Severity Ratings assessment only at weeks 2, 6, 9, and 13', 'Input from caregiver/adult is required for all patients irrespective of age.', 'The choice of YGTSS (specifically the TTS) as a primary efficacy measure is supported by its', 'wide use in clinical practice for evaluation of symptoms associated with TS and its successful', 'use in the Phase 1b study SD-809-C-17 (Section 1.3.2.2).', 'The YGTSS rating scale is a semi-structured clinician rating instrument that provides an', 'evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic', 'tics (Leckman et al 1989). The items pertaining to the tic ratings are scored on 2 subscales:', 'Motor Tics and Vocal Tics. Behaviors are rated on a 6-point scale. The scale has a look-back', 'period of 1 week. Additionally, the scale assesses the severity of tics, which includes overall', 'impairment of the patient, and combines motor and visual tic information into a TTS score. A', ""can then be determined by combining the patient's severity rating with the TTS."", 'A reference sample is provided in Appendix G.', '6.2.', 'Key Secondary Efficacy and Exploratory Measures', '6.2.1.', 'Tourette Syndrome-Clinical Global Impression', 'The TS-CGI is administered at baseline and at weeks 2, 4, 6, 9, 12, and 13. The TS-CGI scale is', 'a 7-point Likert scale that allows the clinician to use all available information to assess the', ""impact of tics on the patient's quality of life. The TS-CGI is rated as follows: 1 (normal),"", '2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme).', 'A reference sample is provided in Appendix H.', '6.2.2.', 'Tourette Syndrome-Patient Global Impression of Impact', 'The TS-PGII is administered at baseline and weeks 2, 4, 6, 9, 12, and 13. Input from the', 'caregiver/adult is permitted.', 'The TS-PGII is a single-item questionnaire that asks the patient to assess the degree of impact', 'due to current tics. The TS-PGII uses a 5-point scale, ranging from not at all (1) to very', 'much (5), to assess overall response to therapy. In general, patient-rated global measures of', '76']"
77,page_78,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'change have face validity and have been shown to correlate with disability for a number of', 'chronic conditions.', '6.2.3.', '6.2.4.', 'Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Scale', 'The C&A-GTS-QOL is administered at baseline, week 6, and week 12. Children 13 years of age', 'and under may be interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should be', 'encouraged to add relevant information.', 'The C&A-GTS-QOL is a 27-item questionnaire specific to TS patients that asks the patient to', 'assess the extent to which their quality of life is impacted by their symptoms. The C&A-GTS-', 'QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-', 'compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme', 'problem. Patients will also be asked how satisfied they feel overall with their life at that moment', 'by using a VAS scale between 0 and 100 (Su et al 2017).', 'A reference sample is provided in Appendix K.', '6.2.5.', '6.2.6.', '77']"
78,page_79,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6.2.7.', '78']"
79,page_80,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.', 'ASSESSMENT OF SAFETY', 'In this study, safety will be assessed by qualified study personnel by evaluating the following:', 'reported adverse events, clinical laboratory test results, vital signs measurements, ECG findings,', 'physical examination findings (including body weight and height measurements), use of', 'concomitant medication, neurological examination, C-SSRS, and CDI-2.', '7.1.', 'Adverse Events', '7.1.1.', 'Definition of an Adverse Event', 'Any untoward medical occurrence in a patient or clinical investigation subject administered a', 'pharmaceutical product and which does not necessarily have to have a causal relationship with', 'this treatment.', 'An adverse event can, therefore, be any unfavorable and unintended physical sign, symptom, or', 'laboratory parameter that develops or worsens in severity during the course of this study, or', 'significant worsening of the disease under study or of any concurrent disease, whether or not', 'considered related to the IMP (TEV-50717). A new condition or the worsening of a pre-existing', 'condition will be considered an adverse event. Stable chronic conditions (such as arthritis) that', 'are present before study entry and do not worsen during this study will not be considered adverse', 'events.', 'Accordingly, an adverse event can include any of the following:', 'intercurrent illnesses', 'physical injuries', 'events possibly related to concomitant medication', 'significant worsening (change in nature, severity, or frequency) of the disease under', 'study or other pre-existing conditions (Note: A condition recorded as pre-existing that', 'is intermittently symptomatic [eg, headache and that occurs during this study should', 'be recorded as an adverse event.)', 'drug interactions', 'events occurring during diagnostic procedures or during the washout phase of this', 'study', 'laboratory or diagnostic test abnormalities that result in the withdrawal of the patient', 'from the study, are associated with clinical signs and symptoms or a serious adverse', 'event, or require medical treatment or further diagnostic work-up, or are considered', 'by the investigator to be clinically significant (Note: Abnormal laboratory test results', 'at the screening visit that preclude a patient from entering the study or receiving study', 'treatment are not considered adverse events.)', '79']"
80,page_81,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.1.2.', 'Recording and Reporting Adverse Events', 'For recording of adverse events, the study period is defined for each patient as that time period', 'from signature of the informed consent/assent form to the end of the follow-up period. For this', 'study, the follow-up period for recording of adverse events is defined as 1 week of washout for', 'patients who will participate in the open-label safety extension study TV50717-CNS-30047 and', '2 weeks after the last dose of IMP for patients who will not roll over into Study TV50717-CNS-', '30047.', 'All adverse events that occur during the defined study period must be recorded both on the', 'source documentation and the CRF, regardless of the severity of the event or judged relationship', 'to the IMP. For serious adverse events, the Serious Adverse Event Form must be completed, and', 'the serious adverse event must be reported immediately (see Section 7.1.5.3.1). The investigator', 'does not need to actively monitor patients for adverse events after the defined period. Serious', 'adverse events occurring to a patient after the treatment of that patient has ended should be', 'reported to the sponsor if the investigator becomes aware of them, following the procedures', 'described in Section 7.1.5.3.1.', 'At each contact with the patient, the investigator or designee must question the patient about', 'adverse events by asking an open-ended question such as, ""Have you had any unusual symptoms', 'or medical problems since the last visit? If yes, please describe."" All reported or observed signs', 'and symptoms will be recorded individually, except when considered manifestations of a', 'medical condition or disease state. A precise diagnosis will be recorded whenever possible.', 'When such a diagnosis is made, all related signs, symptoms, and any test findings will be', 'recorded collectively as a single diagnosis on the CRF and, if it is a serious adverse event, on the', 'Serious Adverse Event Form.', 'The clinical course of each adverse event will be monitored at suitable intervals until resolved,', 'stabilized, or returned to baseline; until the patient is referred for continued care to a health care', 'professional; or until a determination of a cause unrelated to the IMP or study procedure is made.', 'The onset and end dates, duration (in case of adverse event duration of less than 24 hours), action', 'taken regarding IMP, treatment administered, and outcome for each adverse event must be', 'recorded both on the source documentation and the CRF.', 'The relationship of each adverse event to IMP and study procedures, and the severity and', 'seriousness of each adverse event, as judged by the investigator, must be recorded as described', 'below.', 'Further details are given in the safety monitoring plan.', '7.1.3.', 'Severity of an Adverse Event', 'The severity of each adverse event must be recorded as 1 of the following:', 'Mild:', 'No limitation of usual activities', 'Moderate: Some limitation of usual activities', 'Severe:', 'Inability to carry out usual activities', '80']"
81,page_82,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.1.4.', 'Relationship of an Adverse Event to the IMP', 'The relationship of an adverse event to the IMP is characterized as follows:', 'Term', 'Definition', 'Clarification', 'No', 'This category applies to adverse', 'The relationship of an adverse event may be', 'reasonable', 'events that, after careful', 'considered ""no reasonable possibility"" if it is clearly', 'possibility', 'consideration, are clearly due to', 'due to extraneous causes or if at least 2 of the', '(not related)', 'extraneous causes (disease,', 'following apply:', 'environment, etc) or to adverse', 'It does not follow a reasonable temporal sequence', 'events that, after careful medical', 'from the administration of the IMP.', 'consideration at the time they are', ""It could readily have been produced by the patient's"", 'evaluated, are judged to be', 'clinical state, environmental, or toxic factors, or other', 'unrelated to the IMP.', 'modes of therapy administered to the patient.', 'It does not follow a known pattern of response to the', 'IMP.', 'It does not reappear or worsen when the IMP is', 're-administered.', 'Reasonable', 'This category applies to adverse', 'The relationship of an adverse event may be', 'possibility', 'events for which, after careful', 'considered ""reasonable possibility"" if at least 2 of', '(related)', 'medical consideration at the time', 'the following apply:', 'they are evaluated, a connection', 'It follows a reasonable temporal sequence from', 'with the administration of IMP', 'administration of the IMP.', 'cannot be ruled out with certainty.', 'It cannot be reasonably explained by the known', ""characteristics of the patient's clinical state,"", 'environmental or toxic factors, or other modes of', 'therapy administered to the patient.', 'It disappears or decreases on cessation or reduction in', 'dose. There are important exceptions when an', 'adverse event does not disappear after', 'discontinuation of the IMP, yet an IMP relationship', 'clearly exists.', 'It follows a known pattern of response to the IMP.', '7.1.5.', 'Serious Adverse Events', 'An additional blood sample for the measurement of IMP concentration should be collected, if', 'possible, from each patient experiencing a serious adverse event leading to discontinuation of', 'IMP at any time during the study. If study center personnel are unable to obtain a blood sample', 'in a timely fashion, this should be discussed with the medical monitor to determine whether the', 'sample still needs to be obtained.', 'For recording of serious adverse events, the study period is defined for each patient as the time', 'period from signature of the informed consent/assent form to the end of the follow-up period, as', 'defined in Section 7.1.2. If the investigator becomes aware of serious adverse events occurring in', 'a patient after the end of the follow-up period, the serious adverse events should be reported to', 'the sponsor following the procedures described in Section 7.1.5.3.1.', '81']"
82,page_83,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.1.5.1.', 'Definition of a Serious Adverse Event', 'A serious adverse event is an adverse event occurring at any dose that results in any of the', 'following outcomes or actions:', 'results in death', 'is a life-threatening adverse event (ie, the patient was at risk of death at the time of', 'the event); it does not refer to an event which hypothetically might have caused death', 'if it were more severe.', 'requires inpatient hospitalization or prolongation of existing hospitalization, which', 'means that hospital inpatient admission or prolongation of hospital stay were required', 'for treatment of an adverse event, or that they occurred as a consequence of the event.', 'Hospitalizations scheduled before the patient signed the informed consent form will', 'not be considered serious adverse events, unless there was worsening of the', ""preexisting condition during the patient's participation in this study."", 'results in persistent or significant disability/incapacity (refers to a substantial', ""disruption of one's ability to conduct normal life functions)"", 'is a congenital anomaly/birth defect', 'an important medical event that may not result in death, be life-threatening, or require', 'hospitalization, but may jeopardize the patient and may require medical intervention', 'to prevent one of the outcomes listed in this definition.', 'Examples of such events are intensive treatment in an emergency room or at home for', 'allergic bronchospasm; blood dyscrasias or convulsions that do not result in', 'hospitalization; or the development of drug dependency or drug abuse. Note: Any', 'suspected transmission of an infectious agent via a medicinal product is considered an', 'important medical event.', ""All occurrences of possible drug-induced liver injury that meet Hy's law criteria, defined as all"", 'of the below, must be reported by the investigator to the sponsor as a serious adverse event:', 'alanine aminotransferase (ALT) or aspartate aminotransferase (AST) increase of', '>3 X the upper limit of normal (ULN)', 'total bilirubin increase of >2 X ULN', 'absence of initial findings of cholestasis (ie, no substantial increase of alkaline', 'phosphatase [ALP])', 'An adverse event that does not meet any of the criteria for seriousness listed above will be', 'regarded as a nonserious adverse event.', '7.1.5.2. Expectedness', 'A serious adverse event that is not included in the adverse reaction section of the relevant', 'reference safety information (RSI) by its specificity, severity, outcome, or frequency is', 'considered an unexpected adverse event. The RSI for this study is the IB.', '82']"
83,page_84,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'A serious adverse event that is not included in the listing of adverse reactions in the RSI by its', 'specificity, severity, outcome, or frequency is considered an unexpected adverse event.', ""The sponsor's GPSP will determine the expectedness for all serious adverse events."", 'For the purpose of SUSAR reporting, the version of the IB at the time of occurrence of the', 'SUSAR applies.', '7.1.5.3.', 'Reporting a Serious Adverse Event', '7.1.5.3.1. Investigator Responsibility', 'To satisfy regulatory requirements, all serious adverse events that occur during the study,', 'regardless of judged relationship to administration of the IMP, must be reported by the', 'investigator according to the instructions provided on the serious adverse event form. The event', 'must be reported within 24 hours of when the investigator learns about it. Completing the', 'Serious Adverse Event Form and reporting the event must not be delayed, even if not all the', 'information is available. The investigator does not need to actively monitor patients for adverse', 'events once this study has ended.', 'Serious adverse events occurring to a patient after the last administration of IMP of that patient', 'has ended should be reported to the sponsor if the investigator becomes aware of them.', 'The serious adverse event form should be sent to the local safety officer (LSO) or designee (a', 'contract research organization in a country without a sponsor LSO) (contact information is in the', 'Clinical Study Personnel Contact Information section); the LSO will forward the report to the', ""sponsor's GPSP."", 'The following information should be provided to record the event accurately and completely:', 'study number', 'investigator and investigational center identification', 'patient number', 'onset date and detailed description of adverse event', ""investigator's assessment of the relationship of the adverse event to the IMP (no"", 'reasonable possibility, reasonable possibility)', 'Additional information includes:', 'age and sex of patient', 'date of first dose of IMP', 'date and amount of last administered dose of IMP', 'action taken', 'outcome, if known', 'severity', 'explanation of assessment of relatedness', '83']"
84,page_85,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'concomitant medication (including doses, routes of administration, and regimens) and', 'treatment of the event', 'pertinent laboratory or other diagnostic test data', 'medical history', 'results of dechallenge/rechallenge, if known', 'for an adverse event resulting in death:', '-', 'cause of death (whether or not the death was related to IMP)', '-', 'autopsy findings (if available)', 'Each report of a serious adverse event will be reviewed and evaluated by the investigator and the', 'sponsor to assess the nature of the event and the relationship of the event to the IMP, study', 'procedures, and to underlying disease.', 'Additional information (follow-up) about any serious adverse event unavailable at the initial', 'reporting should be forwarded by the investigator within 24 hours of when it becomes known to', 'the same address as the initial report.', ""For all countries, the sponsor's GPSP will distribute the Council for International Organizations"", 'of Medical Sciences (CIOMS) form/Extensible Markup Language (XML) file to the', 'LSO/Syneos Health for submission to the competent authorities, IEC/IRBs, and investigators,', 'according to regulations. The investigator must ensure that the IEC/IRB is also informed of the', 'event, in accordance with national and local regulations.', 'Blinding will be maintained for all study personnel. Therefore, in case of a SUSAR, only the', 'LSO/Syneos Health will receive the unblinded report for regulatory submission; the others will', 'receive a blinded report.', 'Note: Although pregnancy is not a serious adverse event, the process for reporting a pregnancy is', 'the same as that for reporting a serious adverse event, but using the pregnancy form (see', 'Section 7.3).', '7.1.5.3.2. Sponsor Responsibility', 'If a serious unexpected adverse event is believed to be related to the IMP or study procedures,', 'the sponsor will take appropriate steps to notify all investigators participating in sponsored', 'clinical studies of TEV-50717 and the appropriate competent authorities (and IEC/IRB, as', 'appropriate).', 'In addition to notifying the investigators and regulatory authorities (and IEC/IRB, as', 'appropriate), other action may be required, including the following:', 'altering existing research by modifying the protocol', 'discontinuing or suspending the study', 'modifying the existing consent form and informing current study participants of new', 'findings', '84']"
85,page_86,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'modifying listings of expected toxicities to include adverse events newly identified as', 'related to TEV-50717', '7.1.6.', 'Protocol-Defined Adverse Events of Special Interest', 'No protocol-defined adverse events of special interest were identified for this study.', '7.1.7.', 'Withdrawal Due to an Adverse Event', 'Any patient who experiences an adverse event may be withdrawn from the study or from study', 'treatment at any time at the discretion of the investigator or sponsor. If a post-baseline QTcF', 'value >500 msec or change from baseline >60 msec is found, the investigator should repeat the', 'ECG assessment twice and compare the average of the 2 pre-treatment QTcF values (baseline', 'and screening) to the average of the 3 post-baseline QTcF values. The IMP must be stopped for', 'any confirmed post-baseline QTcF value >500 msec or increase from baseline >60 msec. If a', 'patient is withdrawn wholly or in part because of an adverse event, both the adverse events page', 'and termination page of the CRF will be completed at that time.', 'In addition, a blood sample should be obtained for the measurement of IMP concentrations, if', 'possible. The patient will be monitored at the discretion of the investigator (eg, until the event', 'has resolved or stabilized, until the patient is referred to the care of a health care professional, or', 'until a determination of a cause unrelated to the IMP or study procedure is made). The', 'investigator must inform the clinical project physician/clinical leader as soon as possible of any', 'patients who are being considered for withdrawal due to adverse event(s). Additional reports', 'must be provided when requested.', 'If a patient is withdrawn from the study for multiple reasons that include adverse events, the', 'termination page of the CRF should indicate that the withdrawal was related to an adverse event.', 'An exception to this requirement will be the occurrence of an adverse event that, in the opinion', 'of the investigator, is not severe enough to warrant discontinuation but that requires the use of a', 'prohibited medication, thereby requiring discontinuation of the patient. In such a case, the reason', 'for discontinuation would be need to take a prohibited medication, not the adverse event.', '7.1.8.', 'Protocol Deviations Because of an Adverse Event', 'If a patient experiences an adverse event or medical emergency, deviations from the protocol', 'may be allowed on a case-by-case basis. To ensure patient safety, after the event has stabilized or', 'treatment has been administered (or both), the investigator or other physician in attendance must', 'contact the physician identified in the Clinical Study Personnel Contact Information section of', 'this protocol as soon as possible to discuss the situation. The investigator, in consultation with', 'the sponsor, will decide whether the patient should continue to participate in the study.', '7.2.', 'Psychometric Rating Scales', 'Site-administered safety scales include the MINI Kid and C-SSRS, and self-administered safety', 'scales include CDI-2.', '85']"
86,page_87,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.2.1.', 'Mini International Neuropsychiatric Interview for Children and Adolescents', 'Select MINI Kid modules are administered at screening only. Children 13 years of age and under', 'may be interviewed separately or jointly with the caregiver/adult as appropriate or defined by the', 'scale. For children over 13 years of age, caregiver/adult involvement is strongly encouraged.', 'Questions should be directed to the child, but the caregiver/adult should be encouraged to add', 'relevant information.', 'The MINI Kid is a short questionnaire to be administered by a trained clinician. The MINI Kid', 'assesses symptoms of psychiatric disorders as outlined in the International Classification of', 'Diseases-10 and the DSM in children 6 to 17 years of age by self-report. For children under', '13 years old, the patient may be interviewed separately or jointly with the caregiver/adult as', 'appropriate or defined by the scale, and the caregiver/adult is encouraged to participate when', 'needed. The MINI Kid version 6 is composed of 24 modules overall, and questions are largely', 'yes-or-no questions. The current study will focus on 8 modules: Major Depressive Episode', '(Module A), (Hypo) Manic Episode (Module D), OCD (Module J), Alcohol Dependence/Abus-', '(Module L), Substance Dependence/Abuse (Non-alcohol; Module M), ADHD (Module O),', 'Conduct Disorder (Module P), and Psychotic Disorders and Mood Disorders with Psychotic', 'Features (Module R).', 'A reference sample is provided in Appendix C.', '7.2.2.', 'Columbia-Suicide Severity Rating Scale', ""The C-SSRS children's baseline/screening scale assesses past and current suicidal ideation and"", ""behaviors to determine suicide risk and is administered at screening. The C-SSRS children's"", 'SLV scale is administered at baseline and at weeks 2, 4, 6, 9, 12, and 13. Children 13 years of', 'age and under may be interviewed separately or jointly with the caregiver/adult as appropriate or', 'defined by the scale. For children over 13 years of age, caregiver/adult involvement is strongly', 'encouraged. Questions should be directed to the child, but the caregiver/adult should be', 'encouraged to add relevant information. The C-SSRS is an interview by trained study personnel.', 'Suicidal ideation', 'Patients with a positive C-SSRS suicidal ideation score on either items 1 or 2 or a change', 'on the CDI-2 Parent or Self-Report Profiles consistent with increasing depressive', 'symptoms must be 1) discussed with the medical monitor, 2) re-evaluated within 2 to 3', ""days in a clinic visit, and 3) treated according to the investigator's medical judgment."", 'Consultation with a child and adolescent psychiatrist or licensed child/adolescent mental', 'health provider is advised, followed by close ongoing monitoring.', 'If patients endorse or report a C-SSRS suicidal ideation level of 3, 4, or 5, subjects will', 'be evaluated immediately by the study investigator and referred for psychiatric', 'evaluation. The medical monitor will be immediately consulted. If it is determined by the', 'investigator, after consultation with the medical monitor and the consulting psychiatrist,', 'that exposure to the IMP may have contributed to this change in C-SSRS and/or', 'increased depressive symptoms, IMP will be immediately discontinued and the patient', 'terminated from the study. In cases where it is determined that IMP did not contribute to', 'changes in depression or suicidality, the investigator will consult with the medical', '86']"
87,page_88,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'monitor, the consulting psychiatrist, and/or sponsor to determine whether the patient', 'should continue in the study.', 'Suicidal behavior', 'Actual attempt:', 'If patients report any suicidal behavior that is an actual attempt as assessed in the C-', 'SSRS, they will be evaluated immediately by the study investigator, referred for', 'psychiatric evaluation, and terminated from the study.', 'Interrupted attempt, aborted attempt, or Preparatory Acts or Behavior:', 'If patients report any suicidal behavior that is interrupted, aborted, or preparatory as', 'assessed in the C-SSRS, they will be evaluated immediately by the study investigator and', 'referred for psychiatric evaluation. In cases where it is determined in the psychiatric', 'evaluation that IMP did not contribute to changes in suicidal behavior, the investigator', 'will consult with the medical monitor, the consulting psychiatrist, and/or sponsor to', 'determine whether the patient should continue in the study.', 'A reference sample is provided in Appendix E.', '7.2.3.', ""Children's Depression Inventory, Second Edition"", 'The CDI-2 (parent and self-report profiles) is administered at screening, baseline, and weeks 2,', '4, 6, 9, 12, and 13. As the CDI-2 is designed for children 7 to 17 years of age, children 6 years of', 'age at baseline will not complete the Self-report version; the caregiver/adult will complete the', 'Parent version.', 'The CDI-2 Self-report is a 28-item self-report questionnaire assessing depressive symptoms in', 'children 7 to 17 years of age with basic reading and comprehension skills. In the CDI-2, children', 'are asked to choose 1 of 3 statements that most closely aligns with their feelings in the previous', '2 weeks. The questionnaire covers both the major and minor symptoms of depression as outlined', 'in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Sun', 'and Wang 2015).', 'The CDI-2 Parent is a 17-item questionnaire administered to parents to assess depression-related', ""behaviors observed in their children. In the CDI-2 Parent, parents are asked to rate their child's"", 'behaviors in the past 2 weeks on a 4-point Likert scale from ""not at all"" to ""much or most of the', 'time"". The questionnaire allows for the division of depressive symptoms into functional', 'problems and emotional problems (Sun and Wang 2015).', 'A reference sample is provided in Appendix D.', '7.3.', 'Pregnancy', 'Any female patient becoming pregnant during the study will discontinue IMP.', 'All pregnancies of female patients participating in the study that occur during the study, or', 'within 14 days after the end of the study, are to be reported immediately to the individual', 'identified in the Clinical Study Personnel Contact Information section of this protocol, and the', 'investigator must provide the sponsor (LSO/Syneos Health) with the completed pregnancy form.', '87']"
88,page_89,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The process for reporting a pregnancy is the same as that for reporting a serious adverse event', 'but using the pregnancy form (see Section 7.1.5.3).', 'The investigator is not required to report patients who are found to be pregnant between', 'screening and baseline, provided no IMP was given. All female patients who become pregnant', 'will be monitored for the outcome of the pregnancy (including spontaneous, elective, or', 'voluntary abortion). If the pregnancy continues to term, the outcome (health of the infant up to', '8 weeks of age), including details of birth and presence or absence of any birth defect, congenital', 'abnormalities, or maternal and newborn complications, will be reported to the sponsor. Any', 'complication of pregnancy during the study and any complication of pregnancy that the', 'investigator becomes aware of after withdrawal from the study will be reported as an adverse', 'event or serious adverse event, as appropriate.', 'If the pregnancy in the female patients participating in the study does not continue to term, 1 of', 'the following actions will be taken:', 'For a spontaneous abortion, report as a serious adverse event.', 'For an elective abortion due to developmental anomalies, report as a serious adverse', 'event.', 'For an elective abortion not due to developmental anomalies, report on the pregnancy', 'form; do not report as an adverse event.', '7.4.', 'Medication Error and Special Situations Related to the', 'Investigational Medicinal Product', 'Any administration of IMP that is not in accordance with the study protocol should be reported', 'on the CRF either as a violation, if it meets the violation criteria specified in the protocol', '(Section 11.1.2), or as a deviation, in the patients source documents, regardless of whether or not', 'an adverse event occurs as a result. All instances of incorrect medication administration should', 'be categorized on the CRF as ""Non-Compliance with IMP""', 'The following are types of medication errors and special situations:', '1. Medication error: Any unintentional error in the prescribing, dispensing, or', 'administration of a medicinal product while in the control of the healthcare professional,', 'patient, or consumer.', '2. Overdose: Administration of a quantity of a medicinal product given per administration', 'or cumulatively which is above the maximum recommended dose according to the', 'authorized product information. Clinical judgment should always be applied. Any dose of', 'IMP (whether the test IMP or placebo), whether taken intentionally or unintentionally in', 'excess of the dose prescribed, must be immediately reported to the sponsor.', '3. Misuse: Situations where the IMP is intentionally and inappropriately used not in', 'accordance with the authorized product information.', '4. Abuse: Persistent or sporadic, intentional excessive use of IMP, which is accompanied by', 'harmful physical or psychological effects.', '88']"
89,page_90,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '5. Off-label use: Situations where an IMP is intentionally used for a medical purpose not in', 'accordance with the authorized product information.', ""6. Occupational exposure: Exposure to an IMP, as a result of one's professional or non-"", 'professional occupation.', '7. Breastfeeding: Suspected adverse reactions that occur in infants following exposure to a', 'medicinal product from breast milk.', '7.5.', 'Clinical Laboratory Tests', 'All clinical laboratory test results outside of the reference range will be judged by the', 'investigator as belonging to one of the following categories:', 'abnormal and not clinically significant', 'abnormal and clinically significant', 'The clinical significance of the laboratory values will be evaluated by the criteria described in', 'the laboratory manual and by the judgement of the investigator. A laboratory test result that is', 'judged by the investigator as clinically significant will be recorded both on the source', 'documentation and the CRF as an adverse event, and monitored as described in Section 7.1.2. An', 'event may include a laboratory or diagnostic test abnormality (once confirmed by repeated', 'testing) that results in the withdrawal of the patient from the study, the temporary or permanent', 'cessation of IMP or medical treatment, or further diagnostic work-up. Abnormal laboratory tests', 'can be repeated without approval from the medical monitor. (Note: Abnormal laboratory or', 'diagnostic test results at the screening visit that preclude a patient from entering the study or', 'receiving IMP are not considered adverse events.)', '7.5.1.', 'Serum Chemistry, Hematology, and Urinalysis', 'Clinical laboratory tests (eg, serum chemistry, hematology, urinalysis) will be performed at the', 'time points detailed in Table 1. Clinical laboratory tests will be performed using the central', 'laboratory. Specific laboratory tests to be performed are provided in Table 4.', '89']"
90,page_91,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 4:', 'Clinical Laboratory Tests', 'Serum Chemistry', 'Hematology', 'Urinalysis', 'calcium', 'hemoglobin', 'protein', 'phosphate', 'hematocrit', 'glucose', 'sodium', 'red blood cell (RBC) count', 'ketones', 'potassium', 'mean cell volume', 'blood (hemoglobin)', 'chloride', 'platelet count', 'pH', 'creatinine', 'white blood cell (WBC) count, and', 'specific gravity', 'glucose', 'differential count', 'microscopic', 'magnesium', '-', 'absolute neutrophil', '-', 'bacteria', 'count (ANC)', 'blood urea nitrogen (BUN)', '-', 'RBCs', 'total cholesterol', '- polymorphonuclear leukocytes', '-', 'WBCs', '(neutrophils)', 'uric acid', '-', 'casts', '-', 'lymphocytes', 'alanine aminotransferase (ALT)', '-', '-', 'eosinophils', 'crystals', 'aspartate aminotransferase (AST)', '-', 'monocytes', 'lactate dehydrogenase (LDH)', '-', 'basophils', 'alkaline phosphatase (ALP)', 'bicarbonate or carbon dioxide', 'total protein', 'albumin', 'total bilirubin', 'direct bilirubin', '7.5.2.', 'Other Clinical Laboratory Tests', '7.5.2.1.', 'Human Chorionic Gonadotrophin Test', 'Human chorionic gonadotrophin tests in urine or serum will be performed for all females who', 'are postmenarchal or >12 years of age as detailed in Table 1, and if clinically indicated. Any', 'female patient who becomes pregnant during the study will be withdrawn. Procedures for', 'reporting the pregnancy are provided in Section 7.3.', '7.5.2.2.', 'Urine Drug Screen', 'A UDS will be performed at time points specified in Table 1. The UDS detects the presence of', 'drugs prohibited according to the laboratory manual. If a given parameter cannot be tested using', ""urine, an alternative matrix (eg, serum) may be considered acceptable. The sponsor's medical"", 'expert must be made aware in advance of, and provide approval for, drug screen parameters to', 'which this will apply.', 'A positive result for any of the specified drugs or their metabolites, without medical explanation,', 'will preclude the patient from enrollment or continued participation in the study.', '90']"
91,page_92,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.5.3.', 'Cytochrome P450 2D6 Genotyping', 'One 3-mL sample for CYP2D6 genotyping will be collected from all patients in the study at', 'screening. Sample testing results will not be provided to the study team until the study is', 'unblinded.', 'This assessment potentially includes the association analysis of the variation in CYP2D6 gene', 'with clinical treatment responses to the IMP (eg, efficacy, pharmacokinetics, tolerability, and', 'safety features or disease susceptibility and severity features). See Section 8.3.1 for further', 'details.', '7.6.', 'Vital Signs', 'Vital signs (pulse, BP, body temperature, and respiratory rate) will be measured at the time', 'points detailed in Table 1. All vital signs results outside of the reference ranges will be judged by', 'the investigator as belonging to one of the following categories:', 'abnormal and not clinically significant', 'abnormal and clinically significant', 'Before pulse and BP are measured, the patient must rest in a supine or semi-erect/seated position', 'for at least 5 minutes. (The same position and arm should be used each time vital signs are', 'measured for a given patient). At baseline, week 4, and week 12, orthostatic BP and pulse will be', 'measured after the patient is in a standing position for at least 3 minutes.', 'For any abnormal vital sign finding, the measurement should be repeated as soon as possible.', 'Any vital sign value that is judged by the investigator as clinically significant will be recorded', 'both on the source documentation and the CRF as an adverse event, and monitored as described', 'in Section 7.1.2.', '7.7.', 'Electrocardiography', 'A 12-lead ECG will be conducted at the time points detailed in Table 1. All ECGs will be', 'performed after at least 5 minutes rest in a supine or semi-supine position. A qualified physician', 'at a central diagnostic center will be interpreting the ECG.', 'All ECG results outside of the reference ranges will be judged by the investigator as belonging to', 'one of the following categories:', 'abnormal and not clinically significant', 'abnormal and clinically significant', 'Any ECG finding that is judged by the investigator as clinically significant (except at the', 'screening visit) will be considered an adverse event, recorded on the source documentation and', 'in the CRF, and monitored as described in Section 7.1.2.', 'If a post-baseline QTcF value >500 msec or change from baseline >60 msec is found, the', 'investigator should repeat the ECG assessment twice and compare the average of the 2 pre-', 'treatment QTcF values (baseline and screening) to the average of the 3 post-baseline QTcF', 'values. The IMP must be stopped for any confirmed post-baseline QTcF value >500 msec or', 'increase from baseline >60 msec.', '91']"
92,page_93,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7.8.', 'Physical Examinations', 'Physical examination, including height and weight, general appearance, skin, head, eyes, ears,', 'nose, throat, neck, lymph nodes, cardiovascular, respiratory, musculoskeletal, abdominal, and', 'extremities will be performed at the time points detailed in Table 1.', 'Weight must be measured with shoes and outerwear off.', 'Any physical examination finding that is judged by the investigator as a clinically significant', '(except at the screening visit) will be considered an adverse event, recorded on the CRF, and', 'monitored as described in Section 7.1.2.', '7.9.', 'Assessment of Suicidality', 'TEV-50717 is considered to be CNS-active. In addition, there have been some reports of suicidal', 'ideation or behavior as reported in the product label when it has been given to some patients with', 'certain conditions. The sponsor considers it important to monitor for such events before and', 'during this clinical study.', 'Some CNS-active IMPs may be associated with an increased risk of suicidal ideation or behavior', 'when given to some patients with certain conditions. Although this IMP or other similar', 'medicinal products in this class have not been shown to be associated with an increased risk of', 'suicidal thinking or behavior when given to this study population, the sponsor considers it', 'important to monitor for such events before or during this clinical study.', 'The study population being administered TEV-50717 should be monitored appropriately and', 'observed closely for suicidal ideation and behavior or any other unusual changes in behavior.', 'Consideration should be given to discontinuing TEV-50717 in participants who experience signs', 'of suicidal ideation or behavior and detailed recommendations are provided in Section 7.2.2.', 'Baseline assessment of suicidal ideation and behavior and treatment-emergent suicidal ideation', 'and behavior will be assessed during the study using the C-SSRS described in Section 7.2.2.', 'Depression and Suicidality as an Adverse Event', 'Families and caregivers of subjects in Study 30046 will be instructed to monitor patients for any', 'changes in or new onset of depressive symptoms; unusual changes in mood, cognition, or', 'behavior; or onset of and/or changes in suicidal ideation or behavior, and to report such', 'symptoms immediately to the study investigator. Telephone contacts and clinic visits also allow', 'opportunities for investigators to assess adverse events.', 'If a relevant change in status is identified, patients will be seen immediately for an unscheduled', 'visit by the study investigator and discussed with the medical monitor. The patient will be', 'referred for further psychiatric evaluation if there is any suspected suicidal ideation with any', 'level of intent, suicidal behavior, or clinical findings suggesting that the patient may be', 'dangerous to self or others, and/or experiencing depression. The investigator will record these', 'symptoms as an adverse event of depression and/or suicidality. If it is determined by the', 'investigator, after consultation with the medical monitor and the consulting psychiatrist, that', 'exposure to the IMP may have contributed to the adverse event of depression or suicidality, IMP', 'will be immediately discontinued and the patient will be terminated from the study. Follow up', '92']"
93,page_94,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'with a pediatric psychiatrist or licensed child and adolescent mental health clinician will be', 'arranged.', 'In cases where it is determined that IMP did not contribute to the adverse event of depression or', 'suicidality, the investigator will consult with the medical monitor and/or sponsor to determine', 'whether the patient should continue in the study.', 'A reference sample is provided in Appendix E.', '7.10.', 'Neurological Examinations', 'Neurological examination, including mental status, cranial nerves, motor system (strength, tone,', 'and posture), coordination, gait and balance, tendon reflexes, and sensation, will be performed at', 'the time points detailed in Table 1. Any neurological examination finding that is judged by the', 'investigator as a potentially clinically significant change (worsening) compared with the', 'screening value will be considered an adverse event, recorded on the CRF, and monitored as', 'described in Section 7.1.2.', '7.11.', 'Concomitant Therapy or Medication', 'Concomitant therapy or medication usage will be monitored throughout the study.', 'Parents/patients will be instructed during the course of the study to notify the investigator if any', 'new medication is prescribed/administered, including over-the-counter medications. Any', 'prescribed/administered medication should be reviewed with the investigator.', 'Medications that are allowed, provided that conditions outlined in the table are met, are shown in', 'Appendix A, Table 5. The tables of allowed and prohibited medications are not comprehensive', 'and may not include all possible concomitant medications.', 'The medical monitor must be contacted if a patient is receiving (or has to begin or stop receiving', 'during the study) a medication that is associated with QTc prolongation or that is a known strong', 'CYP inhibitor. Prohibited medications that are associated with QTc prolongation are listed in', 'Appendix A, Table 6, while prohibited antipsychotic drugs are listed in Appendix A, Table 7.', '7.12.', 'Methods and Timing of Assessing, Recording, and Analyzing Safety', 'Data', 'All adverse events will be reviewed on a periodic basis by the clinical project physician/medical', 'monitor according to the safety monitoring plan (eg, scheduled safety reviews for TEV-50717)', 'as preliminary safety databases become available.', 'Methods and timing of assessing safety data are discussed in Section 3.13. Procedures for', 'recording safety data are discussed in Section 13.1, and methods of analyses are discussed in', 'Section 9.7.2.', 'Information about the IDMC used for this study is provided in Section 3.7.3.', '93']"
94,page_95,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '8.', 'ASSESSMENT OFPHARMACOKINETICS AND SCREENING', 'ASSESSMENTS', '8.1.', 'Pharmacokinetic Assessment', 'Blood samples will be obtained for the measurement of plasma concentrations of TEV-50717', '(deutetrabenazine), -HTBZ, B-HTBZ, and other metabolites, as needed.', 'Blood sampling for pharmacokinetic analysis will be performed at the week 12 visit. Two', 'samples will be collected. The first sample will be collected upon arrival at the clinic. The', 'second sample will be collected 2 to 3 hours after the first pharmacokinetic sample collection.', 'The time between samples should be maximized in order to provide the most useful information.', 'Patients with early morning visits (ie, within 2 hours of their scheduled AM dosing) should take', 'their dose in the clinic after the first pharmacokinetic sample is collected.', 'Patients will be provided with a diary to provide critical information on dosing before the', 'week 12 visit. The date and time of the last dose of study medication before the week 12 visit', 'should be recorded in the diary by the patient or caregiver/adult. The site will document the date', 'and time of the sample collection. Prior to the clinic visit at week 12, patients will be reminded to', 'record the start time of their last meal and the time of their last dose in their diary.', 'Plasma samples for both a-HTBZ and ß-HTBZ metabolites will be pooled with previous data', 'and incorporated into a population pharmacokinetic analysis. The population pharmacokinetic', 'analysis will result in a final structural model that best describes the data. A covariate assessment', 'will evaluate the relationship between potential covariates (ie, body weight, age, height, etc) and', 'concentrations of a-HTBZ and B-HTBZ metabolites. The final population pharmacokinetic', 'analysis will be included in a separate report.', 'Additional details regarding sampling and handling as well as shipment and analysis of samples', 'will be provided in the laboratory manual.', '8.2.', 'Pharmacodynamics Assessment', 'Exposure-response (eg, pharmacodynamic [PD] and/or safety endpoints) may be assessed if the', 'appropriate data are available.', '8.3.', 'Pharmacogenetics', '8.3.1.', 'CYP2D6 Genotyping/Pharmacogenetics', 'At the screening visit, a blood sample (3 mL) will be obtained for analysis of CYP2D6 genotype.', ""The patient's genotype for CYP2D6 will remain blinded during the conduct of the study. If the"", 'patient elects for PGx evaluation on the optional informed consent/assent, a pharmacogenetic', '(PGx) sample (2 mL) will be obtained and stored for exploratory PGx evaluation. This PGx', ""assessment will investigate the relationship between subjects' genetic variability and study"", 'outcomes. Candidate genes included in this assessment may be related to, or hypothesized to be', 'related to pharmacokinetics, safety features, drug mechanism of action, Tourette syndrome, or', '94']"
95,page_96,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'related diseases. The final list of genes to be evaluated will be determined at the time of analysis', 'to be able to account for the most current research.', '95']"
96,page_97,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9.', 'STATISTICS', 'This section describes the statistical analysis as foreseen at the time of planning the study.', 'Changes, additions, and further details about the analyses will be described in the statistical', 'analysis plan. After finalization of the statistical analysis plan, any additional analyses or', 'changes to analyses that may be required will be fully disclosed in the clinical study report.', '9.1.', 'Sample Size and Power Considerations', 'It is estimated that approximately 58 patients per arm will enable a power of at least 90% to', 'detect a beneficial standardized effect of 63% or more when the TEV-50717 arm is compared to', 'placebo (difference of 6.0 in the change from baseline to week 12 in TTS, assuming a standard', 'deviation of 9.5 in each arm) in a 2-sided type I error rate of 5% after accounting for potential', 'dropouts.', '9.2.', 'Analysis Sets', '9.2.1.', 'Intent-to-Treat Analysis Set', 'The intent-to-treat (ITT) analysis set will include all randomized patients. In this population,', 'treatment will be assigned based on the treatment to which patients were randomized, regardless', 'of which treatment they actually received.', '9.2.2.', 'Safety Analysis Set', 'The safety analysis set will include all patients who receive at least 1 dose of IMP. In this', 'population, treatment will be assigned based upon the treatment patients actually receive,', 'regardless of the treatment to which they were randomized.', '9.2.3.', 'Modified Intent-to-Treat Analysis Set', 'The Modified Intent-to-Treat (mITT) analysis set will include all patients in the ITT population', 'who receive at least 1 dose of IMP and have both a baseline and at least 1 post-baseline YGTSS', 'assessment. In this population, treatment will be assigned based on the treatment to which', 'patients were randomized, regardless of which treatment they actually received. All primary and', 'secondary analyses will be based on the mITT set.', '9.2.4.', 'Per-Protocol Analysis Set', 'The per-protocol analysis set will include patients who are compliant with study medication', '(80% to 105%), have a YGTSS assessment at baseline and at week 9 or week 12, who have not', 'taken prohibited concomitant medications as indicated in exclusion criterion, and who have no', '96']"
97,page_98,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'major protocol deviations that affect the validity of the efficacy measurements. The list of', 'protocol deviations will be reviewed before unblinding and major protocol deviations that could', 'affect the primary and secondary variables will be determined. All exclusions from the per-', 'protocol analysis set will be reviewed in the blinded data review meeting before database lock.', '9.3.', 'Data Handling Conventions', 'For all variables, only the observed data from the patients will be used in the primary and', 'secondary statistical analyses.', '9.4.', 'Study Population', 'The mITT analysis set (see Section 9.2) will be used for all efficacy summaries and analyses', 'unless otherwise noted. The safety analyses set will be used for all safety summaries. Sensitivity', 'analyses of primary and key secondary endpoints will be conducted using the per-protocol', 'analysis set. Summaries will be presented by treatment group and for all patients.', '9.4.1.', 'Patient Disposition', 'Data from patients screened; patients screened but not randomized (and reason not randomized);', 'patients who are randomized; patients randomized but not treated (and reason); patients in the', 'ITT, safety, and other analysis sets; patients who complete the study; and patients who withdraw', 'from the study will be summarized using descriptive statistics. Data from patients who withdraw', 'from the study will also be summarized by reason for withdrawal using descriptive statistics.', '9.4.2.', 'Demographic and Baseline Characteristics', 'Patient demographic and baseline characteristics, including medical history, prior medications,', 'and ECG findings, will be examined to assess the comparability of the treatment groups and will', 'be summarized using descriptive statistics. For continuous variables, descriptive statistics', '(number [n], mean, standard deviation, median, minimum, and maximum) will be provided. For', 'categorical variables, patient counts and percentages will be provided. Categories for missing', 'data will be presented if necessary.', '9.5.', 'Efficacy Analysis', '9.5.1.', 'Primary Endpoint', 'The primary efficacy endpoint for this study is the change in the TTS (of the YGTSS) from', 'baseline to week 12.', '9.5.2.', 'Key Secondary Enppoints', 'Key secondary endpoints for this study are as follows:', '1.', 'Change in the TS-CGI score from baseline to week 12', '2. Change in the TS-PGII score from baseline to week 12', '3. Change in the C&A-GTS-QOL ADL subscale score from baseline to week 12', '97']"
98,page_99,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9.5.3.', 'Exploratory Enppoints', 'Exploratory endpoints for this study are as follows:', '9.5.4.', 'Planned Method of Analysis', 'The mITT analysis set (see Section 9.2) will be used for all efficacy analyses. Summaries will be', 'presented by treatment group.', '9.5.4.1.', 'Primary Efficacy Analysis', 'The primary analysis will be a mixed-model, repeated-measures with the change in the TTS as', 'the dependent variable. The model will include fixed effects for treatment group, week (5 levels:', 'weeks 2, 4, 6, 9, and 12), and the treatment group by week interaction. The baseline TTS, region,', 'and age group at baseline (2 levels: 6 to 11 years, 12 to 16 years) will be included as covariates.', 'The unstructured covariance matrix for repeated observations within patients will be used. In', 'case that the model does not converge, the Maximum-Likelihood estimation method will be used', 'instead of the default Restricted Maximum-Likelihood. If the model still does not converge, then', 'a simpler covariance structure with fewer parameters will be used, according to the following', 'order: Heterogeneous Autoregressive (1), Heterogeneous Compound Symmetry, Autoregressive', '(1), and Compound Symmetry. The least squares means of the change in TTS from baseline at', 'week 12 will be compared (the active treatment arm and the placebo arm) using a 2-sided test at', 'the alpha=0.05 level of significance.', 'In addition, actual values and changes in the TTS from baseline to each visit will be summarized', 'using descriptive statistics.', '98']"
99,page_100,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9.5.4.2.', 'Sensitivity Analysis', 'Sensitivity analyses for missing data, the statistical model, and the increase in sample size will be', 'provided in the statistical analysis plan.', '9.5.4.3.', 'Key Secondary Efficacy Analyses', 'A hierarchical (fixed-sequence) testing approach will be used for the analysis of the primary and', 'key secondary endpoints to maintain the experiment-wise type I error rate of 5%. If an endpoint', 'is not statistically significant, confirmatory hypothesis testing will not be carried out on the', 'remaining hypotheses, and remaining hypotheses will be considered exploratory rather than', 'confirmatory. The change in the TS-CGI (1) and C&A-GTS-QOL ADL subscale (3) scores from', 'baseline to week 12 will be summarized and analyzed in the same fashion as the primary', 'analysis, with the exception that the baseline value of the given endpoint will be included as the', 'covariate. TS-PGII (2) will be analyzed using a Cochran-Mantel-Haenszel row mean score test', 'with a modified ridit scoring that controls for age group.', '9.5.4.4.', 'Exploratory Analyses', '99']"
100,page_101,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9.6.', 'Multiple Comparisons and Multiplicity', 'The hierarchical testing method will be used to maintain the experiment-wise type I error of 5%', 'level for the primary and key secondary analyses. The primary efficacy endpoint will first be', 'tested at the 5% type I error level. If the p-value of the primary analysis is 0.05, the secondary', 'hypotheses will be tested in the order listed for the secondary endpoints (Section 9.5.2) until', 'either an analysis produces a p-value >0.05 or all analyses result in a p-value 0.05.', '9.7.', 'Safety Enppoints and Analysis', 'Safety analyses will be performed on the safety analysis set.', '9.7.1.', 'Safety Enppoints', 'Safety endpoints for this study are as follows:', 'incidence of adverse events', 'observed values and changes from baseline in vital signs', 'observed values and change from baseline in the CDI-2 (Parent and Self-report', 'versions)', 'observed values in the C-SSRS', 'observed values in ECG parameters and shifts from screening for clinically', 'significant abnormal findings', 'observed values and changes from screening in clinical laboratory parameters', '(hematology, chemistry, and urinalysis)', '9.7.2.', 'Safety Analysis', 'All adverse events will be coded using the Medical Dictionary for Regulatory Activities. Each', 'patient will be counted only once in each preferred term or system organ class category for the', 'analyses of safety. Summaries will be presented for all adverse events, adverse events', 'determined by the investigator to be related to study treatment, serious adverse events, and', 'adverse events causing withdrawal from the study. Summaries will be presented by treatment', 'group and for all patients. Patient listings of serious adverse events and adverse events leading to', 'withdrawal will be presented.', 'Observed values and changes from baseline in laboratory results and vital signs will be', 'summarized descriptively.', 'Observed values in ECG parameters will be summarized, and counts and percentages of', 'abnormal findings will be presented. In addition, the number and percentage of patients with', 'on-treatment QTcF values >450, >480, or >500 msec and change from baseline >30 or >60 msec', 'will be presented.', '100']"
101,page_102,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The use of concomitant medications will be summarized by therapeutic class using descriptive', 'statistics. Concomitant medications will include all medications taken while the patient is treated', 'with IMP.', 'Observed values in the C-SSRS and observed values and changes from baseline in the CDI-2', '(Parent and Self-report versions) will be presented by treatment group for all patients.', '9.8.', 'Pharmacokinetic Analysis', 'The pharmacokinetic endpoint is listed in Section 2.3.5. Samples collected for pharmacokinetic', 'analysis will be quantified for -HTBZ and ß-HTBZ of TEV-50717, and other metabolites (as', 'needed), will be analyzed using population pharmacokinetic techniques. Analysis methods will', 'be detailed in a separate population pharmacokinetic analysis plan. Exploratory', 'pharmacokinetic/PD analysis may be performed on PD/safety endpoints.', '9.9.', 'Planned Interim Analysis', 'No interim analysis is planned for this study.', '9.10.', 'Reporting Deviations from the Statistical Plan', 'Deviations from the statistical plan, along with the reasons for the deviations, will be described', 'in protocol amendments, the statistical analysis plan, the clinical study report, or any', 'combination of these, as appropriate, and in accordance with applicable national, local, and', 'regional requirements and regulations.', '101']"
102,page_103,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '10.', 'DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS', 'The medical experts, study monitors, auditors, IEC/IRB, and inspectors from competent', 'authority (or their agents) will be given direct access to source data and documents (eg, medical', 'charts/records, laboratory test results, printouts, videotapes) for source data verification, provided', 'that patient confidentiality is maintained in accordance with national and local requirements.', ""The investigator must maintain the original records (ie, source documents) of each patient's data"", 'at all times. Examples of source documents are hospital records, office visit records, examining', ""physician's finding or notes, consultant's written opinion or notes, laboratory reports, drug"", 'inventory, IMP label records, diary data, protocol-required worksheets, and CRFs that are used', 'as the source (see Section 3.12).', 'The investigator will maintain a confidential patient identification list that allows the', 'unambiguous identification of each patient. All study-related documents must be kept until', 'notification by the sponsor.', '102']"
103,page_104,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '11.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '11.1.', 'Protocol Amendments and Protocol Deviations and Violations', '11.1.1.', 'Protocol Amendments', 'No changes from the final approved (signed) protocol will be initiated without the prior written', 'approval or favorable opinion of a written amendment by the IEC/IRB and national and local', 'competent authorities, as applicable, except when necessary to address immediate safety', 'concerns to the patients or when the change involves only nonsubstantial logistics or', 'administration. The principal investigator at each investigational center, the coordinating', 'investigator (if applicable), and the sponsor will sign the protocol amendment.', '11.1.2.', 'Protocol Violations', 'Any deviation from the protocol that affects, to a significant degree, (a) the safety, physical, or', 'mental integrity of the patients of the study and/or (b) the scientific value of the study will be', 'considered a protocol violation. Protocol violations may include non-adherence on the part of the', 'patient, the investigator, or the sponsor to protocol-specific inclusion and exclusion criteria,', 'primary objective variable criteria, or GCP guidelines; noncompliance to IMP administration;', 'use of prohibited medications. Protocol violations will be identified and recorded by', 'investigational center personnel in a log or as part of the CRF. All protocol violations will be', 'reported to the responsible IEC/IRB, as required.', 'When a protocol violation is reported, the sponsor will determine whether to discontinue the', 'patient from the study or permit the patient to continue in the study, with documented approval', 'from the medical expert. The decision will be based on ensuring the safety of the patient and', 'preserving the integrity of the study.', 'Changes in the inclusion and exclusion criteria of the protocol are not prospectively granted by', 'the sponsor. If investigational center personnel learn that a patient who did not meet protocol', 'inclusion and exclusion criteria was entered in a study, they must immediately inform the', 'sponsor of the protocol violation. If such patient has already completed the study or has', 'withdrawn early, no action will be taken but the violation will be recorded.', '11.2.', 'Information to Study Personnel', 'The investigator is responsible for giving information about the study to all personnel members', 'involved in the study or in any element of patient management, both before starting the study and', 'during the course of the study (eg, when new personnel become involved). The investigator must', 'ensure that all study personnel are qualified by education, experience, and training to perform', 'their specific task. These study personnel members must be listed on the investigational center', ""authorization form, which includes a clear description of each personnel member's"", 'responsibilities. This list must be updated throughout the study, as necessary.', 'The study monitor is responsible for explaining the protocol to all study personnel, including the', 'investigator, and for ensuring they comply with the protocol. Additional information will be', '103']"
104,page_105,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'made available during the study when new personnel members become involved in the study and', 'as otherwise agreed upon with either the investigator or the study monitor.', '11.3.', 'Study Monitoring', 'To ensure compliance with GCP guidelines, the study monitor or representative is responsible', 'for ensuring that patients have signed the informed consent form, and the study is conducted', 'according to applicable Standard Operating Procedures (SOPs), the protocol, and other written', 'instructions and regulatory guidelines.', 'The study monitor is the primary association between the sponsor and the investigator. The main', 'responsibilities of the study monitor are to visit the investigator before, during, and after the', 'study to ensure adherence to the protocol; that all data are correctly and completely recorded and', ""reported; and that informed consent/assent, depending on the child's age, as appropriate, is"", 'obtained and recorded for all patients before they participate in the study and when changes to', 'the consent form are warranted, in accordance with IEC/IRB approvals.', 'The study monitor will contact the investigator and visit the investigational center at regular', 'intervals throughout the study. The study monitor will be permitted to check and verify the', 'various records (CRFs and other pertinent source data records, including specific electronic', 'source document [see Section 3.12]) relating to the study to verify adherence to the protocol and', 'to ensure the completeness, consistency, and accuracy of the data being recorded. If electronic', 'CRFs are used for the study, the study monitor will indicate verification by electronically', 'applying source document verification flags to the CRF and will ensure that all required', 'electronic signatures are being implemented accordingly.', 'As part of the supervision of study progress, other sponsor personnel may, on request,', 'accompany the study monitor on visits to the investigational center. The investigator and', 'assisting personnel must agree to cooperate with the study monitor to resolve any problems,', 'errors, or possible misunderstandings concerning the findings detected in the course of these', 'monitoring visits or provided in follow-up written communication.', '11.4.', 'Clinical Product Complaints', 'A clinical product complaint is defined as a problem or potential problem with the physical', 'quality or characteristics of clinical drug supplies or clinical device supplies used in a clinical', 'research study sponsored by Teva. Examples of a product complaint include but are not limited', 'to:', 'suspected contamination', 'questionable stability (eg, color change, flaking, crumbling, etc)', 'defective components', 'missing or extra units (eg, primary container is received at the investigational center', 'with more or less than the designated number of units inside)', 'incorrect packaging, or incorrect or missing labeling/labels', 'unexpected or unanticipated taste or odor, or both', '104']"
105,page_106,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'device not working correctly or appears defective in some manner', 'Each investigational center will be responsible for reporting a possible clinical product complaint', 'by completing the product complaint form provided by Teva and emailing it to', 'within 48 hours of becoming aware of the issue.', 'For complaints involving a device or other retrievable item, it is required that the device (or', 'item) be sent back to the sponsor for investigative testing whenever possible. For complaints', ""involving a drug product, all relevant samples (eg, the remainder of the patient's drug supply)"", 'should be sent back to the sponsor for investigative testing whenever possible.', '11.4.1.', 'Product Complaint Information Needed from the Investigational Center', 'In the event that the product complaint form cannot be completed, the investigator will obtain the', 'following information, as available:', 'investigational center number and principal investigator name', 'name, phone number, and address of the source of the complaint', 'clinical protocol number', 'patient identifier (patient study number) and corresponding visit numbers, if', 'applicable', 'patient number, blister pack, and kit numbers (if applicable) for double-blind studies', 'product available for return Yes/No', 'product was taken or used according to protocol Yes/No', 'description or nature of complaint', 'associated serious adverse event Yes/No', 'clinical supplies unblinded (for blinded studies) Yes/No', 'date and name of person receiving the complaint', 'Note: Reporting a product complaint must not be delayed even if not all the required information', 'can be obtained immediately. Known information must be reported immediately. The sponsor', 'will collaborate with the investigator to obtain any outstanding information.', '11.4.2.', 'Handling of IMP at the Investigational Center', 'The investigator is responsible for retaining the product in question in a location separate from', ""the investigator's clinical study supplies. The sponsor may request that the investigator return the"", 'product for further evaluation and/or analysis. If this is necessary, the clinical study monitor or', 'designee will provide the information needed for returning the IMP.', 'If it is determined that the investigational center must return all IMP, the sponsor will provide the', 'information needed to handle the return.', '105']"
106,page_107,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'The integrity of the randomization code and corresponding blinded clinical supplies will be', 'maintained whenever possible. A serious adverse event or the potential for a product quality', 'problem existing beyond the scope of the complaint may be a reason to unblind the clinical', 'supplies for an affected patient.', '11.4.3.', 'Adverse Events or Serious Adverse Events Associated with a Product Complaint', 'If there is an adverse event or serious adverse event due to product complaint, the protocol', 'should be followed for recording and reporting (Section 7.1.2 and Section 7.1.5.3, respectively).', '11.4.4.', 'Documenting a Product Complaint', 'The investigator will record in the source documentation a description of the product complaint,', 'and any actions taken to resolve the complaint and to preserve the safety of the patient. Once the', 'complaint has been investigated by the sponsor and the investigator, if necessary, an event', 'closure letter may be sent to the investigational center where the complaint originated or to all', 'investigational centers using the product.', '11.5.', 'Audit and Inspection', 'The sponsor or delegate may audit the investigational center to evaluate study conduct and', 'compliance with protocols, SOPs, GCP guidelines, and applicable regulatory requirements. The', ""sponsor's Global Clinical Quality Assurance, independent of Global Clinical Development, is"", 'responsible for determining the need for (and timing of) an investigational center audit.', 'The investigator must accept that competent authorities and sponsor representatives may conduct', 'inspections and audits to verify compliance with GCP guidelines.', '106']"
107,page_108,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '12.', 'ETHICS', 'Details of compliance with regulatory requirements and applicable laws are provided in', 'Section 1.6.', '12.1.', 'Informed Consent/Assent', 'The investigator, or a qualified person designated by the investigator, should fully inform the', 'patient and parent/legally acceptable representative of all pertinent aspects of the study,', 'including the written information approved by the IEC/IRB. All written and oral information', 'about the study will be provided in a language as nontechnical as practical to be understood by', 'the parent/legally acceptable representative and the patient. The patient and parent/legally', 'acceptable representative should be given ample time and opportunity to inquire about details of', 'the study and to decide whether or not to participate in the study. The above should be detailed in', 'the source documents.', 'A personally signed and dated informed consent form will be obtained from parent/legally', ""acceptable representative, and a signed and dated assent, depending on the child's age, as"", 'appropriate, will be obtained from each patient (if the patient is able) before any study-specific', 'procedures or assessments are done and after the aims, methods, anticipated benefits, and', 'potential hazards are explained; according to national and local IEC/IRB requirements. The', 'forms will be signed and dated also by the person who conducted the informed consent', 'discussion. The investigator will keep the original informed consent/assent forms, depending on', ""the child's age, as appropriate, and copies will be given to the patients. It will also be explained"", 'to the patients (and parent/legally acceptable representative) that they are free to refuse', 'participation in the study and free to withdraw from the study at any time without prejudice to', 'future treatment.', '12.2.', 'Competent Authorities and Independent Ethics', 'Committees/Institutional Review Boards', 'Before this study starts, the protocol will be submitted to the national and local competent', 'authority and to each IEC/IRB for review. As required, the study will not start at a given', 'investigational center before the IEC/IRB and competent authority (where applicable) for the', 'investigational center give written approval or a favorable opinion.', '12.3.', 'Confidentiality Regarding Study Patients', 'The investigator must ensure that the privacy of the patients, including their identity and all', 'personal medical information, will be maintained at all times. In CRFs and other documents or', 'image material submitted to the sponsor, patients will be identified not by their names, but by an', 'identification number.', 'Personal medical information may be reviewed for the purpose of patient safety or for verifying', 'data in the source and transcribed to the CRF. This review may be conducted by the study', 'monitor, properly authorized persons on behalf of the sponsor, Global Quality Assurance, or', 'competent authorities. Personal medical information will always be treated as confidential.', '107']"
108,page_109,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '12.4.', 'Declaration of the End of Clinical Study', 'The end of study is defined as the date of the week 14 visit of the last participant.', 'For investigational centers located in the European Union, a declaration of the end of the clinical', 'study will be made according to the procedures outlined in Directive 2001/20/EC, Article 10(c);', 'for other countries, national and local regulations will be followed.', '12.5.', 'Registration of the Clinical Study', 'In compliance with national and local regulations and in accordance with Teva standard', 'procedures, this clinical study may be registered on clinical studies registry websites.', '108']"
109,page_110,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '13.', 'DATA HANDLING, DATA QUALITY CONTROL, AND RECORD', 'KEEPING', '13.1.', 'Data Collection', 'Data will be collected using CRFs that are specifically designed for this study. The data collected', 'on the CRFs will be captured in a clinical data management system (CDMS) that meets the', 'technical requirements described in 21CFR Part 11. The CDMS will be fully validated to ensure', 'that it meets the scientific, regulatory, and logistical requirements of the study before it is used to', 'capture data from this study. Before using the CDMS, all users will receive training on the', 'system and study-specific training. After they are trained, users will be provided with individual', 'system access rights.', 'Data will be collected at the investigational center by appropriately designated and trained', 'personnel, and CRFs must be completed for each patient who provided informed consent/assent.', 'Patient identity should not be discernible from the data provided on the CRF. Data will be', 'verified by the study monitor using the data source, and reviewed for consistency by Data', 'Management using both automated logical checks and manual review. All data collected will be', 'approved by the investigator at the investigational center. This approval acknowledges the', ""investigator's review and acceptance of the data as being complete and accurate."", 'If data are processed from other sources (eg, central laboratory, bioanalytical laboratory, central', 'ECG center, diary data, electronic patient-reported outcome [ePRO] Tablet), the results will be', 'sent to the investigational center, where they will be retained but not entered in the CRF, unless', 'otherwise specified in the protocol. These data may also be sent electronically to the sponsor (or', 'organization performing data management) for direct entry in the clinical database. Laboratory', 'test results will not be entered in the CRF unless otherwise specified in the protocol. All data', 'from other sources will be available to the investigators.', 'For patients who enter a study but do not meet entry criteria, at a minimum, data for screening', 'failure reason, demography, and adverse events from the time of informed consent/assent will be', 'entered in the CRF.', '13.2.', 'Data Quality Control', 'Data Management is responsible for the accuracy, quality, completeness, and internal', 'consistency of the data from this study. Data handling, including data quality control, will', 'comply with international regulatory guidelines, including ICH GCP guidelines. Data', 'management and control processes specific to this study, along with all steps and actions taken', 'regarding data management and data quality control, will be described in a data management', 'plan.', 'CRFs received will be processed and reviewed for completeness, consistency, and the presence', 'of mandatory values. Applicable terms will be coded according to the coding conventions for', 'this study. Logical checks will be implemented to ensure data quality and accuracy. Any', 'necessary changes will be made in the clinical database, and data review and validation', 'procedures will be repeated as needed. Data from external sources will be compared with the', 'information available in the CDMS. Discrepancies found will be queried.', '109']"
110,page_111,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Data corrections in the CDMS will be made using the CDMS update function. The system', 'requires a reason for each change and keeps a complete audit trail of the data values, dates, and', 'times of modifications, and authorized electronic approvals of the changes.', 'At the conclusion of the study, the CDMS and all other study data will be locked to further', 'additions or corrections. Locking the study data represents the acknowledgement that all data', 'have been captured and confirmed as accurate.', '13.3.', 'Archiving of Case Report Forms and Source Documents', '13.3.1.', 'Sponsor Responsibilities', 'The sponsor or delegate will have final responsibility for the quality of the data.', 'Day to day data management tasks for this study are delegated to Syneos Health, and these', 'functions may be carried out as described in the SOPs for clinical studies at that organization.', 'These SOPs will be reviewed by the sponsor or delegate before the start of data management', 'activities. The original CRFs will be archived by the sponsor. Investigational center-specific', 'CRFs will be provided to the respective investigational centers for archiving.', '13.3.2.', 'Investigator Responsibilities', 'The investigator must maintain all written and electronic records, accounts, notes, reports, and', 'data related to the study and any additional records required to be maintained under country,', 'state/province, or national and local laws, including, but not limited to:', 'full case histories', 'signed informed consent/assent forms', 'patient identification lists', 'CRFs for each patient on a per-visit basis', 'data from other sources (eg, central laboratory, bioanalytical laboratory, central ECG', 'center, diary)', 'safety reports', 'financial disclosure reports/forms', 'reports of receipt, use, and disposition of the IMP', 'copies of all correspondence with sponsor, the IEC/IRB, and any competent authority', 'The investigator will retain all records related to the study and any additional records required, as', 'indicated by the protocol and according to applicable laws and regulations, until Syneos Health', 'or sponsor notifies the institution in writing that records may be destroyed. If, after 25 years from', 'study completion, or earlier in the case of the investigational center closing or going out of', 'business, the investigator reasonably determines that study record retention has become unduly', 'burdensome, and sponsor has not provided written notification of destruction, then the', 'investigator may submit a written request to sponsor at least 60 days before any planned', 'disposition of study records. After receipt of such request, the sponsor may make arrangements', 'for appropriate archival or disposition, including requiring that the investigator deliver such', '110']"
111,page_112,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'records to the sponsor. The investigator shall notify the sponsor of any accidental loss or', 'destruction of study records.', '111']"
112,page_113,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '14.', 'FINANCING AND INSURANCE', 'A separate clinical study agreement, including a study budget, will be signed between each', 'principal investigator and Syneos Health before the IMP is delivered.', 'This clinical study is insured in accordance with applicable legal provisions. The policy coverage', 'is subject to the full policy terms, conditions, extensions, and exclusions. Excluded from the', 'insurance coverage are inter alia, damages to health, and worsening of previous existing disease', 'that would have occurred or continued if the patient had not taken part in the clinical study.', 'The policy of Clinical Trials Insurance will be provided to the investigational centers by the', 'sponsor.', 'For covered clinical studies (see 21CFR54), the investigator will provide the sponsor with', 'financial information required to complete FDA 3454 form. Each investigator will notify the', 'sponsor of any relevant changes during the conduct of the study and for 1 year after the study has', 'been completed.', '112']"
113,page_114,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '15.', 'REPORTING AND PUBLICATION OF RESULTS', 'The sponsor is responsible for ensuring that the public has access to the appropriate information', 'about the study by conforming to national, local, and regional requirements and regulations for', 'registration and posting of results.', 'The sponsor is responsible for the preparation of a clinical study report in cooperation with the', 'coordinating investigator. The final report is signed by the sponsor and, if applicable, by the', 'coordinating investigator.', 'When the sponsor generates reports from the data collected in this study for presentation to', 'competent authorities, drafts may be circulated to the principal investigator for comments and', 'suggestions. An endorsement of the final report will be sought from the principal investigator.', 'All unpublished information given to the investigator by the sponsor shall not be published or', 'disclosed to a third party without the prior written consent of the sponsor. The primary', 'publication from this study will report the results of the study in accordance with the', '""Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in', 'Medical Journals"" (www.ICMJE.org). Publication of the results will occur in a timely manner', 'according to applicable regulations. Authorship will be based on meeting all the following', '4 criteria:', 'substantial contributions to the conception or design of the work; or the acquisition,', 'analysis, or interpretation of data for the work', 'drafting the work or revising it critically for important intellectual content', 'final approval of the version to be published', 'agreement to be accountable for all aspects of the work in ensuring that questions', 'related to the accuracy or integrity of any part of the work are appropriately', 'investigated and resolved', 'The publications committee established by the sponsor will oversee this process. Additional', 'publications may follow. Policies regarding the publication of the study results are defined in the', 'financial agreement.', 'No patent applications based on the results of the study may be made by the investigator nor may', 'assistance be given to any third party to make such an application without the written', 'authorization of the sponsor.', '113']"
114,page_115,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '16.', 'REFERENCES', 'Fuenmayor LD, Vogt M. The influence of cerebral 5-hydroxytryptamine on catalepsy induced by', 'brain-amine depleting neuroleptics or by cholinomimetics. B J Pharmacol 1979;67(2):309-18.', 'Gilbert D, Jankovic J. Pharmacological treatment of Tourette syndrome. J Obsessive Compuls', 'Rel Disord 2014;3:407-14.', 'Heitjan F and Little RJA. Multiple Imputation for the Fatal Accident Reporting System. Applied', 'Statistics 1991;40:13-29.', 'Jain S, Greene PE, Frucht SJ. Tetrabenazine therapy of pediatric hyperkinetic movement', 'disorders. Mov Disord 2006;21(11):1966-72.', 'Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord', '2015;30(11): 1566-73.', 'Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin', 'Neuropharmacol 1995;18(3):197-214.', ""Jankovic J. Tourette's syndrome. N Engl J Med 2001;345(16): 1184-92."", 'Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement. Neurology', '1997;48(2):358-62.', 'Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord 2011;26(6):1149.', 'Kenney C, Hunter C, N M, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J', 'Pediatric Neurol 2007;5(1):9-13.', 'Kurlan R, Como PG, Miller B, Palumbo D, Deeley C, Andresen EM, et al. The behavioral', 'spectrum of tic disorders: a community-based study. Neurology 2002;59(3):414-20', 'Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic', 'Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc', 'Psychiatry 1989;28(4):566-73.', 'Little RJA and Rubin DB. Statistical Analysis with Missing Data, Second Edition. New York:', 'John Wiley & Sons 2002.', 'Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert', 'Rev Neurother 2010Jun;10(6):893-901', 'Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6', 'genotype and response to tetrabenazine. Mov Disord 2013 Feb;28(2):210-5.', 'Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S. Tetrabenazine treatment in', 'movement disorders. Clin Neuropharmacol 2004;27(5):230-3.', 'Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to', 'disordered movement-a review of the clinical benefits and medicolegal risks of', 'metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3(3):138-48.', 'Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to', 'aripiprazole. Mov Disord 2011 Jan;26(1):147-52.', '114']"
115,page_116,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D. Tourette's syndrome and"", 'role of tetrabenazine: review and personal experience. Clin Drug Investig 2008;28(7):443.', 'Rubin DB. Multiple Imputation for Nonresponse in Surveys, New York: John Wiley & Sons.', '1987.', ""Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WL, et al. Children's"", 'Yal-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc', 'Psychiatry 1997;36(6):844-52', 'Schenker N and Taylor JMG. Partially Parametric Techniques for Multiple Imputation.', 'Computational Statistics and Data Analysis 1996;22:425-446.', 'Scherman D, Gasnier B, Jaudon P, Henry JP. Hydrophobicity of the tetrabenazine-binding site of', 'the chromaffin granule monoamine transporter. Mol Pharmacol 1988;33(1):72-7.', 'Shaw Z, Coffey B. Tics and Tourette syndrome. Psychiatr Clin North Am 2014 Sep;37(3):269-', '86.', 'Su M, McFarlane F, Cavanna A, et al. The English Version of the Gilles de la Tourette', 'Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL). J Child', 'Neurol 2017;32(1):76-83', ""Sun S, Wang S. The Children's Depression Inventory in worldwide child development research:"", 'a reliability generalization study. J Child Fam Stud 2015;24(8):2352-63.', 'Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor', 'and other hyperkinetic movements. Tremor Other Hyperkinet Mov 2013;3', 'Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with', 'Tourette syndrome. Mov Disord 2014 Jan;29(1):126-30', 'Xenazine: Highlights of Prescribing Information. 2015. Available at:', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021894s010lbl.pdf. Accessed 27', 'Oct 2015.', '115']"
116,page_117,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '17.', 'SUMMARY OF CHANGES TO PROTOCOL', '17.1.', 'Amendment 01 Dated 22 June 2017', 'The primary reason for this amendment is to change aspects of the conduct, concomitant', 'mediations, titration instructions, sample size, acceptable contraceptive methods, analysis of the', 'data, and clinical study personnel.', 'This amendment is considered to be substantial (ie, requires approval by CA, IEC, and/or IRB)', ""by the sponsor's Authorized Representative. Other nonsubstantial changes have been made to the"", 'protocol (and protocol synopsis, as appropriate). These changes are unlikely to affect the safety', 'or rights (physical or mental integrity) of the patients in this clinical study or the scientific value', 'of the clinical study.', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', 'For medical issues, contact the physician listed', 'For medical issues, contact the', 'This change', 'below:', 'physician listed below:', 'was made to', 'update the', 'medical issue', 'contact', 'physician.', 'For operational issues, contact the operational', 'For operational issues, contact the', 'This change', 'lead listed below:', 'operational lead listed below:', 'was made to', 'update the', 'protocol', 'contact', 'physicians.', '116']"
117,page_118,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'For protocol issues, contact the study leader', 'listed below:', '1.4. Known and Potential Risks and Benefits to Human Patients (Other sections affected by this', 'change: 1.4.1.1., 1.4.1.2., 1.4.2.)', 'Additional information regarding benefits and', 'Additional information regarding', 'The section', 'risks to patients may be found in the current IB', 'benefits and risks to patients may be', 'was modified', 'and in the United States prescribing information', 'found in the current IB and in the', 'to reflect', 'for AUSTEDO"" (deutetrabenazine).', 'United States prescribing', 'accurate', 'Benefits of TEV50717', 'information for AUSTEDOT', 'information', 'Although the efficacy of TEV 50717 in patients', '(deutetrabenazine).', 'regarding', 'known and', 'with TS has not yet been definitively', 'established, preliminary efficacy data from', 'potential', 'benefits and', 'Study SD 809 € 1 7 indicates a clinically', 'risks to', 'meaningful reduction in motor and phonic ties', 'observed by patients, parents, and treating', 'patients.', 'clinicians. Furthermore, TEV 50717 has the', 'same mechanism of action and indistinguishable', 'pharmacology as tetrabenazine, an agent that is', 'generally accepted among movement disorder', 'experts to provide clinical benefit in this patient', 'population (Jankovie and Kurlan 2011). Based', 'on the nonclinical data discussed above and', 'similar efficacy observed for tetrabenazine and', 'TEV 50717 in studies of other indications (see', '117']"
118,page_119,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'IB), TEV 50717 has the potential to offer', 'effective treatment in children and adolescents', 'with TS.', '1.4.1.2. Potential Risks of TEV 50717', 'The following nformation is based on clinical', 'trial experience with TEV 50717 and the United', 'States prescribing information for Xenazine', '(tetrabenazine):', 'TEV 50717 is contraindicated in patients', 'who are actively suicidal, or in patients with', 'untreated or inadequately treated', 'depression.', 'TEV 50717 is contraindicated in patients', 'with impaired hepatic function.', 'TEV 50717 is contraindicated in patients', 'taking monoamine oxidase inhibitors', '(MAOIs). TEV 50717 should not be used in', 'combination with an MAOI, or within a', 'minimum of 14 days of discontinuing', 'therapy with an MAOI.', 'TEV 50717 is contraindicated in patients', 'taking reserpine. At least 21 days should', 'elapse after stopping reserpine before', 'starting TEV 50717.', 'Additional information regarding each potential', 'issue may be found in the current IB.', '1.4.2. Overall Risk and Benefit Assessment', 'for This Study', 'There is a significant need to identify new', 'treatments for TS that do not antagonize', 'dopamine receptors, as those latter agents pose', 'serious risks such as metabolie syndrome and', 'TD, a movement disorder that is often', 'irreversible. The results from Study SD 809 €', '17 demonstrated meaningful efficacy in the', 'context of good tolerability and no signal on', 'safety scales, vital signs, laboratory parameters,', 'or 12 lead electrocardiograms (ECGs). Those', 'findings are consistent with results in other', 'study populations, such as HD, where the rates', 'for TEV 50717 and placebo were similar for', 'overall adverse events, neurologie and', 'psychiatric adverse events, as well as dose', 'reduction or dose suspension for adverse events', '(see IB for details).', '118']"
119,page_120,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', '3.1.2 Screening Period (Other sections affected by this change: Sections 3.13, 3.13.1., 4.1, 12.1.)', 'After informed consent (and written assent', 'After informed consent (and written', 'An option was', 'and/or co-consent for patients 14 years of age', 'assent and/or co-consent for patients', 'added for co-', 'and older, as appropriate) is obtained, patients', '14 years of age and older, as', 'consent for', 'who are stable from a medical and psychiatric', 'appropriate) is obtained, patients', 'patients', 'standpoint will undergo a screening evaluation,', 'who are stable from a medical and', '14 years of age', 'including medical history, physical and', 'psychiatric standpoint will undergo', 'and older.', 'neurological examination, laboratory testing,', 'a screening evaluation, including', 'and 12-lead ECG, along with rating scales to', 'medical history, physical and', 'assess severity, frequency, and impairment of', 'neurological examination,', 'tics and comorbid TS symptoms and behavioral', 'laboratory testing, and 12-lead ECG,', 'status.', 'along with rating scales to assess', 'severity, frequency, and impairment', 'of tics and comorbid TS symptoms', 'and behavioral status.', '3.1.3 Titration Period (Other sections affected by this change: Section 5.1)', 'Patients who remain eligible for participation in', 'Patients who remain eligible for', 'A statement', 'the study will be randomized at the baseline', 'participation in the study will be', 'was added to', 'visit (day 1), and that evening (ie, after the', 'randomized at the baseline visit', 'further clarify', 'study visit) will receive 6 mg of blinded IMP', '(day 1), and that evening (ie, after', 'that the IMP', 'with food. Tablets should be taken with food', 'the study visit) will receive 6 mg of', 'should be taken', '(eg, a snack) and should not be taken on an', 'blinded IMP with food. Tablets', 'with a snack', 'empty stomach.', 'should be taken with food (eg, a', 'and not on an', 'snack) and should not be taken on', 'empty stomach.', 'an empty stomach.', '3.1.3 Titration Period', 'The dose of the study drug IMP should be', 'The dose of the IMP should be', 'The titration', 'increased on a weekly basis until one of the', 'increased on a weekly basis until', 'instructions', 'following criteria is met:', 'one of the following criteria is met:', 'were modified', 'The investigator determines there', 'to provide more', 'The investigator determines there has been', 'has been a clinically meaningful', 'objective', 'a clinically meaningful reduction in tics, as', 'indicated by a sustained reduction in the', 'reduction in tics, as indicated by', 'guidance to', 'TS-CGI', 'a sustained reduction in the TS-', 'investigators,', 'CGI', 'who are now', 'there is optimal reduction of ties, as', 'directed to', 'determined by the investigator, in', 'increase the', 'consultation with the patient and', 'dose until there', 'earegiver/adult', 'is a sustained', 'reduction in the', 'TS-CGI.', '119']"
120,page_121,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', '3.1.5. Washout Period and Follow-up', 'Patients who complete the study may be eligible', 'Patients who complete the study', 'The study', 'to begin participation in an open-label safety', 'may be eligible to begin', 'number of the', 'extension study of TEV-50717 at that', 'participation in an open-label safety', 'extension study', 'time(Study TV50717-CNS-30047). For this', 'extension study of TEV-50717', 'was added, the', 'study, the follow-up period is defined as 1 week', '(Study TV50717-CNS-30047). For', 'washout period', 'of washout for patients who will participate in', 'this study, the follow-up period is', 'was clarified,', 'the open-label safety extension study TV50717-', 'defined as 1 week of washout for', 'and', 'CNS-30047 and 2 weeks after the last dose of', 'patients who will participate in the', 'concomitant', 'IMP (1 week after the end of the washout', 'open-label safety extension study', 'medications', 'period) for patients who will not roll over into', 'TV50717-CNS-30047 and 2 weeks', 'allowed during', 'the open-label safety extension study TV50717-', 'after the last dose of IMP (1 week', 'the washout', 'CNS-30047. Patients not participating in the', 'after the end of the washout period)', 'period were', 'open-label safety extension study for', 'for patients who will not roll over', 'clarified.', 'TEV-50717 will have a follow-up telephone', 'into the open-label safety extension', 'contact for safety evaluation 1 week after the', 'study TV50717-CNS-30047.', 'end of the treatment period (2 weeks after their', 'Patients not participating in the', 'last dose of IMP).', 'open-label safety extension study', 'The end of study is defined as the date of the', 'for TEV-50717 will have a follow-', 'week 10 telephone contact with the last', 'up telephone contact for safety', 'participant.', 'evaluation 1 week after the end of', 'Prohibited drugs will remain the same during', 'the treatment period (2 weeks after', 'the washout period for patients who will', 'their last dose of IMP).', 'participate in the open-label extension study', 'The end of study is defined as the', 'TV50717-CNS-30047.', 'date of the week 10 telephone', 'Patients who will not participate in the', 'contact with the last participant.', 'extension study (Study TV50717-CNS-30047)', 'Prohibited drugs will remain the', 'may begin/resume tic therapy medication after', 'same during the washout period for', 'the first week of the washout period.', 'patients who will participate in the', 'open-label extension study', 'TV50717-CNS-30047', 'Patients who will not participate in', 'the extension study (Study', 'TV50717-CNS-30047) may', 'begin/resume tic therapy medication', 'after the first week of the washout', 'period.', '3.6 Randomization and Blinding', ""In addition, the sponsor's clinical personnel and"", ""In addition, the sponsor's clinical"", 'Statement was', 'all vendors (with exception of the Interactive', 'personnel and all vendors (with', 'added about', 'Response Technology [IRT] vendor and the', 'exception of the Interactive', 'blinding until', 'bioanalytical sample analysis vendor) involved', 'Response Technology [IRT] vendor', 'completion of', 'in the study will be blinded to the IMP identity', 'and the bioanalytical sample', 'the safety', 'until the database is locked for analysis and the', 'analysis vendor) involved in the', 'extension study', 'treatment assignment revealed. After unblinding', 'study will be blinded to the IMP', 'TEV-50717-', '120']"
121,page_122,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'of this study, the study site may remain blinded', 'identity until the database is locked', 'CNS-30047.', 'to patient treatment assignments until', 'for analysis and the treatment', 'completion of the safety extension study', 'assignment revealed. After', 'TV50717-CNS-30047.', 'unblinding of this study, the study', 'site may remain blinded to patient', 'treatment assignments until', 'completion of the safety extension', 'study TV50717-CNS-30047.', '3.8.1 IMP (Other sections affected by this change: Section 1.2)', 'The IMP is a matrix formulation and is', 'The IMP is a matrix formulation and', 'Additional', 'designed as a gastro-erosional tablet to be', 'is designed as a gastro-erosional', 'details were', 'administered with food and should not be taken', 'tablet to be administered with food', 'added to the', 'on an empty stomach. The IMP is coated with a', 'and should not be taken on an empty', 'description of', 'white polymer coating to aid in swallowing.', 'stomach. The IMP is coated with a', 'IMP.', 'TEV-50717 tablets have been manufactured', 'white polymer coating to aid in', 'according to current Good Manufacturing', 'swallowing. TEV-50717 tablets', 'Practice regulations. TEV-50717 tablets are', 'have been manufactured according', 'available in the following strengths: 6, 9, 12, 15,', 'to current Good Manufacturing', 'and 18 mg, all of which are identical in size,', 'Practice regulations. TEV-50717', 'shape, and color (white). IMP will be supplied', 'tablets are available in the following', 'in 20-count tablets per dose strength per bottle.', 'strengths: 6, 9, 12, 15, and 18 mg,', 'The placebo tablets and packaging will match', 'all of which are identical in size,', 'those for TEV-50717. Each bottle (20-count', 'shape, and color (white). IMP will', 'tablets per dose strength per bottle) will contain', 'be supplied in 20-count tablets per', 'a sufficient supply of drug until the next', 'dose strength per bottle. The', 'specified visit/telephone contact, plus overage', 'placebo tablets and packaging will', 'to account for potential delays in study visits.', 'match those for TEV-50717. Each', 'bottle (20-count tablets per dose', 'strength per bottle) will contain a', 'sufficient supply of drug until the', 'next specified visit/telephone', 'contact, plus overage to account for', 'potential delays in study visits.', '3.13. Study Procedures', 'Study procedures and assessments with their', 'Study procedures and assessments', 'The section', 'timinge points are summarized presented in', 'with their time points are presented', 'was modified', 'Table 1. During a visit, study procedures and', 'in Table 1. During a visit, study', 'to provide', 'assessments should be performed in the order', 'procedures and assessments should', 'guidance that', 'specified in the study manual.', 'be performed in the order specified', 'the order of', 'in the study manual.', 'procedures will', 'be determined', 'in a study', 'manual.', '121']"
122,page_123,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', '3.13. Study Procedures (Other sections affected by this change: Sections 5.3, 7.10)', 'At each clinic visit after the screening visit, the', 'At each clinic visit after the', 'This additional', 'investigator will ask patients whether they have', 'screening visit, the investigator will', 'instruction will', 'taken any medications (other than IMP),', 'ask patients whether they have taken', 'allow the', 'including over-the-counter medications,', 'any medications (other than IMP),', 'investigator to', 'vitamins, or herbal or nutritional supplements,', 'including over-the-counter', 'monitor new', 'since the previous visit. Parents/patients will be', 'medications, vitamins, or herbal or', 'concomitant', 'instructed during the course of the study to', 'nutritional supplements, since the', 'medications,', 'notify the investigator if any new medication is', 'previous visit. Parents/patients will', 'thus enhancing', 'prescribed, including over-the-counter', 'be instructed during the course of', 'patient safety.', 'medications. Any prescribed medication should', 'the study to notify the investigator if', 'be reviewed with the investigator. Indication,', 'any new medication is prescribed,', 'dosage, and start and end dates should be', 'including over-the-counter', 'entered on the CRF.', 'medications. Any prescribed', 'medication should be reviewed with', 'the investigator. Indication, dosage,', 'and start and end dates should be', 'entered on the CRF.', '3.13.1. Procedures for Screening and Enrollment', 'After informed consent is obtained, patients', 'This paragraph', 'who are screened will be assigned an 8 digit', 'was deleted to', 'permanent identification number such that all', 'remove the', 'patients from each investigational center are', 'detailed', 'given consecutive identification numbers in', 'specificity for', 'successive order of inclusion. The first 2 digits', 'patient ID', 'of the screening number will be the number', 'assignment.', 'assigned to the country where the', 'investigational center is located, the next', '3 digits will be the designated in restigator', 'center number, and the last 3 digits will be', 'assigned at the investigator center (eg, if the', 'number assigned to the country is 01, the', 'third patient screened at center 5 would be', 'given the number of 01005003).', '3.13.1. Procedures for Screening and Enrollment', 'administer the following questionnaires', 'administer the following', 'Specific', '(Note: For MINI Kid and C-SSRS, children', 'questionnaires (Note: For MINI', 'instruction was', '13 years of age and under must be', 'Kid and C-SSRS, children 13', 'provided for', 'interviewed in conjunction with the', 'years of age and under must be', 'the YGTSS', 'caregiver/adult. For children over 13 years of', 'interviewed in conjunction with', 'assessment to', 'age, caregiver/adult involvement is strongly', 'the caregiver/adult. For children', 'be performed', 'encouraged. Questions should be directed to', 'over 13 years of age,', 'before any', 'the child, but the caregiver/adult should be', 'caregiver/adult involvement is', 'blood draws or', 'encouraged to add relevant information. The', 'strongly encouraged. Questions', 'ECG.', '122']"
123,page_124,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'YGTSS questionnaire should be performed', 'should be directed to the child,', 'before any blood draws or ECG', 'but the caregiver/adult should be', 'assessments.):', 'encouraged to add relevant', 'information. The YGTSS', 'questionnaire should be', 'performed before any blood', 'draws or ECG assessments.):', '3.13.1.1. YGTSS Rater Certification', '3.13.1.1. YGTSS Rater Certification', 'This section', '3.13.1.1. YGTSS Rater Certification', 'was added for', 'All investigators and subinvestigators who will', 'All investigators and', 'instruction', 'be administering the YGTSS from screening', 'subinvestigators who will be', 'related to', 'through the end of study visit must undergo and', 'administering the YGTSS from', 'protocol', 'pass a Rater Certification Program which will', 'screening through the end of study', 'specific', 'visit must undergo and pass a Rater', 'be provided separately from this protocol. Every', 'YGTSS rater', 'Certification Program which will be', 'certification.', 'effort must be made to ensure that the same', 'provided separately from this', 'certified rater administers the YGTSS to a', 'protocol. Every effort must be made', 'specific patient at all visits, especially at the', 'to ensure that the same certified', 'baseline and week 12/early termination visits.', 'rater administers the YGTSS to a', 'However, if due to unforeseen circumstances', 'specific patient at all visits,', 'the same rater is absolutely unavailable to', 'especially at the baseline and week', 'complete a visit rating, the YGTSS can be', '12/early termination visits.', 'administered only by another certified', 'However, if due to unforeseen', 'individual from that study site.', 'circumstances the same rater is', 'absolutely unavailable to complete a', 'visit rating, the YGTSS can be', 'administered only by another', 'certified individual from that study', 'site.', '3.13.2. Procedures before IMP Treatment (Baseline/Day 1) (Other sections affected by this change:', '3.13.3.1.2., 3.13.3.2.1., 3.13.3.2.2., 3.13.4.1.)', 'administer the following questionnaires', 'administer the following', 'Specific', 'instruction was', '(Note: For C-SSRS,', 'questionnaires (Note: For C-', 'provided for', 'and GTS-QOL, children 13 years', 'SSRS,', 'the YGTSS,', 'of age and under must be interviewed in', 'and GTS-QOL,', 'TS-CGI, and', 'conjunction with the caregiver/adult. For', 'children 13 years of age and', 'children over 13 years of age, caregiver/adult', 'under must be interviewed in', 'assessments to', 'involvement is strongly encouraged.', 'conjunction with the', 'be performed', 'Questions should be directed to the child, but', 'caregiver/adult. For children over', 'before any', 'the caregiver/adult should be encouraged to', '13 years of age, caregiver/adult', 'blood draws or', 'add relevant information. The YGTSS, TS-', 'involvement is strongly', 'ECG.', 'CGI, and', 'questionnaires should be', 'encouraged. Questions should be', 'performed before any blood draws or ECG', 'directed to the child, but the', '123']"
124,page_125,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'assessments.):', 'caregiver/adult should be', 'encouraged to add relevant', 'information. The YGTSS, TS-', 'CGI, and', 'questionnaires', 'should be performed before any', 'blood draws or ECG', 'assessments.):', '4.1 Patient Inclusion Criteria', 'j. Females may be included only if they have', 'j.', 'Females may be included only if', 'Additional', 'a negative ß-HCG test at baseline or are sterile.', 'they have a negative ß-HCG test at', 'inclusion', 'Definitions of sterile given in Appendix L.', 'baseline or are sterile. Definitions of', 'criteria for', 'k. Females of childbearing potential whose', 'sterile given in Appendix L.', 'females were', 'male partners are potentially fertile (ie, no', 'k. Females of childbearing', 'added to', 'vasectomy) must use highly effective birth', 'potential whose male partners are', 'include ß-HCG', 'control methods for the duration of the study', 'potentially fertile (ie, no vasectomy)', 'test and the', '(ie, starting at screening) and for 30 days or 5', 'must use highly effective birth', 'requirement to', 'half-lives, whichever is longer after last dose of', 'control methods for the duration of', 'use highly', 'IMP. Further details are included in Appendix', 'the study (ie, starting at screening)', 'effective birth', 'L.', 'and for 30 days or 5 half-lives,', 'control', 'whichever is longer after last dose', 'methods.', 'of IMP. Further details are included', 'in Appendix L.', '4.2 Patient Exclusion Criteria', 'm. Patient has a QT interval corrected for heart', 'm. Patient has a QT interval', 'The exclusion', ""rate using Frederica's formula (QTcF) interval"", 'corrected for heart rate using', 'criteria were', 'value >4450 msec (males) or >460 msec', ""Frederica's formula (QTcF) interval"", 'modified to', '(females) or >480 msec (with right bundle', 'value >450 msec (males) or >460', 'define criteria', 'branch block) on 12-lead ECG at screening.', 'msec (females) or >480msec (with', 'for QTc.', 'n. Patients with a history of torsade de pointes,', 'right bundle branch block) on 12-', 'congenital long QT syndrome,', 'lead ECG at screening.', 'bradyarrhythmias, or uncompensated heart', 'n. Patients with a history of', 'failure.', 'torsade de pointes, congenital long', 'QT syndrome, bradyarrhythmias, or', 'uncompensated heart failure.', '4.2 Patient Exclusion Criteria', 's.t. The pPatient is a pregnant or lactating', 't.', 'The patient is a pregnant or', 'Wording of', 'female, breastfeeding or plans to become', 'lactating female, or plans to become', 'patient', 'pregnant during the study.', 'pregnant during the study.', 'exclusion', 'criteria', 'regarding', 'pregnancy or', 'lactation was', '124']"
125,page_126,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'changed.', '4.4 Withdrawal Criteria and Procedures (Other sections affected by this change: 7.1.7; Section 7.5)', 'In accordance with the Declaration of Helsinki', 'In accordance with the Declaration', 'Text to identify', ""(in accordance with the applicable country's"", 'of Helsinki (in accordance with the', 'QTc changes', 'acceptance), each patient is free to withdraw', ""applicable country's acceptance),"", 'that will require', 'from the study at any time. The investigator also', 'each patient is free to withdraw', 'IMP', 'has the right to withdraw a patient from the', 'from the study at any time. The', 'suspension was', 'study in the event of intercurrent illness,', 'investigator also has the right to', 'added.', 'adverse events, pregnancy (see Section 7.3), or', 'withdraw a patient from the study in', 'other reasons concerning the health or', 'the event of intercurrent illness,', 'well-being of the patient, or in the event of lack', 'adverse events, pregnancy (see', 'of cooperation. If a post-baseline QTcF value', 'Section 7.3), or other reasons', '>500 msec or change from baseline >60 msec is', 'concerning the health or well-being', 'found, the investigator should repeat the ECG', 'of the patient, or in the event of lack', 'assessment twice and compare the average of', 'of cooperation. If a post-baseline', 'the 2 pre-treatment QTcF values (baseline and', 'QTcF value >500 msec or change', 'screening) to the average of the 3 post-baseline', 'from baseline >60 msec is found,', 'QTcF values. The IMP must be stopped for any', 'the investigator should repeat the', 'confirmed post-baseline QTcF value >500 msec', 'ECG assessment twice and compare', 'or increase from baseline >60 msec.', 'the average of the 2 pre-treatment', 'QTcF values (baseline and', 'screening) to the average of the 3', 'post-baseline QTcF values. The IMP', 'must be stopped for any confirmed', 'post-baseline QTcF value >500', 'msec or increase from baseline >60', 'msec.', '5.1. Drugs Administered During the Study', 'Weight category Daily dose', 'Daily dose (mg) at', 'The table was', '(mg) at the start of visit/week', 'the start of', 'updated with', 'visit/week', 'weight details', 'Study', '20 to <30', '30 to', '>40 kg', 'and', 'week', 'kg', '<40 kg', '(>88 lbs)', 'Stud', '20 to', '30 to', '>40', 'clarifications', '(44 to', '66 to', 'y', '<30', '<40', 'kg', 'regarding how', '<66 lbs)', '<88 lbs)', 'week', 'kg', 'kg', '(88', 'study weeks are', 'a', 'Week 1', '(66', 'defined with', '6 mg', '6 mg', '6 mg', '(44 to', 'lbs)', '(Days 1', '<66', 'to', 'the occurring at', 'Baseline', 'and 2)', 'lbs)', '<88 l', 'the beginning', 'bs)', 'of the week.', '12 mgb', 'Week Z 1', '12 mg', '12 mg', '18 mg', 'Week 3 2', '18 mg', '18 mg', '24 mg', 'Week 43', '18 mgc', '24 mgc', '30 mg', '125']"
126,page_127,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'Week 54', '24 mgc', '30 mgc', '36 mgc', 'Basel', '6 mg', '6 mg', '6 mg', 'ine', 'Week 6 5', '24 mgc', '36 mgc', '42 mgc', '(Days', '1 and', 'Week 7 6', '30 mgc', '42 mgc', '48 mgc', '2)', '12', 'mgb', 'Wee', '12', '12', '18', 'k 1', 'mg', 'mg', 'mg', 'Wee', '18', '18', '24', 'k 2', 'mg', 'mg', 'mg', 'Wee', '18', '24', '30', 'k 3', 'mgc', 'mgc', 'mg', 'Wee', '24', '30', '36', 'k 4', 'mgc', 'mgc', 'mgc', 'Wee', '24', '36', '42', 'k 5', 'mgc', 'mgc', 'mgc', 'Wee', '30', '42', '48', 'k 6', 'mgc', 'mgc', 'mgc', '7.5. Clinical Laboratory Tests', 'The clinical significance of the lab values will', 'The clinical significance of the lab', 'This sentence', 'be evaluated by the criteria described in the', 'values will be evaluated by the', 'included to', 'study lab manual and by the judgment of the', 'criteria described in the study lab', 'provide further', 'investigator.', 'manual and by the judgment of the', 'guidance', 'investigator.', 'regarding', 'clinical', 'significance of', 'laboratory', 'values and', 'investigator', 'judgement.', '7.7. Electrocardiography', 'A 12-lead ECG will be conducted at the time', 'A 12-lead ECG will be conducted at', 'Twelve-lead', 'points detailed in Table 1. All ECGs will be', 'the time points detailed in Table 1.', 'ECG', 'performed after at least 5 minutes rest in a', 'All ECGs will be performed after at', 'interpretation', 'supine or semi-supine position. A qualified', 'least 5 minutes rest in a supine or', 'details were', 'physician at a central diagnostic center will be', 'semi-supine position. A qualified', 'updated.', 'interpreting the ECG.', 'physician at a central diagnostic', 'All ECG results outside of the reference ranges', 'center will be interpreting the ECG.', 'will be judged by the investigator as belonging', 'All ECG results outside of the', 'to one of the following categories:', 'reference ranges will be judged by', '126']"
127,page_128,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'abnormal and not clinically significant', 'the investigator as belonging to one', 'of the following categories:', 'abnormal and clinically significant', 'Any ECG finding that is judged by the', 'abnormal and not clinically', 'investigator as clinically significant (except at', 'significant', 'the screening visit) will be considered an', 'abnormal and clinically', 'adverse event, recorded on the source', 'significant', 'documentation and in the CRF.The 12 lead', 'Any ECG finding that is judged by', 'ECGs will be interpreted by a cardiologist at', 'the investigator as clinically', 'central diagnostic center. Heart rate and ECG', 'significant (except at the screening', 'intervals (PR, QRS, QT, and QTcF) and clinical', 'visit) will be considered an adverse', 'interpretation will be assessed by the central', 'event, recorded on the source', 'eardiologist, recorded, and monitored as', 'documentation and in the CRF, and', 'described in Section 7.1.2.', 'monitored as described in', 'Section 7.1.2', '8.1. Pharmacokinetic Assessment', 'Plasma samples for both a-HTBZ and ß-HTBZ', 'Plasma samples for both a-HTBZ', 'Samples for', 'metabolites will be pooled with previous data', 'and ß-HTBZ metabolites will be', 'pharmacokinetic', 'and incorporated into a population', 'pooled with previous data and', 'assessment were', 'pharmacokinetic analysis. The population', 'incorporated into a population', 'updated.', 'pharmacokinetic analysis will result in a final', 'pharmacokinetic analysis. The', 'structural model that best describes the data. A', 'population pharmacokinetic analysis', 'covariate assessment will evaluate the', 'will result in a final structural model', 'relationship between potential covariates (ie,', 'that best describes the data. A', 'body weight, age, height, etc) and', 'covariate assessment will evaluate', 'concentrations of a-HTBZ and ß-HTBZ', 'the relationship between potential', 'metabolites. The final population', 'covariates (ie, body weight, age,', 'pharmacokinetic analysis will be included in a', 'height, etc) and concentrations of', 'separate report.', 'a-HTBZ and ß-HTBZ metabolites.', 'Blood samples (5 mL) will be collected via', 'The final population', 'venipuncture for plasma oncentration', 'pharmacokinetic analysis will be', 'measurements of TEV 50717 and metabolites', 'included in a separate report.', 'or other analytes.', 'The dates and times of IMP administration and', 'the date and time of each pharmacekinetic', 'sample will be recorded on the source', 'documentation and transcribed onto the CRF.', '9.1 Sample Size and Power Considerations', '127']"
128,page_129,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', '9.5.4.2 Sensitivity Analysis', 'The primary analysis at week 12 will be', 'The primary analysis at week 12', 'Sensitivity', 'repeated on a complete data set using', 'will be repeated on a complete', 'analyses were', 'multiple imputation methodology for', 'data set using multiple', 'simplified and', 'imputing missing data using an MNAR', 'imputation methodology for', 'made', 'missing data assumption to investigate', 'imputing missing data using an', 'consistent with', 'when statistical significance disappears.', 'MNAR missing data assumption', 'Study', 'Using the same repeated measures model as', 'to investigate when statistical', 'TV50717-', 'described for the primary analysis, the', 'significance disappears.', 'CNS-30060.', 'groups will be compared at each of weeks', '2, 4, 6, and 9.', 'An analysis of covariance (ANCOVA)', 'model will be fit using the change from', 'baseline to week 12 as the dependent', 'variable, treatment group, and the baseline', 'value as a covariate. For patients with', 'missing data at week 12, the least favorable', 'change from baseline to week 12 observed', 'in either treatment group will be used as the', 'dependent variable.', 'An ANCOVA model, as described above,', 'will be fit. For patients with missing data at', 'week 12, the last available change from', 'baseline for the patients will be used as the', 'dependent variable.', '9.5.4.3. Key Secondary Efficacy Analyses', 'A hierarchical (fixed-sequence) testing', 'A hierarchical (fixed-sequence)', 'The purpose of', 'approach will be used for the analysis of the', 'testing approach will be used for the', 'the hierarchical', 'primary and key secondary endpoints to', 'analysis of the primary and key', 'analysis was', 'maintain the experiment-wise type I error rate', 'secondary endpoints to maintain the', 'added.', 'of 5%. If an endpoint is not statistically', 'experiment-wise type I error rate of', 'significant, confirmatory hypothesis testing will', '5%. If an endpoint is not statistically', 'not be carried out on the remaining hypotheses,', 'significant, confirmatory hypothesis', '128']"
129,page_130,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'and remaining hypotheses will be considered', 'testing will not be carried out on the', 'exploratory rather than confirmatory. The', 'remaining hypotheses, and', 'change in the TS-CGI (1),', '(2), and', 'remaining hypotheses will be', 'GTS-QOL physical/ADL subscale (3) scores', 'considered exploratory rather than', 'from baseline to week 12 will be summarized', 'confirmatory. The change in the', 'and analyzed in the same fashion as the primary', 'TS-CGI (1),', '2), and GTS-', 'analysis, with the exception that the baseline', 'QOL physical/ADL subscale (3)', 'value of the given endpoint will be included as', 'scores from baseline to week 12 will', 'the covariate.', 'be summarized and analyzed in the', 'same fashion as the primary', 'analysis, with the exception that the', 'baseline value of the given endpoint', 'will be included as the covariate.', 'APPENDIX A ALLOWED AND DISALLOWED MEDICATIONS', 'Prohibited QTc Prolonging Drugs', 'Not applicable', 'The restriction', 'on the use of', 'Generie', 'Class/clinical use', 'Note', 'concomitant', 'medications', 'Azithromye', 'Antibiotic/bacterial', 'that are', 'in', 'infection', 'commonly used', 'Chloroquin', 'Anti malarial/malaria', 'within the', 'et', 'infection', 'pediatric', 'Mefloquine', 'population and', 'that prolong the', 'Clarithromy', 'Antibiotic/bacterial', 'QT interval', 'cin', 'infection', '(eg, antibiotics)', 'Domperido', 'Anti nausea /nausea', 'Not', 'was removed.', 'ne', 'availa', 'Antipsychotic', 'ble in', 'medications', 'USA', 'remain', 'prohibited', 'Droperidol', 'Sedative; anti-', '-', 'owing to their', 'ausea/anesthesia', 'ability to', 'adjunct, nausea', 'confound the', 'Erythromye', 'Antibiotic;', 'efficacy and', 'in', 'gastrointestinal (GI)', 'safety of TEV-', 'stimulant; GI motility', '50717. These', 'changes were', 'Moxifloxac', 'Antibiotic/bacterial', 'made based on', 'in', 'infection', 'the', 'Sevoflurane', 'Anesthetic,', 'cardiodynamic', 'data from the', 'general/anesthesia', 'thorough QT', 'Probucol', 'Antilipemic/hypercholest', 'Not', 'study, the PK-', 'erolemia', 'availa', 'PD modeling of', 'ble in', 'maximal steady', '129']"
130,page_131,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'USA', 'exposure in', 'studies with', 'Sparfloxaci', 'Antibiotio/bacterial', 'Not', 'HD and TD,', 'n', 'infection', 'availa', 'and with', 'ble in', 'observed data', 'USA', 'from the TD', 'a', 'Systemic use only. Topical use is allowed.', 'program in', 'USA=United States of America.', 'which QT', 'prolonging', 'drugs were', 'safely', 'administered in', 'conjunction', 'with TEV-', '50717.', 'APPENDIX I TOURETTE SYNDROME-PATIENT GLOBAL IMPRESSION OF SEVERITY', 'Not applicable', 'Pictorial added', 'A pictorial of', 'the recently', 'tested PGIS', 'questions', 'designed for', 'pediatric', 'patients was', 'inserted.', 'APPENDIX L BIRTH CONTROL METHODS AND PREGNANCY TESTING', 'Not applicable', 'Birth Control Methods and', 'Acceptable', 'Pregnancy Testing', 'contraceptive', 'Contraception recommendations and', 'methods for', 'pregnancy testing should encompass', 'females have', 'all IMPs as well as non-', 'been altered to', 'investigational medicinal products,', 'include', 'eg, background therapy, and the', 'abstinence in', 'measures to be followed should be', 'the definition', 'based on the medicinal product with', 'of highly', 'highest risk.', 'effective birth', 'control.', 'Assessment of likelihood of possible', 'interaction between IMP or', 'concomitant medications and', 'hormonal contraception should be', 'conducted. Hormonal contraception', 'may be susceptible to interaction', 'with the IMP, which may reduce the', 'efficacy of the contraception', 'method, eg, CYP 4A inducers. In', 'case of suspected interaction,', '130']"
131,page_132,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'hormonal contraceptive alone may', 'not be sufficient. In the absence of', 'clinical pharmacokinetic interaction', 'study data in IMPs with', 'demonstrated or suspected human', 'teratogenicity/fetotoxicity,', 'recommendation for use of', 'hormonal contraceptives should be', 'thoroughly justified by the sponsor.', 'Additional contraceptive methods,', 'including supplementary barrier', 'methods, may be considered.', 'Females of childbearing potential', 'are defined as:', 'not surgically (documented', 'hysterectomy, bilateral', 'oophorectomy, or bilateral', 'salpingectomy) or congenitally', 'sterile', 'not postmenopausal', 'Description of different birth control', 'methods', 'Highly effective birth control', 'methods:', 'Highly effective birth control', 'methods that can achieve a failure', 'rate of less than 1% per year when', 'used consistently and correctly are', 'considered. Such methods include:', 'Combined estrogen and', 'progestogen hormonal contraception', '(oral, intravaginal, transdermal)', 'associated with inhibition of', 'ovulation; these should be initiated', 'at least 7 days (for IMPs without', 'suspected', 'teratogenicity/genotoxicity): and 1', 'month (for IMPs potentially', 'teratogenic/genotoxic) before the', 'first dose of IMP.', 'Progestogen-only hormonal', 'contraception (oral, injectable,', 'implantable) associated with', 'inhibition of ovulation; these should', 'be initiated at least 7 days (for IMPs', '131']"
132,page_133,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'without suspected', 'teratogenicity/genotoxicity) and 1', 'month (for IMPs potentially', 'teratogenic/genotoxic) before the', 'first dose of IMP.', 'Intrauterine device and', 'intrauterine hormone-releasing', 'system need to be in place at least 2', 'months before screening.', 'Bilateral tubal occlusion', 'Vasectomized partner provided', 'he is the sole sexual partner and has', 'received medical assessment of the', 'surgical process.', 'Sexual abstinence is only', 'considered a highly effective', 'method if defined as refraining from', 'heterosexual intercourse in the', 'defined period. The reliability of', 'sexual abstinence needs to be', 'evaluated in relation to the duration', 'of the clinical study and the', 'preferred and usual lifestyle of the', 'patient.', 'Periodic abstinence (eg,', 'calendar, ovulation, symptothermal,', 'post-ovulation methods), declaration', 'of abstinence for the duration of a', 'study, and withdrawal are not', 'acceptable methods of contraception', '(according to the Medicines and', 'Healthcare Products Regulatory', 'Agency).', 'Acceptable birth control methods:', 'Acceptable birth control methods', 'that result in a failure rate of more', 'than 1% per year include:', 'progestogen-only oral hormonal', 'contraception for which the', 'inhibition of ovulation is not the', 'primary mode of action; male or', 'female condom with or without', 'spermicide; cap, diaphragm, or', 'sponge with spermicide. The', 'combination of male condom with', '132']"
133,page_134,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'either cap, diaphragm, or sponge', 'with spermicide (double barrier', 'methods) are also considered', 'acceptable but not highly effective', 'methods of birth control.', 'Unacceptable birth control methods:', 'Periodic abstinence (calendar,', 'symptothermal, post-ovulation', 'methods), withdrawal (coitus', 'interruptus), spermicides only, and', 'lactational amenorrhoea method', '(LAM) are not acceptable methods', 'of contraception. Female condom', 'and male condom should not be', 'used together.', 'Male contraception:', 'Male patients must always use a', 'condom, except in cases of no', 'genotoxicity; or no demonstrated or', 'suspected human', 'teratogenicity/fetotoxicity', 'Vasectomy:', 'Use of contraceptive methods', 'applies also to vasectomized men,', 'because of the risk associated with', 'transfer of a drug via seminal fluid.', 'Contraception for female partners of', 'male study participants:', 'Female partners (who are not', 'pregnant) of male study participants', 'must use contraception for non-', 'pregnant WOCBP until the end of', 'relevant systemic exposure in case', 'of IMPs with genotoxicity or IMPs', 'with no genotoxicity but', 'demonstrated or suspected human', 'teratogenicity/fetotoxicity.', 'Pregnancy tests in females of', 'childbearing potential:', '1. Conduct monthly pregnancy', 'testing from first dose of IMP', 'until last dose of IMP and', 'additional 30 days in case the', 'IMP does not have a marketing', 'authorization and has suspected', '133']"
134,page_135,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'human', 'teratogenicity/genotoxicity/fetoto', 'xicity. Conduct monthly', 'pregnancy testing and in case the', 'IMP has a marketing', 'authorization, if the IMP has a', 'demonstrated or suspected human', 'eratogenicity/genotoxicity/fetoto', 'xicity according to Risk Safety', 'Information. Shorter testing', 'intervals are to be considered', 'depending on drug dosing', 'schedule.', '2. Consider additional pregnancy', 'testing, but at least at the end of', 'relevant systemic exposure, in', 'case of possible human', 'teratogenicity/fetotoxicity. This', 'refers to IMPs, for which human', 'data on pregnancies is limited or', 'not available, there is no', 'suspicion of human teratogenicity', 'based on class effects or', 'genotoxic potential, and', 'nonclinical reproductive toxicity', 'studies of relevance for early', 'human pregnancy show positive', 'findings that do not generate a', 'strong suspicion of human', 'teratogenicity/ fetotoxicity.', '3. For IMPs with unlikely risk of', 'human', 'teratogenicity/fetotoxicity', 'additional pregnancy testing is', 'generally not necessary. This', 'refers to IMPs for which', 'assessment of the completed', 'necessary nonclinical studies', 'does not indicate teratogenicity/', 'fetotoxicity in early pregnancy', 'and human data are not available', 'or do not contradict these', 'findings or there is already', 'sufficient evidence for lack of', 'risk based on human data.', 'Pregnant female partners of male', '134']"
135,page_136,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'study participants:', 'Male study participants must use', 'condoms during intercourse if their', 'female partners are pregnant.', '135']"
136,page_137,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '17.2.', 'Amendment 02 Dated 03 October 2017', 'The primary reason for this amendment is to incorporate CYP2D6 genotyping results into the', 'IRT in order to allow for a dose cap to be applied in a blinded manner, update drug packaging to', 'ensure blinding of CYP2D6 impairment status, reorder the statistical testing methodology (ie, the', 'inclusion of TS-PGII assessment after TS-CGI and before the C&A-GTS-QOL ADL subscale),', 'clarify the study day window for each visit or call, and include prohibited medications that are', 'associated with QTc prolongation.', 'This amendment is considered to be substantial (ie, requires approval by Competent Authority,', ""IEC, and/or IRB) by the sponsor's Authorized Representative. Other nonsubstantial changes"", 'have been made to the protocol (and protocol synopsis, as appropriate). These changes are', 'unlikely to affect the safety or rights (physical or mental integrity) of the patients in this clinical', 'study or the scientific value of the clinical study.', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'CLINICAL LABORATORY AND OTHER DEPARTMENTS AND INSTITUTIONS', 'Central Institutional Review Board', 'Copernicus Group IRB', 'Change to central', 'Quorum Review IRB', '1 Triangle Drive', 'IRB', '1501 Fourth Avenue, Suite 800', 'Durham, NC 27709', 'Seattle, WA 98101', 'USA', 'USA', 'Copernicus Group IRB', '1 Triangle Drive', 'Durham, NC 27709', 'USA', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', 'For operational issues, contact the', 'For operational issues, contact the', 'Change in', 'operational lead listed below:', 'operational lead listed below:', 'Nuvelution study', 'personnel', 'For protocol issues, contact the study', 'leader listed below:', 'For protocol issues, contact the study', '136']"
137,page_138,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'leader listed below:', '1.2 Name and Description of IMP (Other sections affected by this change: 3.8.1, 3.13 [Table 1,', 'footnote ""y""], 3.13.2, 3.13.3.1.1, 3.13.3.1.2, 3.13.3.2.1, 3.13.3.2.2, 3.13.5, 5.1, 11.4.1)', 'The IMP will be supplied in', 'The IMP will be supplied in 40-count', 'Blister pack IMP', '2040-count tablets per dose strength', 'blister packs', 'replacing bottled', 'per bottleblister packs', 'IMP for blinding', 'maintenance', 'purposes', '1.5.1 Justification for Dosage of Active Drug (Other section affected by this change: 3.1.3 and 5.1)', 'The dose ranges to be evaluated in this', 'The dose ranges to be evaluated in this', 'CYP2D6 genotyping', 'study, based on body weight and the', 'study, based on body weight and', 'adjusted to be', 'use of strong CYP2D6 inhibitors', 'CYP2D6 impairment status at baseline,', 'incorporated at', 'impairment status at baseline, were', 'were selected on the basis of the safety,', 'screening and by', 'selected on the basis of the safety,', 'preliminary efficacy, and population', 'CYP Impairment', 'preliminary efficacy, and population', 'pharmacokinetic data generated from', 'status', 'pharmacokinetic data generated from', 'Study SD-809-C-17 (Table 2).', 'Study SD-809-C-17 (Table 2 and Table', '3).', '1.8 Location and Study Duration', 'This study is planned to be conducted', 'This study is planned to be conducted', 'Study start date', 'in the North America, Russia, and', 'in North America, Russia, and Europe,', 'pushed out to', 'Europe, at approximately 50 centers. It', 'at approximately 50 centers. It is', 'January 2018, and', 'is expected to start in October 2017', 'expected to start in January 2018 and', 'Russia was specified', 'January 2018 and have a duration of', 'have a duration of approximately', 'as a location to be', 'approximately 15 months.', '15 months.', 'included for this', ""study's conduct."", '137']"
138,page_139,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '2.3.2 Key Secondary Efficacy Endpoint (Other sections affected by this change: 3.13 [Table 1]),', '9.5.2, 3.3.2', 'The key secondary efficacy endpoints', 'The key secondary efficacy endpoints', 'Adjusting of the Key', 'are as follows:', 'are as follows:', 'secondary efficacy', '1. Change in the TS-CGI score from', '1. Change in the TS-CGI score from', 'endpoint hierarchy.', 'baseline to week 12', 'baseline to week 12', 'was', '2. Change in the', '2. Change in the Tourette Syndrome-', 'removed, and placed', 'Patient Global Impression of Impact', 'as an exploratory', 'score from baseline to week', '(TS-PGII) score from baseline to', 'endpoint. TS-PGII', 'was inserted as the', '12 Change in the Tourette Syndrome-', 'week 12', 'Patient Global Impression of Impact', 'new (2) Secondary', '3. Change in the Child and', '(TS-PGII) score from baseline to', 'efficacy endpoint.', 'Adolescent Gilles de la Tourette', 'The child and', 'week 12', 'Syndrome - Quality of Life (C&A-', 'adolescent version of', '3. Change in the Child and', 'GTS-QOL) activities of daily living', 'the GTS-QOL scale', 'Adolescent Gilles de la Tourette', '(ADL) subscale score from baseline to', 'is now being used to', 'Syndrome - Quality of Life (C&A-', 'week 12', 'assess the (3)', 'GTS-QOL) physical/activities of daily', 'secondary efficacy', 'living (ADL) subscale score from', 'endpoint.', 'baseline to week 12', '2.3.3 Exploratory Endpoints (Other sections affected by this change: 3.3.3 and 9.5.3)', 'Exploratory endpoints are as follows:', 'Exploratory endpoints are as follows:', 'was moved', '(removed as a', 'secondary efficacy', 'endpoint) and is now', 'included as an', 'exploratory endpoint.', '138']"
139,page_140,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '3.1.1 Overall Design and Screening Period (Other section affected by this change: 5.1)', 'Throughout the study, patients will', 'Throughout the study, patients will', 'CYP2D6 genotyping', 'interact regularly with investigative site', 'interact regularly with investigative site', 'adjusted to be', 'personnel, in clinic and by telephone,', 'personnel, in clinic and by telephone,', 'incorporated at', 'for the evaluation of safety, tic severity,', 'for the evaluation of safety, tic', 'screening and by', 'and behavioral status (in clinic only).', 'severity, and behavioral status (in', 'CYP Impairment', 'Based on this information, the The', 'clinic only). The target dose for each', 'status. Text has also', 'target dose for each patient receiving', 'patient receiving TEV-50717 will be', 'been updated to', 'TEV-50717 will be based on body', 'based on body weight and CYP2D6', 'indicate that', 'weight and CYP2D6 impairment status', 'impairment status at baseline. Patients', 'investigators will be', 'at baseline. Patients will be classified', 'will be classified as CYP2D6 impaired', 'blinded to CYP', 'as CYP2D6 impaired if they are', 'if they are receiving a strong CYP2D6', 'impairment status', 'receiving a strong CYP2D6 inhibitor or', 'inhibitor or are a CYP2D6 poor', 'and how that will be', 'are a CYP2D6 poor metabolizer based', 'metabolizer based on blinded', 'addressed throughout', 'on blinded assessment of CYP2D6', 'assessment of CYP2D6 genotype at', 'the study.', 'genotype at baseline. CYP2D6 status', 'baseline. CYP2D6 status will be used', 'Clarification on the', 'will be used by Interactive Response', 'by Interactive Response Technology', 'involvement of the', 'Technology (IRT) for randomization', '(IRT) for randomization into the study.', 'adult/caregiver was', 'into the study. The dose of IMP for', 'The dose of IMP for each patient will', 'provided for the', 'each patient will be titrated to an', 'be titrated to an optimal level followed', 'scales to be used.', 'optimal level followed by maintenance', 'by maintenance therapy at that dose.', 'therapy at that dose. Investigators will', 'Investigators will be blinded to CYP', 'be blinded to CYP status, with a dose', 'status, with a dose cap for poor', 'cap for poor metabolizers prespecified', 'metabolizers prespecified by the IRT', 'by the IRT (Table 2). The overall', '(Table 2). The overall treatment period', 'treatment period will be 12 weeks in', 'will be 12 weeks in duration, including', 'duration, including a titration period of', 'a titration period of 7 weeks, a', '7 weeks, a maintenance period of 5', 'maintenance period of 5 weeks,', 'weeks, followed by a washout period of', 'followed by a washout period of 1', '1 week. Site-administered scales', 'week. Site- administered scales include', 'include the YGTSS,', 'Mini', 'the YGTSS,', ', Mini', 'International Neuropsychiatric', 'International Neuropsychiatric', 'Interview For Children and', 'Interview For Children and', 'Adolescents (MINI Kid), and the', 'Adolescents (MINI Kid), and the', 'C-SSRS; and self-administered scales', 'C-SSRS; and self-administered scales', '139']"
140,page_141,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'include the TS-PGII, TS PGIS,', 'include the TS-PGII, TS PGIS,', 'CDI-2, and C&A-GTS QOL.', 'CDI-2, and C&A-GTS QOL.', 'For the YGTSS, input from the', 'For the YGTSS, input from the', 'caregiver/adult is required. For both the', 'caregiver/adult is required. For both the', 'TS-PGII and TS PGIS, input from the', 'TS-PGII and TS PGIS, input from the', 'caregiver/adult is required-permitted.', 'caregiver/adult is permitted. For all', 'For all other scales, for children 13', 'other scales, for children 13 years of', 'years of age and under must, interviews', 'age and under, interviews may be', 'may be interviewed in conjunction', 'performed separately or jointly with the', 'performed separately or jointly with the', 'caregiver/adult as appropriate or', 'caregiver/adult as appropriate or', 'defined by the scale; for children over', 'defined by the scale; for children over', '13 years of age, caregiver/adult', '13 years of age, caregiver/adult', 'involvement is strongly encouraged.', 'involvement is strongly encouraged.', '3.1.2 Screening Period (Other sections affected by this change: 3.10, 3.13 [Table 1], 3.13.1, 3.13.2)', 'The screening period in this study is up', 'The screening period in this study is up', 'The screening period', 'to 4 weeks 31 days (and a minimum of', 'to 31 days.', 'was updated to more', '3 days).', 'Patients may be rescreened 1 time if', 'clearly indicate a', 'Patients may be rescreened 1 time if', ""there is a change in the patient's"", 'maximum of', ""there is a change in the patient's"", 'medical background, a modification of', '31 days, and a', 'medical background, a modification of', 'study entry criteria, or other relevant', 'minimum of 3 days.', 'study entry criteria, or other relevant', 'change. (Note: Details of rescreening', 'Specific details on', 'change. (Note: Details of rescreening', 'must be approved.)', 'who must approve of', 'must be approved by the study', 'rescreening were', 'monitor.)', 'removed.', '3.1.4 Maintenance Period (Other section affected by this change: 6)', 'At week 12, patients will undergo a', 'At week 12, patients will undergo a', 'An adjustment was', 'complete evaluation, including physical', 'complete evaluation, including', 'made to the scales', 'and neurological examination, safety', 'physical and neurological examination,', 'used due to the', 'laboratory testing, 12-lead ECG, CDI-', 'safety laboratory testing, 12-lead ECG,', 'addition of the', '2, and C SSRS assessments, as well as', 'CDI-2, and C SSRS assessments, as', 'TS-PGII assessment', 'the YGTSS, TS-CGI, TS-PGII, TS', 'well as the YGTSS, TS-CGI, TS-PGII,', 'and child and', 'PGIS,', 'and', 'TS PGIS,', 'adolescent version of', 'C&A-GTS-QOL.', 'and C&A-GTS-QOL.', 'the GTS-QOL.', '3.9.2 Drug Accountability', 'A record of IMP accountability (ie,', 'A record of IMP accountability (ie,', 'This update was', 'IMP and other materials received, used,', 'IMP and other materials received, used,', 'made to clarify that', 'retained, returned, or destroyed) must', 'retained, returned, or destroyed) must', 'unused IMP should', 'be prepared and signed by the principal', 'be prepared and signed by the principal', 'be returned to the', 'investigator or designee, with an', 'investigator or designee, with an', 'sponsor or its', 'account given for any discrepancies.', 'account given for any discrepancies.', 'designee.', 'Empty, partially used, and unused IMP', 'Empty, partially used, and unused IMP', 'will be disposed of per site policy, or', 'will be returned to the sponsor or its', 'returned to the sponsor or its designee,', 'designee, as agreed with the sponsor.', 'as agreed with the sponsor.', '140']"
141,page_142,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '3.12 Source Data Recorded on the Case Report Form (Other sections affected by this change: 13.1', 'and 13.3.2)', 'If patient data are processed from other', 'If patient data are processed from other', 'A paper diary will be', 'vendors (eg, clinical laboratory, central', 'used. The indication', 'vendors (eg, clinical laboratory, central', 'ECG, diary data), the results will be', 'of an ""electronic""', 'ECG, electronie-diary data), the results will', 'sent to the investigational center, where', 'diary was removed.', 'be sent to the investigational center, where', 'they will be retained but not entered', 'they will be retained but not entered into', 'into the CRF.', 'the CRF.', '3.13 Study Procedures', 'Table 1 was updated', 'Screening was updated to 31 days', 'The table of', 'Study days were added in addition to', 'procedures was', 'the study weeks for clarification of', 'updated to provide', 'study procedure timing.', 'greater clarity of', 'The visit window was increased', 'study procedure', 'throughout titration from 1 day to', 'timing, to include', 'additional/clarified', '3 days', 'assessments, and to', 'A 12-lead ECG assessment was added', 'provide overall', 'as a baseline assessment', 'consistency to all', 'The TS-PGII assessment was added to', 'changes made during', 'the table, because it was added as a key', 'this amendment.', 'secondary efficacy endpoint', '3.13.1 Procedures for Screening and Enrollment (Other sections affected by this change: 3.1.1,', '3.13.2, 3.13.3.1.2, 3.13.3.2.1, 3.13.3.2.2, 3.13.4.1, 3.13.5, 6.2.4, 6.2.6, 6.2.7, 7.2.1, 7.2.2)', 'The screening visit will take place not', 'The screening visit will take place not', 'The procedures to be', 'more than 4 weeks-31 days and no less', 'more than 31 days and no less than', 'followed (ie, the', 'than 3 days before the baseline visit.', '3 days before the baseline visit. The', 'involvement of the', 'The screening visit may be conducted', 'screening visit may be conducted over', 'adult/caregiver) for', 'over 2 separate visits at the discretion', '2 separate visits at the discretion of the', 'various scales used', 'of the investigator. The following', 'investigator. The following procedures', 'to assess results of', 'procedures will be performed at', 'will be performed at screening:', 'patients in this study', 'screening:', 'obtain written informed', 'have been further', 'obtain written informed', 'consent/assent and/or co-consent for', 'clarified for children', 'consent/assent and/or co-consent for', 'patients 14 years of age and older', 'under the age of 13.', 'patients 14 years of age and older', 'before any other study related', 'before any other study related', 'procedures are performed', 'procedures are performed', 'review eligibility (inclusion and', 'review eligibility (inclusion and', 'exclusion) criteria', 'exclusion) criteria', 'inform patients of study restrictions', 'inform patients of study restrictions', 'and compliance requirements', 'and compliance requirements', 'review medical and psychiatric', 'review medical and psychiatric', 'history', 'history', 'review demographics information', '141']"
142,page_143,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'review demographics information', 'measure vital signs (pulse, BP,', 'measure vital signs (pulse, BP,', 'body temperature, and respiratory rate)', 'body temperature, and respiratory rate)', 'perform full physical and', 'perform full physical and', 'neurological examinations (including', 'neurological examinations (including', 'height and weight. Note: Weight must', 'height and weight. Note: Weight must', 'be measured with shoes and outerwear', 'be measured with shoes and outerwear', 'off)', 'off)', 'perform 12-lead ECG (Note: ECG', 'perform 12-lead ECG (Note: ECG', 'will be performed after at least 5', 'will be performed after at least 5', 'minutes rest in a supine or semi-supine', 'minutes rest in a supine or semi-supine', 'position)', 'position)', 'perform clinical laboratory tests,', 'perform clinical laboratory tests,', 'including chemical, hematological, and', 'including chemical, hematological, and', 'urine analyses', 'urine analyses', 'obtain a blood sample (5 mL) for', 'obtain a blood sample (5 mL) for', 'analysis of CYP2D6 genotype', 'analysis of CYP2D6 genotype', 'perform urine drug screen (UDS)', 'perform urine drug screen (UDS)', 'perform a serum pregnancy (beta', 'perform a serum pregnancy (beta', 'human chorionic gonadotropin [ß-', 'human chorionic gonadotropin [ß-', 'HCG]) test (only in females of', 'HCG]) test (only in females of', 'childbearing potential)', 'childbearing potential)', 'administer the following', 'administer the following', 'questionnaires (Note: For MINI Kid', 'questionnaires (Note: For MINI Kid', 'and C-SSRS, children 13 years of age', 'and C-SSRS, children 13 years of age', 'and under may be interviewed', 'and under must-may be interviewed in', 'separately or jointly with the', 'conjunction separately or jointly with', 'caregiver/adult as appropriate or', 'the caregiver/adult as appropriate or', 'defined by the scale. For children over', 'defined by the scale. For children over', '13 years of age, caregiver/adult', '13 years of age, caregiver/adult', 'involvement is strongly encouraged.', 'involvement is strongly encouraged.', 'Questions should be directed to the', 'Questions should be directed to the', 'child, but the caregiver/adult should be', 'child, but the caregiver/adult should be', 'encouraged to add relevant', 'encouraged to add relevant', 'information. The YGTSS questionnaire', 'information. The YGTSS questionnaire', 'should be performed before any blood', 'should be performed before any blood', 'draws or ECG assessments.)', 'draws or ECG assessments.):', '-', 'MINI Kid (Note: The following', '-', 'MINI Kid (Note: The following', 'modules will be used: Major', 'modules will be used: Major', 'Depressive Episode [Module A],', 'Depressive Episode [Module A],', '[Hypo] Manic Episode [Module D],', '[Hypo] Manic Episode [Module D],', 'OCD [Module J], Alcohol', 'OCD [Module J], Alcohol', 'Dependence/Abuse [Module L],', 'Dependence/Abuse [Module L],', 'Substance Dependence/Abuse [Non-', 'Substance Dependence/Abuse [Non-', 'alcohol; Module M], Attention Deficit', 'alcohol; Module M], Attention Deficit', 'Hyperactivity Disorder [ADHD;', 'Hyperactivity Disorder ADHD;', 'Module O], Conduct Disorder [Module', '142']"
143,page_144,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'Module O], Conduct Disorder [Module', 'P], and Psychotic Disorders and Mood', 'P], and Psychotic Disorders and Mood', 'Disorders with Psychotic Features', 'Disorders with Psychotic Features', '[Module R])', '[Module R])', '-', 'CDI-2, Parent and Self-report', '-', 'CDI-2, Parent and Self-report', '(Note: Children 6 years of age at', '(Note: Children 6 years of age at', 'baseline will not complete the Self-', 'baseline will not complete the Self-', 'report version; the caregiver/adult will', 'report version; the caregiver/adult will', 'complete the Parent version.)', 'complete the Parent version.)', '-', ""C-SSRS (children's"", '-', ""C-SSRS (children's"", 'baseline/screening)', 'baseline/screening)', '-', 'YGTSS (Note: Input from the', '-', 'YGTSS (Note: Input from the', 'caregiver/adult is required.)', 'caregiver/adult is required.)', 'review medication history and', 'review medication history and', 'concomitant medications', 'concomitant medications', 'inquire about adverse events', 'inquire about adverse events', '3.13.2 Procedures Before IMP Treatment (Baseline/Day 1) (Other sections affected by this change:', '3.13.3.1.2, 3.13.3.2.1, 3.13.3.2.2, 3.13.4.1', 'Patients who meet the', 'Patients who meet the', 'The procedures to be', 'inclusion/exclusion criteria at screening', 'inclusion/exclusion criteria at screening', 'followed at certain', 'will continue to the baseline visit, when', 'will continue to the baseline visit, when', 'time points/days and', 'baseline evaluations will be conducted.', 'baseline evaluations will be conducted.', 'the involvement of', 'The following procedures will be', 'The following procedures will be', 'the adult/caregiver', 'performed at baseline:', 'performed at baseline:', 'for various scales', 'used to assess results', 'review eligibility (inclusion and', 'review eligibility (inclusion and', 'exclusion) criteria', 'exclusion) criteria', 'of patients in this', 'study have been', 'measure vital signs (orthostatic', 'measure vital signs (orthostatic', 'further', 'pulse and BP [after standing for at least', 'pulse and BP [after standing for at least', 'clarified/updated.', '3 minutes], body temperature, and', '3 minutes], body temperature, and', 'The process of IMP', 'respiratory rate)', 'respiratory rate)', 'randomization has', 'measure weight (Note: Weight', 'measure weight (Note: Weight', 'also been clarified.', 'must be measured with shoes and', 'must be measured with shoes and', 'outerwear off)', 'outerwear off)', 'perform 12-lead ECG (Note: ECG', 'perform 12-lead ECG (Note: ECG', 'will be performed after at least', 'will be performed after at least', '5 minutes rest in a supine or semi-', '5 minutes rest in a supine or semi-', 'supine position)', 'supine position)', 'perform urine pregnancy (B-HCG)', 'perform urine pregnancy (B-HCG)', 'test (only in females of childbearing', 'test (only in females of childbearing', 'potential)', 'potential)', 'randomization with stratification', 'randomization with stratification', 'by age at baseline (6 to 11 years, 12 to', 'by age at baseline (6 to 11 years, 12 to', '16 years)', '16 years)', 'administer the following', 'administer the following', '143']"
144,page_145,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'questionnaires (Note: For C-SSRS, Tic-', 'questionnaires (Note: For C-SSRS,', 'free Interval, CY BOCS, and C&A-', 'CY BOCS, and', 'GTS-QOL, children 13 years of age', 'C&A-GTS-QOL, children 13 years of', 'and under must may be interviewed in', 'age and under may be interviewed', 'conjunction separately or jointly with', 'separately or jointly with the', 'the caregiver/adult: as appropriate or', 'caregiver/adult as appropriate or', 'defined by the scale. For children over', 'defined by the scale. For children over', '13 years of age, caregiver/adult', '13 years of age, caregiver/adult', 'involvement is strongly encouraged.', 'involvement is strongly encouraged.', 'Questions should be directed to the', 'Questions should be directed to the', 'child, but the caregiver/adult should be', 'child, but the caregiver/adult should be', 'encouraged to add relevant', 'encouraged to add relevant', 'information. The YGTSS, TS-CGI,', 'information. The YGTSS, TS-CGI,', 'TS-PGII, and', 'questionnaires', 'TS-PGII, and', 'questionnaires', 'should be performed before any blood', 'should be performed before any blood', 'draws or ECG assessments.):', 'draws or ECG assessments.):', '-', 'CDI-2, Parent and Self-report', '-', 'CDI-2, Parent and Self-report', '(Note: Children 6 years of age at', '(Note: Children 6 years of age at', 'baseline will not complete the Self-', 'baseline will not complete the Self-', 'report version; the caregiver/adult will', 'report version; the caregiver/adult will', 'complete the Parent version.)', 'complete the Parent version.)', '-', ""C-SSRS (children's SLV)"", '-', ""C-SSRS (children's SLV)"", '-', 'YGTSS (Note:Input from the', '-', 'YGTSS (Input from the', 'caregiver/adult is required.)', 'caregiver/adult is required.)', '- TS-CGI', '- TS-CGI', '-', 'TS-PGII (Input from the', '-', 'TS-PGII (Input from the', 'caregiver/adult is permitted.)', 'caregiver/adult is permitted.)', '-', '(Note: Input from the', '-', '(Input from the', 'caregiver/adult is required-permitted.)', 'caregiver/adult is permitted.)', '-', '-', '-', 'CY BOCS', '-', 'CY BOCS', '-', 'C&A-GTS QOL', '-', 'C&A-GTS QOL', 'dispense IMP (patients will receive', 'dispense IMP (patients will receive', 'doses for 2 weeks [current dose level', 'doses for 2 weeks [current dose level', 'and next dose level] to cover the', 'and next dose level to cover the', 'telephone contacts)', 'telephone contacts)', 'provide patients with a diary to', 'provide patients with a diary to', 'record meal times and critical', 'record meal times and critical', 'information on dosing', 'information on dosing', 'review concomitant medications', 'review concomitant medications', 'inquire about adverse events', 'inquire about adverse events', 'A patient who is not enrolled in the', 'A patient who is not enrolled in the', 'study on the basis of results of baseline', 'study on the basis of results of baseline', 'assessments (eg, because inclusion and', 'assessments (eg, because inclusion and', 'exclusion criteria were not met or', 'exclusion criteria were not met or', '144']"
145,page_146,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'enrollment did not occur within the', 'enrollment did not occur within the', 'specified time) may be screened again', 'specified time) may be screened again', '1 more time if there is a change in the', '1 more time if there is a change in the', ""patient's medical background, a"", ""patient's medical background, a"", 'modification of study entry criteria, or', 'modification of study entry criteria, or', 'other relevant change. (Note: Details of', 'other relevant change. (Note: Details of', 'rescreening must be approved.)', 'rescreening must be approved.)', 'Patients will be assigned a permanent', 'Patients will be assigned a permanent', 'unique number at screening (see', 'unique number at screening (see', 'Section 3.13.1). Patients who continue', 'Section 3.13.1). Patients who continue', 'to meet the inclusion/exclusion criteria', 'to meet the inclusion/exclusion criteria', 'at baseline will be assigned randomized', 'at baseline will be randomized to a', 'to a treatment (active or placebo)', 'treatment (active or placebo) using an', 'number (kit, bottle) using an IRT, and', 'IRT, and the appropriate IMP will be', 'the appropriate IMP will be dispensed.', 'dispensed.', '4.1 Inclusion Criteria', 'j. Females of childbearing potential', 'j.', 'Females of childbearing potential', 'Pregnancy language', 'may be included only if they have a', 'may be included only if they have a', 'was updated to more', 'negative B- HCG test at baseline or are', 'negative B- HCG test at baseline or are', 'clearly specify that', 'sterile. Definitions of sterile is given in', 'sterile. Definitions of sterile is given in', 'only women of', 'Appendix L.', 'Appendix L.', 'childbearing', 'k. Females of childbearing potential', 'k. Females of childbearing potential', 'potential would', 'whose male partners are potentially', 'whose male partners are potentially', 'undergo ß-HCG test', 'fertile (ie, no vasectomy) or female', 'fertile (ie, no vasectomy) or female', 'at baseline. Female', 'partners of male participants must use', 'partners of male participants must use', 'partners of male', 'highly effective birth control methods', 'highly effective birth control methods', 'participants were', 'for the duration of the study (ie,', 'for the duration of the study (ie,', 'also included in the', 'starting at screening) and for 30 days or', 'starting at screening) and for 30 days or', 'inclusion criteria to', '5 half-lives, whichever is longer after', '5 half-lives, whichever is longer after', 'use effective means', 'last dose of IMP. Further details are', 'last dose of IMP. Further details are', 'of birth control.', 'included in Appendix L.', 'included in Appendix L.', '4.2 Exclusion Criteria', 'm. Patient has a QT interval corrected', 'm. Patient has a QT interval', 'Exclusion criteria', ""for heart rate using Frederica's formula"", 'corrected for heart rate using', '""m"" was updated to', '(QTcF) interval value >450 msec (males)', ""Frederica's formula (QTcF) interval"", 'account for the', 'or >460 msec (females) or >480 msec', 'value >450 msec (males) or >460', 'exclusion of patients', '(with right bundle branch block) on 12-', 'msec (females) or >480 msec (with', 'who require', 'lead ECG at screening, OR requires', 'right bundle branch block) on 12-', 'treatment with drugs', 'treatment with drugs known to prolong', 'lead ECG at screening, OR requires', 'known to prolong the', 'the QT interval (see Appendix A for a', 'treatment with drugs known to', 'QT interval.', 'complete list of prohibited QT-prolonging', 'prolong the QT interval (see', 'Exclusion criteria', 'drugs).', 'Appendix A for a complete list of', '""u"" was updated to', 'u.', 'Patient has a history of or', 'prohibited QT-prolonging drugs).', 'be more consistent', 'acknowledges alcohol or substance abuse', 'u. Patient has a history of or', 'with the current', 'related disorder in the previous', 'acknowledges alcohol related', 'language in the fifth', 'edition of the DSM.', '145']"
146,page_147,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '12 months, as defined in the DSM-V.', 'disorder in the previous 12 months,', 'Exclusion criteria', 'W. Patient has a DSM-V diagnosis based', 'as defined in the DSM-V', '""x"" was updated to', 'on the MINI Kid modules performed at', 'W. Patient has a DSM diagnosis', 'remove fifth edition', 'screening that, in the opinion of the', 'based on the MINI Kid modules', 'from the DSM', 'investigator, makes the patient unsuitable', 'performed at screening that, in the', 'diagnosis criteria.', 'for the study.', 'opinion of the investigator, makes', 'the patient unsuitable for the study.', '5.1 Drugs Administered During the Study', 'IMP (see Section 3.8) will be', 'IMP (see Section 3.8) will be', 'Updated to clarify', 'administered as oral tablets at a starting', 'administered as oral tablets at a starting', 'dosing instructions', 'dose of 6 mg once daily. Titration', 'dose of 6 mg. Titration schemes based', 'and the timing of', 'schemes based on body weight at', 'on body weight at baseline are shown', 'dosing for patients.', 'baseline are shown in Table 2. The', 'in Table 2. The maximum daily dose is', 'Text has also been', 'maximum daily dose is determined by', 'determined by body weight and', 'updated to indicate', 'body weight and CYP2D6 impairment', 'CYP2D6 impairment status at baseline.', 'that investigators will', 'status at baseline and any use of strong', 'Although dose adjustments can be', 'be blinded to CYP', 'CYP2D6 inhibitors (see Table', 'made up to and including the week 7', 'impairment status.', 'Although dose adjustments can be', 'telephone call, if a stable dose is', 'made up to and including the week 7', 'reached before then, the patient should', 'telephone call, if a stable dose is', 'continue taking that dose for the', 'reached before then, the patient should', 'remainder of the titration period and', 'continue taking that dose for the', 'throughout maintenance dosing. If a', 'remainder of the titration period and', 'patient experiences a ""clinically', 'throughout maintenance dosing. If a', 'significant"" adverse event that is', 'patient experiences a ""clinically', 'attributed to the IMP, the investigator', 'significant"" adverse event that is', 'will determine if a dose reduction or', 'attributed to the IMP, the investigator', 'suspension is necessary. At the end of', 'will determine if a dose reduction or', ""the titration period, the patient's dose"", 'suspension is necessary. At the end of', 'will be established for the maintenance', ""the titration period, the patient's dose"", 'period. If a patient experiences an', 'will be established for the maintenance', 'adverse event during the maintenance', 'period. If a patient experiences an', 'period and the investigator believes a', 'adverse event during the maintenance', 'dose reduction is warranted, the dose', 'period and the investigator believes a', 'may be reduced.', 'dose reduction is warranted, the dose', 'IMP will be dispensed in the clinic.', 'may be reduced.', 'Patients will receive doses for 2 weeks', 'IMP will be dispensed in the clinic.', 'at baseline, week 2, and week 4 visits', 'Patients will receive doses for 2 weeks', '(current dose level and next dose level)', 'at baseline, week 2, and week 4 visits', 'to cover the telephone contacts. At', '(current dose level and next dose level)', 'week 6 and week 9 visits, patients will', 'to cover the telephone contacts. At', 'receive doses for 3 weeks.', 'week 6 and week 9 visits, patients will', 'IMP will be administered as follows:', 'receive doses for 3 weeks.', 'IMP should be swallowed whole', 'IMP will be administered as follows:', 'and taken with food. Tablets should be', 'IMP should be swallowed whole', 'taken with food (eg, a snack) and', 'and taken with food. Tablets should be', 'should not be taken on an empty', '146']"
147,page_148,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'taken with food (eg, a snack) and', 'stomach.', 'should not be taken on an empty', 'Dosing will be based on body', 'stomach.', 'weight and CYP2D6 impairment status', 'Dosing will be based on body', 'at the baseline visit, as shown in Table', 'weight and CYP2D6 impairment status', '2.', 'at the baseline visit and strong', 'The starting dose is 6 mg in all', 'CYP2D6 inhibitor use, as shown in', 'patients. Daily doses will be', 'Table 2 and Table 3.', 'administered twice daily,', 'The starting dose is 6 mg in all', 'approximately 8 to 10 hours apart', 'patients. This dose will be administered', 'during the day. A minimum of 6 hours', 'in the evening on days 1 and 2,', 'should elapse between doses. If a', 'followed by AM administration for the', 'patient misses a dose and it is within', 'remainder of week 1 (if body weight is', '6 hours of their next dose, the missed', '<40 kg). Subsequent Daily doses of', 'dose should be skipped.', '12 mg and higher will be administered', 'After week 1, dose increases may', 'twice daily in 2 divided doses,', 'not occur more frequently than every', 'approximately 8 to 10 hours apart', '5 days.', 'during the day. A minimum of 6 hours', 'Dose reductions, if required,', 'should elapse between doses. If a', 'should be in increments of 6 mg. If', 'patient misses a dose and it is within', 'more than 1 dose reduction is required', '6 hours of their next dose, the missed', 'for an adverse event, the medical', 'dose should be skipped. If patients', 'monitor should be notified.', 'experience insomnia while taking the', 'initial 6 mg dose in the evening, they', 'During the titration period, the', 'may switch to taking it as a morning', 'dose of the IMP will be adjusted', 'dose on day 2.', 'weekly according to Table 2 to identify', 'a dose level that optimally reduces tics', 'After week 1, dose increases may', 'and is well tolerated. Investigators will', 'not occur more frequently than every', 'be blinded to CYP status, with a dose', '5 days.', 'cap for poor metabolizers prespecified', 'Dose reductions, if required, should', 'by the IRT.', 'be in increments of 6 mg. If more than', 'IMP will be packaged in blister packs', '1 dose reduction is required for an', 'and provided for patients to take at', 'adverse event, the medical monitor', 'home (see Section 3.8).', 'should be notified.', 'During the titration period, the dose', 'of the IMP should will be adjusted', 'weekly according to Table 2 to identify', 'a dose level that optimally reduces tics', '(as determined by the investigator, in', 'consultation with the patient €', 'earegiver/adult) and is well tolerated.', 'Investigators will be blinded to CYP', 'status, with a dose cap for poor', 'metabolizers prespecified by the IRT.', 'IMP will be packaged in bottles blister', 'packs and provided for patients to take', '147']"
148,page_149,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'at home (see Section 3.8).', 'Table 2 was updated', 'Table 2 was updated to include CYP', 'Updates wer made to', 'Impairment status. Column headers', 'account for CYP2D6', 'remained divided by weight, but also to', 'genotyping status', 'include ""not impaired"" versus', 'determined at', '""impaired"" daily doses by weight', 'baseline, and to', 'categories. Additional editorial changes', 'specify daily dosing', 'were made to the table and table', 'from baseline', 'footnotes to more clearly specify daily', 'through week 6', 'dosing expectations by weight category', 'based on both weight', 'and by CYP impairment status, and to', 'category and CYP', 'enhance study visit clarity.', 'impairment.', 'Table 3 from version 01 was removed.', 'Table 3 from the previous version', 'Table 3 was removed', 'protocol amendment 01 was removed,', 'to remove duplicate', 'as Table 2 was updated to include the', 'protocol detail.', 'additional information provided by this', 'table.', '5.3 Prior and Concomitant Medications', 'Medications that are allowed, provided', 'Medications that are allowed, provided', 'Updates were made', 'that conditions outlined in the table are', 'that conditions outlined in the table are', 'to clarify that the', 'met, are shown in Appendix A, Table €', 'met, are shown in Appendix A,', 'addition of strong', 'Table 5.', 'Table 5.', 'CYP inhibitors are', 'The medical monitor must be contacted', 'The medical monitor must be contacted', 'prohibited once a', 'if a patient is receiving (or has to begin', 'if a patient is receiving (or has to begin', 'patient is enrolled. In', 'or stop receiving during the study) a', 'or stop receiving during the study) a', 'addition, prohibited', 'medication that is associated with QTc', 'medication that is associated with QTc', 'medications', 'prolongation or that is a known strong', 'prolongation or that is a known strong', 'associated with QTc', 'CYP inhibitor.', 'CYP inhibitor.', 'prolongation have', 'been inserted into the', 'Addition of a strong CYP inhibitor is', 'Addition of a strong CYP inhibitor is', 'prohibited.', 'prohibited.', 'protocol appendices', 'and are referenced', 'Prohibited medications that are', 'Prohibited medications that are', 'here.', 'associated with QTc prolongation are', 'associated with QTc prolongation are', 'listed in Appendix A, Table 6, while', 'listed in Appendix A, Table 6, while', 'prohibited antipsychotic drugs are', 'prohibited antipsychotic drugs are', 'listed in Appendix A, Table 7.', 'listed in Appendix A, Table 7.', '6.2.2 Tourette Syndrome-Patient Global Impression of Impact', 'The TS-PGII is administered at', 'The TS-PGII is administered at', 'The TS-PGII was', 'baseline and weeks 2, 4, 6, 9, 12, and', 'baseline and weeks 2, 4, 6, 9, 12, and', 'included as a key', '13. Input from the caregiver/adult is', '13. Input from the caregiver/adult is', 'secondary efficacy', 'permitted.', 'permitted.', 'endpoint, so a brief', '148']"
149,page_150,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'The TS-PGII is a single-item', 'The TS-PGII is a single-item', 'description of the', 'questionnaire that asks the patient to', 'questionnaire that asks the patient to', 'scale has been', 'assess the degree of impact due to', 'assess the degree of impact due to', 'included.', 'current tics. The TS-PGII uses a 5 point', 'current tics. The TS-PGII uses a 5', 'scale, ranging from not at all (1) to very', 'point scale, ranging from not at all (1)', 'much (5), to assess overall response to', 'to very much (5), to assess overall', 'therapy. In general, patient rated global', 'response to therapy. In general, patient', 'measures of change have face validity', 'rated global measures of change have', 'and have been shown to correlate with', 'face validity and have been shown to', 'disability for a number of chronic', 'correlate with disability for a number', 'conditions.', 'of chronic conditions.', '6.2.3', '6.2.4 Child and Adolescent Gilles de la Tourette Syndrome-Quality of Life Scale', 'The C&A-GTS-QOL is administered at', 'The C&A-GTS-QOL is administered at', 'The child and', 'baseline, week 6, and week 12.', 'baseline, week 6, and week 12.', 'adolescent version of', 'Children 13 years of age and under', 'Children 13 years of age and under', 'the GTS-QOL is now', 'must may be interviewed in', 'may be interviewed separately or', 'to be used in this', 'conjunction separately or jointly with', 'jointly with the caregiver/adult as', 'study.', 'the caregiver/adult: as appropriate or', 'appropriate or defined by the scale. For', 'Adult/caregiver', 'defined by the scale. For children over', 'children over 13 years of age,', 'involvement has', '13 years of age, caregiver/adult', 'caregiver/adult involvement is strongly', 'been clarified, and', 'involvement is strongly encouraged.', 'encouraged. Questions should be', 'the scale now', 'Questions should be directed to the', 'directed to the child, but the', 'contains 6 subscales.', 'child, but the caregiver/adult should be', 'caregiver/adult should be encouraged', 'The reference for this', 'encouraged to add relevant', 'to add relevant information.', 'version of the scale', 'information.', 'The C&A-GTS-QOL is a 27-item', '(""C&A"" version)', 'The C&A-GTS-QOL is a 27-item', 'questionnaire specific to TS patients', 'replaced the prior', 'questionnaire specific to TS patients', 'that asks the patient to assess the extent', 'reference.', 'that asks the patient to assess the extent', 'to which their quality of life is', 'to which their quality of life is', 'impacted by their symptoms. The', 'impacted by their symptoms. The', 'C&A-GTS-QOL contains 6 subscales', '149']"
150,page_151,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'C&A-GTS-QOL contains-46 subscales', '(cognitive, coprophenomena,', '(cognitive, coprophenomena,', 'psychological, physical, obsessive-', 'psychological, physical, obsessional', 'compulsive, and ADL) and uses a', 'obsessive-compulsive, and cognitive', '5-point Likert scale ranging from no', 'ADL) and uses a 5- point Likert scale', 'problem to extreme problem. Patients', 'ranging from no problem to extreme', 'will also be asked how satisfied they', 'problem. Patients will also be asked', 'feel overall with their life at that', 'how satisfied they feel overall with', 'moment by using a VAS scale between', 'their life at that moment by using a', '0 and 100 (Su et al 2017).', 'VAS scale between 0 and 100', '(Cavanna et al 2008).St et al 2017).', '6.2.5 Yale Global Tic Severity Scale', 'This was updated to', 'specify that input', 'from the', 'are', 'are', 'caregiver/adult is', 'exploratory measures. YGTSS and its', 'exploratory measures. YGTSS and its', 'required when', 'components are described in Section', 'components are described in Section', 'performing the', '6.1. Input from the caregiver/adult is', '6.1. Input from the caregiver/adult is', 'YGTSS.', 'required.', 'required.', '7.1.1 Definition of an Adverse Event', 'n adverse event is any Any untoward', 'Any untoward medical occurrence in a', 'This was updated to', 'medical occurrence in a patient or', 'patient or clinical investigation subject', 'include the most', 'clinical investigation subject', 'administered a pharmaceutical product', 'recent definition of', 'administered a pharmaceutical product,', 'and which does not necessarily have to', 'an adverse event per', 'regardless of whether it has and which', 'have a causal relationship with this', 'Teva template text.', 'does not necessarily have to have a', 'treatment.', 'causal relationship with this treatment.', 'An adverse event can, therefore, be any', 'In this study, any adverse event', 'unfavorable and unintended physical', 'occurring after the clinical study patient', 'sign, symptom, or laboratory parameter', 'has signed the informed consent form', 'that develops or worsens in severity', 'should be recorded and reported as an', 'during the course of this study, or', 'adverse event.', 'significant worsening of the disease', 'An adverse event can, therefore, be any', 'under study or of any concurrent', 'unfavorable and unintended physical', 'disease, whether or not considered', 'sign, symptom, or laboratory parameter', 'related to the IMP (TEV-50717). A', 'that develops or worsens in severity', 'new condition or the worsening of a', 'during the course of this study, or', 'pre existing condition will be', 'significant worsening of the disease', 'considered an adverse event. Stable', 'under study or of any concurrent', 'chronic conditions (such as arthritis)', 'disease, whether or not considered', 'that are present before study entry and', 'related to the IMP. (TEV-50717). A', 'do not worsen during this study will', 'new condition or the worsening of a pre', 'not be considered adverse events.', 'existing condition will be considered an', 'adverse event. Stable chronic', 'conditions (such as arthritis) that are', '150']"
151,page_152,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'present before study entry and do not', 'worsen during this study will not be', 'considered adverse events.', '7.1.5 Serious Adverse Events', 'An additional blood sample for the', 'An additional blood sample for the', 'Additional text was', 'measurement of IMP concentration', 'measurement of IMP concentration', 'included to define', 'should be collected, if possible, from', 'should be collected, if possible, from', 'the period for', 'each patient experiencing a serious', 'each patient experiencing a serious', 'recording serious', 'adverse event or an adverse event', 'adverse event or an adverse event', 'adverse events', 'leading to discontinuation of IMP at', 'leading to discontinuation of IMP at', 'occurring in patients,', 'any time during the study. If study', 'any time during the study. If study', 'and to specify the', 'center personnel are unable to obtain a', 'center personnel are unable to obtain a', 'actions to be taken', 'blood sample in a timely fashion, this', 'blood sample in a timely fashion, this', 'by the investigator', 'should be discussed with the medical', 'should be discussed with the medical', 'should they become', 'monitor to determine whether the', 'monitor to determine whether the', 'aware of a serious', 'sample still needs to be obtained.', 'sample still needs to be obtained.', 'adverse event after', 'For recording of serious adverse', 'For recording of serious adverse', 'the end of the follow-', 'events, the study period is defined for', 'events, the study period is defined for', 'up period.', 'each patient as the time period from', 'each patient as the time period from', 'signature of the informed consent form', 'signature of the informed consent form', 'to the end of the follow up period, as', 'to the end of the follow up period, as', 'defined in Section 7.1.2. If the', 'defined in Section 7.1.2. If the', 'investigator becomes aware of serious', 'investigator becomes aware of serious', 'adverse events occurring in a patient', 'adverse events occurring in a patient', 'after the end of the follow up period,', 'after the end of the follow up period,', 'the serious adverse events should be', 'the serious adverse events should be', 'reported to the sponsor following the', 'reported to the sponsor following the', 'procedures described in Section', 'procedures described in Section', '7.1.5.3.1.', '7.1.5.3.1.', '7.1.5.1 Definition of a Serious Adverse Event', 'A serious adverse event is an adverse', 'A serious adverse event is an adverse', 'This was updated to', 'event occurring at any dose that results', 'event occurring at any dose that results', 'include the most', 'in any of the following outcomes or', 'in any of the following outcomes or', 'recent definition of a', 'actions:', 'actions:', 'serious adverse event', 'results in death', 'results in death', 'per Teva template', 'text.', 'is a life threatening adverse event', 'is a life threatening adverse event', '(ie, the patient was at immediate risk of', '(ie, the patient was at risk of death at', 'death from-at the time of the event as);', 'the time of the event); it does not refer', 'it occurred); does not include refer to', 'to an event which hypothetically might', 'an event that, had it occurred in a more', 'have caused death if it were more', 'severe form, which hypothetically', 'severe.', 'might have caused death if it were', 'requires inpatient hospitalization or', 'more severe.', 'prolongation of existing', 'requires inpatient hospitalization or', 'hospitalization, which means that', 'prolongation of existing', 'hospital inpatient admission or', '151']"
152,page_153,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'hospitalization, which means that', 'prolongation of hospital stay were', 'hospital inpatient admission and/or', 'required for treatment of an adverse', 'prolongation of hospital stay were', 'event, or that they occurred as a', 'required for treatment of an adverse', 'consequence of the event.', 'event, or that they occurred as a', 'Hospitalizations scheduled before the', 'consequence of the event.', 'patient signed the informed consent', 'Hospitalizations scheduled prior to', 'form will not be considered serious', 'study entry before the patient signed', 'adverse events, unless there was', 'the informed consent form will not be', 'worsening of the preexisting condition', 'considered serious adverse events,', ""during the patient's participation in this"", 'unless there was worsening of the', 'study.', 'preexisting condition during the', 'results in persistent or significant', ""patient's participation in this study."", 'disability or /incapacity (refers to a', 'results in persistent or significant', ""substantial disruption of one's ability to"", 'disability or /incapacity (refers to a', 'conduct normal life functions)', ""substantial disruption of one's ability to"", 'is a congenital anomaly/birth', 'conduct normal life functions)', 'defect', 'is a congenital anomaly/birth defect', 'an important medical event that', 'an important medical event that', 'may not result in death, be life', 'may not result in death, be life', 'threatening, or require hospitalization,', 'threatening, or require hospitalization,', 'but may jeopardize the patient and may', 'but may jeopardize the patient and may', 'require medical intervention to prevent', 'require medical intervention to prevent', 'one of the outcomes listed in this', 'one of the outcomes listed in this', 'definition.', 'definition.', 'Examples of such events are intensive', 'Examples of such events are intensive', 'treatment in an emergency room or at', 'treatment in an emergency room or at', 'home for allergic bronchospasm; blood', 'home for allergic bronchospasm; blood', 'dyscrasias or convulsions that do not', 'dyscrasias or convulsions that do not', 'result in hospitalization; or the', 'result in hospitalization; or the', 'development of drug dependency or', 'development of drug dependency or', 'drug abuse. Note: Any suspected', 'drug abuse. Note: Any suspected', 'transmission of an infectious agent via', 'transmission of an infectious agent via', 'a medicinal product is considered an', 'a medicinal product is considered an', 'important medical event.', 'important medical event.', '7.1.5.3.1 Investigator Responsibility', 'The investigator must ensure that the', 'Each report of a serious adverse event', 'Updates were made', 'IEC/IRB is also informed of the event,', 'will be reviewed and evaluated by the', 'to more clearly', 'in accordance with national and local', 'investigator and the sponsor to assess', 'indicate investigator', 'regulations.', 'the nature of the event and the', 'responsibilities and', 'Each report of a serious adverse event', 'relationship of the event to the IMP,', 'expectations.', 'will be reviewed and evaluated by the', 'study procedures, and to underlying', 'investigator and the sponsor to assess', 'disease.', 'the nature of the event and the', 'Additional information (follow up)', 'relationship of the event to the IMP,', 'about any serious adverse event', 'study procedures, and to underlying', 'unavailable at the initial reporting', '152']"
153,page_154,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'disease.', 'should be forwarded by the investigator', 'Additional information (follow up)', 'within 24 hours of when it becomes', 'about any serious adverse event', 'known to the same address as the initial', 'unavailable at the initial reporting', 'report.', 'should be forwarded by the', ""For all countries, the sponsor's GPSP"", 'investigational center investigator', 'will distribute the Council for', 'within 24 hours of when it becomes', 'International Organizations of Medical', 'known to the same address as the initial', 'Sciences (CIOMS) form/Extensible', 'report.', 'Markup Language (XML) file to the', ""For all countries, the sponsor's GPSP"", 'LSO/INC Research for submission to', 'will distribute the Council for', 'the competent authorities, IEC/IRBs,', 'International Organizations of Medical', 'and investigators, according to', 'Sciences (CIOMS) form/Extensible', 'regulations. The investigator must', 'Markup Language (XML) file to the', 'ensure that the IEC/IRB is also', 'LSO/INC Research for submission to', 'informed of the event, in accordance', 'the competent authorities, IEC/IRBs,', 'with national and local regulations.', 'and investigators, according to', 'Blinding will be maintained for all', 'regulations. The investigator is', 'study personnel. Therefore, in case of a', 'responsible for ensuring must ensure', 'SUSAR, only the LSO/INC Research', 'that the IEC/IRB is also informed of', 'will receive the unblinded report for', 'the event, in accordance with national', 'regulatory submission; the others will', 'and local regulations.', 'receive a blinded report.', 'Blinding will be maintained for the', 'people who are involved directly in the', 'all study personnel. Therefore, in case', 'of a SUSAR, only the LSO/INC', 'Research will receive the unblinded', 'report for regulatory submission; the', 'others will receive a blinded report.', '7.1.6. Protocol-Defined Adverse Events for Expedited Reportingof Special Interest', 'No protocol defined adverse events for', 'No protocol defined adverse events of', 'This was updated to', 'expedited reportingo special interest', 'special interest were identified for this', 'more specifically', 'were identified for this study.', 'study.', 'state adverse events', 'of special interest', '7.1.8 Overdose of IMP', 'Any dose of IMP (whether the IMP or', 'Not applicable', 'Section 7.1.8 of the', 'a placebo), whether taken intentionally', 'previous version has', 'or unintentionally, in excess of that', 'been deleted.', 'prescribed during the given time period', 'must be immediately reported to the', 'sponsor. When the identification of the', 'IMP must be known, the investigator', 'must follow the procedures outlined in', 'Section 3.7.', '153']"
154,page_155,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '7.3 Pregnancy', 'Any female patient becoming pregnant', 'Any female patient becoming pregnant', 'This was updated to', 'during the study will discontinue IMP.', 'during the study will discontinue IMP.', 'include additional', 'All pregnancies of females female', 'All pregnancies of female patients', 'pregnancy details', 'patients participating in the study and', 'participating in the study and female', 'and guidance for the', 'female partners of male patients', 'partners of male patients participating', 'patients and study', 'participating in the study that occur', 'in the study that occur during the study,', 'personnel (ie, when', 'during the study, or within 14 days of', 'or within 14 days after the end of the', 'reporting of events is', 'completion after the end of the study,', 'study, are to be reported immediately', 'expected, where the', 'are to be reported immediately to the', 'to the individual identified in the', 'information must be', 'individual identified in the clinical', 'clinical study personnel contact', 'provided, how the', 'study personnel contact information', 'information section of this protocol,', 'pregnancy should be', 'section of this protocol, and the', 'and the investigator must provide the', 'reported, and the', 'investigator must provide the sponsor', 'sponsor (LSO/INC Research) with the', 'investigators', '(LSO/INC Research) with the', 'completed pregnancy form. The', 'responsibilities).', 'completed pregnancy form. The', 'process for reporting a pregnancy is the', 'process for reporting a pregnancy is the', 'same as that for reporting a serious', 'same as that for reporting a serious', 'adverse event but using the pregnancy', 'adverse event but using the pregnancy', 'form (see Section 7.1.5.3).', 'form (see Section 7.1.5.3).', 'The investigator is not required to', 'Any female patient becoming The', 'report patients who are found to be', 'investigator is not required to report', 'pregnant between screening and', 'patients who are found to be pregnant', 'baseline, provided no IMP was given.', 'during between screening and baseline,', 'All female patients or female partners', 'provided no IMP was given. All female', 'of male patients participating in the', 'patients or female partners of male', 'study who become pregnant will be', 'patients participating in the study will', 'monitored for the outcome of the', 'discontinue treatment. All Patients who', 'pregnancy (including spontaneous,', 'become pregnant will be monitored for', 'elective, or voluntary abortion). If the', 'the outcome of the pregnancy', 'pregnancy continues to term, the', '(including spontaneous, elective, or', 'outcome (health of the infant up to 8', 'voluntary termination-abortion). If the', 'weeks of age), including details of birth', 'pregnancy continues to term, the', 'and presence or absence of any birth', 'outcome (health of the infant up to 168', 'defect, congenital abnormalities, or', 'weeks of age), including details of birth', 'maternal and newborn complications,', 'and presence or absence of any birth', 'will be reported to the sponsor. Any', 'defect, congenital abnormalities, or', 'complication of pregnancy during the', 'maternal and newborn complications,', 'study and any complication of', 'will be reported to the sponsor. Any', 'pregnancy that the investigator', 'complication of pregnancy during the', 'becomes aware of after withdrawal', 'study and any complication of', 'from the study will be reported as an', 'pregnancy that the investigator', 'adverse event or serious adverse event,', 'becomes aware of after withdrawal', 'as appropriate.', 'from the study will be reported as an', 'Since this IMP has suspected human', 'adverse event or serious adverse event,', 'teratogenicity, genotoxicity,', 'as appropriate.', 'fetotoxicity, or spermatoxicity, female', 'Since this IMP has suspected human', 'partners of male patients participating', '154']"
155,page_156,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'teratogenicity, genotoxicity,', 'in the study who become pregnant will', 'fetotoxicity, or spermatoxicity, female', 'be asked to sign an informed consent', 'partners of male patients participating', 'form and will be monitored for the', 'in the study who become pregnant will', 'outcome of the pregnancy (including', 'be asked to sign an informed consent', 'spontaneous, elective, or voluntary', 'form and will be monitored for the', 'abortion). If the pregnancy continues to', 'outcome of the pregnancy (including', 'term, the outcome (health of the infant', 'spontaneous, elective, or voluntary', 'up to 8 weeks of age), including details', 'abortion). If the pregnancy continues to', 'of birth and presence or absence of any', 'term, the outcome (health of the infant', 'birth defect, congenital abnormalities,', 'up to 8 weeks of age), including details', 'or maternal and newborn', 'of birth and presence or absence of any', 'complications, will be reported to the', 'birth defect, congenital abnormalities,', 'sponsor. Any complication of', 'or maternal and newborn', 'pregnancy during the study and any', 'complications, will be reported to the', 'complication of pregnancy that the', 'sponsor. Any complication of', 'investigator becomes aware of after', 'pregnancy during the study and any', 'termination withdrawal from the study', 'complication of pregnancy that the', 'will be reported as an adverse event or', 'investigator becomes aware of after', 'serious adverse event, as appropriate.', 'termination withdrawal from the study', 'If the pregnancy in the female patients', 'will be reported as an adverse event or', 'participating in the study and/or the', 'serious adverse event, as appropriate.', 'female partners of male patients', 'If the pregnancy in the female patients', 'participating in the study does not', 'participating in the study and/or the', 'continue to term, 1 of the following', 'female partners of male patients', 'actions will be taken:', 'participating in the study does not', 'For a spontaneous abortion, report', 'continue to term, 1 of the following', 'as a serious adverse event.', 'actions will be taken:', 'For an elective abortion due to', 'For a spontaneous abortion, report', 'developmental anomalies, report as a', 'as a serious adverse event.', 'serious adverse event.', 'For an elective abortion due to', 'For an elective abortion not due to', 'developmental anomalies, report as a', 'developmental anomalies, report on the', 'serious adverse event.', 'pregnancy form; do not report as an', 'For an elective abortion not due to', 'adverse event.', 'developmental anomalies, report on the', 'pregnancy form; do not report as an', 'adverse event.', '7.4 Medication Error and Special Situations Related to the Investigational Medicinal Product', 'Any administration of medication-IMP', 'Any administration of IMP that is not', 'Updates were made', 'that is not in accordance with the study', 'in accordance with the study protocol', 'to clarify medication', 'protocol should be reported on the CRF', 'should be reported on the CRF either as', 'error could be with', 'either as a violation, if it meets the', 'a violation, if it meets the violation', 'both the test product', 'violation criteria specified in the', 'criteria specified in the protocol', 'and IMP.', 'protocol (Section 11.1.2), or as a', '(Section 11.1.2), or as a deviation, in', 'Breastfeeding was', 'deviation, in the patients source', 'the patients source documents,', 'added as an', 'documents, regardless of whether or', 'regardless of whether or not an adverse', 'additional special', '155']"
156,page_157,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'not an adverse event occurs as a result.', 'event occurs as a result. All instances', 'situation.', 'All instances of incorrect medication', 'of incorrect medication administration', 'administration should be categorized', 'should be categorized on the CRF as', 'on the CRF as ""Non-Compliance with', '""Non-Compliance with IMP""', 'IMP""', 'The following are types of medication', 'Types-The following are types of', 'errors and special situations:', 'medication errors and special', '1. Medication error: Any', 'situations:', 'unintentional error in the prescribing,', '1. Medication error: Any', 'dispensing, or administration of a', 'unintentional error in the prescribing,', 'medicinal product while in the control', 'dispensing, or administration of a', 'of the healthcare professional, patient,', 'medicinal product while in the control', 'or consumer.', 'of the healthcare professional, patient,', '2. Overdose: Administration of a', 'or consumer.', 'quantity of a medicinal product given', '2. Overdose: Administration of a', 'per administration or cumulatively', 'quantity of a medicinal product given', 'which is above the maximum', 'per administration or cumulatively', 'recommended dose according to the', 'which is above the maximum', 'authorized product information.', 'recommended dose according to the', 'Clinical judgment should always be', 'authorized product information.', 'applied. Any dose of IMP (whether the', 'Clinical judgment should always be', 'test IMP or placebo IMP), whether', 'applied. Any dose of IMP (whether the', 'taken intentionally or unintentionally in', 'test IMP or placebo IMP), whether', 'excess of the dose prescribed, must be', 'taken intentionally or unintentionally in', 'immediately reported to the sponsor.', 'excess of the dose prescribed, must be', '3. Misuse: Situations where the IMP', 'immediately reported to the sponsor.', 'is intentionally and inappropriately', '3. Misuse: Situations where the', 'used not in accordance with the', 'medicinal produet-IMP is intentionally', 'authorized product information.', 'and inappropriately used not in', '4. Abuse: Persistent or sporadic,', 'accordance with the authorized product', 'intentional excessive use of IMP,', 'information.', 'which is accompanied by harmful', '4. Abuse: Persistent or sporadic,', 'physical or psychological effects.', 'intentional excessive use of medicinal', '5. Off-label use: Situations where an', 'products IMP, which is accompanied', 'IMP is intentionally used for a medical', 'by harmful physical or psychological', 'purpose not in accordance with the', 'effects.', 'authorized product information.', '5. Off-label use: Situations where', '6. Occupational exposure: Exposure', 'medicinal product an IMP is', ""to an IMP, as a result of one's"", 'intentionally used for a medical', 'professional or non-professional', 'purpose not in accordance with the', 'occupation.', 'authorized product information.', '7. Breastfeeding: Suspected adverse', '6. Occupational exposure: Exposure', 'reactions that occur in infants', 'to a medicinal product an IMP, as', 'a', 'following exposure to a medicinal', ""result of one's professional or non-"", 'product from breast milk.', 'professional occupation.', '7. Breastfeeding: Suspected adverse', '156']"
157,page_158,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'reactions that occur in infants following', 'exposure to a medicinal product from', 'breast milk.', '7.5 Clinical Laboratory Tests', 'All clinical laboratory test results', 'All clinical laboratory test results', 'A note was added to', 'outside of the reference range will be', 'outside of the reference range will be', 'clarify that abnormal', 'interpreted-judged by the investigator', 'judged by the investigator as belonging', 'test results at', 'as belonging to one of the following', 'to one of the following categories:', 'screening that', 'categories:', 'abnormal and not clinically', 'preclude a patient', 'abnormal and not clinically', 'significant', 'from entering the', 'significant', 'abnormal and clinically significant', 'study are not', 'considered adverse', 'abnormal and clinically significant', 'The clinical significance of the', 'events.', 'The clinical significance of the', 'laboratory values will be evaluated by', 'laboratory values will be evaluated by', 'the criteria described in the laboratory', 'the criteria described in the laboratory', 'manual and by the judgement of the', 'manual and by the judgement of the', 'investigator. A laboratory test result', 'investigator. A laboratory test result', 'that is judged by the investigator as', 'that is judged by the investigator as', 'clinically significant will be recorded', 'clinically significant will be recorded', 'both on the source documentation and', 'both on the source documentation,', 'the CRF as an adverse event, and', 'transcribed to and the CRF as an', 'monitored as described in Section', 'adverse event, and monitored as', '7.1.2. An event may include a', 'described in Section 7.1.2. An event', 'laboratory or diagnostic test', 'may include a laboratory or diagnostic', 'abnormality (once confirmed by', 'test abnormality (once confirmed by', 'repeated testing) that results in the', 'repeated testing) that results in the', 'withdrawal of the patient from the', 'withdrawal of the patient from the', 'study, the temporary or permanent', 'study, the temporary or permanent', 'cessation of IMP or medical treatment,', 'cessation of treatment with IMP or', 'or further diagnostic work up.', 'medical treatment, or further diagnostic', 'Abnormal laboratory tests can be', 'work up. Abnormal laboratory tests can', 'repeated without approval from the', 'be repeated without approval from the', 'medical monitor. (Note: Abnormal', 'medical monitor. (Note: Abnormal', 'laboratory or diagnostic test results at', 'laboratory or diagnostic test results at', 'the screening visit that preclude a', 'the screening visit that preclude a', 'patient from entering the study or', 'patient from entering the study or', 'receiving IMP are not considered', 'receiving IMP are not considered', 'adverse events.)', 'adverse events.)', '7.6 Vital Signs', 'Vital signs (pulse, BP, body', 'Vital signs (pulse, BP, body', 'This was updated to', 'temperature, and respiratory rate) will', 'temperature, and respiratory rate) will', 'specify that patients', 'be measured at the time points detailed', 'be measured at the time points detailed', 'must rest in a supine', 'in Table 1. All vital signs results', 'in Table 1. All vital signs results', 'or semi-erect', 'outside of the reference ranges will be', 'outside of the reference ranges will be', 'position for', 'judged by the investigator as belonging', 'judged by the investigator as belonging', '5 minutes before', '157']"
158,page_159,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'to one of the following categories:', 'to one of the following categories:', 'pulse and BP are', 'abnormal and not clinically', 'abnormal and not clinically', 'measured.', 'significant', 'significant', 'abnormal and clinically significant', 'abnormal and clinically significant', 'Before pulse and BP are measured, the', 'Before pulse and BP are measured, the', 'patient must be-rest in a supine or semi', 'patient must be-rest in a supine or semi', 'erect/seated position and resting for at', 'erect/seated position for at least 5', 'least 35 minutes. (The same position', 'minutes. (The same position and arm', 'and arm should be used each time vital', 'should be used each time vital signs are', 'signs are measured for a given patient).', 'measured for a given patient). At', 'At baseline, week 4, and week 12,', 'baseline, week 4, and week 12,', 'orthostatic BP and pulse will be', 'orthostatic BP and pulse will be', 'measured after the patient is in a', 'measured after the patient is in a', 'standing position for at least 3 minutes.', 'standing position for at least 3 minutes.', 'For any abnormal vital sign finding, the', 'For any abnormal vital sign finding, the', 'measurement should be repeated as', 'measurement should be repeated as', 'soon as possible. Any vital sign value', 'soon as possible. Any vital sign value', 'that is judged by the investigator as a', 'that is judged by the investigator as a', 'clinically significant will be recorded', 'clinically significant will be recorded', 'both on the source documentation;', 'both on the source documentation and', 'transcribed onto and the CRF as an', 'the CRF as an adverse event, and', 'adverse event, and monitored as', 'monitored as described in Section', 'described in Section 7.1.2.', '7.1.2.', 'At baseline, week 4, and week 12,', 'orthostatic BP and pulse will be', 'measured after the patient is in a', 'standing position for at least 3 minutes.', '7.8 Physical Examinations', 'Any physical examination finding that', 'Any physical examination finding that', 'This minor', 'is judged by the investigator as a', 'is judged by the investigator as a', 'clarification was', 'clinically significant (except at the', 'clinically significant (except at the', 'made.', 'screening visit) will be considered an', 'screening visit) will be considered an', 'adverse event, recorded on the CRF,', 'adverse event, recorded on the CRF,', 'and monitored as described in Section', 'and monitored as described in Section', '7.1.2.', '7.1.2.', '7.9. Assessment of Suicidality', 'TEV-50717 is considered to be CNS-', 'TEV-50717 is considered to be CNS-', 'This was updated to', 'active. In addition, there have been', 'active. In addition, there have been', 'include a section on', 'some reports of suicidal ideation or', 'some reports of suicidal ideation or', 'the assessment of', 'behavior as reported in the product', 'behavior as reported in the product', 'suicidality.', 'label when it has been given to some', 'label when it has been given to some', 'patients with certain conditions. The', 'patients with certain conditions. The', 'sponsor considers it important to', 'sponsor considers it important to', 'monitor for such events before and', 'monitor for such events before and', 'during this clinical study.', 'during this clinical study.', '158']"
159,page_160,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'Some CNS-active IMPs may be', 'Some CNS-active IMPs may be', 'associated with an increased risk of', 'associated with an increased risk of', 'suicidal ideation or behavior when', 'suicidal ideation or behavior when', 'given to some patients with certain', 'given to some patients with certain', 'conditions. Although this IMP or other', 'conditions. Although this IMP or other', 'similar medicinal products in this class', 'similar medicinal products in this class', 'have not been shown to be associated', 'have not been shown to be associated', 'with an increased risk of suicidal', 'with an increased risk of suicidal', 'thinking or behavior when given to this', 'thinking or behavior when given to this', 'study population, the sponsor considers', 'study population, the sponsor considers', 'it important to monitor for such events', 'it important to monitor for such events', 'before or during this clinical study.', 'before or during this clinical study.', 'The study population being', 'The study population being', 'administered TEV-50717 should be', 'administered TEV-50717 should be', 'monitored appropriately and observed', 'monitored appropriately and observed', 'closely for suicidal ideation and', 'closely for suicidal ideation and', 'behavior or any other unusual changes', 'behavior or any other unusual changes', 'in behavior. Consideration should be', 'in behavior. Consideration should be', 'given to discontinuing TEV-50717 in', 'given to discontinuing TEV-50717 in', 'participants who experience signs of', 'participants who experience signs of', 'suicidal ideation or behavior.', 'suicidal ideation or behavior.', 'Families and caregivers of participants', 'Families and caregivers of participants', 'being treated with TEV-50717 should', 'being treated with TEV-50717 should', 'be instructed to monitor participants for', 'be instructed to monitor participants for', 'the emergence of unusual changes in', 'the emergence of unusual changes in', 'behavior, as well as the emergence of', 'behavior, as well as the emergence of', 'suicidal ideation and behavior, and to', 'suicidal ideation and behavior, and to', 'report such symptoms immediately to', 'report such symptoms immediately to', 'the study investigator.', 'the study investigator.', 'Baseline assessment of suicidal', 'Baseline assessment of suicidal', 'ideation and behavior and treatment-', 'ideation and behavior and treatment-', 'emergent suicidal ideation and', 'emergent suicidal ideation and', 'behavior will be assessed during the', 'behavior will be assessed during the', 'study using the C-SSRS described in', 'study using the C-SSRS described in', 'Section 7.2.2.', 'Section 7.2.2.', 'A reference sample is provided in', 'A reference sample is provided in', 'Appendix E.', 'Appendix E.', '7.11 Concomitant Therapy or Medication', 'Concomitant therapy or medication', 'Concomitant therapy or medication', 'This was updated to', 'usage will be monitored throughout the', 'usage will be monitored throughout the', 'include a cross', 'study. Parents/patients will be', 'study. Parents/patients will be', 'reference and', 'instructed during the course of the', 'instructed during the course of the', 'statement that', 'study to notify the investigator if any', 'study to notify the investigator if any', 'medications', 'new medication is', 'new medication is', 'associated with QTc', 'prescribed/administered, including', 'prescribed/administered, including', 'prolongation have', 'over-the-counter medications. Any', 'over-the-counter medications. Any', 'been inserted into the', '159']"
160,page_161,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'prescribed/administered medication', 'prescribed/administered medication', 'protocol into', 'should be reviewed with the', 'should be reviewed with the', 'Appendix A.', 'investigator.', 'investigator.', 'Medications that are allowed, provided', 'Medications that are allowed, provided', 'that conditions outlined in the table are', 'that conditions outlined in the table are', 'met, are shown in Appendix A, Table', 'met, are shown in Appendix A, Table', '5.', '5.', 'The medical monitor must be contacted', 'The medical monitor must be contacted', 'if a patient is receiving (or has to begin', 'if a patient is receiving (or has to begin', 'or stop receiving during the study) a', 'or stop receiving during the study) a', 'medication that is associated with QTc', 'medication that is associated with QTc', 'prolongation or that is a known strong', 'prolongation or that is a known strong', 'CYP inhibitor-Table 6', 'CYP inhibitor.', 'Prohibited medications that are', 'Prohibited medications that are', 'associated with QTc prolongation are', 'associated with QTc prolongation are', 'listed in Appendix A, Table 6, while', 'listed in Appendix A, Table 6, while', 'prohibited antipsychotic drugs are', 'prohibited antipsychotic drugs are', 'listed in Appendix A, Table 7.', 'listed in Appendix A, Table 7.', '7.12 Methods and Timing of Assessing, Recording, and Analyzing Safety Data', 'All adverse events will be reviewed on', 'All adverse events will be reviewed on', 'This was updated to', 'a periodic basis by the clinical project', 'a periodic basis by the clinical project', 'remove the ad hoc', 'physician/medical monitor according to', 'physician/medical monitor according to', 'evaluation of safety', 'the safety monitoring plan (eg,', 'the safety monitoring plan (eg,', 'data by the Product', 'scheduled safety reviews for', 'scheduled safety reviews for', 'Safety Group.', 'TEV-50717) as preliminary safety', 'TEV-50717) as preliminary safety', 'databases become available. Safety', 'databases become available.', 'data will additionally be evaluated', 'Methods and timing of assessing safety', 'periodically and ad hoc (if necessary)', 'data are discussed in Section 3.13.', 'in the Product Safety Group.', 'Procedures for recording safety data', 'Methods and timing of assessing safety', 'are discussed in Section 13.1, and', 'data are discussed in Section 3.13.', 'methods of analyses are discussed in', 'Procedures for recording safety data are', 'Section 9.7.2.', 'discussed in Section 13.1, and methods', 'Information about the IDMC used for', 'of analyses are discussed in Section', 'this study is provided in Section 3.7.3.', '9.7.2.', 'Information about the IDMC used for', 'this study is provided in Section 3.7.3.', '8.2 Pharmacodynamics Assessment', 'Exposure-response (eg,', 'Exposure-response (eg,', 'This section was', 'pharmacodynamic [PD] and/or safety', 'pharmacodynamic [PD] and/or safety', 'added to account for', 'endpoints) may be assessed if the', 'endpoints) may be assessed if the', 'possible', 'appropriate data are available.', 'appropriate data are available.', 'pharmacodynamics', 'assessment of data.', '160']"
161,page_162,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', '8.3 Pharmacogenetics', 'Not applicable', 'Level 2 heading added to the protocol', 'This level 2 heading', 'was added to', 'streamline the', 'genotyping portion', 'of the protocol', '8.3.1 CYP2D6 Genotype-Genotyping/Pharmacogenetics', 'At the screening visit, a blood sample', 'At the screening visit, a blood sample', 'This section was', '(5 to 6 mL) will be obtained for', '(5 to 6 mL) will be obtained for', 'updated to include', 'analysis of CYP2D6 genotype. The', 'analysis of CYP2D6 genotype. The', 'greater clarity on the', ""patient's genotype for CYP2D6 will"", ""patient's genotype for CYP2D6 will"", 'process of CYP2D6', 'remain blinded during the conduct of', 'remain blinded during the conduct of', 'genotyping and the', 'the study. If the patient elects this', 'the study. If the patient elects this', 'genetic samples that', 'option on the optional informed', 'option on the optional informed', 'may be obtained', 'consent, the remaining sample will be', 'consent, the remaining sample will be', 'from patients.', 'stored for exploratory', 'stored for exploratory', 'pharmacogenetics (PGx) evaluation.', 'pharmacogenetics (PGx) evaluation.', 'This PGx assessment will investigate', 'This PGx assessment will investigate', ""the relationship between subjects'"", ""the relationship between subjects'"", 'genetic variability and study outcomes.', 'genetic variability and study outcomes.', 'Candidate genes included in this', 'Candidate genes included in this', 'assessment may be related to, or', 'assessment may be related to, or', 'hypothesized to be related to', 'hypothesized to be related to', 'pharmacokinetics, safety features, drug', 'pharmacokinetics, safety features, drug', 'mechanism of action, Tourette', 'mechanism of action, Tourette', 'syndrome, or related diseases. The final', 'syndrome, or related diseases. The final', 'list of genes to be evaluated will be', 'list of genes to be evaluated will be', 'determined at the time of analysis to be', 'determined at the time of analysis to be', 'able to account for the most current', 'able to account for the most current', 'research.', 'research.', '9.5.4.3 Key Secondary Efficacy Analyses', 'A hierarchical (fixed-sequence) testing', 'A hierarchical (fixed-sequence) testing', 'This section was', 'approach will be used for the analysis', 'approach will be used for the analysis', 'updated to present', 'of the primary and key secondary', 'of the primary and key secondary', 'the changes in the', 'endpoints to maintain the experiment-', 'endpoints to maintain the experiment-', 'key secondary', 'wise type I error rate of 5%. If an', 'wise type I error rate of 5%. If an', 'efficacy endpoints', 'endpoint is not statistically significant,', 'endpoint is not statistically significant,', 'and analyses (ie, the', 'confirmatory hypothesis testing will', 'confirmatory hypothesis testing will', 'addition of TS-PGII,', 'not be carried out on the remaining', 'not be carried out on the remaining', 'the removal of TS-', 'hypotheses, and remaining hypotheses', 'hypotheses, and remaining hypotheses', 'PGIS, and the use of', 'will be considered exploratory rather', 'will be considered exploratory rather', 'the child and', 'than confirmatory. The change in the', 'than confirmatory. The change in the', 'adolescent version of', 'TS CGI (1),', '(2), and C&A-', 'TS CGI (1) and C&A-GTS-QOL ADL', 'the GTS-QOL scale.)', 'GTS-QOL physical/ADL subscale (3)', 'subscale (3) scores from baseline to', 'scores from baseline to week 12 will be', 'week 12 will be summarized and', '161']"
162,page_163,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'summarized and analyzed in the same', 'analyzed in the same fashion as the', 'fashion as the primary analysis, with', 'primary analysis, with the exception', 'the exception that the baseline value of', 'that the baseline value of the given', 'the given endpoint will be included as', 'endpoint will be included as the', 'the covariate. TS PGII (2) will be', 'covariate. TS PGII (2) will be analyzed', 'analyzed using a Cochran-Mantel-', 'using a Cochran-Mantel-Haenszel row', 'Haenszel row mean score test with a', 'mean score test with a modified ridit', 'modified ridit scoring that controls for', 'scoring that controls for age group.', 'age group.', '9.5.4.4 Exploratory Analyses', 'This section was', 'updated to present', 'the changes in the', 'exploratory', 'endpoints and', 'analyses', ':', '162']"
163,page_164,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 01 text with', 'New wording', 'Reason/Justification', 'changes shown', 'for change', 'APPENDIX A. ALLOWED AND DISALLOWED MEDICATIONS', 'The medical monitor must be contacted', 'The medical monitor must be contacted', 'Table 6: Prohibited', 'if a patient is receiving (or has to begin', 'if a patient is receiving (or has to begin', 'QTc Prolonging', 'or stop receiving during the study) a', 'or stop receiving during the study) a', 'Drugs"" was added to', 'medication that is associated with QTc', 'medication that is associated with QTc', 'the protocol to', 'prolongation or that is a known strong', 'prolongation or that is a known strong', 'include additional', 'cytochrome P450 inhibitor.', 'cytochrome P450 inhibitor.', 'safety precautions', 'Prohibited medications that are', 'Prohibited medications that are', 'and exclusion', 'associated with QTc prolongation are', 'associated with QTc prolongation are', 'criteria.', 'listed in Table 6, while prohibited', 'listed in Table 6, while prohibited', 'antipsychotic drugs are listed in', 'antipsychotic drugs are listed in', 'Table 7.', 'Table 7.', '""Table 6: Prohibited QTc Prolonging', '""Table 6: Prohibited QTc Prolonging', 'Drugs"" was added to the protocol', 'Drugs"" was added to the protocol', 'APPENDIX I. TOURETTE SYNDROME-PATIENT GLOBAL IMPRESSION OF IMPACT AND', 'SEVERITY', 'Appendix I was updated to include', 'Appendix I was updated to include', 'Appendix I was', 'only PGIS and PGII assessments from', 'only PGIS and PGII assessments from', 'updated to include', 'the latest RTI report. Assessments of', 'the latest RTI report.', 'only PGIS and PGII', 'change and the parent/guardian items', 'assessments from the', 'were removed.', 'latest RTI report.', 'Assessments of', 'change and the', 'parent/guardian', 'items were removed.', 'APPENDIX K.CHILD AND ADOLESCENT GILLES DE LA TOURETTE SYNDROME -', 'QUALITY OF LIFE SCALE FOR PATIENTS AGED 13 TO 18 YEARS (C&A-GTS-QOL 13-18)', 'The existing GTS-QOL scale was', 'The Children and Adolescent version', 'The existing GTS-', 'replaced by the Children and', 'of the scale for patients aged 6 to 12', 'QOL scale was', 'Adolescent version of the scale for', '(C&A-GTS-QOL 6-12) and aged 13 to', 'replaced by the', 'patients aged 6 to 12 (C&A-GTS-QOL', '18 (C&A-GTS-QOL 13-18) replaced', 'Children and', '6-12) and aged 13 to 18 (C&A-GTS-', 'the existing GTS-QOL scale.', 'Adolescent version', 'QOL 13-18)', 'of the scale for', 'patients aged 6 to 12', '(C&A-GTS-QOL', '6-12) and aged 13 to', '18 (C&A-GTS-QOL', '13-18), in alignment', 'with the adjustments', 'made to the', 'secondary and', 'exploratory', 'endpoints.', '163']"
164,page_165,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '17.3.', 'Amendment 03 Dated 06 November 2017', 'The primary reason for this amendment is to update dosing instructions/timing, further specify', 'timing of enrollment into the open-label extension study TV50717-CNS-30047, update', 'pregnancy language, and update the timing/frequency of a few assessments.', 'This amendment is considered to be substantial (ie, requires approval by Competent Authority,', ""IEC, and/or IRB) by the sponsor's Authorized Representative. Other nonsubstantial changes"", 'have been made to the protocol (and protocol synopsis, as appropriate). These changes are', 'unlikely to affect the safety or rights (physical or mental integrity) of the patients in this clinical', 'study or the scientific value of the clinical study.', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'Section 3.1.1 Overall Design and Screening Period (Other section affected by this change: 3.1.5', 'Washout Period and Follow-up)', 'Patients who complete the study may', 'Patients who complete the study', 'Updated to clarify the', 'be eligible to begin participation in an', 'may be eligible to begin', 'timing of', 'open-label safety extension study', 'participation in an open-label', 'participation/enrollment', 'TV50717-CNS-30047 after the end of', 'safety extension study TV50717-', 'into open-label study', 'the washout period. At the week 13', 'CNS-30047 after the end of the', 'TV50717-CNS-30047', 'visit, patients may choose to enter', 'washout period. At the week 13', 'study TV50717-CNS-30047 (on that', 'visit, patients may choose to enter', 'day), or they will have an additional', 'study TV50717-CNS-30047 (on', 'week to make a decision and return for', 'that day), or they will have an', 'day 1. Patients not participating in', 'additional week to make a', 'Study TV50717-CNS-30047 will have', 'decision and return for day 1.', 'a follow-up telephone contact to', 'Patients not participating in Study', 'evaluate safety 1 week after the end of', 'TV50717-CNS-30047 will have a', 'the washout period (2 weeks after their', 'follow-up telephone contact to', 'last dose of IMP).', 'evaluate safety 1 week after the', 'end of the washout period (2', 'weeks after their last dose of', 'IMP).', 'Section 3.1.5 Washout Period and Follow up (Figure 1)', 'Not applicable', '[Minor updates were made to', 'Minor updates were made', 'Figure 1. An updated Figure 1', 'to Figure 1 to enhance the', 'was inserted.]', 'clarity of the study design', 'and anticipated enrollment', 'numbers', 'Section 3.4 Safety Measures and Time Points', '12-lead ECG: Screening; baseline;', '12-lead ECG: Screening;', 'Updated to include specific', 'and weeks 4, 6, and 12', 'baseline; and weeks 4, 6, and 12', 'assessments at additional', 'Pregnancy testing: Screening,', 'Pregnancy testing: Screening,', 'time points', 'baseline, and weekweeks 4 and 12', 'baseline, and weeks 4 and 12', '164']"
165,page_166,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'Section 3.13 Study Procedures (Table 1)', 'Not applicable', '[Minor updates were included in', 'Updates were made to the', 'Table 1. Assessments were', 'table and table footnotes in', 'added/removed, and footnotes', 'alignment with', 'were edited/adjusted. Updates', 'assessments', 'were made in alignment with', 'added/removed within the', 'assessments added/removed', 'protocol, in order to', 'within the protocol. Visit', 'enhance protocol clarity', 'windows were also adjusted]', 'Section 3.13.1 Procedures for Screening and Enrollment (Other sections affected by this change:', '3.13.2 and 3.13.3.2.2)', 'The screening visit will take place not', 'The screening visit will take', 'Screening visit updated to', 'more than 31 days and no less than 3', 'place not more than 31 days', 'be ""up to 31 days"" before', 'days before the baseline visit. The', 'before the baseline visit. The', 'the baseline visit, in', 'screening visit may be conducted over', 'screening visit may be conducted', 'alignment with the table of', '2 separate visits at the discretion of the', 'over 2 separate visits at the', 'assessments', 'investigator. The following procedures', 'discretion of the investigator. The', 'Updated the definition of', 'will be performed at screening:', 'following procedures will be', 'females of childbearing', 'perform a serum pregnancy (beta', 'performed at screening:', 'potential throughout the', 'human chorionic gonadotropin [ß-', 'perform a serum pregnancy', 'protocol', 'HCG]) test (only in females of', '(beta human chorionic', 'childbearing potentialwho are', 'gonadotropin [ß-HCG]) test (only', 'postmenarchal or >12 years of age)', 'in females who are', 'postmenarchal or >12 years of', 'age)', 'Section 3.13.3.1.2 Clinic Visits (Weeks 2, 4, and 6)', 'Not applicable', 'perform urine pregnancy (B-', 'Updated to add the', 'HCG) test at week 4 (only in', 'assessment of a urine', 'females who are postmenarchal', 'pregnancy test at week 4,', 'or >12 years of age)', 'per updates made to Table', '1', 'Section 3.13.5 Unscheduled Visits', 'perform a urine/serum pregnancy', 'perform a urine/serum', 'Updated to include that the', '(B-HCG) test (only in females who are', 'pregnancy (B-HCG) test (only in', 'urine pregnancy test should', 'postmenarchal or >12 years of age)', 'females who are postmenarchal', 'only occur in ""females who', 'or >12 years of age)', 'are postmenarchal or >12', 'years of age""', 'Section 4.1.Patient Inclusion Criteria', 'j. Females of childbearing', 'j.', 'Females who are', 'Updated the inclusion', 'potentialwho are postmenarchal or >12', 'postmenarchal or >12 years of', 'criteria to more specifically', 'years of age may be included only if', 'age may be included only if they', 'define females of', 'they have a negative ß HCG test at', 'have a negative ß HCG test at', 'childbearing potential and', 'baseline or are sterile. Definitions of', 'baseline or are sterile. Definitions', 'to adjust some of the text', '165']"
166,page_167,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'sterile is given in Appendix L', 'of sterile is given in Appendix L.', 'regarding birth-control', 'k. Females who are postmenarchal or', 'k. Females who are', 'methods', '>12 years of age childbearing potential', 'postmenarchal or >12 years of', 'whose male partners are potentially', 'age whose male partners are', 'fertile (ie, no vasectomy) or female', 'potentially fertile (ie, no', 'partners of male participants must use', 'vasectomy) must use highly', 'highly effective birth control methods', 'effective birth control methods', 'for the duration of the study (ie,', 'for the duration of the study (ie,', 'starting at screening) and for 30 days or', 'starting at screening) and for 30', '5 half-lives, whichever is longer after', 'days or 5 half-lives, whichever is', 'last dose of IMP. Further details are', 'longer after last dose of IMP.', 'included in Appendix L', 'Further details are included', 'in Appendix L', 'Section 5.1. Drugs Administered During the Study', 'Dose reductions, if required,', 'Dose reductions, if required,', 'Updated to include more', 'should be in increments of 6 mg. If', 'should be in increments of 6 mg.', 'clear direction and', 'more than 1 dose reduction is required', 'If more than 1 dose reduction is', 'instruction on the timing of', 'for an adverse event, the medical', 'required for an adverse event, the', 'IMP dosing during the', 'monitor shouldmust be notified.', 'medical monitor must be notified.', 'study', 'Table 2 was updated', '[Table 2 was updated to remove', 'specification of dosing ""week.""', 'The timing of dosing and dosing', 'instructions are indicated by', 'study day.]', '[Footnote ""a"" was also updated to', 'correct the start time of a', ""patient's new dose.]"", 'Section 5.5 Dose Reduction and Temporary IMP Discontinuation', 'Dose Reduction', 'Dose Reduction', 'Updated to more clearly', 'If more than 1 dose reduction is', 'If more than 1 dose reduction is', 'guide study personnel on', 'required for an adverse event, the', 'required for an adverse event, the', 'the expectations following', 'medical monitor shouldmust be', 'medical monitor must be notified.', 'dose reductions or', 'notified.', 'suspensions', 'Dose Suspension', 'Dose Suspension', 'The patients who restart IMP', 'The patients who restart IMP treatment', 'treatment will follow the visit', 'will follow the visit schedule as', 'schedule as outlined in Table 1.', 'outlined in Table 1.', 'Section 7.3.Pregnancy', 'All pregnancies of female patients', 'All pregnancies of female', 'Updated pregnancy', 'participating in the study and female', 'patients participating in the study', 'language.', 'partners of male patients participating', 'that occur during the study, or', '166']"
167,page_168,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'in the study that occur during the study,', 'within 14 days after the end of', 'or within 14 days after the end of the', 'the study, are to be reported', 'study, are to be reported immediately', 'immediately to the individual', 'to the individual identified in the', 'identified in the clinical study', 'clinical study personnel contact', 'personnel contact information', 'information section of this protocol,', 'section of this protocol, and the', 'and the investigator must provide the', 'investigator must provide the', 'sponsor (LSO/INC Research) with the', 'sponsor (LSO/INC Research)', 'completed pregnancy form. The', 'with the completed pregnancy', 'process for reporting a pregnancy is the', 'form. The process for reporting a', 'same as that for reporting a serious', 'pregnancy is the same as that for', 'adverse event but using the pregnancy', 'reporting a serious adverse event', 'form (see Section (7.1.5.3', 'but using the pregnancy form', 'The investigator is not required to', '(see Section (7.1.5.3', 'report patients who are found to be', 'The investigator is not required to', 'pregnant between screening and', 'report patients who are found to', 'baseline, provided no IMP was given.', 'be pregnant between screening', 'All female patients or female partners', 'and baseline, provided no IMP', 'of male patients participating in the', 'was given. All female patients', 'study who become pregnant will be', 'who become pregnant will be', 'monitored for the outcome of the', 'monitored for the outcome of the', 'pregnancy (including spontaneous,', 'pregnancy (including', 'elective, or voluntary abortion). If the', 'spontaneous, elective, or', 'pregnancy continues to term, the', 'voluntary abortion). If the', 'outcome (health of the infant up to 8', 'pregnancy continues to term, the', 'weeks of age), including details of birth', 'outcome (health of the infant up', 'and presence or absence of any birth', 'to 8 weeks of age), including', 'defect, congenital abnormalities, or', 'details of birth and presence or', 'maternal and newborn complications,', 'absence of any birth defect,', 'will be reported to the sponsor. Any', 'congenital abnormalities, or', 'complication of pregnancy during the', 'maternal and newborn', 'study and any complication of', 'complications, will be reported to', 'pregnancy that the investigator', 'the sponsor. Any complication of', 'becomes aware of after withdrawal', 'pregnancy during the study and', 'from the study will be reported as an', 'any complication of pregnancy', 'adverse event or serious adverse event,', 'that the investigator becomes', 'as appropriate.', 'aware of after withdrawal from', 'Since this IMP has suspected human', 'the study will be reported as an', 'teratogenicity, genotoxicity,', 'adverse event or serious adverse', 'fetotoxicity, or spermatoxicity, female', 'event, as appropriate.', 'partners of male patients participating', 'If the pregnancy in the female', 'in the study who become pregnant will', 'patients participating in the study', 'be asked to sign an informed consent', 'does not continue to term, 1 of', 'form and will be monitored for the', 'the following actions will be', 'outcome of the pregnancy (including', 'taken:', 'spontaneous, elective, or voluntary', 'abortion). If the pregnancy continues to', 'term, the outcome (health of the infant', '167']"
168,page_169,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'up to 8 weeks of age), including details', 'of birth and presence or absence of any', 'birth defect, congenital abnormalities,', 'or maternal and newborn', 'complications, will be reported to the', 'sponsor. Any complication of', 'pregnancy during the study and any', 'complication of pregnancy that the', 'investigator becomes aware of after', 'withdrawal from the study will be', 'reported as an adverse event or serious', 'adverse event, as appropriate.', 'If the pregnancy in the female patients', 'participating in the study and/or the', 'female partners of male patients', 'participating in the study does not', 'continue to term, 1 of the following', 'actions will be taken:', 'Section 7.5.2.1. Human Chorionic Gonadotrophin Test', 'Human chorionic gonadotrophin tests', 'Human chorionic gonadotrophin', 'Updated to more', 'in urine or serum will be performed for', 'tests in urine or serum will be', 'specifically define females', 'all females of childbearing', 'performed for all females who', 'of childbearing potential', 'potentialwho are postmenarchal or >12', 'are postmenarchal or >12 years', 'years of age as detailed in Table 1, and', 'of age as detailed in Table 1, and', 'if clinically indicated.', 'if clinically indicated.', 'APPENDIX L. FEMALES OF CHILDBEARING POTENTIAL AND BIRTH CONTROL', 'METHODS AND PREGNANCY TESTING', 'Contraception recommendation and', 'Females of childbearing', 'Updated pregnancy', 'pregnancy testing should encompass all', 'potential are defined as:', 'expectations/language/risks', 'IMPs as well as non investigational', 'not surgically (documented', 'to be consistent with', 'medicinal products, eg, background', 'hysterectomy, bilateral', 'changes made to the', 'therapy, and the measures to be', 'oophorectomy, or bilateral', 'protocol', 'followed should be based on the', 'salpingectomy) or congenitally', 'medicinal product with highest risk.', 'sterile', 'Assessment of likelihood of possible', 'postmenarchal or > 12 years', 'interaction between IMP or', 'of age', 'concomitant medications and hormonal', 'Recommendations for', 'contraception should be conducted.', 'application of birth control', 'Hormonal contraception may be', 'methods:', 'susceptible to interaction with the IMP,', 'which may reduce the efficacy of the', 'IMP (TEV-50717) with', 'contraception method, eg, CYP 4A', 'possible human', 'inducers. In case of suspected', 'teratogenicity/fetotoxicity', 'interaction, hormonal contraceptive', '-', 'Highly effective method', 'alone may not be sufficient. In the', 'of contraception', 'absence of clinical pharmacokinetic', '168']"
169,page_170,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'interaction study data in IMPs with', '-', 'Contraception during', 'demonstrated or suspected human', 'treatment and until the end of', 'teratogenicity fetotoxicity,', 'relevant systemic exposure', 'recommendation for use of hormonal', '-', 'Additional pregnancy', 'contraceptives should be thoroughly', 'testing to be considered; as a', 'justified by the sponsor. Additional', 'minimum, at the end of', 'contraceptive methods, including', 'relevant systemic exposure', 'supplementary barrier methods, may be', '-', 'In each case of delayed', 'considered.', 'menstrual period (over 1', 'Females of childbearing potential are', 'month between', 'defined as:', 'menstruations), confirmation', 'not surgically (documented', 'of absence of pregnancy is', 'hysterectomy, bilateral oophorectomy,', 'strongly recommended This', 'or bilateral salpingectomy) or', 'recommendation also applies', 'congenitally sterile', 'to women of childbearing', 'not postmenopausalpostmenarchal', 'potential with infrequent or', 'or > 12 years of age', 'irregular menstrual cycles.', 'Description of', 'Highly effective birth control', 'differentRecommendations for', 'methods:', 'application of birth control methods:', 'Highly effective birth control', 'IMP (TEV-50717) with possible', 'methods that can achieve a', 'human teratogenicity/fetotoxicity', 'failure rate of less than 1% per', 'year when used consistently and', '-', 'Highly effective method of', 'correctly are considered. Such', 'contraception', 'methods include:', '-', 'Contraception during treatment', 'and until the end of relevant', 'Combined estrogen and', 'systemic exposure', 'progestogen hormonal', 'contraception (oral, intravaginal,', '-', 'Additional pregnancy testing to', 'transdermal) associated with', 'be considered; as a minimum, at', 'inhibition of ovulation; these', 'the end of relevant systemic', 'should be initiated at least 1', 'exposure', 'month before the first dose of', '-', 'In each case of delayed', 'IMP.', 'menstrual period (over 1 month', 'Progestogen-only hormonal', 'between menstruations),', 'contraception (oral, injectable,', 'confirmation of absence of', 'implantable) associated with', 'pregnancy is strongly', 'inhibition of ovulation; these', 'recommended. This', 'should be initiated at least before', 'recommendation also applies to', 'the first dose of IMP.', 'women of childbearing potential', 'with infrequent or irregular', 'Unacceptable birth control', 'methods:', 'menstrual cycles.', 'Periodic abstinence (calendar,', 'Highly effective birth control', 'methods:', 'symptothermal, post-ovulation', 'methods), withdrawal (coitus', 'Highly effective birth control methods', 'interruptus), spermicides only,', 'that can achieve a failure rate of less', 'and lactational amenorrhoea', 'than 1% per year when used', '169']"
170,page_171,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'consistently and correctly are', 'method (LAM) are not acceptable', 'considered. Such methods include:', 'methods of contraception. Female', 'Combined estrogen and', 'condom and male condom should', 'progestogen hormonal contraception', 'not be used together.', '(oral, intravaginal, transdermal)', 'Pregnancy tests in females of', 'associated with inhibition of ovulation;', 'childbearing potential:', 'these should be initiated at least 7 days', '1. Consider additional', '(for IMPs without suspected', 'pregnancy testing, but at least at', 'teratogenicity/genotoxicity) and 1', 'the end of relevant systemic', 'month (for IMPs potentially', 'exposure.', 'teratogenie/genotexie) before the first', 'dose of IMP.', 'Progestogen-only hormonal', 'contraception (oral, injectable,', 'implantable) associated with inhibition', 'of ovulation; these should be initiated', 'at least 7 days (for IMPs without', 'suspected eratogenicity/genotoxicity', 'and 1 month (for IMPs potentially', 'teratogenie/genotoxie) before the first', 'dose of IMP.', 'Acceptable birth control methods:', 'Acceptable birth control methods that', 'result in a failure rate of more than 1%', 'per year include: progestogen only oral', 'hormonal contraception for which the', 'inhibition of ovulation is not the', 'primary mode of action; male or', 'female condom with or without', 'spermicide; cap, diaphragm, or sponge', 'with spermicide The combination of', 'male condom with either cap,', 'diaphragm, or sponge with spermicide', '(double barrier methods) are also', 'considered acceptable but not highly', 'effective methods of birth control.', 'Unacceptable birth control methods:', 'Periodic abstinence (calendar,', 'symptothermal, post-ovulation', 'methods), withdrawal (coitus', 'interruptus), spermicides only, and', 'lactational amenorrhoea method', '(LAM) are not acceptable methods of', 'contraception. Female condom and', 'male condom should not be used', 'together.', '170']"
171,page_172,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'Male contraception:', 'Male patients must always use a', 'condom, except in cases of no', 'genotoxicity; or no demonstrated or', 'suspected human', 'eratogenicity/fetotoxicity.', 'Vaseetomy:', 'Use of contraceptive methods applies', 'also to vasectomized men, because of', 'the risk associated with transfer of a', 'drug via seminal fluid.', 'Contraception for female partners of', 'male study participants:', 'Female partners (who are not pregnant)', 'of male study participants must use', 'contraception for non pregnant', 'WOCBP until the end of relevant', 'systemic exposure in case of IMPs with', 'genotoxicity or IMPs with no', 'genotoxicity but demonstrated or', 'suspected human', 'teratogenicity/fetotoxicity.', 'Pregnancy tests in females of', 'childbearing potential:', '1. Conduct monthly pregnancy', 'testing from first dose of IMP until last', 'dose of IMP and additional 30 days in', 'case the IMP does not have a', 'marketing authorization and has', 'suspected human', 'ratogenicity (genotoxicity fetotoxicity.', 'Conduct monthly pregnancy testing', 'and in case the IMP has a marketing', 'authorization, if the IMP has a', 'demonstrated or suspected human', 'teratogenicity genotoxicity. etotoxicity', 'according to Risk Safety Information.', 'Shorter testing intervals are to be', 'considered depending on drug dosing', 'schedule.', '2.-Consider additional pregnancy', 'testing, but at least at the end of', 'relevant systemic exposure, in case of', 'possible human', 'eratogenicity/fetotoxicity This refers', 'to IMPs, for which human data on', '171']"
172,page_173,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 02 text with', 'New wording', 'Reason/Justification for', 'changes shown', 'change', 'pregnancies is limited or not available,', 'there is no suspicion of human', 'teratogenicity based on class effects or', 'genotoxie potential, and nonclinical', 'reproductive toxicity studies of', 'relevance for early human pregnancy', 'show positive findings that do not', 'generate a strong suspicion of human', 'teratogenicity/ fetotoxicity.', '3. For IMPs with unlikely risk of', 'human pratogenicity fetotoxicity,', 'additional pregnancy testing is', 'generally not necessary. This refers to', 'IMPs for which assessment of the', 'completed necessary nonclinical', 'studies does not indicate teratogenicity/', 'fetotoxicity in early pregnancy and', 'human data are not available or do not', 'contradict these findings or there is', 'already sufficient evidence for lack of', 'risk based on human data.', 'Pregnant female partners of male', 'study participants:', 'Male study participants must use', 'condoms during intercourse if their', 'female partners are pregnant.', '172']"
173,page_174,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '17.4.', 'Amendment 04 Dated 13 September 2018', 'The primary reason for this amendment is to include additional nonclinical data observed in rat', 'toxicology studies; further clarify procedures to be carried out during the screening and', 'enrollment periods (eg, informed consent/assent stipulations); update requirements on drug', 'storage and security; update/clarify patient inclusion criteria, exclusion criteria, and withdrawal', 'criteria; provide updates on allowed and prohibited medications; include additional guidance for', 'evaluation and handling of suicidal ideation, suicidal behavior, and depression; and to streamline', 'birth control methods language for females of childbearing potential.', 'This amendment is considered to be substantial (ie, requires approval by Competent Authority,', ""IEC, and/or IRB) by the sponsor's Authorized Representative. Other nonsubstantial changes"", 'have been made to the protocol (and protocol synopsis, as appropriate). These changes are', 'unlikely to affect the safety or rights (physical or mental integrity) of the patients in this clinical', 'study or the scientific value of the clinical study.', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'LABORATORY AND OTHER DEPARTMENTS AND INSTITUTIONS', 'Central Clinical Laboratory', 'Central Clinical Laboratory', 'Administrat', 'Q2 Solutions (Quest) LLC1201 S.', 'Q2 Solutions (Quest) LLC', 'ive change.', 'Collegeville Road', '27027 Tourney Road, Suite 2E', 'Collegeville, PA 19426', 'Valencia, CA 91355', '27027 Tourney Road, Suite 2E', 'USA', 'Valencia, CA 91355', 'USA', 'Contract Research Organization; Safety', 'Contract Research Organization; Safety', 'Administrat', 'and Efficacy Data Analysis', 'and Efficacy Data Analysis', 'ive change.', 'INC Research, LLC, a Syneos health group', 'INC Research, LLC, a Syneos health group', 'company (""Syneos Health"")', 'company (""Syneos Health"")', '3201 Beechleaf Court', '3201 Beechleaf Court', 'Suite 600', 'Suite 600', 'Raleigh, NC 27604-1547', 'Raleigh, NC 27604-1547', 'USA', 'USA', 'Central Electrocardiogram Evaluation', 'Central Electrocardiogram Evaluation', 'Change in', 'Biomedical Systems', 'ERT', 'central ECT', '77 Progress Parkway', '1818 Market Street 10th Floor', 'and IRT', 'St. Louis, MO 63013 ERT', 'Philadelphia, PA 19103', 'vendors.', '1818 Market Street 10th Floor', 'USA', 'Philadelphia, PA 19103', 'USA', 'Integrated Response Technology', 'Endpoint', 'Integrated Response Technology', '55 Francisco Street, Suite 200', '173']"
174,page_175,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'Bracket Global, LLC', 'San Francisco, CA 94133', '575 East Swedesford Road Endpoint', 'USA', '55 Francisco Street, Suite 200', 'Wayne, PA 19087 San Francisco, CA', '94133', 'ePRO, eCOA, and Scales Training', 'Bracket Global, LLC', 'USA', '575 East Swedesford Road, Suite 200', 'Wayne, PA 19087', 'ePRO, eCOA, and Scales Training', 'USA', 'Bracket Global, LLC', '575 East Swedesford Road, Suite 200', 'Wayne, PA 19087', 'USA', 'Bioanalytical Pharmacokineties', 'Evaluation Data Analysis', 'Information will be included in the Trial', 'Master File.', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', ""Sponsor's Authorized Representative:"", ""Sponsor's Authorized Representative:"", 'Update to', 'the', ""Sponsor's"", 'authorized', 'representati', 've. In', 'addition,', 'medical', 'director/me', 'For medical issues, contact the physician', 'For medical issues, contact the physician', 'dical', 'listed below:', 'listed below:', 'monitor', 'contacts', 'outside of', 'North', 'America', 'have been', 'included.', 'Administrat', 'ive changes', 'carried out', 'for clarity.', 'For operational issues, contact the', 'operational lead listed below:', '174']"
175,page_176,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'For protocol issues, contact the study', 'leaders listed below:', '175']"
176,page_177,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'For protocol issues, contact the study', 'leaderleaders listed below:', 'For operational issues, contact the', 'operational lead listed below:', 'CLINICAL STUDY PROTOCOL SYNOPSIS', 'Type of the Study Phase of Clinical', 'Type of the Study: Efficacy and Safety', 'Template', 'Development: Efficacy and Safety (Phase', '(Phase 2/3)', 'update.', '2/3)', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 3.1.2', 'Screening Period, 3.4 Safety Measures and Time Points, 3.13.1 Procedures for Screening and', 'Enrollment, 4.1 Patient Inclusion Criteria, 5.2 Restrictions, 7.1.2 Recording and Reporting Adverse', 'Events, 7.1.5 Serious Adverse Events, 11.3 Study Monitoring, 12.1 Informed Consent/Assent, 13.1', 'Data Collection, 13.3.2 Investigator Responsibilities)', 'After informed consent-(andwritten-/assent', 'After informed consent/assent, depending', 'Provisions', 'and/or co consent for patients 14 years of,', ""on the child's age, as appropriate, is"", 'on informed', ""depending on the child's age-and older, as"", 'obtained', 'consent/ass', 'appropriate), is obtained', 'ent have', 'been more', 'clearly', 'provided', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 3.1.2', 'Screening Period)', '176']"
177,page_178,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'At the discretion of the investigator, the', 'At the discretion of the investigator, the', 'Guidance', 'screening visit may be divided into 2 visits', 'screening visit may be divided into 2 visits', 'provided on', 'if the visit length is felt to be too', 'if the visit length is felt to be too', 'the timing', 'burdensome for the patient. If the screening', 'burdensome for the patient. If the screening', 'of obtaining', 'visit is divided into 2 visits, the blood', 'visit is divided into 2 visits, the blood', 'blood', 'sample should be obtained during the first', 'sample should be obtained during the first', 'samples in', 'of the 2 visits.', 'of the 2 visits.', 'situations', 'where the', 'screening', 'visit is', 'divided into', '2 visits.', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 3.1.2', 'Screening Period, 3.13.1 Procedures for Screening and Enrollment)', '(Note: Details of rescreening must be', '(Note: Details of rescreening must be', 'Further', 'approved.) and documented by the medical', 'approved and documented by the medical', 'elaborated', 'monitor and/or Clinical Surveillance and', 'monitor and/or Clinical Surveillance and', 'on the', 'Training (CST) team.', 'Training [CST] team.)', 'documentat', 'ion process', 'for', 'rescreening', 'of patients.', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 3.13.1', 'Procedures for Screening and Enrollment, 4.1 Patient Inclusion Criteria, 12.1 Informed', 'Consent/Assent)', 'Patient and caregiver/adult (may also', 'Patient and caregiver/adult (may also', 'Provisions', 'include an adult other than a parent or legal', 'include an adult other than a parent or legal', 'on informed', 'representative).', 'representative).', 'consent/ass', 'ent have', 'been more', 'clearly', 'provided.', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 4.2 Patient', 'Exclusion Criteria)', 'Patient has received any of the following', 'Patient has received any of the following', 'Further', 'concomitant medications for tics within the', 'concomitant medications for tics within the', 'guidance', 'specified exclusionary washout windows of', 'specified exclusionary washout windows of', 'provided on', 'screening first dose:', 'first dose:', 'prohibited', 'Withinwithin 3 months: depot neuroleptics,', 'within 3 months: depot neuroleptics,', 'and allowed', 'botulinum toxin, or tetrabenazine', 'botulinum toxin, or tetrabenazine', 'medication.', 'Withinwithin 4 weeks: cannabidiol oil and', 'within 4 weeks: cannabidiol oil and', 'Valbenazine', 'valbenazine', 'within 21 days: reserpine', 'within 21 days: reserpine', '177']"
178,page_179,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'Withinwithin 14 days: neuroleptics (oral),', 'within 14 days: neuroleptics (oral), typical', 'typical and atypical antipsychotics (see', 'and atypical antipsychotics (see', 'Appendix A), metoclopramide, levodopa,', 'Appendix A), metoclopramide, levodopa,', 'and dopamine agonists', 'and dopamine agonists', 'Note: Use of stimulant medications.', 'Note: Use of stimulant medications,', 'including amphetamine, methylphenidate,', 'including amphetamine, methylphenidate,', 'and lisdexamfetamine, is allowed if primary', 'and lisdexamfetamine, is allowed if primary', 'use is for the treatment of ADHD, dosing', 'use is for the treatment of ADHD, dosing', 'has been stable for at least 2 weeks before', 'has been stable for at least 2 weeks before', 'screening, and no changes to dose or', 'screening, and no changes to dose or', 'frequency are anticipated during the course', 'frequency are anticipated during the course', 'of the study.', 'of the study.', 'Note: Use of atomoxetine is allowed if the', 'Note: Use of atomoxetine is allowed if the', 'primary use is for the treatment of ADHD,', 'primary use is for the treatment of ADHD,', 'dosing has been stable for at least 4 weeks', 'dosing has been stable for at least 4 weeks', 'before screening, and no changes to dose or', 'before screening, and no changes to dose or', 'frequency are anticipated during the course', 'frequency are anticipated during the course', 'of the study.', 'of the study.', 'Note: Use of benzodiazepines is allowed if', 'Note: Use of benzodiazepines is allowed if', 'primary use is not for tics and dosing has', 'primary use is not for tics and dosing has', 'been stable for at least 4 weeks before', 'been stable for at least 4 weeks before', 'screening.', 'screening.', 'Note: Use of topiramate (up to 200 mg/day)', 'Note: Use of topiramate (up to 200 mg/day)', 'is allowed if dosing has been stable for at', 'is allowed if dosing has been stable for at', 'least 4 weeks before screening.', 'least 4 weeks before screening.', 'Note: Use of guanfacine or clonidine is', 'Note: Use of guanfacine or clonidine is', 'allowed ifregardless of indication (ie, if', 'allowed regardless of indication (ie, if', 'prescribed for tics or Tourette syndrome) if', 'prescribed for tics or Tourette syndrome) if', 'the dosing has been stable for at least 4', 'the dosing has been stable for at least 4', 'weeks before screening and no changes to', 'weeks before screening and no changes to', 'dose or frequency are anticipated during the', 'dose or frequency are anticipated during the', 'course of the study. If discontinuation of', 'course of the study. If discontinuation of', 'either medication is anticipated due to', 'either medication is anticipated due to', 'ineffectiveness, poor tolerability, or', 'ineffectiveness, poor tolerability, or', 'patient/caregiver preference,', 'patient/caregiver preference,', 'discontinuation should occur 4 or more', 'discontinuation should occur 4 or more', 'weeks prior to the screening visit.', 'weeks prior to the screening visit.', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 8.3.1', 'CYP2D6 Genotyping/Pharmacogenetics)', 'At the screening visit, a blood sample (5 to', 'At the screening visit, a blood sample (3', 'Clarificatio', '63 mL) will be obtained for analysis of', 'mL) will be obtained for analysis of', 'n on PGx', ""CYP2D6 genotype. The patient's genotype"", ""CYP2D6 genotype. The patient's genotype"", 'sampling', 'for CYP2D6 will remain blinded during the', 'for CYP2D6 will remain blinded during the', 'and details.', 'conduct of the study. If the patient elects', 'conduct of the study. If the patient elects for', 'his option for PGx evaluation on the', 'PGx evaluation on the optional informed', '178']"
179,page_180,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'optional informed consent/assent, a', 'consent/assent, a pharmacogenetic (PGx)', 'pharmacogenetic (PGx) the remaining', 'sample (2 mL) will be obtained and stored', 'sample (2 mL) will be obtained and stored', 'for exploratory PGx evaluation.', 'for exploratory pharmacogenetics PGx', 'evaluation.', 'CLINICAL STUDY PROTOCOL SYNOPSIS (Other sections affected by this change: 9.5.4.1', 'Primary Efficacy Analysis)', 'The baseline TTS, region, and age group at', 'The baseline TTS, region, and age group at', 'Addition of', 'baseline will be included as covariates.', 'baseline will be included as covariates.', 'region to', 'covariate', 'list.', 'Section 1.1 Introduction', 'To address the limitations of commercial', 'To address the limitations of commercial', 'Alignment', 'tetrabenazine, (Xenazine) Auspex, a', 'tetrabenazine (Xenazine), Auspex, a', 'of drug', 'wholly owned subsidiary of Teva', 'wholly owned subsidiary of Teva', 'naming and', 'Pharmaceutical Products R&D, Inc, has', 'Pharmaceutical Products R&D, Inc,', 'drug', 'developed a deuterated form of', 'developed deutetrabenazine (referred to as', 'approval', 'tetrabenazinedeutetrabenazine (referred to', 'TEV-50717, previously SD-809) that is', 'status.', 'as TEV-50717-or, previously SD-809) that', 'eliminated more slowly than tetrabenazine.', 'is eliminated more slowly than', 'tetrabenazine.', 'TEV-50717 was granted breakthrough', 'status for treatment of TD by the Food and', 'TEV-50717 was granted breakthrough', 'Drug Administration (FDA) based on the', 'status for treatment of TD by the Food and', 'results of Study SD-809-C-18, and NDA', 'Drug Administration (FDA) based on the', '209885 was granted priority review status.', 'results of Study SD-809-C-18, and NDA', 'TEV-50717 was approved for the treatment', '209885 was granted priority review status.', 'of chorea associated with HD on', 'TEV-50717 was approved for the treatment', '03 April 2017 and for the treatment of', 'of chorea associated with HD on', 'chorea associated with TD on', '03 April 2017: and for the treatment of', '30 August 2017.', 'chorea associated with TD on', '30 August 2017.', 'Section 1.3.1.3 Toxicology', 'Not applicable', 'The NOAEL (no-observed-adverse-effect', 'Nonclinical', 'level) for toxicities in juvenile rats is lower', 'background', 'than that in adults; however, the total (a+B)-', 'information', 'HTBZ exposure multiples or safety margins', 'addition.', 'comparing rat to humans at the adult and', 'juvenile age categories are similar. The', 'potential for increased sensitivity to the', 'effects of TEV-50717 in pediatric patients', 'is mitigated by two factors. First, the effects', 'of TEV-50717 on behavior and weight gain', 'recovered with cessation of test article', '179']"
180,page_181,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'administration in the juvenile rat toxicology', 'study. Second, the clinical significance of', 'tremors and reduced body weight gain in', 'rats dosed with TEV-50717 are unclear', 'because these findings were not adverse', 'events of note in adults or adolescent', 'patients. While hypoactivity has the', 'potential to relate to clinical observations of', 'somnolence, this adverse effect is controlled', 'with dose reduction. In clinical comparison,', 'the adverse event profile of tetrabenazine in', 'adult patients is qualitatively similar to', 'patients from approximately 22 months to', '18 years of age (Jain et al 2006, Kenney et', 'al 2007, Porta et al 2008).', 'Section 1.3.2 Clinical Studies', 'The clinical development plan for TEV', 'The clinical development plan for TEV', 'Update to', '50717 to date includes:', '50717 to date includes:', 'current', '6 completed Phase 1 studies in healthy', '6 completed Phase 1 studies in healthy', 'clinical', 'adult subjects', 'adult subjects', 'study status', 'within the', '1 completed Phase 3 pivotal study for', '1 completed Phase 3 pivotal study for', 'clinical', 'the treatment of chorea associated with HD', 'the treatment of chorea associated with HD', 'developmen', '1 ongoing completed Phase 3 long-term', '1 completed Phase 3 long-term safety', 't plan for', 'safety study in patients with HD', 'study in patients with HD', 'TEV-', '2 completed Phase 2/3 and Phase 3', '2 completed Phase 2/3 and Phase 3', '50717.', 'studies in patients with TD', 'studies in patients with TD', '1 ongoing Phase 3 long-term safety', '1 ongoing Phase 3 long-term safety', 'study in patients with TD', 'study in patients with TD', '1 completed Phase 1b study in patients', '1 completed Phase 1b study in patients', 'with TS', 'with TS', 'Further details may be found in the IB.', 'Further details may be found in the IB.', 'Figure 1: Overall Study Schema', 'a Maximum total daily dose for patients >40', 'a Maximum total daily dose for patients >40', 'Clarity for', 'kg is 48 mg/day (24 mg bid), 30 to <40 kg', 'kg is 48 mg/day (24 mg bid), 30 to <40 kg', 'CYP2D6', 'is 42 mg/day (21 mg bid), and 20 to <30 kg', 'is 42 mg/day (21 mg bid), and 20 to <30 kg', 'impaired.', 'is 30 mg/day (15 mg bid). For those taking', 'is 30 mg/day (15 mg bid). For those', 'strong CYP inhibitors such as', 'considered CYP2D6 impaired maximum', 'paroxetine/fluoxetine/bupropionFor those', 'daily dose for patients >40 kg is 36 mg/day,', 'considered CYP2D6 impaired maximum', '30 to <40 kg is 24 mg/day, and 20 to <30 kg', 'daily dose for patients >40 kg is 36 mg/day,', 'is 18 mg/day (Table 2).', '30 to <40 kg is 24 mg/day, and 20 to <30 kg', 'is 18 mg/day (Table 2).', 'Section 3.9.1 Drug Storage and Security', '180']"
181,page_182,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'The IMP (TEV-50717 and placebo) must be', 'The IMP (TEV-50717 and placebo) must be', 'Drug', 'stored protected from light, at a controlled', 'stored protected from light, at a controlled', 'storage and', 'room temperature, 20°C to 25°C (68°F to', 'room temperature, 20°C to 25°C (68°F to', 'security', '77°F); however, storage between 15°C', '77°F); however, storage between 15°C and', 'specificatio', 'toand 30°C (59°F to is acceptable if', '30°C (59°F to 86°F) is acceptable if there is', 'n.', 'there is no alternative. The IMP should be', 'no alternative. The IMP should be stored in', 'stored in a dry, securely locked,', 'a dry, securely locked, substantially', 'substantially constructed cabinet or', 'constructed cabinet or enclosure with access', 'enclosure with access limited to authorized', 'limited to authorized staff.', 'staff.', 'Section 3.9.2 Drug Accountability', 'Empty, partially used, and unused IMP will', 'Empty, partially used, and unused IMP will', 'Drug', 'be returned to the sponsor or its', 'be disposed of, as agreed with the', 'disposal', 'designeedisposed of, as agreed with the', 'sponsor/development partner.', 'details.', 'sponsor/development partner.', 'Table 1: Study Procedures and Assessments', 'Informed consent/assent and/or co consent', 'Informed consent/assent', 'Provisions', 'for patients 14 years of age and older', 'on informed', 'consent/ass', 'ent have', 'been more', 'clearly', 'provided', 'Not applicable', 'W', 'Contact IRT and dispense IMP and', 'Addition of', 'patient diary.', 'footnote to', 'study', 'procedures', 'for', 'specificatio', 'n.', 'Table 1: Study Procedures and Assessments, footnote c (Other sections affected by this change:', '3.13.2 Procedures Before IMP Treatment [Baseline/Day 1])', 'Patients will be provided with a diary to', 'Patients will be provided with a diary to', 'Clarificatio', 'record meal times and critical information', 'record critical information on dosing.', 'n of diary', 'on dosing.', 'entries.', 'Section 3.13.1 Procedures for Screening and Enrollment', 'obtain a blood sample (53 mL) for', 'obtain a blood sample (3 mL) for', 'Blood', 'analysis of CYP2D6 genotype', 'analysis of CYP2D6 genotype', 'sample', 'quantity', 'specificatio', 'n.', '181']"
182,page_183,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'Section 3.13.2 Procedures Before IMP Treatment (Baseline/Day 1) (Other sections affected by this', 'change: 3.13.3.1.2 Clinic Visits [Weeks 2, 4, and 6] and 3.13.3.2.1 Week 9)', 'dispense IMP (...) and patient diary', 'dispense IMP (...) and patient diary', 'Clarificatio', 'n that', 'patient', 'diaries', 'should also', 'be', 'dispensed at', 'these', 'visits/weeks', 'Section 4.4 Withdrawal Criteria and Procedures', 'The investigator also has the right to', 'The investigator also has the right to', 'Withdrawal', 'withdraw a patient from the study inif any', 'withdraw a patient from the study if any of', 'criteria', 'of the event of following events occur:', 'the following events occur:', 'elaboration.', 'a.', 'intercurrent illness,', 'a.', 'intercurrent illness', 'b. adverse events, (any patient', 'b.', 'adverse events (any patient who', 'who experiences an adverse', 'experiences an adverse event', 'event may be withdrawn from', 'may be withdrawn from the', 'the study or from study', 'study or from study treatment at', 'treatment at any time at the', 'any time at the discretion of the', 'discretion of the investigator as', 'investigator as indicated in', 'indicated in Section 7.1.7)', 'Section 7.1.7)', 'c. pregnancy (see Section 7.3), or', 'c. pregnancy (see Section 7.3)', ')', 'd. other reasons concerning the', 'd. other reasons concerning the', 'health or well-being of the', 'health or well-being of the', 'patient', 'patient, or in the event of', 'e.', 'lack of cooperation', 'e.', 'lack of cooperation- If a', 'f.', 'post-baseline QTcF value >500', 'f.', 'post-baseline QTcF value >500', 'msec or change from baseline', 'msec or change from baseline', '>60 msec (as described in', '>60 msec is found, the as', 'Sections 4.3 and 7.1.7). The', 'described in Sections 4.3 and', 'investigator should repeat the', '7.1.7). The investigator should', 'ECG assessment twice and', 'repeat the ECG assessment', 'compare the average of the 2', 'twice and compare the average', 'pre-treatment QTcF values', 'of the 2 pre-treatment QTcF', '(baseline and screening) to the', 'values (baseline and screening)', 'average of the 3 post-baseline', 'to the average of the 3 post-', 'QTcF values. The IMP must be', 'baseline QTcF values. The IMP', 'stopped for any confirmed post-', 'must be stopped for any', 'baseline QTcF value >500 msec', 'confirmed post-baseline QTcF', 'or increase from baseline >60', 'value >500 msec or increase', 'msec.', '182']"
183,page_184,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'from baseline 60 msec.', 'g. when a blind is broken due to', 'g.', 'when a blind is broken due to', 'safety concerns (see', 'safety concerns (see', 'Section 3.7.2). If a patient is', 'Section 3.7.2). If a patient is', 'unblinded by mistake, they', 'unblinded by mistake, they', 'should not be withdrawn.', 'should not be withdrawn.', 'h.', 'if the investigator or the', 'h.', 'if the investigator or the', 'sponsor determines that the', 'sponsor determines that the', 'patient is not in compliance', 'patient is not in compliance', 'with the study protocol, the', 'with the study protocol, the', 'investigator and the sponsor', 'investigator and the sponsor', 'should determine whether the', 'should determine whether the', 'patient should be withdrawn', 'patient should be withdrawn', 'from the study (Section 5.4).', 'from the study (Section 5.4).', 'Section 5.2 Restrictions', 'While patients receiving strong CYP2D6', 'While patients receiving strong CYP2D6', 'Clarificatio', 'inhibitors (such as paroxetine, fluoxetine,', 'inhibitors such as paroxetine, fluoxetine,', 'n on the use', 'and bupropion) at baseline may be enrolled', 'and bupropion at baseline may be enrolled', 'of quinidine', 'into this study, the addition or removal of', 'into this study, the addition or removal of', 'and', 'strong CYP2D6 inhibitors during treatment', 'strong CYP2D6 inhibitors during treatment', 'terbinafine', 'is discouraged as this would have an effect', 'is discouraged as this would have an effect', 'as', 'on exposure to active circulating drug. If the', 'on exposure to active circulating drug. If the', 'prohibited.', 'addition or removal of a strong CYP2D6', 'addition or removal of a strong CYP2D6', 'inhibitor is required from a clinical', 'inhibitor is required from a clinical', 'perspective, the medical monitor should be', 'perspective, the medical monitor should be', 'contacted so an appropriate change in IMP', 'contacted so an appropriate change in IMP', 'can be made. The use of quinidine and', 'can be made. The use of quinidine and', 'terbinafine are prohibited (see Appendix A,', 'terbinafine are prohibited (see Appendix A,', 'Table 8).', 'Table 8).', 'Section 5.5 Dose Reduction and Temporary IMP Discontinuation', 'Suspension of study medication for up to 1', 'Suspension of study medication for up to 1', 'Blood', 'one week, if warranted for patient safety, is', 'week, if warranted for patient safety, is', 'sampling', 'allowed. If the patient restarts study', 'allowed. If the patient restarts study', 'quantity', 'medication within 7 days of suspension, the', 'medication within 7 days of suspension, the', 'specificatio', 'full dose of TEV-50717 may be resumed', 'full dose of TEV-50717 may be resumed', 'n.', 'without titration. Suspensions of study', 'without titration. Suspensions of study', 'medication for adverse events must be', 'medication for adverse events must be', 'reviewed with the medical monitor before', 'reviewed with the medical monitor before', ""therapy is restarted. If a subject's serum"", ""therapy is restarted. If a subject's serum"", 'potassium or magnesium fallswere tested', 'potassium or magnesium were tested and', 'and found to be below the lower limit of', 'found to be below the lower limit of normal,', 'normal, IMP must be suspended. The', 'IMP must be suspended. The medical', 'Medical Monitor must be contacted to', 'monitor must be contacted to determine the', '183']"
184,page_185,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'determine the appropriate investigation and', 'appropriate investigation and treatment.', 'treatment. SD 809TEV-50717 may only be', 'TEV-50717 may only be restarted once', 'restarted once serum potassium or', 'serum potassium or magnesium have', 'magnesium have normalized. Similarly,', 'normalized.', 'suspensions for more than 7 days must be', 'reviewed by the medical monitor to', 'determine if there is adequate time for', 'patients to be reiterated and complete', 'study evaluations.', 'Table 3: Blood Volumes', 'Type of samples', 'Volu', 'Total', 'Total', 'Type of samples', 'Volu', 'Total', 'Total', 'Blood', 'me', 'numbe', 'volu', 'me', 'numbe', 'volu', 'sampling', 'per', 'r of', 'me', 'per', 'r of', 'me', 'quantity', 'sampl', 'sample', 'samp', 'sample', 'specificatio', 'e', 'S', 'le', 'S', 'n.', 'Clinical', '10', '2', '20', 'Clinical laboratory', '10', '2', '20', 'laboratory', 'mL', 'mL', '(ch mistry/hemat', 'mL', 'mL', '(chemistry/hemato', 'ology)', 'logy)', 'Pharmacokinetic', '5 mL', '1 time', '10', 'Pharmacokinetic', '5 mL', '1 time', '10', 'point', 'mL', 'point', 'mL', '(week', '(week', '12) X', '12) X', 'samp', '2 samp', 'les', 'les', 'CYP2D6', '3 mL', '1', '3 mL', 'CYP2D6', '53', '1', '53', 'genotyping', 'genotyping', 'mL', 'mL', 'Optional', '2 mL', '1', '2 mL', 'Optional', '2 mL', '1', '2 mL', 'pharmacogenetic', 'pharmacogenetic', 'sample', 'sample', 'Total', '35', 'Total', '35', 'mL', 'mL', 'CYP2D6=cytochrome P450 2D6.', 'CYP2D6=cytochrome P450 2D6.', 'Note: beta human chorionic gonadotropin', 'Note: beta human chorionic gonadotropin', 'testing (in females who are postmenarchal', 'testing (in females who are postmenarchal', 'or >12 years of age) is included in the', 'or >12 years of age) is included in the', 'clinical laboratory sample.', 'clinical laboratory sample.', 'Section 7.1.5.3.1 Investigator Responsibility', 'To satisfy regulatory requirements, all', 'To satisfy regulatory requirements, all', 'Clarificatio', 'serious adverse events that occur during the', 'serious adverse events that occur during the', 'n on the', 'study, regardless of judged relationship to', 'study, regardless of judged relationship to', 'expectation', 'administration of the IMP, must be reported', 'administration of the IMP, must be reported', 'of reporting', '184']"
185,page_186,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'to the sponsor by the investigator according', 'by the investigator according to the', 'serious', 'to the instructions provided on the serious', 'instructions provided on the serious adverse', 'adverse', 'adverse event form. The event must be', 'event form. The event must be reported', 'events.', 'reported within 24 hours of when the', 'within 24 hours of when the investigator', 'investigator learns about it.', 'learns about it.', 'Section 7.2.2 Columbia-Suicide Severity Rating Scale', 'The C-SSRS is an interview by trained', 'The C-SSRS is an interview by trained', 'Suicide and', 'study personnel.', 'study personnel.', 'depression', 'Suicidal ideation', 'Suicidal ideation', 'details', 'required by', 'Patients with a positive C-SSRS', 'Patients with a positive C-SSRS', 'authorities.', 'suicidal ideation score on either', 'suicidal ideation score on either', 'items 1 or 2 or a change on the', 'items 1 or 2 or a change on the', 'CDI-2 Parent or Self-Report', 'CDI-2 Parent or Self-Report', 'Profiles consistent with increasing', 'Profiles consistent with increasing', 'depressive symptoms must be 1)', 'depressive symptoms must be 1)', 'discussed with the medical monitor,', 'discussed with the medical monitor,', '2) re-evaluated within 2 to 3 days in', '2) re-evaluated within 2 to 3 days in', 'a clinic visit, and 3) treated', 'a clinic visit, and 3) treated', ""according to the investigator's"", ""according to the investigator's"", 'medical judgment. Consultation', 'medical judgment. Consultation', 'with a child and adolescent', 'with a child and adolescent', 'psychiatrist or licensed', 'psychiatrist or licensed', 'child/adolescent mental health', 'child/adolescent mental health', 'provider is advised, followed by', 'provider is advised, followed by', 'close ongoing monitoring.', 'close ongoing monitoring.', 'If patients 1) endorse or 2) report a', 'If patients 1) endorse or 2) report a', 'C-SSRS suicidal ideation level of 3,', 'C-SSRS suicidal ideation level of 3,', '4, or 5, subjects will be evaluated', '4, or 5, subjects will be evaluated', 'immediately by the study', 'immediately by the study', 'investigator and referred for', 'investigator and referred for', 'psychiatric evaluation. The medical', 'psychiatric evaluation. The medical', 'monitor will be immediately', 'monitor will be immediately', 'consulted. If it is determined by the', 'consulted. If it is determined by the', 'investigator, after consultation with', 'investigator, after consultation with', 'the medical monitor and the', 'the medical monitor and the', 'consulting psychiatrist, that', 'consulting psychiatrist, that', 'exposure to the IMP may have', 'exposure to the IMP may have', 'contributed to this change in C-', 'contributed to this change in C-', 'SSRS and/or increased depressive', 'SSRS and/or increased depressive', 'symptoms, IMP will be', 'symptoms, IMP will be', 'immediately discontinued and the', 'immediately discontinued and the', 'patient terminated from the study.', 'patient terminated from the study.', 'In cases where it is determined that', 'In cases where it is determined that', 'IMP did not contribute to changes', 'IMP did not contribute to changes', 'in depression or suicidality, the', 'in depression or suicidality, the', '185']"
186,page_187,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'investigator will consult with the', 'investigator will consult with the', 'medical monitor, the consulting', 'medical monitor, the consulting', 'psychiatrist, and/or sponsor to', 'psychiatrist, and/or sponsor to', 'determine whether the patient', 'determine whether the patient', 'should continue in the study.', 'should continue in the study.', 'Suicidal behavior', 'Suicidal behavior', 'Actual attempt:', 'Actual attempt:', 'If patients report any suicidal behavior that', 'If patients report any suicidal behavior that', 'is an actual attempt as assessed in the C-', 'is an actual attempt as assessed in the C-', 'SSRS, they will be evaluated immediately', 'SSRS, they will be evaluated immediately', 'by the study investigator, referred for', 'by the study investigator, referred for', 'psychiatric evaluation, and terminated from', 'psychiatric evaluation, and terminated from', 'the study.', 'the study.', 'Interrupted attempt, aborted', 'Interrupted attempt, aborted', 'attempt, or Preparatory Acts or', 'attempt, or Preparatory Acts or', 'Behavior:', 'Behavior:', 'If patients report any suicidal behavior that', 'If patients report any suicidal behavior that', 'is interrupted, aborted, or preparatory as', 'is interrupted, aborted, or preparatory as', 'assessed in the C-SSRS, they will be', 'assessed in the C-SSRS, they will be', 'evaluated immediately by the study', 'evaluated immediately by the study', 'investigator and referred for psychiatric', 'investigator and referred for psychiatric', 'evaluation. In cases where it is determined', 'evaluation. In cases where it is determined', 'in the psychiatric evaluation that IMP did', 'in the psychiatric evaluation that IMP did', 'not contribute to changes in suicidal', 'not contribute to changes in suicidal', 'behavior, the investigator will consult with', 'behavior, the investigator will consult with', 'the medical monitor, the consulting', 'the medical monitor, the consulting', 'psychiatrist, and/or sponsor to determine', 'psychiatrist, and/or sponsor to determine', 'whether the patient should continue in the', 'whether the patient should continue in the', 'study.', 'study.', 'Section 7.5.3 Cytochrome P450 2D6 Genotyping', 'One 53-mL sample for CYP2D6 genotyping', 'One 3-mL sample for CYP2D6 genotyping', 'Blood', 'will be collected from all patients in the', 'will be collected from all patients in the', 'sampling', 'study at screening.', 'study at screening.', 'quantity', 'specificatio', 'n.', 'Section 7.9 Assessment of Suicidality', 'Consideration should be given to', 'Consideration should be given to', 'Suicide and', 'discontinuing TEV-50717 in participants', 'discontinuing TEV-50717 in participants', 'depression', 'who experience signs of suicidal ideation or', 'who experience signs of suicidal ideation or', 'details', 'behavior and detailed recommendations are', 'behavior and detailed recommendations are', 'required by', 'provided in Section 7.2.2.', 'provided in Section 7.2.2.', 'authorities.', 'Families and caregivers of participants', 'Baseline assessment of suicidal ideation and', 'being treated with TEV 50717 should be', 'behavior and treatment-emergent suicidal', 'instructed to monitor participants for the', 'ideation and behavior will be assessed', '186']"
187,page_188,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'emergence of unusual changes in behavior,', ""during the study using the Children's C-"", 'as well as the emergence of suicidal', 'SSRS described in Section 7.2.2.', 'ideation and behavior, and to report such', 'Depression and Suicidality as an Adverse', 'symptoms immediately to the study', 'Event', 'investigator-Baseline assessment of suicidal', 'Families and caregivers of subjects in Study', 'ideation and behavior and treatment-', 'emergent suicidal ideation and behavior will', '30046 will be instructed to monitor patients', 'for any changes in or new onset of', 'be assessed during the study using the', ""Children's C-SSRS described in"", 'depressive symptoms; unusual changes in', 'Section 7.2.2.', 'mood, cognition, or behavior; or onset of', 'and/or changes in suicidal ideation or', 'Depression and Suicidality as an Adverse', 'behavior, and to report such symptoms', 'Event', 'immediately to the study investigator.', 'Families and caregivers of subjects in Study', 'Telephone contacts and clinic visits also', '30046 will be instructed to monitor patients', 'allow opportunities for investigators to', 'for any changes in or new onset of', 'assess adverse events.', 'depressive symptoms; unusual changes in', 'If a relevant change in status is identified,', 'mood, cognition, or behavior; or onset of', 'patients will be seen immediately for an', 'and/or changes in suicidal ideation or', 'unscheduled visit by the study investigator', 'behavior, and to report such symptoms', 'and discussed with the medical monitor.', 'immediately to the study investigator.', 'The patient will be referred for further', 'Telephone contacts and clinic visits also', 'psychiatric evaluation if there is any', 'allow opportunities for investigators to', 'suspected suicidal ideation with any level of', 'assess adverse events.', 'intent, suicidal behavior, or clinical findings', 'If a relevant change in status is identified,', 'suggesting that the patient may be', 'patients will be seen immediately for an', 'dangerous to self or others, and/or', 'unscheduled visit by the study investigator', 'experiencing depression. The investigator', 'and discussed with the medical monitor.', 'will record these symptoms as an adverse', 'The patient will be referred for further', 'event of depression and/or suicidality. If it', 'psychiatric evaluation if there is any', 'is determined by the investigator, after', 'suspected suicidal ideation with any level of', 'consultation with the medical monitor and', 'intent, suicidal behavior, or clinical findings', 'the consulting psychiatrist, that exposure to', 'suggesting that the patient may be', 'the IMP may have contributed to the', 'dangerous to self or others, and/or', 'adverse event of depression or suicidality,', 'experiencing depression. The investigator', 'IMP will be immediately discontinued and', 'will record these symptoms as an adverse', 'the patient will be terminated from the', 'event of depression and/or suicidality. If it', 'study. Follow up with a pediatric', 'is determined by the investigator, after', 'psychiatrist or licensed child and adolescent', 'consultation with the medical monitor and', 'mental health clinician will be arranged.', 'the consulting psychiatrist, that exposure to', 'In cases where it is determined that IMP did', 'the IMP may have contributed to the', 'not contribute to the adverse event of', 'adverse event of depression or suicidality,', 'depression or suicidality, the investigator', 'IMP will be immediately discontinued and', 'will consult with the medical monitor', 'the patient will be terminated from the', 'and/or sponsor to determine whether the', 'study. Follow up with a pediatric', 'patient should continue in the study.', 'psychiatrist or licensed child and adolescent', 'mental health clinician will be arranged.', '187']"
188,page_189,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'In cases where it is determined that IMP did', 'not contribute to the adverse event of', 'depression or suicidality, the investigator', 'will consult with the medical monitor', 'and/or sponsor to determine whether the', 'patient should continue in the study.', 'Section 8.3.1 CYP2D6 Genotyping/Pharmacogenetics', 'At the screening visit, a blood sample (5 to', 'At the screening visit, a blood sample', 'Clarificatio', '63 mL) will be obtained for analysis of', '(3 mL) will be obtained for analysis of', 'n on PGx', ""CYP2D6 genotype. The patient's genotype"", ""CYP2D6 genotype. The patient's genotype"", 'sampling', 'for CYP2D6 will remain blinded during the', 'for CYP2D6 will remain blinded during the', 'and details.', 'conduct of the study. If the patient elects', 'conduct of the study. If the patient elects for', 'this option for PGx evaluation on the', 'PGx evaluation on the optional informed', 'optional informed consent/assent, the', 'consent/assent, a pharmacogenetic (PGx)', 'remaining pharmacogenetic (PGx) sample', 'sample (2 mL) will be obtained and stored', '(2 mL) will be obtained and stored for', 'for exploratory PGx.', 'exploratory pharmacogeneties (PGx)', 'evaluationPGx.', 'Section 9.2.1 Intent-to-Treat Analysis Set', 'Not applicable', 'Enrolled subjects who are not randomized', 'ITT', 'will be summarized separately as ""Not', 'analysis', 'randomized,"" and randomized subjects will', 'population', 'be analyzed based on their randomized', 'specificatio', 'treatment.', 'n.', 'Section 9.2.4 Per-Protocol Analysis Set', 'The per-protocol analysis set will include', 'The per-protocol analysis set will include', 'Protocol', 'patients who are compliant with study', 'patients who are compliant with study', 'deviation', 'medication (80% to 105%), have a YGTSS', 'medication (80% to 105%), have a YGTSS', 'elaboration.', 'assessment at baseline and at week 9 or', 'assessment at baseline and at week 9 or', 'week 12, and-who have not taken prohibited', 'week 12, who have not taken prohibited', 'concomitant medications as indicated in', 'concomitant medications as indicated in', 'exclusion criterion, and who have no major', 'exclusion criterion, and who have no major', 'protocol deviations that affect the validity', 'protocol deviations that affect the validity', 'of the efficacy measurements. The list of', 'of the efficacy measurements. The list of', 'protocol deviations will be reviewed before', 'protocol deviations will be reviewed before', 'unblinding and major protocol deviations', 'unblinding and major protocol deviations', 'that could affect the primary and secondary', 'that could affect the primary and secondary', 'variables will be determined. All exclusions', 'variables will be determined. All exclusions', 'from the per-protocol analysis set will be', 'from the per-protocol analysis set will be', 'reviewed in the blinded data review meeting', 'reviewed in the blinded data review meeting', 'before database lock.', 'before database lock.', 'Section 9.5.4.1 Primary Efficacy Analysis', '188']"
189,page_190,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'The baseline TTS, region, and age group at', 'The baseline TTS, region, and age group at', 'Addition of', 'baseline (2 levels: 6 to 11 years, 12 to 16', 'baseline (2 levels: 6 to 11 years, 12 to 16', 'region to', 'years) will be included as a', 'years) will be included as covariates.', 'covariate', 'covariatecovariates.', 'list.', 'Section 9.5.4.2 Sensitivity Analysis', 'To assess the robustness of the primary', 'Sensitivity analyses for missing data and the', 'Alignment', 'efficacy analysis, the following', 'statistical model are provided in the', 'of', 'additional +Sensitivity analyses will', 'statistical analysis plan.', 'sensitivity', 'include Using the same repeated measures', 'analysis', 'model as described for the primary analysis,', 'text with', 'the groups will be compared using the per', 'SAP.', 'protocol population.', 'The primary analysis at week 12 will be', 'repeated on a complete data set using', 'multiple imputation methodology for', 'imputing missing data using an MNAR', 'missing data assumption to investigate', 'when-and the statistical significance', 'disappears.', 'Data will be imputed for patients missing', 'data at week 12 using the predictive mean', 'matching multiple imputation method', '(Heitjan and Little 1991, Schenker and', 'Taylor 1996). Under a missing not at', 'random data assumption, patients treated', 'with TEV 50717 who discontinue the study', 'for any reason other than ""Lost to Follow', 'Up"" will have their missing data at week 12', 'imputed. Only placebo patients will be', 'included in the imputation model, while all', 'other patients will have data imputed from a', 'model derived from their assigned treatment', 'group. The imputation model will include', 'age group at baseline, baseline TTS score,', 'and TTS scores at all visits up to week 12', 'where the TTS is scheduled to be collected.', 'The resulting complete, imputed datasets', 'will each be analyzee using the same model', 'as the primary analysis model, and the', 'resulting statistics combined using', 'methodology provided by Rubin (1987) and', 'Little and Rubin (2002). Details on', 'imputing missing data and combining', 'inferences from the resultant datasets will', 'bemodel are provided in the statistical', '189']"
190,page_191,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'analysis plan.', 'Section 14 FINANCING AND INSURANCE', 'A separate clinical study agreement,', 'A separate clinical study agreement,', 'Administrat', 'including a study budget, will be signed', 'including a study budget, will be signed', 'ive change.', 'between each principal investigator and the', 'between each principal investigator and', 'sponsor (or-INC Research) before the IMP', 'INC Research before the IMP is delivered.', 'is delivered.', 'APPENDIX A. ALLOWED AND DISALLOWED MEDICATIONS', 'Medications that are allowed, provided that', 'Medications that are allowed, provided that', 'To update', 'conditions outlined in the table are met, are', 'conditions outlined in the table are met, are', 'the list of', 'shown in Table 9. Tables for allowed and', 'shown in Table 9. Tables for allowed and', 'prohibited', 'prohibited medications are not exhaustive', 'prohibited medications are not exhaustive', 'drugs, and', 'and may not include all possible', 'and may not include all possible', 'to clarify', 'concomitant medications.', 'concomitant medications.', 'prior and', 'The medical monitor must be contacted if a', 'The medical monitor must be contacted if a', 'concomitan', 'patient is receiving (or has to begin or stop', 'patient is receiving (or has to begin or stop', 't use of', 'receiving during the study) a medication', 'receiving during the study) a medication', 'guanfacine,', 'that is associated with QTc prolongation or', 'that is associated with QTc prolongation or', 'clonidine,', 'that is a known strong', 'that is a known strong', 'stimulants,', 'cytochrome P450 inhibitor, or if there are', 'cytochrome P450 inhibitor, or if there are', 'and SNRIs.', 'any questions regarding any medication not', 'any questions regarding any medication not', 'listed in the tables below.', 'listed in the tables below.', 'Table 5:', 'Allowed Medications', 'Table 5:', 'Allowed Medications', 'Generic/Drug', 'Condition', 'Generic/Drug', 'Condition', 'class', 'class', 'Stable medications allowed according to', 'Stable medications allowed according to', 'inclusion/exclusions criteria', 'inclusion/exclusions criteria', 'Hormonal', 'Must be receiving stable', 'Hormonal', 'Must be receiving stable', 'birth control', 'treatment (including dose)', 'birth control', 'treatment (including dose)', 'for at least 3 months before', 'for at least 3 months before', 'screening.', 'screening.', 'Antidepressan', 'Must be receiving stable', 'Antidepressan', 'Must be receiving stable', 'its', 'treatment (including dose)', 'ts', 'treatment (including dose)', 'for at least 6 weeks before', 'for at least 6 weeks before', 'screening.', 'screening.', 'Benzodiazepin', 'Primary use must not be', 'Benzodiazepin', 'Primary use must not be', 'es', 'for tics; dosing must have', 'es', 'for tics; dosing must have', 'been stable QT for at least', 'been stable QT for at least', '4 weeks before screening.', '4 weeks before screening.', 'Note: PRN (as needed)', 'Note: PRN (as needed)', '190']"
191,page_192,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'use is prohibited.', 'use is prohibited.', 'Topiramate', 'Must be receiving stable', 'Topiramate', 'Must be receiving stable', '(up to', 'treatment (including dose)', '(up to', 'treatment (including dose)', '200 mg/day)', 'for at least 4 weeks before', '200 mg/day)', 'for at least 4 weeks before', 'screening.', 'screening.', 'Guanfacine', 'Allowed, regardless of', 'Guanfacine', 'Allowed, regardless of', 'indication (ie, if prescribed', 'indication (ie, if prescribed', 'for tics or Tourette', 'for tics or Tourette', 'syndrome). Must be', 'syndrome). Must be', 'receiving stable treatment', 'receiving stable treatment', '(including dose) for at', '(including dose) for at', 'least 4 weeks before', 'least 4 weeks before', 'screening and no changes', 'screening and no changes', 'to dose or frequency are', 'to dose or frequency are', 'anticipated during the', 'anticipated during the', 'course of the study. If', 'course of the study. If', 'discontinuation of', 'discontinuation of', 'guanfacine is anticipated', 'guanfacine is anticipated', 'due to ineffectiveness.', 'due to ineffectiveness,', 'poor tolerability, or', 'poor tolerability, or', 'patient/caregiver', 'patient/caregiver', 'preference, discontinuation', 'preference, discontinuation', 'should occur 4 or more', 'should occur 4 or more', 'weeks prior to the', 'weeks prior to the', 'screening visit.', 'screening visit.', 'Clonidine', 'Allowed, regardless of', 'Clonidine', 'Allowed, regardless of', 'indication (ie, if prescribed', 'indication (ie, if prescribed', 'for tics or Tourette', 'for tics or Tourette', 'syndrome). Must be', 'syndrome). Must be', 'receiving stable treatment', 'receiving stable treatment', '(including dose) for at', '(including dose) for at', 'least 4 weeks before', 'least 4 weeks before', 'screening and no changes', 'screening and no changes', 'to dose or frequency are', 'to dose or frequency are', 'anticipated during the', 'anticipated during the', 'course of the study. If', 'course of the study. If', 'discontinuation of', 'discontinuation of', 'clonidine is anticipated due', 'clonidine is anticipated due', 'to ineffectiveness, poor', 'to ineffectiveness, poor', 'tolerability, or', 'tolerability, or', 'patient/caregiver', 'patient/caregiver', 'preference, discontinuation', 'preference, discontinuation', 'should occur 4 or more', 'should occur 4 or more', 'weeks prior to the', 'weeks prior to the', 'screening visit.', 'screening visit.', '191']"
192,page_193,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'Stimulants', 'Include amphetamine,', 'Stimulants', 'Include amphetamine,', 'methylphenidate, and', 'methylphenidate, and', 'lisdexamfetamine. Primary', 'lisdexamfetamine. Primary', 'use is for the treatment of', 'use is for the treatment of', 'ADHD; dosing must have', 'ADHD; dosing must have', 'been stable for at least 2', 'been stable for at least 2', 'weeks before screening', 'weeks before screening', 'and no changes to dose or', 'and no changes to dose or', 'frequency are anticipated', 'frequency are anticipated', 'during the course of the', 'during the course of the', 'study.', 'study.', 'SNRIs', 'Includes atomoxetine.', 'SNRIs', 'Includes atomoxetine.', 'Primary use is for the', 'Primary use is for the', 'treatment of ADHD;', 'treatment of ADHD;', 'dosing must have been', 'dosing must have been', 'stable for at least 4 weeks', 'stable for at least 4 weeks', 'before screening and no', 'before screening and no', 'changes to dose or', 'changes to dose or', 'frequency are anticipated', 'frequency are anticipated', 'during the course of the', 'during the course of the', 'study.', 'study.', 'Additional medications allowed with', 'Additional medications allowed with', 'preapproval from medical monitor', 'preapproval from medical monitor', 'Albuterol,', 'Asthma', 'Albuterol,', 'Asthma', 'levalbuterol', 'levalbuterol', 'Guaifenesin', 'Cold symptoms', 'Guaifenesin', 'Cold symptoms', 'Antihistamine', 'Allergies', 'Antihistamine', 'Allergies', 'S', 'S', 'Melatonin', 'Insomnia', 'Melatonin', 'Insomnia', 'Allowed strong CYP inhibitors', 'Allowed strong CYP inhibitors', 'Bupropion', 'Antidepressant', 'Bupropion', 'Antidepressant', '(aminoketone)', '(aminoketone)', 'Fluoxetine', 'Antidepressant (selective', 'Fluoxetine', 'Antidepressant (selective', 'serotonin reuptake', 'serotonin reuptake', 'inhibitor)', 'inhibitor)', 'Paroxetine', 'Antidepressant (selective', 'Paroxetine', 'Antidepressant (selective', 'serotonin reuptake', 'serotonin reuptake', 'inhibitor)', 'inhibitor)', 'a', 'The use of these medications will affect', 'a', 'The use of these medications will affect', 'the maximum daily dose of IMP, as shown', 'the maximum daily dose of IMP, as shown', 'in Table 2. ADHD=Attention-', 'in Table 2. ADHD=Attention-', '192']"
193,page_194,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'deficit/hyperactivity disorder;', 'deficit/hyperactivity disorder;', 'CYP=cytochrome P450;', 'CYP=cytochrome P450;', 'IMP=investigational medicinal product;', 'IMP=investigational medicinal product;', 'SNRIs=serotonin-norepinephrine reuptake', 'SNRIs=serotonin-norepinephrine reuptake', 'inhibitor Note: No dosing changes can be', 'inhibitor Note: No dosing changes can be', 'made during the study.', 'made during the study.', 'Table 6:', 'Prohibited Antipsychotic Drugs', 'Table 6:', 'Prohibited Antipsychotic Drugs', 'Typical/first generation', 'Atypical/seco', 'Typical/first generation', 'Atypical/seco', 'antipsychotics', 'nd generation', 'antipsychotics', 'nd generation', 'antipsychotic', 'antipsychotic', 's', 'S', 'Chlorpromazine', 'Aripiprazole', 'Chlorpromazine', 'Aripiprazole', 'Haloperidol', 'Asenapine', 'Haloperidol', 'Asenapine', 'maleate', 'maleate', 'Loxapine', 'Clozapine', 'Loxapine', 'Clozapine', 'Molindone', 'Iloperidone', 'Molindone', 'Iloperidone', 'Perphenazine', 'Lurasidone', 'Perphenazine', 'Lurasidone', 'Pimozide', 'Olanzapine', 'Pimozide', 'Olanzapine', 'Prochlorperazine', 'Olanzapine/flu', 'Prochlorperazine', 'Olanzapine/flu', 'oxetine', 'oxetine', 'Thioridazine', 'Paliperidone', 'Thioridazine', 'Paliperidone', 'Thiothixene', 'Quetiapine', 'Thiothixene', 'Quetiapine', 'Trifluoperazine', 'Risperidone', 'Trifluoperazine', 'Risperidone', 'Promethazine-containing', 'Ziprasidone', 'Promethazine-containing', 'Ziprasidone', 'compounds', 'compounds', 'Fluphenazine', 'Tiapride', 'Fluphenazine', 'Tiapride', 'Note: This table does not apply in the', 'Note: This table does not apply in the', 'second week of washout for patients not', 'second week of washout for patients not', 'rolling over to the open-label extension', 'rolling over to the open-label extension', 'study (Study TV50717-CNS-30047).', 'study (Study TV50717-CNS-30047).', 'Table 8:', 'Other Prohibited Drugs', 'Table 8:', 'Other Prohibited Drugs', 'Generic', 'Class/clinical', 'Note', 'Generic', 'Class/clinical', 'Note', 'use', 'use', 'Cannabidio', 'Cannabis', 'Also', 'Cannabidio', 'Cannabis', 'Also', '1 oil', 'includes', '1 oil', 'includes', 'other forms', 'other forms', '193']"
194,page_195,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 03 text with', 'New wording', 'Reason/Jus', 'changes shown', 'tification', 'for change', 'of', 'of', 'cannabinoid', 'cannabinoid', 'S', 'S', 'Valbenazin', 'Vesicular', 'Ingrezza', 'Valbenazin', 'Vesicular', 'Ingrezza', 'e', 'monoamine', 'off-label', 'e', 'monoamine', 'off-label', 'transporter 2', 'transporter 2', 'inhibitor', 'inhibitor', 'Quinidine', 'Class I', 'Strong', 'Quinidine', 'Class I', 'Strong', 'antiarrhythmic', 'CYP2D6', 'antiarrhythmic', 'CYP2D6', 'agent', 'inhibitor', 'agent', 'inhibitor', 'Terbinafine', 'Antifungal', 'Weak', 'Terbinafine', 'Antifungal', 'Weak', 'medication', 'CYP2D6', 'medication', 'CYP2D6', 'inhibitor', 'inhibitor', '194']"
195,page_196,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '17.5.', 'Amendment 05 Dated 25 March 2019', 'The primary reason for this amendment is to update the anticipated patient enrollment numbers', 'and related statistical considerations, update requirements on drug storage and security, to', 'update/clarify patient inclusion criteria and withdrawal criteria, to update administrative details', 'with regards to clinical study personnel contact information and vendor selection, and to provide', 'additional guidance on dose suspension.', 'This amendment is considered to be substantial (ie, requires approval by Competent Authority,', ""IEC, and/or IRB) by the sponsor's Authorized Representative. Other nonsubstantial changes"", 'have been made to the protocol (and protocol synopsis, as appropriate). These changes are', 'unlikely to affect the safety or rights (physical or mental integrity) of the patients in this clinical', 'study or the scientific value of the clinical study.', '195']"
196,page_197,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'Global', 'INC Research Syneos Health', 'Syneos Health', 'Administrative update to account', 'for vendor name change', 'Title Page', '601 Gateway Boulevard', '101 Main Street, 12th Floor', 'Address update', 'Suite 1270', 'Cambridge, Massachusetts 02142', 'South San Francisco, California 94080', '101 Main Street, 12th Floor', 'Cambridge, Massachusetts 02142', 'This clinical study will be conducted in accordance', 'This clinical study will be conducted in accordance', ""Updates included per Teva's current"", 'with current Good Clinical Practice (GCP) as directed', 'with current Good Clinical Practice (GCP) as directed', 'Confidentiality Statement template', 'by the provisions of the International', 'by the provisions of the International Council for', 'text', 'ConferenceCounc for Harmonisation (ICH); United', 'Harmonisation (ICH); United States (US) Code of', 'States (US) Code of Federal Regulations (CFR), and', 'Federal Regulations (CFR), and European Union (EU)', 'European Union (EU) Directives and Regulations (as', 'Directives and Regulations (as applicable in the region', 'applicable in the region of the study); national country', 'of the study); national country legislation; and the', ""regulationslegislation; and the sponsor's Standard"", ""sponsor's Standard Operating Procedures (SOPs)."", 'Operating Procedures (SOPs).', 'This document contains confidential and proprietary', 'This document contains confidential and proprietary', 'information (including confidential commercial', 'information (including confidential commercial', 'information pursuant to 21CFR§20.61 and is a', 'information pursuant to 21CFR§20.61) and is a', 'confidential communication of Teva Branded', 'confidential communication of Teva Branded', 'Pharmaceutical Products R&D and/or its affiliates and', 'Pharmaceutical Products R&D and/or its affiliates and', 'Nuvelution TS Pharma, INC.', 'Nuvelution TS Pharma, INC.', '© 2019 Teva Branded Pharmaceutical Products R&D,', '© 20172019 Teva Branded Pharmaceutical Products', 'Inc. and Nuvelution TS Pharma, INC. All rights', 'R&D, Inc. and Nuvelution TS Pharma, INC. All rights', 'reserved.', 'reserved.', 'LABORATORY AND OTHER DEPARTMENTS AND INSTITUTIONS', 'Contract Research Organization; Safety and', 'Contract Research Organization; Safety and', 'Administrative change', 'Efficacy Data Analysis', 'Efficacy Data Analysis', 'INC Research, LLC, a Syncos health group company', 'Syneos Health, LLC', '(Syneos Health, LLC)', '1030 Sync Street', '3201 Beechleaf Court', 'Morrisville, NC 27560', '196']"
197,page_198,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'Suite 600', 'USA', 'Raleigh, NC 276041 1547', '1030 Sync Street', 'Morrisville, NC 27560', 'USA', 'CLINICAL STUDY PERSONNEL CONTACT INFORMATION', 'Legal Representative of the Sponsor in the EU', 'Legal Representative of the Sponsor in the EU', ""Update to the sponsor's legal"", 'Syneos Health Netherlands B.V.', 'Syneos Health Netherlands B.V.', 'representative in the EU.', 'Additional administrative changes', 'For medical issues, contact the physician listed', 'For medical issues, contact the physician listed', 'have been carried out.', 'below:', 'below:', 'For protocol issues, contact the study leaders', 'For protocol issues, contact the study leaders', 'listed below:', 'listed below:', '197']"
198,page_199,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'For operational issues, contact the Head of', 'For operational issues, contact the Head of', 'Operationsoperationallead listed below:', 'Operations listed below:', 'Section 1.3.2 Clinical Studies (other section affected: Section 1.3.2.1 Clinical Pharmacology Studies)', 'The clinical development plan for TEV-50717 to date', 'The clinical development plan for TEV-50717 to date', 'The clinical development plan for', 'includes:', 'includes:', 'TEV-50717 has been updated to', '67 completed Phase 1 studies in healthy adult', '7 completed Phase 1 studies in healthy adult', 'reflect the most current program', 'subjects', 'subjects', 'information.', '2 ongoing Phase 1 studies in healthy adult', '2 ongoing Phase 1 studies in healthy adult', 'volunteers', 'volunteers', '1 completed Phase 3 pivotal study for the', '1 completed Phase 3 pivotal study for the', 'treatment of chorea associated with HD', 'treatment of chorea associated with HD', '1 completed Phase 3 long-term safety study', '1 completed Phase 3 long-term safety study', 'in patients with HD', 'in patients with HD', '198']"
199,page_200,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justificatior for change', '2 completed Phase 2/3 and Phase 3 studies in', '2 completed Phase 2/3 and Phase 3 studies in', 'patients with TD', 'patients with TD', '1 ongoing Phase 3 long-term safety study in', '1 ongoing Phase 3 long-term safety study in', 'patients with TD', 'patients with TD', '1 completed Phase 1b study in patients with', '1 completed Phase 1b study in patients with', 'TS', 'TS', '2 ongoing Phase 2/3 and Phase 3 studies in', '2 ongoing Phase 2/3 and Phase 3 studies in', 'patients with TS', 'patients with TS', '1 ongoing Phase 3 long-term safety study in', '1 ongoing Phase 3 long-term safety study in', 'patients with TS', 'patients with TS', 'Section 2.3.3 Exploratory Enppoints (other sections affected: Section 9.5.3 Exploratory Enppoints and Section 9.5.4.4 Exploratory', 'Analyses)', 'Update on and addition of the', 'exploratory endpoints evaluating', 'reduction', 'Section 3.1.2 Screening Period', 'Patients may be rescreened 1 time if there is a change', 'Patients may be rescreened 1 time if there is a change', 'Provided further details about', ""in the patient's medical background, a"", 'in the status of the patient regarding eligibility for the', 'rescreening activities and process', 'modificationstatus of the patient regarding eligibility', 'study.', 'for the study-entry criteria, or other relevant change.', 'Section 3.3.3 Exploratory Measures and Time Points', 'Update on and addition of the', 'exploratory measures and time', 'points evaluating reduction', '199']"
200,page_201,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'Section 3.7.2 Blinding/Unblinding', 'When a blind is broken, the patient will be withdrawn', 'When a blind is broken, the patient will be', 'Provided further guidance to the', 'from the study, and the event will be recorded onto', 'withdrawn from the study, and the event will be', 'investigator in the situation that a', 'the case report form (CRF). However, if a patient is', 'recorded onto the case report form (CRF). However,', 'patient is unblinded by mistake', 'unblinded by mistake, the investigator should discuss', 'if a patient is unblinded by mistake, the investigator', 'with the medical monitor whether or not the patient', 'should discuss with the medical monitor whether or', 'should be withdrawn.', 'not the patient should be withdrawn.', 'Section 3.9.1 Drug Storage and Security', 'The IMP (TEV-50717 and placebo) should be stored', 'The IMP (TEV-50717 and placebo) should be stored', 'Updated temperature range for', 'protected from light, at a controlled room', 'protected from light, at a controlled room', 'storage of the IMP', 'temperature, 20°C to 25°C (68°F to 77°F); however,', 'temperature, 20°C to 25°C (68°F to 77°F); however,', 'storage between 15°C and 3020°C (59°F and 8668°F)', 'storage between 15°C and 20°C (59°F and 68°F) is', 'is acceptable if there is no alternative.', 'acceptable if there is no alternative.', 'Section 3.13.1 Procedures for Screening and Enrollment (other sections affected: Section 3.13.2 Procedures Before IMP Treatment', '(Baseline/Day 1), Section 3.13.3.1.2 Clinic Visits (Weeks 2, 4, and 6), Section 3.13.3.2.1 Week 9, Section 3.13.3.2.2', 'Week', '12/Early', 'Termination, Section 3.13.4.1 Week 13, and Section 3.13.5 Unscheduled Visits)', 'A signed and dated informed consent form will be', 'A signed and dated informed consent form will be', 'Updated language surrounding', 'obtained from the parent/legally acceptable', 'obtained from the parent/legally acceptable', 'who can be involved in the', 'representative (may also include an adult other than a', 'representative, and a signed and dated assent,', 'informed consent/assent process.', 'parent or legal representative), and a signed and dated', ""depending on the child's age, as appropriate, will be"", 'Removed a parenthetical', ""assent, depending on the child's age, as appropriate,"", 'obtained from each patient before screening', 'expression that was inserted', 'will be obtained from each patient before screening', 'procedures commence, according to national laws', 'previously', 'procedures commence, according to national laws', 'and local IEC/IRB requirements. Parents/legally', 'Included ""conduct clinic visit""', 'and local IEC/IRB requirements. Parents/legally', 'acceptable representatives will acknowledge and', 'strictly for clarity at each visit', 'acceptable representatives will acknowledge and', 'agree to the possible use of this information for the', 'where patients are expected to be', 'agree to the possible use of this information for the', 'study by giving informed consent.', 'present at the clinic for', 'study by giving informed consent.', 'assessment', 'A patient who is screened but not enrolled may be', 'A patient who is screened but not enrolled may be', ""rescreened 1 time if there is a change in the patient's"", '200']"
201,page_202,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'medical background, a modification of study entry', 'rescreened 1 time if there is a change in the status of', 'criteria, or other relevant change.status of the patient', 'the patient regarding eligibility for the study.', 'regarding eligibility for the study.', 'The screening visit will take place not more than 31', 'The screening visit will take place not more than 31', 'days before the baseline visit. The screening visit', 'days before the baseline visit. The screening visit', 'may be conducted over 2 separate visits at the', 'may be conducted over 2 separate visits at the', 'discretion of the investigator. The following', 'discretion of the investigator. The following', 'procedures will be performed at screening:', 'procedures will be performed at screening:', 'conduct clinic visit', 'conduct clinic visit', 'Section 4.1. Patient Inclusion Criteria (other section affected: Section 12.1 Informed Consent/Assent)', 'f. Patient and caregiver/adult (may also include an', 'f.', 'Patient and caregiver/adult are willing to adhere', 'Updated language surrounding', 'adult other than a parent or legal representative) are', 'to the medication regimen and to comply with all', 'who can be involved in the', 'willing to adhere to the medication regimen and to', 'study procedures.', 'informed consent/assent process.', 'comply with all study procedures.', ""h. In the investigator's opinion, the patient and"", 'Removed a parenthetical', ""h. In the investigator's opinion, the patient and"", 'caregiver/adult have the ability to understand the', 'expression that was inserted', 'caregiver/adult (may also include an adult other than', 'nature of the study and its procedures, and the patient', 'previously', 'parent or logal representative) have the ability to', 'is expected to complete the study as designed.', 'understand the nature of the study and its procedures,', 'i.', 'Patient and caregiver/adult provide written', 'and the patient is expected to complete the study as', ""informed consent/assent, depending on the child's"", 'designed.', 'age, as appropriate, according to local regulations.', 'i.', 'Patient and caregiver/adult (may also include an', 'adult other than a parent or legal representative)', 'provide written informed consent/assent, depending', ""on the child's age, as appropriate, according to local"", 'regulations.', 'Section 4.4 Withdrawal Criteria and Procedures (other section affected: Section 7.1.7 Withdrawal Due to an Adverse', 'Event)', 'b. adverse events (any patient who experiences an', 'b. adverse events (any patient who experiences an', 'Included clarity that patients who', 'adverse event may be withdrawn from the study or', 'adverse event may be withdrawn from the study or', 'experience an adverse event can', 'from study treatment at any time at the discretion of', 'from study treatment at any time at the discretion of', 'also be withdrawn by the sponsor.', 'the investigator or sponsor as indicated in Section', 'the investigator or sponsor as indicated in Section', 'Provided further guidance to the', '201']"
202,page_203,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', '7.1.7)', '7.1.7)', 'investigator in the situation that a', 'g. when a blind is broken due to safety concerns', 'g. when a blind is broken due to safety concerns', 'patient is unblinded by mistake', '(see Section 3.7.2). If a patient is unblinded by', '(see Section 3.7.2). If a patient is unblinded by', 'mistake, theythe investigator should discuss with the', 'mistake, the investigator should discuss with the', 'medical monitor whether or not the patient should be', 'medical monitor whether or not the patient should be', 'withdrawn.', 'withdrawn.', 'Section 5.5 Dose Reduction and Temporary IMP Discontinuation', 'Dose Suspension', 'Dose Suspension', 'Updated dose suspension text to', ""If a subject's serum potassium or magnesium were"", ""If a subject's serum potassium or magnesium were"", 'provide further guidance', 'tested and found to be below the lower limit of', 'tested and found to be below the lower limit of', 'normal, IMP must be suspended and clinically', 'normal and clinically significant, the laboratory test', 'significant, the laboratory test should be repeated at', 'should be repeated at least once. If the abnormality in', 'least once. If the abnormality in the repeated', 'the repeated laboratory test is consistent with the', 'laboratory test is consistent with the prior laboratory', 'prior laboratory test, the IMP must be suspended.', 'test, the IMP must be suspended.', 'Section 6.2.5 Yale Global Tic Severity Scale', 'are', 'Updated to more properly capture', 'exploratory measures.', 'the YGTSS measures', 're exploratory', 'measures.', 'Section 7.11 Concomitant Therapy or Medication', 'Medications that are allowed, provided that', 'Medications that are allowed, provided that', 'Updated allowed medications to', 'conditions outlined in the table are met, are shown in', 'conditions outlined in the table are met, are shown in', 'clarify that the list of concomitant', 'Appendix A, Table 9. The tables of allowed and', 'Appendix A, Table 9. The tables of allowed and', 'medications provided is not', 'prohibited medications are not comprehensive and', 'prohibited medications are not comprehensive and', 'comprehensive', 'may not include all possible concomitant', 'may not include all possible concomitant', 'medications.', 'medications.', 'Section 9.1 Sample Size and Power Considerations (other section affected: Figure 1: Overall Study Schema)', 'It is estimated that approximately 5058 patients per', 'It is estimated that approximately 58 patients per arm', 'Recently, a Phase 2 study', 'arm will enable a power of at least 90% to detect a', 'will enable a power of at least 90% to detect a', 'assessing the safety and efficacy', 'beneficial standardized effect of 6.5 points63° or', 'beneficial standardized effect of 63% or more when', 'of valbenazine in the treatment of', '202']"
203,page_204,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'more when the TEV-50717 arm is compared to', 'the TEV-50717 arm is compared to placebo', 'pediatric and adolescent TS', 'placebo (difference of 6.0 in the change from', '(difference of 6.0 in the change from baseline to', 'patients (T FORCE GOLD study)', 'baseline to week 12 in TTS when the TEV 50717', 'week 12 in TTS, assuming a standard deviation of', 'failed to meet its primary efficacy', 'arm is compared to placebo, assuming a standard', '9.5 in each arm) in a 2-sided type I error rate of 5%', 'objective. The details on the', 'deviation of 9.5 and in each arm) in a 2-sided type I', 'after accounting for potential dropouts.', 'results from this study have not', 'error rate of 5% after accounting for potential', 'The sample size for this study has been increased', 'yet been made public. Based on', 'dropouts.', 'from 100 total patients (50 patients per arm) to 116', 'this negative efficacy outcome,', 'The sample size for this study has been increased', 'total patients (58 patients per arm). This adjustment', 'the sample size assumptions for', 'from 100 total patients (50 patients per arm) to 116', 'is based solely on external data (ie, valbenazine', 'Study TV50717-CNS-30046 were', 'total patients (58 patients per arm). This adjustment is', 'Phase 2 study results, efficacy of TEV-50717 in the', 're-evaluated using data external to', 'based solely on external data (ie, valbenazine Phase 2', 'treatment of HD and TD, and ABILIFYR Phase 3', 'the ongoing TEV 50717 Phase 3', 'study results, efficacy of TEV-50717 in the treatment', 'data). Data from the ongoing TEV-50717 Phase 2/3', 'TS program.', 'of HD and TD, and ABILIFY® Phase 3 data). Data', 'and Phase 3 studies, TV50717-CNS-30046 and', 'from the ongoing TEV-50717 Phase 2/3 and Phase 3', 'TV50717-CNS-30060, respectively, are blinded and', 'After review of the standardized', 'studies, TV50717-CNS-30046 and TV50717-CNS-', 'were not used to inform the sample size calculation.', 'effect in the TEV-50717 placebo-', '30060, respectively, are blinded and were not used to', 'controlled pivotal studies in HD', 'inform the sample size calculation.', 'and TD and in collaboration with', 'the scientific advisors to the TEV-', '50717 TS program (ie, Dr.', 'Jankovic, Dr. Coffey, and Dr.', 'Jimenez-Shahed), a treatment', 'effect of 6.0 difference in TTS', 'reflecting a 63% beneficial', 'standardized effect was deemed to', 'be a more appropriate assumption', 'to base the sample size', 'calculation.', 'Section 9.2.1 Intent-to-Treat Analysis Set', 'The intent-to-treat (ITT) analysis set will include all', 'The intent-to-treat (ITT) analysis set will include all', 'Updated the definition of the ITT', 'randomized patients. In this population, treatment', 'randomized patients. In this population, treatment', 'analysis set', 'will be assigned based on the treatment to which', 'will be assigned based on the treatment to which', 'patients were randomized, regardless of which', 'patients were randomized, regardless of which', 'treatment they actually received. Enrolled subjects', 'treatment they actually received.', '203']"
204,page_205,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'who are not randomized will be summarized', 'separately as ""Not randomized, and randomized', 'subjects will be analyzed based on their randomized', 'treatment.', 'Section 9.5.4.2 Sensitivity Analysis', 'Sensitivity analyses for missing dataand, the', 'Sensitivity analyses for missing data, the statistical', 'Updated the protocol to state that', 'statistical model-are, and the increase in sample size', 'model, and the increase in sample size will be', 'sensitivity analysis will also be', 'will be provided in the statistical analysis plan.', 'provided in the statistical analysis plan.', 'done for the increased sample size', 'and further details will be', 'provided in the statistical analysis', 'plan', '204']"
205,page_206,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX A. ALLOWED AND DISALLOWED MEDICATIONS', 'Medications that are allowed, provided that conditions outlined in the table are met, are shown in Table 5. Tables for allowed and', 'prohibited medications are not exhaustive and may not include all possible concomitant medications.', 'The', 'medical', 'monitor must be contacted if a patient is receiving (or has to begin or stop receiving during the study) a medication that is', 'associated with QTc prolongation or that is a known strong cytochrome P450 inhibitor, or if there are any questions', 'regarding', 'any', 'medication not listed in the tables below.', 'Prohibited medications that are associated with QTc prolongation are listed in Table 6, while prohibited antipsychotic drugs are listed', 'in Table 7.', 'Table 5:', 'Allowed Medications', 'Generic/Drug class', 'Condition', 'Stable medications allowed according to inclusion/exclusions criteria', 'Hormonal birth control', 'Must be receiving stable treatment (including dose) for at least 3 months before screening.', 'Antidepressants', 'Must be receiving stable treatment (including dose) for at least 6 weeks before screening.', 'Benzodiazepines', 'Primary use must not be for tics; dosing must have been stable QT for at least 4 weeks before', 'screening.', 'Note: PRN (as needed) use is prohibited.', 'Topiramate', 'Must be receiving stable treatment (including dose) for at least 4 weeks before screening.', '(up to 200 mg/day)', 'Guanfacine', 'Allowed, regardless of indication (ie, if prescribed for ties or Tourette syndrome). Must be', 'receiving stable treatment (including dose) for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study. If discontinuation', 'of guanfacine is anticipated due to ineffectiveness, poor tolerability, or patient/caregiver', 'preference, discontinuation should occur 4 or more weeks prior to the screening visit.', 'Clonidine', 'Allowed, regardless of indication (ie, if prescribed for tics or Tourette syndrome). Must be', 'receiving stable treatment (including dose) for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study. If discontinuation', '205']"
206,page_207,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Generic/Drug class', 'Condition', 'Stable medications allowed according to inclusion/exclusions criteria', 'of clonidine is anticipated due to ineffectiveness, poor tolerability, or patient/caregiver', 'preference, discontinuation should occur 4 or more weeks prior to the screening visit.', 'Stimulants', 'Include amphetamine, methylphenidate, and lisdexamfetamine. Primary use is for the', 'treatment of ADHD; dosing must have been stable for at least 2 weeks before screening and', 'no changes to dose or frequency are anticipated during the course of the study.', 'Table 5:', 'Allowed Medications (Continued)', 'Generic/Drug class', 'Condition', 'SNRIs', 'Includes atomoxetine. Primary use is for the treatment of ADHD; dosing must have been', 'stable for at least 4 weeks before screening and no changes to dose or frequency are', 'anticipated during the course of the study.', 'Additional medications allowed with preapproval from medical monitor', 'Albuterol, levalbuterol', 'Asthma', 'Guaifenesin', 'Cold symptoms', 'Antihistamines', 'Allergies', 'Melatonin', 'Insomnia', 'Allowed strong CYP inhibitors', 'Bupropion', 'Antidepressant (aminoketone)', 'Fluoxetine', 'Antidepressant (selective serotonin reuptake inhibitor)', 'Paroxetine', 'Antidepressant (selective serotonin reuptake inhibitor)', 'a', 'The use of these medications will affect the maximum daily dose of IMP, as shown in Table 2.', 'ADHD=Attention-deficit/hyperactivity disorder; CYP=cytochrome P450; IMP=investigational medicinal product; SNRIs=serotonin-norepinephrine reuptake', 'inhibitor', 'Note: No dosing changes can be made during the study.', '206']"
207,page_208,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Table 6:', 'Prohibited QTc-Prolonging Drugs', 'Generic', 'Class/clinical use', 'Note', 'Azithromycin', 'Antibiotic/bacterial infection', 'Chloroquine/Mefloquine', 'Anti-malarial/malaria infection', 'Clarithromycinb', 'Antibiotic/bacterial infection', 'Domperidone', 'Anti-nausea/nausea', 'Not available in the USA', 'Droperidol', 'Sedative; anti-nausea/anesthesia adjunct, nausea', 'Erythromycinb', 'Antibiotic; GI stimulant; GI motility', 'Moxifloxacin', 'Antibiotic/bacterial infection', 'Sevoflurane', 'Anesthetic, general/anesthesia', 'Probucol', 'Antilipemic/hypercholesterolemia', 'Not available in the USA', 'Sparfloxacin', 'Antibiotic/bacterial infection', 'Not available in the USA', 'a', 'Patients are allowed to take up 500 mg/day of azithromycin.', 'b', 'Systemic use only. Topical use is allowed.', 'Gl=gastrointestinal; QTc=corrected QT; USA=United States of America.', 'Table 7:', 'Prohibited Antipsychotic Drugs', 'Typical/first generation antipsychotics', 'Atypical/second generation antipsychotics', 'Chlorpromazine', 'Aripiprazole', 'Haloperidol', 'Asenapine maleate', 'Loxapine', 'Clozapine', 'Molindone', 'Iloperidone', 'Perphenazine', 'Lurasidone', 'Pimozide', 'Olanzapine', 'Prochlorperazine', 'Olanzapine/fluoxetine', 'Thioridazine', 'Paliperidone', '207']"
208,page_209,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Thiothixene', 'Quetiapine', 'Trifluoperazine', 'Risperidone', 'Promethazine-containing compounds', 'Ziprasidone', 'Fluphenazine', 'Tiapride', 'Note: This table does not apply in the second week of washout for patients not rolling over to the open-label extension study (Study', 'TV50717-CNS-30047).', 'Table 8:', 'Other Prohibited Drugs', 'Generic', 'Class/clinical use', 'Note', 'Cannabidiol oil', 'Cannabis', 'Also includes other forms of', 'cannabinoids', 'Valbenazine', 'Vesicular monoamine transporter 2 inhibitor', 'Ingrezza off-label', 'Quinidine', 'Class I antiarrhythmic agent', 'Strong CYP2D6 inhibitor', 'Terbinafine', 'Antifungal medication', 'Weak CYP2D6 inhibitor', '208']"
209,page_210,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX B. DISTRIBUTION OF AUC BY WEIGHT CATEGORIES AND CYP2D6 STATUS', 'Figure 2:', 'Distribution of AUC of Total (a+B)-HTBZ for Selected Doses Based on Weight Categories', 'Functional CYP2D6', 'Impaired CYP2D6', '15 mg bid', '21 mg bid', '24 mg bid', '24 mg bid', '9 mg bid', '(non-impaired)', '12 mg bid', '18 mg bid', '24 mg bid', '(non impaired)', '5000', '5000', '4000', '4000', '3000', '3000', '2000', '2000', '1000', '1000', 'Weight Group', 'Weight Group', 'AUC=area under the curve; CYP2D6=cytochrome P450 2D6; a/ß-HTBZ=alpha/beta-dihydrotetrabenazine', '209']"
210,page_211,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX C. MINI INTERNATIONAL NEUROPSYCHIATRIC', 'INTERVIEW FOR CHILDREN AND ADOLESCENTS', 'The sample provided in this appendix is for reference only.', 'Modules:', 'Major Depressive Episode (Module A),', '(Hypo) Manic Episode (Module D),', 'OCD (Module J),', 'Alcohol Dependence/Abuse (Module L),', 'Substance Dependence/Abuse (Non-alcohol; Module M),', 'ADHD (Module O),', 'Conduct Disorder (Module P), and', 'Psychotic Disorders and Mood Disorders with Psychotic Features (Module R).', '210']"
211,page_212,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'A. MAJOR DEPRESSIVE EPISODE', 'MEANS: GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE)', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-6-', '211']"
212,page_213,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-7-', '212']"
213,page_214,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'D. (HYPO) MANIC EPISODE', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-11-', '213']"
214,page_215,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-12-', '214']"
215,page_216,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-13-', '215']"
216,page_217,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'J. OBSESSIVE COMPULSIVE DISORDER', '(-> MEANS: GOTOTHE DIAGNOSTIC BOX. CIRCLE NEXT MODULE)', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-20-', '216']"
217,page_218,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'L. ALCOHOL DEPENDENCE / ABUSE', 'MEANS: GO TOTHE DIAGNOSTICBOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE)', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-23-', '217']"
218,page_219,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-24-', '218']"
219,page_220,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M. SUBSTANCE DEPENDENCE / ABUSE (NON-ALCOHOL)', 'MEANS : GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE)', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-25-', '219']"
220,page_221,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-26-', '220']"
221,page_222,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'o. ATTENTION-DEFICIT/HYPERACTIVITY DISORDER', 'MEANS : GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE)', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-29-', '221']"
222,page_223,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-30-', '222']"
223,page_224,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'P. CONDUCT DISORDER', 'MEANS : GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE)', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-31-', '223']"
224,page_225,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid6.0 (October 10, 2010) (10/10/10)', '-32-', '224']"
225,page_226,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'R. PSYCHOTIC DISORDERS AND MOOD DISORDERS WITH PSYCHOTIC FEATURES', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-34-', '225']"
226,page_227,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-35-', '226']"
227,page_228,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'M.I.N.I. Kid 6.0 (October 10, 2010) (10/10/10)', '-36-', '227']"
228,page_229,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""APPENDIX D. CHILDREN'S DEPRESSION INVENTORY, SECOND"", 'EDITION, PARENT AND SELF-REPORT PROFILES', 'The sample provided in this appendix is for reference only.', 'CDI-2 Parent Profile', '228']"
229,page_230,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '229']"
230,page_231,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '230']"
231,page_232,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'CDI-2 Self-Report', '231']"
232,page_233,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '232']"
233,page_234,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '233']"
234,page_235,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '234']"
235,page_236,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '235']"
236,page_237,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""APPENDIX E. CHILDREN'S COLUMBIA-SUICIDE SEVERITY RATING"", 'SCALE', 'The sample provided in this appendix is for reference only.', ""Children's Baseline/Screening"", 'COLUMBIA-SUICIDE SEVERITY', 'RATING SCALE', '(C-SSRS)', ""Children's Baseline/Screening"", 'Version 6/23/10', 'Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.;', 'Burke, A.; Oquendo, M.; Mann, J.', 'Disclaimer:', 'This scale is intended to be used by individuals who have received training in its administration. The questions contained', 'in the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of', 'suicidal ideation or behavior depends on the judgment of the individual administering the scale.', 'Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History', 'Form, developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders', '(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A.,', 'Halberstam B. & Mann J.J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First', '[Ed.] Standardized Evaluation in Clinical Practice, pp. 103 - 130, 2003.)', 'For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New', 'York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu', 'C 2008 The Research Foundation for Mental Hygiene, Inc.', '236']"
237,page_238,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'e 2008 Research Foundation for Mental Hygiene, Inc.', ""C-SSRS-Children's Baseline/Screening (Version 6/23/10)"", 'Page 1 of 2', '237']"
238,page_239,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '238']"
239,page_240,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""Children's Since Last Visit"", 'COLUMBIA-SUICIDE SEVERITY', 'RATING SCALE', '(C-SSRS)', ""Children's Since Last Visit"", 'Version 6/23/10', 'Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.;', 'Burke, A.; Oquendo, M.; Mann, J.', 'Disclaimer:', 'This scale is intended to be used by individuals who have received training in its administration. The questions contained', 'in the Columbia-Suicide Severity Rating Scale are suggested probes. Ultimately, the determination of the presence of', 'suicidal ideation or behavior depends on the judgment of the individual administering the scale.', 'Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History', 'Form, developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders', '(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A.,', 'Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First', '[Ed.] Standardized Evaluation in Clinical Practice, pp. 103 - 130, 2003.)', 'For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New', 'York, New York, 10032; inquiries and training requirements contact posnerk@nyspi.columbia.edu', 'C 2008 The Research Foundation for Mental Hygiene, Inc.', '239']"
240,page_241,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'C 2008 Research Foundation for Mental Hygiene, Inc.', ""C-SSRS-Children's Since Last Visit (Version 6/23/10)"", 'Page 1 of 2', '240']"
241,page_242,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '241']"
242,page_243,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', ""APPENDIX F. CHILDREN'S YALE-BROWN OBSESSIVE-"", 'COMPULSIVE SCALE', 'The sample provided in this appendix is for reference only.', 'Original: 10/1/86', 'First Revision: 3/1/90', 'Second Revision: 5/1/91', 'Third Revision: 5/1/93', 'Fourth Revision: 6/17/99', 'Fifth Revision: 12/07/07', 'Sixth Revision 8/20/08', ""CHILDREN'S"", 'YALE-BROWN', 'OBSESSIVE COMPULSIVE SCALE', '(CY-BOCS)', 'DEVELOPED BY', 'WAYNE K. GOODMAN, M.D.¹', 'LAWRENCE SCAHILL, MSN, PhD²', 'LAWRENCE H. PRICE, M.D.³', 'STEVEN A. RASMUSSEN, M.D. 3', 'MARK A. RIDDLE, M.D.4', 'JUDITH L. RAPOPORT, M.D.', '5', 'NATIONAL INSTITUTE OF MENTAL HEALTH¹', 'THE CHILD STUDY CENTER²', 'YALE UNIVERSITY SCHOOL OF MEDICINE', 'DEPARTMENT OF PSYCHIATRY³', 'BROWN UNIVERSITY SCHOOL OF MEDICINE', 'CHILD PSYCHIATRY DIVISION4', 'JOHNS HOPKINS SCHOOL OF MEDICINE', 'and', 'CHILD PSYCHIATRY BRANCH', 'NATIONAL INSTITUTE OF MENTAL HEALTH', 'Investigators interested in using this rating scale should contact Lawrence Scahill, M.S.N., Ph.D., at the Yale', 'Child Study Center, P.O. Box 207900, New Haven, CT 06520 or Wayne Goodman, M.D., at the National', 'Institute of Mental Health, Bethesda, MD.', 'Scahill, L., Riddle, M.A., McSwiggin-Hardin, M., Ort, S.I., King, R.A., Goodman, W.K., Cicchetti, D. & Leckman,', ""J.F. (1997). Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc"", 'Psychiatry, 36(6):844-852.', '1', '242']"
243,page_244,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'GENERAL INSTRUCTIONS', '2', '243']"
244,page_245,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3', '244']"
245,page_246,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '4', '245']"
246,page_247,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '5', '246']"
247,page_248,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6', '247']"
248,page_249,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7', '248']"
249,page_250,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '8', '249']"
250,page_251,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9', '250']"
251,page_252,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '10', '251']"
252,page_253,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '11', '252']"
253,page_254,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '12', '253']"
254,page_255,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '13', '254']"
255,page_256,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX G. YALE GLOBAL TIC SEVERITY SCALE', 'The sample provided in this appendix is for reference only.', 'ID #:', 'Y G T S S', 'Yale Global Tic Severity Scale', 'Yale Child Study Center', 'October 1992 version', '1', '255']"
256,page_257,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'NAME:', ""TODAY'S DATE"", '1', 'RATER:', '2', '256']"
257,page_258,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '3', '257']"
258,page_259,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '4', '258']"
259,page_260,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '5', '259']"
260,page_261,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '6', '260']"
261,page_262,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '7', '261']"
262,page_263,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '8', '262']"
263,page_264,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '9', '263']"
264,page_265,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX H.', 'The sample provided in this appendix is for reference only.', '264']"
265,page_266,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX I.', 'The sample provided in this appendix is for reference only.', '265']"
266,page_267,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '266']"
267,page_268,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX J.', 'The sample provided in this appendix is for reference only.', '267']"
268,page_269,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX K.', 'The sample provided in this appendix is for reference only.', '268']"
269,page_270,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '269']"
270,page_271,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '270']"
271,page_272,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Quality of life scale for patients aged 13 to 18 years (C&A-GTS-QOL 13-18)', '271']"
272,page_273,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '272']"
273,page_274,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '273']"
274,page_275,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'APPENDIX L.', '274']"
275,page_276,"['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', '275']"
